
<html lang="en"     class="pb-page"  data-request-id="baa3f334-f915-4135-8f19-518084c9e1fc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-14;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b01306"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Current Insights of BRAF Inhibitors in Cancer" /></meta><meta name="dc.Creator" content="Bogos  Agianian" /></meta><meta name="dc.Creator" content="Evripidis  Gavathiotis" /></meta><meta name="dc.Description" content="Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extend..." /></meta><meta name="Description" content="Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extend..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 20, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01306" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01306" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01306" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01306" /></link>
        
    
    

<title>Current Insights of BRAF Inhibitors in Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01306" /></meta><meta property="og:title" content="Current Insights of BRAF Inhibitors in Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0008.jpeg" /></meta><meta property="og:description" content="Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors. This review provides an overview of recent structural and biochemical insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clinical activity, clinical liabilities, and medicinal chemistry properties. The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclinical and clinical development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01306"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01306">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01306&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01306&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01306&amp;href=/doi/10.1021/acs.jmedchem.7b01306" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 5775-5793</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b01314" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Current Insights of BRAF Inhibitors in Cancer</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bogos Agianian</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bogos Agianian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Department of Medicine, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, United States</div></div><span class="conrtib-corresp"><strong>*</strong>B.A.: e-mail, <a href="/cdn-cgi/l/email-protection#a8cac7cfc7db86c9cfc1c9c6c1c9c6e8cdc1c6dbdccdc1c686d1dd86cdccdd"><span class="__cf_email__" data-cfemail="593b363e362a77383e303837303837193c30372a2d3c303777202c773c3d2c">[email protected]</span></a>; phone, (718) 430-8590.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bogos++Agianian">Bogos Agianian</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Evripidis Gavathiotis</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Evripidis Gavathiotis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Department of Medicine, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E.G.: e-mail, <a href="/cdn-cgi/l/email-protection#365340445f465f525f451851574057425e5f59425f4576535f584542535f58184f4318535243"><span class="__cf_email__" data-cfemail="2d485b5f445d4449445e034a4c5b4c5945444259445e6d4844435e5948444303545803484958">[email protected]</span></a>; phone, (718) 430-3725.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Evripidis++Gavathiotis">Evripidis Gavathiotis</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6319-8331" title="Orcid link">http://orcid.org/0000-0001-6319-8331</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01306&amp;href=/doi/10.1021%2Facs.jmedchem.7b01306" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 5775–5793</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 20, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 September 2017</li><li><span class="item_label"><b>Published</b> online</span>20 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 July 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01306</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5775%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBogos%2BAgianian%252C%2BEvripidis%2BGavathiotis%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D14%26contentID%3Dacs.jmedchem.7b01306%26title%3DCurrent%2BInsights%2Bof%2BBRAF%2BInhibitors%2Bin%2BCancer%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5793%26publicationDate%3DJuly%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01306"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4663</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">35</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01306" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Current Insights of BRAF Inhibitors in Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bogos&quot;,&quot;last_name&quot;:&quot;Agianian&quot;},{&quot;first_name&quot;:&quot;Evripidis&quot;,&quot;last_name&quot;:&quot;Gavathiotis&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;5775-5793&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01306&quot;},&quot;abstract&quot;:&quot;Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors. This review provides an overview of recent structural and biochemical insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clinical activity, clinical liabilities, and medicinal chemistry properties. The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclinical and clinical development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF confo&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01306&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01306" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01306&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01306" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01306&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01306" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01306&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01306&amp;href=/doi/10.1021/acs.jmedchem.7b01306" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01306" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01306" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26pmid%3D29461827%26genre%3Darticle%26aulast%3DAgianian%26date%3D2018%26atitle%3DCurrent%2BInsights%2Bof%2BBRAF%2BInhibitors%2Bin%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D14%26spage%3D5775%26epage%3D5793%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292425" title="Oligomers">Oligomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/jmcmar.2018.61.issue-14/20180726/jmcmar.2018.61.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors. This review provides an overview of recent structural and biochemical insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clinical activity, clinical liabilities, and medicinal chemistry properties. The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclinical and clinical development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway controls cell growth, proliferation, and survival.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The RAF family of protein kinases (ARAF, BRAF, and CRAF) are critical effectors of this pathway.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Recruitment of RAFs on membrane associated RAS upon upstream activation signals<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> leads to a cascade of downstream events (ERK-signaling) that involve phosphorylation of MEK1 and MEK2 by RAFs, which in turn phosphorylate and activate ERK1 and ERK2.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Oncogenic mutations of this pathway are observed frequently in many cancers.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> RAS is considered a central therapeutic target of the pathway because it is mutated in approximately 30% of human cancers;<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4,6)</a> however drugging RAS has been notoriously challenging.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> As a result, efforts to inhibit RAF, MEK, and ERK kinases have gained significant momentum.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> A key step in the activation of RAF proteins is the formation of homo- and heterodimers, as RAF monomers are inactive due to autoinhibition by the N-terminal domain (NTD).<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> BRAF-CRAF heterodimers are major activators of ERK signaling by mutated RAS;<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> however physiological RAS signals mainly via BRAF dimers.<a onclick="showRef(event, 'ref2 ref3 ref10'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref10">(2,3,10)</a> In addition, oncogenic kinase-impaired BRAF mediates CRAF transactivation in a RAS-independent way.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">The first report of an oncogenic BRAF mutant in 2002<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> generated wide interest in targeting this protein. Over 45 oncogenic mutations have since been described for BRAF, with the V600E mutation accounting for ∼90% of them.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Overall, BRAF mutations are present in about 8% of human tumors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> BRAF mutants are present in >50% of melanoma patients as well as in colorectal (5–10%), thyroid carcinomas (25–45%), hairy-cell leukemia (∼100%) and less commonly in ovarian and lung malignancies.<a onclick="showRef(event, 'ref6 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref6 ref12 ref13 ref14">(6,12−14)</a> BRAFV600E mutation promotes constitutive kinase activation through signaling as a monomer, as well as insensitivity to ERK negative feedback mechanisms.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In addition to V600E, a number of other hyperactivating point mutations at positions 600 (V600K, V600D, V600R), 601 (K601E, K601D, K601R), 469 (G469A, G469V), and others have been reported.<a onclick="showRef(event, 'ref6 ref11 ref16'); return false;" href="javascript:void(0);" class="ref ref6 ref11 ref16">(6,11,16)</a> Moreover, fusions and frame deletions are also found in certain tumor types, resulting in constitutive RAS-independent dimerization and activation of BRAF and downstream ERK signaling.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a></div><div class="NLM_p">BRAF mutational analysis intensified efforts for the development of selective and potent BRAF inhibitors. BRAF inhibitor development targeting oncogenic BRAFV600E has yielded two FDA-approved drugs for advance stage melanoma, <b>5</b> (vemurafenib, Zelboraf) and <b>6</b> (dabrafenib, Tafinlar), approved in 2011 and 2013, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b). These drugs have produced remarkable responses and improved survival of melanoma patients with BRAFV600 mutant tumors, but their acquired resistance limits their effectiveness and most patients relapse within a year.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Moreover, colorectal and thyroid BRAFV600E tumors are resistant to <b>5</b> and <b>6</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> as well as 15–30% of non-small-cell lung carcinomas (NSCLC)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and ∼85% of pancreatic cancer cells.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The clinical importance of RAF dimerization in melanoma has been demonstrated by numerous observations whereby current FDA-approved inhibitors are failing to produce sustained tumor remission partly because they unsuccessfully target BRAF and CRAF dimers.<a onclick="showRef(event, 'ref2 ref3 ref4 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref23 ref24">(2−4,23,24)</a> Specifically, a major mechanism of acquired resistance involves signaling via BRAF homodimeric<a onclick="showRef(event, 'ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28">(25−28)</a> or BRAF-CRAF heterodimeric<a onclick="showRef(event, 'ref23 ref29'); return false;" href="javascript:void(0);" class="ref ref23 ref29">(23,29)</a> species. Clinically resistant tumors may also possess splice variants of BRAFV600E which form resistant dimers.<a onclick="showRef(event, 'ref27 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref30">(27,30)</a> Approved combination therapies of RAF and MEK inhibitors have improved responses in melanoma patients, although resistance to RAF and MEK inhibitor combination therapy is generated by mechanisms similar to the ones observed in RAF inhibitor monotherapy (see below).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Additionally, promising ongoing studies evaluate the combination of RAF/MEK inhibitors with immunotherapy.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p last">The above clinical challenges of RAF inhibitor tumor treatment underscore the pressing need to sustain further development of novel RAF small molecule inhibitors that evade resistance mechanisms. In addition, RAF drug design efforts should address recent breakthroughs in our understanding of the structural, biochemical, and cellular basis of sensitivity and resistance to inhibitors. In this review, we focus on current developments in our understanding of structural and biochemical BRAF inhibitor-driven effects and their clinical implications. We also discuss the medicinal chemistry properties of RAF inhibitors and focus on the most recent, third generation of BRAF inhibitors, which are developed with the objective to bypass resistance mechanisms. Several inhibitors are currently under clinical trials and hold promise to further improve our repertoire against BRAF-dependent tumors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Structural Basis of BRAF Physiological and Aberrant Activation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">RAFs have a typical kinase structure.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Two domains, the N-terminal and C-terminal lobes, are linked via a flexible hinge which allows relative movement of the lobes with respect to each other. A deep cleft at the interface of the kinase lobes creates the active site pocket where the nucleotide ATP and peptide substrate (or inhibitors) bind (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a). Several regulatory elements play a key role in kinase activation: the DFG motif, which comprises the Mg-binding (of ATP) site D594, and the regulatory F595 residue, the phospho-acceptor site (activation segment, AS), which is the beginning of the flexible activation loop (α-loop) adjacent to DFG, the αC-helix, which contains the catalytic E501 residue that often pairs with conserved K483 residue, and a glycine–proline rich loop (p-loop), which stabilizes the β-phosphate of ATP (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a,b). Under physiological kinase activation, F595 of the DFG motif oscillates between an “inactive” DFG-OUT conformation, in which it occupies part of the ATP binding site, and an “active” DFG-IN conformation, where it swings in toward the base of αC-helix. In the absence of inhibitors, the DFG-OUT conformation favors allosteric movement of the αC-helix away from the ATP site (αC-OUT position), whereas DFG-IN enables the reverse movement (αC-IN position). In most BRAF crystal structures, as with other kinases, the α-loop is highly flexible and thus often structurally unresolved. The floor of the BRAF active site is lined mainly with hydrophobic residues, and the site can be subdivided into the adenine (ATP base), ribose (ATP ribose), hydrophobic, type I, and type II (see below) subpockets (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b). It is widely accepted that the catalytically active kinase conformation necessitates a DFG-IN/αC-IN conformation, a closed interlobe configuration, and an extended α-loop with unfolded AS (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The relative spatial orientation of certain hydrophobic residues of the kinase with each other has been shown to be critical for kinase activation. These residues create the so-called C (catalytic) and R (regulator) spines.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Precise vertical alignment of the R-spine residues, which involves F595 of DFG motif, is essential for productive catalysis. This linear R-spine alignment, in contrast to other inactive orientations (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a–c), has been demonstrated for a prototype active BRAF protomer seen in a recently determined structure of dimeric BRAF bound to MEK<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d). Consistent with an active structure, the αC-helix of this active protomer adopts an IN position which enables catalysis and a fully extended α-loop (and AS).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. BRAF structure. (a) Ribbon representation of a BRAF protomer kinase domain structure bound to inhibitor <b>18</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VAM">5VAM</a>). The kinase consists of the N-lobe (salmon) and the C-lobe (blue) linked by a short flexible linker (hinge). The key structural elements for kinase activation, p-loop (yellow),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> αC-helix (magenta), and activation loop (α-loop, green) are highlighted. The regulatory F595 residue of the DFG motif (orange) adopts the DFG-OUT conformation, the αC-helix is in the IN position, and the α-loop is disordered. The floor of the inhibitor binding pocket (gray) is depicted in surface and the bound inhibitor in sticks. (b) Close-up view of BRAF active site illustrating schematically its ribose (pink), adenine (orange), hydrophobic (blue), type I (brown), and type II (green) subpockets (see text for details). The “gatekeeper” residue T529 and the catalytic residues E501 and D594 (DFG motif) are shown. A salt-bridge between catalytic E501 and K483, a hallmark of active kinase,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> is also shown. (c) The BRAF dimer (ribbons) demonstrates the spatial arrangement of protomers. Packing of residues R509 (ball-and-sticks, green) from each protomer, at the dimer interface, is essential for dimerization. αC-helix residue R506 (ball-and-sticks, yellow) can move toward OUT (red arrow) or IN (green arrow) conformations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0011.jpeg" id="GRAPHIC-d7e364-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inactive and active BRAF conformations. Ribbon representations of three representative inactive BRAF protomers and a monomer BRAF structure. Residues forming the C-spine (brown) and R-spine (white) (see text for details) are shown in Corey–Pauling–Koltun (CPK) representation. DFG residue F595 is part of the R-spine and is colored magenta. Fully assembled R-spine is depicted schematically with a straight red line, while a fully disassembled R-spine is depicted with a dashed red line. (a, b) BRAF-inhibitor inactive protomer structures showing disordered (part a, complex with <b>1</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH">1UWH</a>) or ordered (part b, β3αC-deletion mutant in complex with <b>10</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HID">5HID</a>) α-loop. In both structures, the, inactive DFG-OUT position of F595 prevents full alignment of the R-spines. (c) A monomeric BRAF structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>) demonstrates an inactive kinase conformation in which the α-loop is folded into a helical conformation. The AS forms a short helix that stabilizes αC-helix in the inactive OUT position. The R-spine is assembled but kinked (kinked red line), indicative of inactive kinase.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (d) Protomer of the active BRAF dimer (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNE">4MNE</a>). The active kinase conformation is illustrated by the αC-IN position, the unfolding and full extension of the α-loop (including the AS) and the full assembly of the R-spine residues into a straight line (red line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Under nonactivating conditions, cytosolic BRAF adopts a closed and inactive kinase conformation, which is the result of the inhibitory interaction of the N-terminal regulatory domain on the C-terminal kinase domain.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> As mentioned above, dimerization is essential for BRAF activation. Upon upstream receptor signaling activation, GTP-RAS levels increase on the plasma membrane. This leads to the release of RAF kinase inhibition due to the recruitment of the N-terminal domain to RAS via strong interactions with its RAS-binding domain (RDB).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> A series of subsequent events that involve BRAF kinase domain homo- or hetero- (with CRAF) dimerization and autophosphorylation of each protomer conclude full activation.<a onclick="showRef(event, 'ref4 ref36'); return false;" href="javascript:void(0);" class="ref ref4 ref36">(4,36)</a> In the vast majority of cases, reported BRAF (or CRAF) structures are dimers<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and almost invariably the constituting protomers adopt inactive kinase conformations (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a–c). The dimerization interface is mediated by the C-terminal of the kinase domain and the αC-helix (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c). Importantly, R509 residues at the C-terminal ends of each protomer αC-helix in the dimer pack together with strong van der Waals bonds as well as H-bonds to opposing protomers. These interactions are essential to maintain dimerization as demonstrated in a number of mutagenesis studies.<a onclick="showRef(event, 'ref8 ref27 ref38'); return false;" href="javascript:void(0);" class="ref ref8 ref27 ref38">(8,27,38)</a> It has been suggested that the orientation of another aC-helix residue, R506, which belongs to the conserved RKTR motif at the dimer interface<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c), determines inhibitor-driven interaction with GTP-RAS<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (see below).</div><div class="NLM_p">An inactive inhibitor-bound monomeric BRAF structure was recently revealed.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> This structure demonstrates a closed configuration of kinase lobes, the AS is folded as a short helix which stabilized the αC-helix at the OUT position, and the R-spine is kinked as expected for inactive kinase (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c). In both BRAF active MEK-bound protomer and the inactive monomer structures, F595 adopts a DFG-IN conformation, suggesting that movement of αC-helix and dimerization are not dependent on the positioning of DFG. These two BRAF structures, along with the collection of other BRAF structures (currently 65 records in the PDB), provided key insights on allosteric conformational transitions that affect the activation and dimerization of the kinase and demonstrated the large structural plasticity of RAFs.</div><div class="NLM_p">Despite these advances, the structural basis of activating BRAF cancer point mutations is not fully understood. On the basis of structures of BRAF bound to first generation RAF inhibitor <b>1</b> (sorafenib), Wan et al.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> proposed that disruption of hydrophobic interactions of V600 with residues of the p-loop relieves a closed interlobe kinase conformation and promotes activating dimerization. V600 residue is usually disordered in BRAF crystal structures; however, recent structural insights on inactive monomers and protomers as well as active BRAF have shed light on the potential role of V600 in oncogenic activation.<a onclick="showRef(event, 'ref17 ref34 ref41'); return false;" href="javascript:void(0);" class="ref ref17 ref34 ref41">(17,34,41)</a> So far, two general modes of interaction of V600 within BRAF seem to promote inhibited kinase states: The first is observed in a distinctive inactive monomeric BRAFWT structure.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> In this conformation, the AS folds into a short helix that makes hydrophobic contacts with the αC-helix. This arrangement allows V600 to be part of an extended hydrophobic cluster that stabilizes αC-helix to the inactive OUT conformation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). Steric clashes to αC-helix upon V600E mutation may induce movement of αC-helix toward the IN conformation and allosteric activation. A second mode of V600 interaction, observed in a few inactive BRAFWT structures (in complex with inhibitors) with folded α-loops, is characterized by interactions of V600 with p-loop residues and a closed, active-like, interlobe conformation, as originally proposed.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These interactions may involve direct V600 hydrophobic clustering or contacts via other α-loop residues<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). In contrast, it is currently accepted that V600E mutation induces unfolding of the AS and an extension of the α-loop which relieves the above inhibited kinase states. The active kinase conformation is stabilized, at least partly, by a salt bridge between V600E and K507 of αC-helix, which is implicit in the active BRAFWT-MEK complex<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c) and is explicitly observed in the BRAFV600E-<b>5</b> cocrystal structure<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>d).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural mapping of BRAF activating mutations. Structural mapping of common cancer activation point mutations on inactive BRAF monomer (panel a, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZV">4RZV</a>), an inactive protomer (panel b, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HID">5HID</a>), and active protomers (panel c, BRAFWT/MEK1 complex structure, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNE">4MNE</a>; panel d, BRAFV600E, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a>). Most mutations are concentrated at the AS of the α-loop and the p-loop. Mutations shown are the following: p-loop, G464, G466, S467, G469; α-loop, D594, G596, L597, T599, V600, K601; other locations, L485 and deletions in the 486–490 loop. Cα atoms of mutated residues are shown schematically as gold and magenta spheres, respectively, and F595 of DFG motif in sticks (orange). Residue V600 (pink) participates in a cluster of van der Waals contacts with p-loop or αC-helix residues (molecular surface) which stabilize inactive BRAF conformations (see text). In the inactive BRAF monomer (a) the cluster involves L597, L485, and αC-helix residue F498. In an inactive protomer (b) which comprise an in-frame deletion of BRAF<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> positioned at the short segment connecting αC-helix to β3-strand of the N-lobe (β3αC), it involves T599 and the p-loop residue S467. In active BRAF structures, release of steric V600 contacts upon MEK complexation (c) or mutation (d) leads to α-loop extension and positions V600 (or E600) within interaction distance to K507 at the base of αC-helix, which adopts the “active” IN position.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In most studies, BRAFV600E adopts a dimeric structure, demonstrating the importance of dimerization for BRAF activation; however BRAFV600E can act as an active monomer in cancer cells with low GTP-RAS levels.<a onclick="showRef(event, 'ref8 ref23 ref32 ref38'); return false;" href="javascript:void(0);" class="ref ref8 ref23 ref32 ref38">(8,23,32,38)</a> Similar structural mechanisms of activation to BRAFV600E seem to apply to other V600 oncogenic mutants (V600K, V600D, or V600R) which also can act as monomers.<a onclick="showRef(event, 'ref26 ref40'); return false;" href="javascript:void(0);" class="ref ref26 ref40">(26,40)</a> In addition, in-frame β3αC-deletions of the loop connecting the αC-helix and the β-sheet of the N-lobe are also oncogenic, with highest prevalence in pancreatic, lung, ovarian, and thyroid carcinomas.<a onclick="showRef(event, 'ref17 ref42'); return false;" href="javascript:void(0);" class="ref ref17 ref42">(17,42)</a> Structural analysis revealed that the αC-helix-IN conformation of these mutants (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b) is incompatible to compound <b>5</b> binding due to steric clashes.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Besides V600, several other point mutations including BRAFL597V, BRAFK601E, and BRAFG466E are located in the α-loop and the p-loop of BRAF (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Several cellular experiments have shown that activation of these non-V600 mutants depends largely on their spontaneous dimerization capacity, which is RAS-independent;<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> however, it is controversial whether this is also the case for β3αC-deletions.<a onclick="showRef(event, 'ref17 ref42'); return false;" href="javascript:void(0);" class="ref ref17 ref42">(17,42)</a> In a mutually nonexclusive model, interference of certain mutations to inhibitory autophosphorylation of p-loop residue S467 may also play a role in activation.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Finally, another class of RAS-dependent catalytically impaired or inactive BRAF mutants mainly found in colorectal, melanoma, and lung tumors,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> such as D594N, G466V, S467L, G596R, were recently shown to depend on dimerization.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The exact mechanism by which all these mutants dimerize is not very clear due to lack of structural information from these BRAF species.</div><div class="NLM_p last">Regardless of the spectacular recent progress in BRAF biology, a better arsenal of BRAF crystal structures, including several mutant structures and the full-length protein which includes the inhibitory N-terminal and the RDB, will be required to obtain a more definitive and detailed understanding of the mechanisms involved in BRAF regulation.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Conformational and Functional Effects of BRAF Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A large number of structurally diverse RAF inhibitors have been developed.<a onclick="showRef(event, 'ref4 ref46'); return false;" href="javascript:void(0);" class="ref ref4 ref46">(4,46)</a> The recent burst in the number of BRAF-inhibitor structures and intense investigation on their biochemical and cellular effects have enlarged our understanding on their detailed targeting mode and conformational effects on RAF structure. A central observation has been that RAF inhibitors induce allosteric structural rearrangements, which “lock” their target kinases in discrete conformations and resemble inactive or active kinase states of the αC-helix and DFG motif.<a onclick="showRef(event, 'ref3 ref40'); return false;" href="javascript:void(0);" class="ref ref3 ref40">(3,40)</a> These conformations broadly classify inhibitors as type I (αC-helix-IN/DFG-IN), type II (αC-helix-IN/DFG-OUT), or type I<sup>1</sup>/<sub>2</sub> (αC-helix-OUT/DFG-IN).<a onclick="showRef(event, 'ref42 ref49'); return false;" href="javascript:void(0);" class="ref ref42 ref49">(42,49)</a> Clinical RAF inhibitors <b>5</b> and <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) belong to type I<sup>1</sup>/<sub>2</sub>.</div><div class="NLM_p">Inhibitor binding induces allosteric conformational transition on the structure of protomers in BRAF dimers, which is characterized by the position of αC-helix, either to the IN or to the OUT conformation. A typical type I<sup>1</sup>/<sub>2</sub> example is <b>5</b> which binds only one BRAF protomer of the dimer and induces an αC-OUT conformation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). The αC-OUT position of compound <b>5</b> bound to protomer creates negative allostery to the second protomer by inducing the αC-IN conformation, which thus becomes incompatible with binding <b>5</b>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Thus, BRAF-<b>5</b> dimers are highly asymmetric. By contrast, typical type II inhibitors, like <b>10</b> (AZ-628) (see below), stabilize an IN conformation of αC-helix in the first protomer and do not create large allosteric αC-helix movements in the second protomer, which remains in the αC-IN conformation allowing another inhibitor binding (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> First and second generation RAF inhibitors (see below) belong mostly to I or I<sup>1</sup>/<sub>2</sub> types (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). They are αC-IN or αC-OUT inducers (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) creating asymmetric BRAF dimers (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). A notable exception is <b>6</b>, which occupies both protomers due to a brake in negative allostery exemplified by a less profound αC-OUT conformation in both protomers.<a onclick="showRef(event, 'ref42 ref47'); return false;" href="javascript:void(0);" class="ref ref42 ref47">(42,47)</a> The position of DFG does not appear to influence negative allostery as both DFG-IN and OUT conformations are observed in BRAF complexes with αC-OUT and αC-IN inhibitor inducers (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitor binding to BRAF structure impacts aC-helix conformation. 3D-superposition of protomers from BRAF dimers illustrate allosteric movements of αC-helix upon inhibitor binding. (a) Binding of type I<sup>1</sup>/<sub>2</sub> inhibitor <b>5</b> induces the OUT position of αC-helix (magenta) in one protomer, while the αC-IN position is observed in the inhibitor-free second protomer (cyan). PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a>. (b) Type II inhibitor <b>10</b> binds to both protomers of a BRAF dimer (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>). αC-helices of both protomers are stabilized in the αC-IN position (within some variation). (c) The position of DFG motif is not priming the conformation of αC-helix. DFG-IN or DFG-OUT conformations are sterically compatible with either IN or OUT αC-helix positions. The corresponding inhibitors and the conformations of BRAF-inhibitor crystal structures are noted. β-Sheets are represented in ribbons and helices as cylinders. Some protein parts of the C-lobe are not shown for clarity. Inhibitors and F595 (part c) are shown in sticks and molecular surface representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitors induce asymmetric BRAF dimers. Illustration of a BRAF dimer showing the two protomers in a molecular surface representation (brown, blue). OUT and IN positions of αC-helices of inhibitor bound protomers A from different BRAF dimers in complex with <b>5</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OG7">5OG7</a>), <b>9</b> (magenta, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX">5CSX</a>), <b>10</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>), and <b>2</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FB8">2FB8</a>) are shown after structural superposition. F595 residues (in sticks) adopt either the IN (yellow, cyan) or OUT (magenta, green) positions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Representative BRAF Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">RAF inhibitor</th><th class="colsep0 rowsep0" align="center">class</th><th class="colsep0 rowsep0" align="center">originator/developer</th><th class="colsep0 rowsep0" align="center">in vitro IC<sub>50</sub>/<i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">in cellulo IC<sub>50</sub>/EC<sub>50</sub> (viability) (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">in cellulo IC<sub>50</sub>/EC<sub>50</sub> (pERK) (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">stage of development</th><th class="colsep0 rowsep0" align="center">refs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">first generation</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Bayer/Onyx</td><td class="colsep0 rowsep0" align="left">22<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3900<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref58 ref64 ref123'); return false;" href="javascript:void(0);" class="ref ref58 ref64 ref123">(58,64,123)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">370</td><td class="colsep0 rowsep0" align="left">290</td><td class="colsep0 rowsep0" align="left">preclnical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Genentech</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Plexxikon</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref58 ref69'); return false;" href="javascript:void(0);" class="ref ref58 ref69">(58,69)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">second generation</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Plexxikon/Hoffman La Roche</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">310<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref58 ref124'); return false;" href="javascript:void(0);" class="ref ref58 ref124">(58,124)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">43<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">FDA approved</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub><a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">Array BioPharma</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Exelixis</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">200<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">2000<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">phase I (completed)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">I/II<a class="ref internalNav" href="#t1fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">Boehringer Ing.</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">third generation</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">383<a class="ref internalNav" href="#t1fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Eli Lilly</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">9.2</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Takeda/Millennium</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Takeda/Millennium</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">248<a class="ref internalNav" href="#t1fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">∼70<a class="ref internalNav" href="#t1fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref90 ref128'); return false;" href="javascript:void(0);" class="ref ref90 ref128">(90,128)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">ICR/Basilea</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15<a class="ref internalNav" href="#t1fn11" aria-label="k">k</a></td><td class="colsep0 rowsep0" align="left">∼5</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">ICR/Basilea</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">∼5</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Beigene</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">157<a class="ref internalNav" href="#t1fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Beigene</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">0.4<a class="ref internalNav" href="#t1fn13" aria-label="m">m</a></td><td class="colsep0 rowsep0" align="left">950<a class="ref internalNav" href="#t1fn13" aria-label="m">m</a></td><td class="colsep0 rowsep0" align="left">100<a class="ref internalNav" href="#t1fn13" aria-label="m">m</a></td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">140<a class="ref internalNav" href="#t1fn14" aria-label="n">n</a></td><td class="colsep0 rowsep0" align="left">160<a class="ref internalNav" href="#t1fn14" aria-label="n">n</a></td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Plexxikon</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">170</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub><a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">Plexxikon</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">∼800<a class="ref internalNav" href="#t1fn15" aria-label="o">o</a></td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref58 ref106'); return false;" href="javascript:void(0);" class="ref ref58 ref106">(58,106)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">II<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">Ambit Bio./Ignyta</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">84</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref108 ref109">(108,109)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">Hanmi/Genentech</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">118<a class="ref internalNav" href="#t1fn16" aria-label="p">p</a></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">ICR/Basilea</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref51 ref91'); return false;" href="javascript:void(0);" class="ref ref51 ref91">(51,91)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Activity on BRAFV600E mutant except if noted otherwise.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Viability/pERK activity in melanoma A375 (BRAFV600E) cells except if noted otherwise.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Activity on BRAFWT. Viability in SK-MEL-30 cells.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">SK-MEL-32 cells.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">SK-MEL-28 cells.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Predicted.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">pERK activity in Jurkat T cells. Viability in SK-MEL-19 cells.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">αC-OUT/DFG-OUT.</p></div><div class="footnote" id="t1fn9"><sup><sup>i</sup></sup><p class="last">SK-MEL-239 cells.</p></div><div class="footnote" id="t1fn10"><sup><sup>j</sup></sup><p class="last">Viability and pERK activity in synthetic pediatric low-grade astrocytomas (PLGAs) expressing BRAFV600E.</p></div><div class="footnote" id="t1fn11"><sup><sup>k</sup></sup><p class="last">WM266.4(BRAFV600D) cells.</p></div><div class="footnote" id="t1fn12"><sup><sup>l</sup></sup><p class="last">SK-MEL-239 (BRAFV600E) cells.</p></div><div class="footnote" id="t1fn13"><sup><sup>m</sup></sup><p class="last">Activity on BRAFWT. pERK activity and viability in Calu-6 cells.</p></div><div class="footnote" id="t1fn14"><sup><sup>n</sup></sup><p class="last">SK-MEL-28 cells.</p></div><div class="footnote" id="t1fn15"><sup><sup>o</sup></sup><p class="last">HCC364 lung adenocarcinoma cells expressing p61-V600E.</p></div><div class="footnote" id="t1fn16"><sup><sup>p</sup></sup><p class="last">Colo-205 cells.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structural Data and Specificity of BRAF Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">RAF inhibitor</th><th class="colsep0 rowsep0" align="center">co-structure protein</th><th class="colsep0 rowsep0" align="center">BRAF conformation</th><th class="colsep0 rowsep0" align="center">BRAF specificity, monomer (M)/dimer (D)</th><th class="colsep0 rowsep0" align="center">PDB codes</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">first generation</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">BRAFWT, BRAFV600E, β3αC-BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH">1UWH</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ">1UWJ</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HI2">5HI2</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-IN</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FB8">2FB8</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">BRAFV600E</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-IN</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNF">4MNF</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-OUT/DFG-IN</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4C">3C4C</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WO5">4WO5</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">second generation</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">BRAFWT(R509H), BRAFV600E</td><td class="colsep0 rowsep0" align="left">αC-OUT/DFG-IN</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZV">4RZV</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">BRAFWT, BRAFV600E, β3αC-BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-OUT/DFG-IN</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSW">5CSW</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV2">4XV2</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HIE">5HIE</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-OUT/DFG-IN<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-IN<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M/D<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-OUT/DFG-OUT<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX">5CSX</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">third generation</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">BRAFWT(R509H), BRAFV600E, β3αC-BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R">4G9R</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HID">5HID</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">BRAFV600E</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C9C">5C9C</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M/D<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M/D<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M/D<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M/D<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">BRAFV600E</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R5Y">4R5Y</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VAM">5VAM</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">BRAFWT</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT</td><td class="colsep0 rowsep0" align="left">M/D</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CT7">5CT7</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">BRAFV600E</td><td class="colsep0 rowsep0" align="left">αC-OUT/DFG-IN</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV1">4XV1</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-OUT/DFG-IN<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">αC-IN/DFG-OUT<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">M/D<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">N/A</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Predicted.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The DGF-OUT conformation is induced by crystallization conditions.</p></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Structural Effects of RAF Inhibitors Are Associated with Their Preclinical and Clinical Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several preclinical and clinical studies of RAF inhibitors demonstrated unusual pharmacologic behavior.<a onclick="showRef(event, 'ref9 ref28 ref48'); return false;" href="javascript:void(0);" class="ref ref9 ref28 ref48">(9,28,48)</a> While the inhibitors suppressed tumors harboring BRAFV600E or other mutants, in tumors expressing BRAF wild type (BRAFWT), they do not inhibit but instead paradoxically activate RAF activity and downstream ERK signaling (RAF inhibitor paradox or “paradoxical activation”).<a onclick="showRef(event, 'ref4 ref28 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref4 ref28 ref48 ref49">(4,28,48,49)</a> These studies further established that paradoxical activation of full length BRAF requires active RAS and induced BRAF or BRAF-CRAF dimers. The general trend is that type I inhibitors exhibit more paradoxical activation, followed by type II and type I<sup>1</sup>/<sub>2</sub> RAF inhibitors, an observation with important clinical implications.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Recently, integration of previous cell-based studies with crystallographic data enabled the link between structural and biochemical properties of RAF inhibitors and their pharmacological effectiveness in tumors.<a onclick="showRef(event, 'ref34 ref40 ref41 ref49'); return false;" href="javascript:void(0);" class="ref ref34 ref40 ref41 ref49">(34,40,41,49)</a> It has become apparent that these effects are dictated by distinct inhibitor-driven allosteric mechanisms that prime specific RAF conformations, as well as the cellular context of active RAS.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">The model of negative allostery described above explains the clinical effectiveness of the current FDA approved αC-OUT RAF inhibitors <b>5</b> and <b>6</b>. These inhibitors are selective for tumors that depend on BRAFV600 mutations (RAF monomers); however tumors driven by BRAF dimers are resistant<a onclick="showRef(event, 'ref26 ref27 ref40 ref45'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref40 ref45">(26,27,40,45)</a> due to the intrinsic inability of these inhibitors to bind both protomers in the dimers. Reduction of the affinity of αC-OUT inhibitors for the second protomer allows it to engage in catalysis, which is the basis of upregulation of ERK signaling.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> At the same time, such inhibitors are predicted to be ineffective to all dimeric BRAF oncogenic mutants. The inability of αC-OUT RAF inhibitors to inhibit physiologically activated dimeric BRAF in normal cells provides a wide therapeutic window for such inhibitors. However, prolonged treatment with αC-OUT inhibitors may lead to drug-induced lesions due to activated RAF signaling induced by negative allostery and resultant transactivation of unbound protomers. Such skin lesions include keratocarcinomas and squamous cell carcinomas.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">In contrast, αC-IN inhibitors can target efficiently BRAF dimers by binding both protomers, usually with similar affinity. In addition, these inhibitors can also target monomeric RAF forms, so they could be viewed as equipotent inhibitors of both monomeric (e.g., BRAFV600 mutants) and dimeric (e.g., non-V600 mutants) BRAF.<a onclick="showRef(event, 'ref26 ref40 ref45'); return false;" href="javascript:void(0);" class="ref ref26 ref40 ref45">(26,40,45)</a> Despite these favorable properties, the tumor suppression effectiveness of αC-IN inhibitor monotherpy is limited by a narrower therapeutic window and by allosteric RAF priming. The former is a consequence of concurrent inhibition of BRAFWT (which adopts the active αC-IN conformation) in healthy tissue.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The latter phenomenon is based on the intrinsic propensity of αC-IN inhibitors to promote transactivating dimerization of an inhibitor-bound protomer with another monomer, which then leads to the interaction of RAF with GTP-RAS, followed by activating phosphorylation.<a onclick="showRef(event, 'ref2 ref3 ref40'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref40">(2,3,40)</a> Ultimate levels of primed RAF signaling would be context dependent, based on how completely a RAF inhibitor could bind to both protomers in the signaling dimer.</div><div class="NLM_p">Some aC-IN inhibitors target RAF homo- and heterodimers;<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50−52)</a> however allosteric RAF priming again restricts this inhibitory activity. Allosteric priming by inhibitors has been observed with other kinases, for example, with AKT, protein kinase C (PKC), and Janus kinase (JAK),<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a> as has inhibitor-induced dimerization for instance in the cases of inositol requiring enzyme 1α (IRE1α) or JAK2.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a></div><div class="NLM_p">Paradoxical activation of ERK signaling is a property of both αC-OUT and αC-IN inhibitors which is based on their propensity to promote RAF transactivating dimerization as well as their overall inhibition mode.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Both αC-OUT and αC-IN inhibitors induce dimerization; however, αC-IN inhibitors do so typically more potently. Effective inhibition of such dimers depends on the ability of inhibitors to target effectively and durably both protomers. Usually, αC-OUT inhibitors promote paradoxical activation at low (submicromolar to nanomolar) concentrations because they fail to inhibit dimers due to negative allostery. In contrast, αC-IN inhibitors promote RAF priming at low concentrations due to enhanced dimerization; however these dimers are often inhibited due to lower negative allostery, which eventually leads to less paradoxical activation. Thus, transactivation, negative allostery, and potency for individual protomers determine final BRAF inhibitor activity.<a onclick="showRef(event, 'ref2 ref40'); return false;" href="javascript:void(0);" class="ref ref2 ref40">(2,40)</a></div><div class="NLM_p">Structural comparison of various BRAF-inhibitor complexes led to the hypothesis that the position of αC-helix residue R506 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c) determines the extent of inhibitor-induced RAF-RAS interaction.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> This model predicts that displacement of the R506 from the OUT position toward IN (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c, blue arrow<b>)</b> is compatible to RAF priming, whereas stabilization of R506 to the OUT position (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c, red arrow) is not. Indeed, αC-IN inhibitors <b>2</b> (SB-590885) and <b>3</b> (GDC-0879) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) (R506-IN conformation) promote RAF-RAS interaction, while the “paradox breakers” <b>20</b> (PLX7904, PB04) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>d) and <b>21</b> (PLX8394) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) (R506-OUT conformation) do not promote priming and paradoxical activation.<a onclick="showRef(event, 'ref40 ref58'); return false;" href="javascript:void(0);" class="ref ref40 ref58">(40,58)</a> Paradox breakers are typically αC-OUT inducers. Notably, <b>6</b> and to a lesser extent <b>5</b> promote RAF-RAS interaction and RAF dimerization, due to displacement of the R506 residue from the OUT position, despite being αC-OUT inhibitors.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Moreover, among the group of αC-IN RAF inhibitors, those stabilizing the DGF-IN conformation, e.g., <b>2</b> or <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c), display more pronounced paradoxical activation compared to their DFG-OUT counterparts.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> This observation may be the result of allosteric formation of RAF-MEK complex by these inhibitors, which activates ERK pathway.<a onclick="showRef(event, 'ref34 ref40'); return false;" href="javascript:void(0);" class="ref ref34 ref40">(34,40)</a> In contrast, αC-OUT inhibitors like the clinically used <b>5</b> and <b>6</b> do not promote RAF interaction with MEK.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of BRAF inhibitors. First (a), second (b), and third (c) generation BRAF inhibitors. Inhibitor moieties interacting with subpockets of BRAF active site are highlighted in different colors as in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. Coloring key of subpockets: ribose (pink), adenine (orange), hydrophobic (blue), type I (brown), and type II (green). Groups exposed to solvent are colored in gray.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Recognition of BRAF active site by type I and I<sup>1</sup>/<sub>2</sub> BRAF inhibitors. Close-up on the active site of BRAF showing binding mode of various type I or I<sup>1</sup>/<sub>2</sub> inhibitors: (a) <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a>); (b) <b>6</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSW">5CSW</a>); (c) <b>9</b>, a mixed type (I/II, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) inhibitor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX">5CSX</a>); (d) <b>20</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV1">4XV1</a>). Active-site subpockets are colored according to <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. Key H-bonds are shown (see text for details). In all complexes the terminal sulfonamide of the inhibitors is recognized by specific H-bonds. The E501-K483 salt-bridge is broken, and the αC-helix adopts the OUT position.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Two nonmutually exclusive hypotheses attempt to explain the mode of action of paradox breakers. The first claims that they modulate dimerization through altered interaction with αC-helix via residue L505 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>d) as a result of terminal sulfonamide and sulfamide substitutions (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), which stabilize the αC-helix in the dimerization-resistant OUT conformation.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The other structural hypothesis involves overall conformational changes mediated by hydrogen-bond interactions with the BRAF gatekeeper residue T529<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b). Nonetheless, all studies demonstrate the critical role of RAF dimerization and the requirement of GTP-RAS for paradoxical activation.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Progress in RAF Kinase Inhibitor Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71587" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71587" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> First Generation RAF Kinase Inhibitors</h3><div class="NLM_p last">Initial attempts to inhibit the oncogenic effect of CRAF in tumors identified the first reported ATP-competitive BRAF kinase inhibitor, ZM336372,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> a benzamide analogue. Work by Bayer/Onyx Pharmaceuticals developed the biarylurea derivative <b>1</b> (αC-IN/DFG-OUT inducer), the only first generation RAF inhibitor that received FDA approval for advanced renal cell carcinoma and hepatocellular carcinoma tumors that express BRAFWT.<a onclick="showRef(event, 'ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63">(61−63)</a> Preclinical studies using <b>1</b> demonstrated weak affinity for mutated BRAFV600<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and broad specificity. Therefore, it is suggested that the clinical effects of <b>1</b> arise from multikinase targeting. Development of several other first generation compounds did not produce any clinically approved RAF inhibitors. These included the indol-2-one derivative GW5074,<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> the triarylimidazole derivative <b>2</b> (SB-590885),<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> the pyridylpyrazole derivative <b>3</b> (GDC-0879),<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and the azaindole derivative <b>4</b> (PLX-4720)<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). With the exception of <b>1</b>, which is a type II inhibitor, first generation RAF inhibitors belong to type I or I<sup>1</sup>/<sub>2</sub>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Second Generation RAF Kinase Inhibitors</h3><div class="NLM_p">The discovery of the key role of BRAFV600E in melanoma<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> advanced interest to develop RAF inhibitors against this mutant. These efforts generated second generation inhibitors which include <b>5</b>,<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> an azaindole compound, and the pyrimidine derivative <b>6</b>,<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> the only such inhibitors to obtain FDA approval (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). <b>5</b> was approved for the treatment of BRAFV600E metastatic melanoma, while <b>6</b> was approved for therapy of melanoma tumors driven by BRAFV600E/K. Both <b>5</b> and <b>6</b> are αC-OUT/DFG-IN inducers and, as noted above, demonstrate paradoxical activation and allosteric BRAF dimer transactivation. Thus, healthy (BRAFWT) cells can be activated upon treatment with these inhibitors, which may lead to secondary cancers.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> These drugs show remarkable effectiveness in BRAFV600E tumors; however tumors driven by non-V600 mutants are resistant.<a onclick="showRef(event, 'ref26 ref38 ref40'); return false;" href="javascript:void(0);" class="ref ref26 ref38 ref40">(26,38,40)</a> As mentioned above, central to the development of resistance is induced RAF dimerization and RAF priming. In a crystal structure of <b>5</b> with BRAFV600E the inhibitor demonstrated typical type I<sup>1</sup>/<sub>2</sub> binding mode; the azaindole moiety forms two specific H-bonds to the backbone of hinge residues W531 and C532, the difluorophenyl group occupies the hydrophobic pocket, while the sulfonamide inserts into the type I pocket and H-bonds to K483 and the DFG motif (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a). A similar orientation in the BRAF active site is observed for <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>b) wherein the aminopyrimidyl moiety is docked in the adenine pocket. In contrast to <b>5</b>, the ribose site is occupied by the butylthiazol group of <b>6</b>.</div><div class="NLM_p">Another second generation inhibitor that has demonstrated promising preclinical and clinical properties is <b>7</b> (LGX818) (encorafenib, Array BioPharma).<a onclick="showRef(event, 'ref74 ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref74 ref75 ref76">(74−76)</a> These properties included a low off-rate from BRAF compared to <b>5</b> or <b>6</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> which leads to a clinically longer residence time and a high selectivity for BRAFV600E.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> There is no available BRAF-LGX818 structure; however, the presence of a terminal type I sulfonamide (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), similar to albeit shorter than that in <b>5</b> and <b>6</b>, suggests that <b>7</b> is a type I<sup>1</sup>/<sub>2</sub> inhibitor predicted to induce the αC-OUT/DFG-IN conformation. Similar to other pyrazolylpyrimidine kinase inhibitors, the aminopyrimidine is expected to contact via H-bonds the hinge, whereas the pyrazolyl moiety extends to the ribose pocket. Currently <b>7</b> is in phase III clinical trials.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p"><b>8</b> (XL281, BMS-908662; Exelixis), a benzimidazole derivative<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78,79)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), is a second generation RAF inhibitor which held initial promise in biochemical and preclinical studies and advanced to phase I clinical trials.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> In this clinical study, out of 30 patients, one with ocular melanoma achieved a partial remission and 12 subjects had stable disease lasting >3 months. <b>8</b> was well tolerated up to 150 mg/day.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> However, its clinical development was discontinued. <b>8</b> is predicted to be an αC-IN/DFG-IN inducer, yet structural information on its mode of binding to BRAF is lacking.</div><div class="NLM_p">Lastly, a class of second generation αC-OUT RAF inhibitors has been developed by Boehringer Ingelheim, with most promising member compound <b>9</b> (BI882370),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> a pyrolopyridine derivative containing a sulfonamide moiety typical of type I inhibitors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). This inhibitor demonstrates remarkable potency in inhibition of kinase activity and specific cancer cell proliferation (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In biochemical experiments, it shows low selectivity among BRAF isoforms (IC<sub>50</sub>(BRAFWT) = 0.8 nM, IC<sub>50</sub>(CRAF) = 0.6 nM, compared to BRAFV600E IC<sub>50</sub> value in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a><b>9</b> is effective in melanoma and colorectal xenograft models; treatment of mice with established A375 melanomas (doses of 6.25 or 12.5 mg/kg twice daily), G-361 melanoma (dose 12.5 mg/kg twice daily), or a COLO205 model (25 mg/kg twice daily) resulted in significant shrinkage of tumors.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> At the same time, the toxicologic profile of <b>9</b> in male rats provided no evidence of pathologic changes.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Oddly, the structure of <b>9</b> with BRAFWT illustrates a unique αC-OUT/DFG-OUT conformation, indicative of a mixed type I and type II mode. However, this unique DGF-OUT binding mode is most probably an artifact of the crystallization milieu; a glucose solvent molecule occupies the type II pocket (similar to αC-IN inhibitors), sterically prohibiting movement of F595 toward its DFG-IN position (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>c). Nonetheless, <b>9</b> shows characteristic type I active site contacts wherein the pyrimidine interacts with the kinase hinge and the pyrolopyridine group occupies the ribose pocket. Notably, binding of <b>9</b> partially orders the α-loop and allows residue K601 to H-bond a sulfonamide oxygen (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>c).</div><div class="NLM_p last">Second generation inhibitors can target successfully BRAFV600E melanoma tumors; however, in colorectal and thyroid BRAFV600 tumors their response is limited.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> This is attributed to upstream RAS and RTK activation<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> which is maintained by pronounced feedback reactivation mechanisms and enhanced RAF dimerization.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Third Generation RAF Kinase Inhibitors</h3><div class="NLM_p">The notion that RAF dimerization confers resistance to first and second generation RAF inhibitors<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> has recently shifted focus of RAF inhibitor design to the development of compounds that stabilize BRAF in the αC-IN conformation to enable binding to both protomers in dimeric structures and are also capable of inhibiting cellular CRAF. The aim of these efforts has been to design small molecules that inhibit equipotently the monomeric and dimeric forms of RAFs or do not permit dimer formation. Such molecules would be able to target tumors resistant to <b>5</b> or <b>6</b>, in contrast to αC-OUT inhibitors. Many third generation inhibitors have been produced, and several of them are currently undergoing phase I or phase II clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Most known third generation RAF inhibitors bind BRAF in type II mode (αC-IN/DFG-OUT), whereby additional, compared to type I or type I<sup>1</sup>/<sub>2</sub>, chemical groups insert into a hydrophobic pocket (type II pocket) deep in the BRAF active site cleft (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b). In most cocrystal structures of BRAF with third generation inhibitors, strong hydrogen bonding of the inhibitor to the catalytic residue E501 of αC-helix or backbone NH of D594 of DFG motif is observed (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) which is facilitated by the movement of αC-helix toward the IN position. Often, the strong salt-bridge between E501 and K483 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b), which stabilizes the αC-IN orientation, is not broken. A collection of key third generation BRAF inhibitors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) is described below.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Recognition of BRAF active site by type II BRAF inhibitors. Close-up on the active site of BRAF showing binding mode of various type II inhibitors: (a) <b>11</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C9C">5C9C</a>); (b) <b>12</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>); (c) <b>18</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VAM">5VAM</a>); (d) <b>17</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R5Y">4R5Y</a>). Active-site subpockets are colored according to <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. The αC-helix adopts the IN position, typical for type II inhibitors complexes. The catalytic E501 recognizes linker or ring nitrogens of the inhibitors, and in some cases (see panels b and c) the salt-bridge to K483 is maintained.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among the early αC-IN BRAF inhibitors was the quinazolinole derivative <b>10</b> (AstraZeneca) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). This compound showed reduced phospho-ERK (pERK) and phospho-MEK (pMEK) levels in RAS mutant cells.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> However, despite suppression of ERK signaling, the inhibitor demonstrated pan-RAF and multikinase inhibition profiles, similar to <b>1</b>, and induced acquired resistance due to elevated CRAF expression in various cell lines.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>10</b> inhibits equipotently monomeric and dimeric BRAF<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> as indicated by crystal structures with BRAF monomers (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b, BRAFR509H mutation, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and dimes (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R">4G9R</a>).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Compound <b>10</b> induces the αC-IN/DFG-OUT conformation in these structures (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The type II binding to BRAF may correlate with the very slow dissociation rate of <b>10</b> from CRAF.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Due to unfavorable pharmacological properties, <b>10</b> did not advance to clinical trials.</div><div class="NLM_p"><b>11</b> (LY3009120),<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> a urea-linked pyridopyrimidine compound developed by Elli Lilly, is a third generation αC-IN/DFG-OUT inhibitor which binds to both RAF protomers creating a mostly symmetrical dimer.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a><b>11</b> therefore inhibits BRAF monomers and dimers with equal affinity.<a onclick="showRef(event, 'ref52 ref87'); return false;" href="javascript:void(0);" class="ref ref52 ref87">(52,87)</a> Interestingly, this inhibitor was also potent versus BRAF deletion mutants that spontaneously form dimers<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> An X-ray structure of BRAFV600E in complex to <b>11</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C9C">5C9C</a>) shows that the inhibitor adopts a type II binding mode; the pyridopyrimidine moiety binds at the adenine pocket and the urea linker H-bonds to E501 and the base of DFG motif, while the hydrophobic <i>tert</i>-butylethyl group extends into the type II pocket (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a). <b>11</b> displayed antitumor activity in melanoma resistant to <b>1</b> and in RAS-dependent tumors<a onclick="showRef(event, 'ref52 ref86'); return false;" href="javascript:void(0);" class="ref ref52 ref86">(52,86)</a> as well as against pancreatic and thyroid tumors.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In HCT116 cells harboring BRAFWT, <b>11</b> induced minor paradoxical activation of pERK at >100 nM concentrations, due to its pan-RAF activity profile, in particular its low IC<sub>50</sub> for CRAF (15 nM).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In patient-derived xenograft (PDX) studies, significant dose-dependent growth inhibition of tumors bearing BRAFV600E was observed upon oral treatment of rats with <b>11</b> (15–30 mg/kg b.i.d.). Similar results were reported for xenograft models harboring BRAF and NRAS/KRAS mutations.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In pharmacokinetic experiments, <b>11</b> displayed initially low bioavailability in rats, dogs, and monkeys, which was significantly increased using solid dispersion technology.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Currently <b>11</b> is under phase I clinical investigation.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p">Similar to <b>11</b>, compounds <b>12</b> (TAK632),<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a><b>13</b> (MLN2480/TAK580),<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> (Takeda/Millennium) and <b>25</b> (CCT-3833/BAL3833)<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> (ICR/Basilea) are equipotent inhibitors of BRAF dimers and monomers.<a onclick="showRef(event, 'ref40 ref50'); return false;" href="javascript:void(0);" class="ref ref40 ref50">(40,50)</a> They are therefore expected to induce the αC-IN/DFG-OUT conformation and bind to both protomers of BRAF dimer.</div><div class="NLM_p">The benzothiazole derivative <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) has been effective in multiple cancers harboring RAS mutations,<a onclick="showRef(event, 'ref40 ref50'); return false;" href="javascript:void(0);" class="ref ref40 ref50">(40,50)</a> in vemurafenib-resistant melanomas, and in BRAFV600E colorectal or thyroid tumors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a><b>12</b> is a potent inhibitor of BRAFV600E (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>); however it also inhibits BRAFWT (IC<sub>50</sub> = 8.3 nM) and CRAF (IC<sub>50</sub> = 1.4 nM). <b>12</b> demonstrated strong antiproliferative activity in HMVII cells (BRAFG469V, NRAS mutant) resistant to <b>5</b>, which is thought to be mediated by BRAFWT and CRAF.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In a human melanoma xenograft model (A375, BRAFV600E) in nude rats, <b>12</b> exhibited dose-dependent antitumor efficacy without severe body weight reduction over a dose range of 3.9–24.1 mg/kg. In the same study, the pharmacokinetic profile of <b>12</b> showed significant oral absorption (<i>F</i> = 51% at dose 25 mg/kg)<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The X-ray crystal structure of <b>12</b> in complex with BRAFWT demonstrated type II binding for the inhibitor. The benzothiozole group makes specific H-bonds to the hinge residues in the adenine site and the phenylacetamide linker interacts with residue E501 and the backbone of residue G592 before the DFG (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b). As expected for a type II binder, the trifluoromethylphenyl moiety of <b>12</b> inserts into the type II hydrophobic pocket. The cyano substitution points into the ribose pocket.</div><div class="NLM_p"><b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), a pyrimidine derivative, has advanced in phase I clinical trials for patients with melanomas and other tumors<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> as well as in combinatorial trials with small molecule kinase inhibitors, chemotherapy, and therapeutic antibodies.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> A recent study using neuronal cells expressing mutated BRAF showed that <b>13</b> inhibits both BRAF monomers and dimers and does not elicit strong paradoxical activation.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> In a clinical study with patients with relapsed or refractory tumors, <b>13</b> exhibited rapid absorption (median <i>T</i><sub>max</sub> of 2 h), low fluctuation at steady state (mean peak to trough ratio 2.1), and mean accumulation half-life of 67 h, with acceptable safety profile.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> A BRAF structure with <b>13</b> has not been reported; however, based on its chemical structure, <b>13</b> is expected to be a type II inhibitor, whereby the pyrimidine group recognizes the kinase hinge and the trifluoromethylpyridine moiety inserts into the type II pocket.</div><div class="NLM_p"><b>14</b> (CCT196969) and <b>15</b> (CCT241161) are similar pyridopyrazine derivatives (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Both compounds are RAF and sarcoma kinase (SRC) inhibitors and display antiproliferative activity in BRAFV600E melanomas and colorectal malignancies as well as in tumors resistant to second generation RAF inhibitors.<a onclick="showRef(event, 'ref51 ref91 ref96'); return false;" href="javascript:void(0);" class="ref ref51 ref91 ref96">(51,91,96)</a> Structurally, the pyridopyrazine moiety of these compounds is expected to contact the hinge of BRAF and the butylphenylpyrazole end to recognize the type II pocket; however this has not been shown experimentally by X-ray crystallography. These compounds do not drive paradoxical pathway activation and inhibit the growth of tumors resistant to compound <b>4</b> (A375 xenograft model), without causing adverse effects to the mice.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><b>14</b> and <b>15</b> have not yet progressed to clinical trials; however <b>25</b>, a parent compound of the same chemical series which blocks both CRAF and BRAF, has entered phase I clinical trials for BRAF mutant and BRAF inhibitor-resistant melanomas.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> However, chemical details or the structure of <b>25</b> have not been disclosed.</div><div class="NLM_p">On the basis of an original report on new tetrahydronaphthalene RAF inhibitors,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> the Chinese company Beigene developed the naphthyridine compound <b>16</b> (BGB659) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), another αC-IN/DFG-OUT third generation RAF inhibitor that displays inhibition of both BRAF dimers and monomers.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Because of the ability of <b>16</b> to bind to both protomers of BRAF dimer, it evades paradoxical activation and inhibits V600 and non-V600-dependent melanomas as well as melanomas resistant to <b>1</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> A cyclopropabenzofuran derivative compound from the same company, <b>17</b> (BGB283) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), inhibits BRAF and EGFR and is effective in BRAFV600E colorectal tumors.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In a recent study, 15 tumor cell lines with mutant BRAF (bearing mutations BRAFV600E, BRAFV600K, BRAF mutants that constitutively dimerize and p61-BRAFV600E) were sensitive to <b>16</b> with IC<sub>50</sub> values from 100 to 600 nM.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In subcutaneous murine xenografts studies carrying SK-MEL-239 (BRAF monomer) and SK-MEL-239 C4 (BRAF dimer) melanoma tumors <b>16</b> given daily (100 mg/kg) effectively inhibited growth, with no toxicity to other organs.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> BGB-283 has been shown to be a pan-RAF inhibitor, inhibiting BRAFV600E (IC<sub>50</sub> = 23 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), BRAFWT (IC<sub>50</sub> = 32 nM), CRAF (IC<sub>50</sub> = 7 nM), and ARAF (IC<sub>50</sub> = 5.6 nM).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In vivo, <b>17</b> was efficient in suppressing tumor growth in xenograft models of HCC827 lung carcinoma (dose 10 mg/kg b.i.d.), COLO205 colorectal cancer harboring the BRAFV600E mutation (dose 30 mg/kg b.i.d.), and human derived (PDX) colorectal cancer. <b>17</b> has entered phase I clinical trials.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> A recent BRAF crystal structure with <b>17</b> demonstrated typical αC-IN/DFG-OUT, type II inhibitor binding (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>d) with the naphthyridine ring occupying the adenine site, while the benzimidazole group, which makes a specific H-bond to E501, inserts into the type II pocket.</div><div class="NLM_p">RAF inhibitors developed from Novartis, replaced the urea linker of <b>1</b> with an aminoimidazole bioisostere group.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> A dipyridine derivative <b>18</b> (RAF709)<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> and a benzimidazole derivative <b>19</b> (RAF265/CHIR-265)<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) are lead compounds of this series. <b>18</b> inhibits BRAFWT (IC<sub>50</sub> = 0.4 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and CRAF (IC<sub>50</sub> = 0.5 nM) with similar potency. This high potency is attributed to very slow dissociation kinetics (<i>T</i><sub>1/2</sub> > 6.5 h).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> However, moderate inhibition of proliferation of Calu-6 cells was observed for this compound (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). By use of a Calu-6 xenograft nude mouse model, compound <b>18</b> was well tolerated on doses up to 200 mg/kg showing a maximum tumor regression of 92%.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> A recent X-ray structure of the structurally diverse <b>18</b> with BRAFWT demonstrated specific protein contacts in all available pockets of the active site, with the morpholino group recognizing the hinge at the adenine pocket, the pyridine moiety extending into the ribose site, and the benzamide linker H-bonding to E501 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>c). Interestingly, <b>18</b> induces a partial structuring of the α-loop which positions residue W604 in proximity to the type II pocket, where it creates van der Waals contacts to the terminal trifluoromethylphenyl group of the inhibitor (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>c). This extensive network of contacts probably explains the very low IC<sub>50</sub> of kinase inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and the slow dissociation kinetics. <b>19</b> is a potent inhibitor of BRAFV600E (IC<sub>50</sub> of 0.5 nM, see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, in comparison to IC<sub>50</sub> of 70 nM and 19 nM for BRAFWT and CRAF, respectively), displaying long half-life in PK studies and pronounced tumor growth inhibition in a A375M xenograft model.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Phase I clinical trials on subjects with various tumors are ongoing for compound <b>19</b>.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The BRAFWT-<b>19</b> cocrystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CT7">5CT7</a>) shows that the imidazolopyridine group docks in the adenine pocket and the amine linker of the benzimidazole creates a typical type II inhibitor H-bond with E501. <b>19</b> and <b>18</b> induce the αC-IN/DFG-OUT conformation.</div><div class="NLM_p">In contrast to the above group of compounds, certain third generation inhibitors are αC-OUT inducers. aC-OUT paradox breakers comprise a distinct group among them. Typical members include azaindole derivatives developed by Plexxikon: <b>20</b> (PLX7904/PB04)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and its analog <b>21</b> (PLX8394/PB03)<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). These molecules are more potent than <b>5</b> in targeting BRAFV600E.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> They are type I<sup>1</sup>/<sub>2</sub> inhibitors with terminal sulfonamides, resembling <b>5</b> and <b>6</b>; however the sulfonamide substitutions are bulkier. In contrast to αC-IN paradox breakers, like inhibitors from Beigene (see above), these compounds circumvent paradoxical activation because they do not induce RAF dimers.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Data suggest that because of their higher potency against BRAF compared to clinically used <b>5</b> (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), these inhibitors are effective in a number of tumors.<a onclick="showRef(event, 'ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref105 ref106">(105,106)</a> However, in vivo, <b>20</b> and <b>5</b> produced similar antitumor effects in a subcutaneous COLO205 xenograft model (doses 25 mg/kg twice daily) and good plasma exposures.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The structure of <b>20</b> in complex with BRAF (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV1">4XV1</a>) confirmed stabilization of αC-helix in the OUT conformation;<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> however this position is further OUT as opposed to the one observed with <b>5</b>, a result of van der Waals contacts of the terminal ethylmethylsulfamoyl group with L505 of αC-helix (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>d). Interestingly, L505 is one of the four residues of the kinase R-spine (see above). As a consequence, <b>20</b>, as most members of this series, binds only one BRAF protomer. This demonstrates that as with all αC-OUT inhibitors, the clinical effectiveness of paradox breakers will be limited by RAF dimerization.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The binding mode of <b>20</b> in the BRAF active site (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>d) is typical for a type I<sup>1</sup>/<sub>2</sub> inhibitor; the azaindole ring serves as the hinge binder and the terminal sulfonamide moiety recognizes the type I pocket, while the cyclopropylpyrimidine extends to the solvent.</div><div class="NLM_p">The preclinical efficiency of compound <b>21</b> was tested in vivo against lung cancer tumors with non-V600 mutant BRAF (BRAFG469A) in a xenograft model using H1755 cells insensitive to <b>5</b> treatment. <b>21</b> suppressed effectively tumor growth in these xenograft tumors with no overt toxicity in mice treated at a dose of 150 mg/kg per day.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a><b>21</b> is undergoing phase 1 clinical trial.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><div class="NLM_p">A few third generation BRAF inhibitors, for which limited chemical and functional data are reported and crystallographic information is lacking, are undergoing clinical trials. <b>22</b> (CEP-32496)<a onclick="showRef(event, 'ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref108 ref109">(108,109)</a> (Ambit Bio/Ignyta), a quinazolinyloxydiarylurea BRAF and multikinase inhibitor (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), is cytotoxic to cell lines harboring BRAFV600E.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Compound <b>22</b> also demonstrated significant oral efficacy in a 14-day human COLO-205 (BRAFV600E) tumor xenograft mouse model. In the same xenograft experiment, <b>22</b> dosed at 30 mg/kg exhibited tumor stasis and a 40% incidence of partial tumor regressions.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a><b>22</b> is under phase I clinical evaluation in patients with solid malignancies.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a><b>23</b> (HM95573) (Hanmi Pharmaceutical/Genentech) is currently in an expansion clinical trial in patients with advanced solid tumors harboring mutations in BRAF and RAS.<a onclick="showRef(event, 'ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113">(111−113)</a> Lastly, a compound from Novartis, <b>24</b> (LXH254), is an equipotent BRAF monomer–dimer inhibitor currently in clinical phase I development.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The chemical structures of <b>23</b> and <b>24</b> have not been disclosed.</div><div class="NLM_p last">Finally, a number of BRAF structures with additional selective and nonselective BRAF inhibitors are available in the PDB. Most of these inhibitors are derivatives of inhibitors discussed here. Noteworthy among them is a purinylpyridinylamino-based inhibitor crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FD2">5FD2</a>) showing both inhibitor-bound BRAFWT dimer and monomer,<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> a low paradoxical activating diarylthiazole inhibitor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CQE">4CQE</a>),<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> and a nonhinge binding pyrazolopyrimidine inhibitor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3II5">3II5</a>).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Challenges and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The development of BRAF inhibitors of variable chemical classes has progressed significantly in the past few years. This fast pace has been supported by technologies that allowed prompt crystallization of BRAF kinase domain constructs, which brought an explosive growth in BRAF-inhibitor complex structures. Structure-guided design efforts helped in the design of the second generation FDA-approved inhibitors <b>5</b> and <b>6</b> (αC-OUT), which displayed remarkable clinical results and improved survival of patients with BRAFV600E melanoma tumors. However, resistance limits their clinical value.</div><div class="NLM_p">Many challenges in the design of RAF inhibitors with desirable clinical properties remain. αC-OUT first and second generation BRAF inhibitors are highly selective for tumors dependent on monomeric BRAF species and therefore display a wide therapeutic window. However, they suffer from negative allostery and paradoxical activation and are ineffective against malignancies driven by dimer BRAF mutants. In an effort to bypass resistance to αC-OUT inhibitors and achieve potent and durable inhibition of ERK signaling, combinatory regimes containing a mix of BRAF inhibitors and inhibitors of downstream MEK kinase have recently been developed, demonstrating superior efficacy over RAF inhibitor monotherapies. These efforts resulted in two clinically approved combinations, <b>6</b> with trametinib<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> (Novartis/GSK, FDA approved in 2014) and <b>5</b> with cobimetinib<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> (Roche/Genentech, FDA approved in 2015). These combinations are currently the current standard of care for melanoma patients with BRAFV600E/K mutations. Clinical trials of drug combinations with second generation encorafenib (LGX818, Array BioPharma) are ongoing.<a onclick="showRef(event, 'ref120 ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref120 ref121 ref122">(120−122)</a></div><div class="NLM_p last">Third generation, αC-IN, RAF inhibitors should overcome resistance due to RAF dimerization by occupying both protomers of RAF dimers and be effective in a broad range of non-BRAFV600 or RAS-dependent tumors. However, they display allosteric priming and possibly a narrow therapeutic window in patients because they may also suppress physiological BRAFWT dimers in healthy tissue, as suggested by preclinical data.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> On the other hand, third generation αC-OUT paradoxical breakers are expected to generate less secondary tumors in normal tissue due to reduced paradoxical ERK activation. Preclinically, they display a wider therapeutic window compared to second generation inhibitors; however their action is refractory to RAF dimerization and they are not predicted to be effective in tumors with non-V600 mutant BRAF. A number of third generation RAF inhibitors are currently in clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Nevertheless, due to their aforementioned preclinical limitations, their eventual clinical use as monotherapies is unclear. Designing αC-OUT RAF inhibitors that avert negative allosteric and paradoxical activation will be challenging; however, adding small doses of αC-IN inhibitors to currently used RAF-MEK combinations may be a successful strategy to target both BRAFV600E monomers and non-V600 dimers in the same tumors.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Alternatively, superior type II, αC-IN, inhibitors that bind and effectively inhibit at the same time both promoters of BRAF dimer and BRAF monomers may be developed in the future. Finally, another avenue in RAF inhibitor design may explore non-ATP competitive inhibitors that allosterically prevent RAF dimerization or suppress priming via suppressing RAS binding to the BRAF N-terminal inhibitory domain or prevent BRAF-CRAF heterodimerization. Peptide BRAF dimerization breakers have been reported;<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> however whether this can be achieved with small molecules remains to be determined. Hopefully, further insights on allosteric transitions of RAF kinases upon inhibitor binding and chemical intuition will provide the next generation of RAF inhibitors.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01306" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bogos Agianian</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry
and Department of Medicine, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5c7cac2cad68bc4c2ccc4cbccc4cbe5c0cccbd6d1c0cccb8bdcd08bc0c1d0"><span class="__cf_email__" data-cfemail="ccaea3aba3bfe2adaba5ada2a5ada28ca9a5a2bfb8a9a5a2e2b5b9e2a9a8b9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Evripidis Gavathiotis</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry
and Department of Medicine, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6319-8331" title="Orcid link">http://orcid.org/0000-0001-6319-8331</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7c190a0e150c1518150f521b1d0a1d0814151308150f3c1915120f0819151252050952191809"><span class="__cf_email__" data-cfemail="741102061d041d101d075a13150215001c1d1b001d0734111d1a0700111d1a5a0d015a111001">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24357" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24357" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Bogos Agianian</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=BIO-d7e3595-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Bogos Agianian</b>, Ph.D., is a Research Assistant Professor at Albert Einstein College of Medicine. He completed his doctoral studies in Biophysics at the European Molecular Biology Laboratory (EMBL) and received his Ph.D. from Heidelberg University. He was a postdoctoral fellow at the Bijvoet Center for Biomolecular Research and a Marie Curie fellow at EMBL. His research focuses on rational small-molecule drug design and structural mechanisms in allosteric regulation of pharmacologically important proteins.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Evripidis Gavathiotis</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=BIO-d7e3600-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Evripidis Gavathiotis</b>, Ph.D., is an Associate Professor of Biochemistry and Medicine at the Albert Einstein College of Medicine. He received his Ph.D. in Chemistry from the University of Nottingham, U.K., for studies on biomolecular structure and molecular recognition. He worked at De Novo Pharmaceuticals, applying in silico drug design to several therapeutic targets. He pursued postdoctoral studies at Rockefeller University and Dana Farber Cancer Institute/Harvard Medical School on chemical and structural biology of apoptosis signaling. His research program focuses on the use of chemical biology, structural biology, and drug discovery to investigate molecular mechanisms of oncogenic signaling pathways regulating cell survival and cell death and the development of new therapeutics.</p></figure></div><div class="ack" id="ACK-d7e3588-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Poulikos Poulikakos for stimulating discussions and collaborative work on BRAF inhibitors. We acknowledge the support from the Melanoma Research Alliance and the Irma T. Hirschl Trust.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">α-loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">AS</td><td class="NLM_def"><p class="first last">activation segment</p></td></tr><tr><td class="NLM_term">CPK</td><td class="NLM_def"><p class="first last">Corey–Pauling–Koltun</p></td></tr><tr><td class="NLM_term">C-spine</td><td class="NLM_def"><p class="first last">catalytic spine</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">IRE1α</td><td class="NLM_def"><p class="first last">inositol requiring enzyme 1α</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung carcinomas</p></td></tr><tr><td class="NLM_term">NTD</td><td class="NLM_def"><p class="first last">N-terminal domain</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient-derived xenograft</p></td></tr><tr><td class="NLM_term">pERK</td><td class="NLM_def"><p class="first last">phospho-ERK</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">p-loop</td><td class="NLM_def"><p class="first last">proline rich loop</p></td></tr><tr><td class="NLM_term">pMEK</td><td class="NLM_def"><p class="first last">phospho-MEK</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">rat sarcoma</p></td></tr><tr><td class="NLM_term">RDB</td><td class="NLM_def"><p class="first last">RAS-binding domain</p></td></tr><tr><td class="NLM_term">R-spine</td><td class="NLM_def"><p class="first last">regulator spine</p></td></tr><tr><td class="NLM_term">SRC</td><td class="NLM_def"><p class="first last">sarcoma kinase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 128 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wellbrock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasarides, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">The RAF Proteins Take Centre Stage</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1038/nrm1498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrm1498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=15520807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=875-885&issue=11&author=C.+Wellbrockauthor=M.+Karasaridesauthor=R.+Marais&title=The+RAF+Proteins+Take+Centre+Stage&doi=10.1038%2Fnrm1498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF proteins take center stage</span></div><div class="casAuthors">Wellbrock, Claudia; Karasarides, Maria; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">875-885</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their discovery over 20 years ago, the RAF proteins have been intensely studied.  For most of that time, the focus of the field has been the C-RAF isoform and its role as an effector of the RAS proteins.  However, a report that implicates B-RAF in human cancer has highlighted the importance of all members of this protein kinase family and recent studies have uncovered intriguing new data relating to their complex regulation and biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvN4GggcdfU7Vg90H21EOLACvtfcHk0lh4U7yZObNL8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D&md5=95f0a579b4c852fbe80a54befb88b052</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm1498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1498%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DKarasarides%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DThe%2520RAF%2520Proteins%2520Take%2520Centre%2520Stage%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26issue%3D11%26spage%3D875%26epage%3D885%26doi%3D10.1038%2Fnrm1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">New Perspectives for Targeting RAF Kinase in Human Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28984291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=676-691&issue=11&author=Z.+Karouliaauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=New+Perspectives+for+Targeting+RAF+Kinase+in+Human+Cancer&doi=10.1038%2Fnrc.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives for targeting RAF kinase in human cancer</span></div><div class="casAuthors">Karoulia, Zoi; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">676-691</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The discovery that a subset of human tumors is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics.  The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and improved survival of patients with BRAF-V600E/K melanoma, but their effectiveness is limited by resistance.  Beyond melanoma, current clin. RAF inhibitors show modest efficacy when used for colorectal and thyroid BRAF-V600E tumors or for tumors harboring BRAF alterations other than the V600 mutation.  Accumulated exptl. and clin. evidence indicates that the complex biochem. mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumor resistance to them.  Recently, a no. of next-generation RAF inhibitors, with diverse structural and biochem. properties, have entered preclin. and clin. development.  In this Review, we discuss the current understanding of RAF kinase regulation, mechanisms of inhibitor action and related clin. resistance to these drugs.  The recent elucidation of crit. structural and biochem. aspects of RAF inhibitor action, combined with the availability of a no. of structurally diverse RAF inhibitors currently in preclin. and clin. development, will enable the design of more effective RAF inhibitors and RAF-inhibitor-based therapeutic strategies, tailored to different clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUrKAljS7SrVg90H21EOLACvtfcHk0lh5nDTH33rZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN&md5=7e8ee4222467a2d5c12b23ccce99fc62</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DNew%2520Perspectives%2520for%2520Targeting%2520RAF%2520Kinase%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D11%26spage%3D676%26epage%3D691%26doi%3D10.1038%2Fnrc.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Regulation of RAF Protein Kinases in ERK Signalling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/nrm3979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrm3979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25907612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=281-298&issue=5&author=H.+Lavoieauthor=M.+Therrien&title=Regulation+of+RAF+Protein+Kinases+in+ERK+Signalling&doi=10.1038%2Fnrm3979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of RAF protein kinases in ERK signalling</span></div><div class="casAuthors">Lavoie, Hugo; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">281-298</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF family kinases were among the first oncoproteins to be described more than 30 years ago.  They primarily act as signalling relays downstream of RAS, and their close ties to cancer have fuelled a large no. of studies.  However, we still lack a systems-level understanding of their regulation and mode of action.  The recent discovery that the catalytic activity of RAF depends on an allosteric mechanism driven by kinase domain dimerization is providing a vital new piece of information towards a comprehensive model of RAF function.  The fact that current RAF inhibitors unexpectedly induce ERK signalling by stimulating RAF dimerization also calls for a deeper structural characterization of this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzK227mPD3rVg90H21EOLACvtfcHk0lh5nDTH33rZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D&md5=1f4c4fbbacb1e3d790b81dbb027520b9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3979%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520RAF%2520Protein%2520Kinases%2520in%2520ERK%2520Signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26issue%3D5%26spage%3D281%26epage%3D298%26doi%3D10.1038%2Fnrm3979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS-ERK Signalling in Cancer: Promises and Challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1038/nrd4281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&issue=12&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS-ERK+Signalling+in+Cancer%3A+Promises+and+Challenges&doi=10.1038%2Fnrd4281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0lh5nDTH33rZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS-ERK%2520Signalling%2520in%2520Cancer%253A%2520Promises%2520and%2520Challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D12%26spage%3D928%26epage%3D942%26doi%3D10.1038%2Fnrd4281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3291</span>– <span class="NLM_lpage">3310</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&issue=22&author=P.%0AJ.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+Mitogen-Activated+Protein+Kinase+Cascade+for+the+Treatment+of+Cancer&doi=10.1038%2Fsj.onc.1210422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0lhQZ8E6GLkyhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520Mitogen-Activated%2520Protein%2520Kinase%2520Cascade%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D22%26spage%3D3291%26epage%3D3310%26doi%3D10.1038%2Fsj.onc.1210422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woffendin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayatilake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusterson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard-Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevix-Trench, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigler, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations of the BRAF Gene in Human Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span> (<span class="NLM_issue">6892</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&issue=6892&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+Gene+in+Human+Cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lhQZ8E6GLkyhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520Gene%2520in%2520Human%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26issue%3D6892%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucek, L.</span></span> <span> </span><span class="NLM_article-title">Drugging the “undruggable” Cancer Targets</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc.2017.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28643779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVChu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=502-508&issue=8&author=C.+V.+Dangauthor=E.+P.+Reddyauthor=K.+M.+Shokatauthor=L.+Soucek&title=Drugging+the+%E2%80%9Cundruggable%E2%80%9D+Cancer+Targets&doi=10.1038%2Fnrc.2017.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the 'undruggable' cancer targets</span></div><div class="casAuthors">Dang, Chi V.; Reddy, E. Premkumar; Shokat, Kevan M.; Soucek, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">502-508</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The term 'undruggable' was coined to describe proteins that could not be targeted pharmacol.  However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'.  Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacol. targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies.  In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoElcMCmqGx_rVg90H21EOLACvtfcHk0lhQZ8E6GLkyhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVChu7jP&md5=774da7ed04931a3fd3689eb9acea594a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.36%26sid%3Dliteratum%253Aachs%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSoucek%26aufirst%3DL.%26atitle%3DDrugging%2520the%2520%25E2%2580%259Cundruggable%25E2%2580%259D%2520Cancer%2520Targets%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D8%26spage%3D502%26epage%3D508%26doi%3D10.1038%2Fnrc.2017.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajakulendran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefrançois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">A Dimerization-Dependent Mechanism Drives RAF Catalytic Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span> (<span class="NLM_issue">7263</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/nature08314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature08314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=19727074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=542-545&issue=7263&author=T.+Rajakulendranauthor=M.+Sahmiauthor=M.+Lefran%C3%A7oisauthor=F.+Sicheriauthor=M.+Therrien&title=A+Dimerization-Dependent+Mechanism+Drives+RAF+Catalytic+Activation&doi=10.1038%2Fnature08314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A dimerization-dependent mechanism drives RAF catalytic activation</span></div><div class="casAuthors">Rajakulendran, Thanashan; Sahmi, Malha; Lefrancois, Martin; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7263</span>),
    <span class="NLM_cas:pages">542-545</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ERK (extracellular signal-regulated kinase) pathway is an evolutionarily conserved signal transduction module that controls cellular growth, differentiation and survival.  Activation of receptor tyrosine kinases (RTKs) by the binding of growth factors initiates GTP loading of RAS, which triggers the initial steps in the activation of the ERK pathway by modulating RAF family kinase function.  Once activated, RAF participates in a sequential cascade of phosphorylation events that activate MEK, and in turn ERK.  Unbridled signalling through the ERK pathway caused by activating mutations in RTKs, RAS or RAF has been linked to several human cancers.  Of note, one member of the RAF family, BRAF, is the most frequently mutated oncogene in the kinase superfamily.  Not surprisingly, there has been a colossal effort to understand the underlying regulation of this family of kinases.  In particular, the process by which the RAF kinase domain becomes activated towards its substrate MEK remains of topical interest.  Here, using Drosophila Schneider S2 cells, we demonstrate that RAF catalytic function is regulated in response to a specific mode of dimerization of its kinase domain, which we term the side-to-side dimer.  Moreover, we find that the RAF-related pseudo-kinase KSR (kinase suppressor of Ras) also participates in forming side-to-side heterodimers with RAF and can thereby trigger RAF activation.  This mechanism provides an elegant explanation for the longstanding conundrum about RAF catalytic activation and also provides an explanation for the capacity of KSR, despite lacking catalytic function, to directly mediate RAF activation.  We also show that RAF side-to-side dimer formation is essential for aberrant signalling by oncogenic BRAF mutants, and identify an oncogenic mutation that acts specifically by promoting side-to-side dimerization.  Together, our data identify the side-to-side dimer interface of RAF as a potential therapeutic target for intervention in BRAF-dependent tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbnxNSbvudjbVg90H21EOLACvtfcHk0lj3_4gakOodVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI&md5=2248d71ce37a2bac4e508a1097e95cba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08314%26sid%3Dliteratum%253Aachs%26aulast%3DRajakulendran%26aufirst%3DT.%26aulast%3DSahmi%26aufirst%3DM.%26aulast%3DLefran%25C3%25A7ois%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DA%2520Dimerization-Dependent%2520Mechanism%2520Drives%2520RAF%2520Catalytic%2520Activation%26jtitle%3DNature%26date%3D2009%26volume%3D461%26issue%3D7263%26spage%3D542%26epage%3D545%26doi%3D10.1038%2Fnature08314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&issue=2&author=S.%0AJ.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-Dead+BRAF+and+Oncogenic+RAS+Cooperate+to+Drive+Tumor+Progression+through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0lj3_4gakOodVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-Dead%2520BRAF%2520and%2520Oncogenic%2520RAS%2520Cooperate%2520to%2520Drive%2520Tumor%2520Progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D2%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiala, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhardt, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummer, T.</span></span> <span> </span><span class="NLM_article-title">Distinct Requirement for an Intact Dimer Interface in Wild-Type, V600E and Kinase-Dead B-Raf Signalling</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2629</span>– <span class="NLM_lpage">2647</span>, <span class="refDoi"> DOI: 10.1038/emboj.2012.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Femboj.2012.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=2629-2647&issue=11&author=M.+R%C3%B6ringauthor=R.+Herrauthor=G.+J.+Fialaauthor=K.+Heilmannauthor=S.+Braunauthor=A.+E.+Eisenhardtauthor=S.+Halbachauthor=D.+Capperauthor=A.+von+Deimlingauthor=W.+W.+Schamelauthor=D.+N.+Saundersauthor=T.+Brummer&title=Distinct+Requirement+for+an+Intact+Dimer+Interface+in+Wild-Type%2C+V600E+and+Kinase-Dead+B-Raf+Signalling&doi=10.1038%2Femboj.2012.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.100%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6ring%26aufirst%3DM.%26aulast%3DHerr%26aufirst%3DR.%26aulast%3DFiala%26aufirst%3DG.%2BJ.%26aulast%3DHeilmann%26aufirst%3DK.%26aulast%3DBraun%26aufirst%3DS.%26aulast%3DEisenhardt%26aufirst%3DA.%2BE.%26aulast%3DHalbach%26aufirst%3DS.%26aulast%3DCapper%26aufirst%3DD.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DSchamel%26aufirst%3DW.%2BW.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26aulast%3DBrummer%26aufirst%3DT.%26atitle%3DDistinct%2520Requirement%2520for%2520an%2520Intact%2520Dimer%2520Interface%2520in%2520Wild-Type%252C%2520V600E%2520and%2520Kinase-Dead%2520B-Raf%2520Signalling%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D31%26issue%3D11%26spage%3D2629%26epage%3D2647%26doi%3D10.1038%2Femboj.2012.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.molcel.2005.10.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=963-969&issue=6&author=M.+J.+Garnettauthor=S.+Ranaauthor=H.+Patersonauthor=D.+Barfordauthor=R.+Marais&title=Wild-Type+and+Mutant+B-RAF+Activate+C-RAF+through+Distinct+Mechanisms+Involving+Heterodimerization&doi=10.1016%2Fj.molcel.2005.10.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DWild-Type%2520and%2520Mutant%2520B-RAF%2520Activate%2520C-RAF%2520through%2520Distinct%2520Mechanisms%2520Involving%2520Heterodimerization%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26issue%3D6%26spage%3D963%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2005.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">RAF Protein-Serine/Threonine Kinases: Structure and Regulation</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>399</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2010.07.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bbrc.2010.07.092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=399&publication_year=2010&pages=313-317&issue=3&author=R.+Roskoski&title=RAF+Protein-Serine%2FThreonine+Kinases%3A+Structure+and+Regulation&doi=10.1016%2Fj.bbrc.2010.07.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2010.07.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2010.07.092%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DRAF%2520Protein-Serine%252FThreonine%2520Kinases%253A%2520Structure%2520and%2520Regulation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2010%26volume%3D399%26issue%3D3%26spage%3D313%26epage%3D317%26doi%3D10.1016%2Fj.bbrc.2010.07.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiello, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergameno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normanno, N.</span></span> <span> </span><span class="NLM_article-title">The RAS/RAF/MEK/ERK and the PI3K/AKT Signalling Pathways: Role in Cancer Pathogenesis and Implications for Therapeutic Approaches</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">Suppl. 2</span>),  <span class="NLM_fpage">S17</span>– <span class="NLM_lpage">S27</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.639361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1517%2F14728222.2011.639361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22443084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XksFWmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=S17-S27&issue=Suppl.+2&author=A.+De%0ALucaauthor=M.+R.+Maielloauthor=A.+D%E2%80%99Alessioauthor=M.+Pergamenoauthor=N.+Normanno&title=The+RAS%2FRAF%2FMEK%2FERK+and+the+PI3K%2FAKT+Signalling+Pathways%3A+Role+in+Cancer+Pathogenesis+and+Implications+for+Therapeutic+Approaches&doi=10.1517%2F14728222.2011.639361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches</span></div><div class="casAuthors">De Luca, Antonella; Maiello, Monica R.; D'Alessio, Amelia; Pergameno, Maria; Normanno, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">S2</span>),
    <span class="NLM_cas:pages">S17-S27</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The RAS/RAF/MAP kinase-ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) (MAPK) and the PI3K/AKT/mammalian target of rapamycin (mTOR) (PI3K) pathways are frequently deregulated in human cancer as a result of genetic alterations in their components or upstream activation of cell-surface receptors.  These signalling cascades are regulated by complex feedback and cross-talk mechanisms.Areas covered: In this review the key components of the MAPK and AKT pathways and their mol. alterations are described.  The complex interactions between these signalling cascades are also analyzed.Expert opinion: The observation that the MAPK and the PI3K pathways are often deregulated in human cancer makes the components of these signalling cascades interesting targets for therapeutic intervention.  Recently, the presence of compensatory loops that activate one pathway following the blockade of the other signalling cascade has been demonstrated.  Therefore, the blockade of both pathways with combinations of signalling inhibitors might result in a more efficient anti-tumor effect as compared with a single agent.  In addn., the MAPK and PI3K pathways are activated by mutations that coexist or can be mutually exclusive.  In this regard, a large-scale characterization of the cancer genome might offer personalized cancer genomic information, which may improve the anti-tumor efficacy of signalling inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2jyP6LXY3vrVg90H21EOLACvtfcHk0ljylnMhvLCpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksFWmt70%253D&md5=4a83930e8d8554a97e33eec64f76a814</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.639361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.639361%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DMaiello%26aufirst%3DM.%2BR.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DA.%26aulast%3DPergameno%26aufirst%3DM.%26aulast%3DNormanno%26aufirst%3DN.%26atitle%3DThe%2520RAS%252FRAF%252FMEK%252FERK%2520and%2520the%2520PI3K%252FAKT%2520Signalling%2520Pathways%253A%2520Role%2520in%2520Cancer%2520Pathogenesis%2520and%2520Implications%2520for%2520Therapeutic%2520Approaches%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26issue%3DSuppl.%25202%26spage%3DS17%26epage%3DS27%26doi%3D10.1517%2F14728222.2011.639361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Hyperactive Ras in Developmental Disorders and Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1038/nrc2109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc2109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=17384584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=295-308&issue=4&author=S.+Schubbertauthor=K.+Shannonauthor=G.+Bollag&title=Hyperactive+Ras+in+Developmental+Disorders+and+Cancer&doi=10.1038%2Fnrc2109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactive Ras in developmental disorders and cancer</span></div><div class="casAuthors">Schubbert, Suzanne; Shannon, Kevin; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-308</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ras genes are the most common targets for somatic gain-of-function mutations in human cancer.  Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Nonan, Costello and cardio-facio-cutaneous syndromes.  Many of these mutant alleles encode proteins with aberrant biochem. and functional properties.  Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRvjqrp1ho7Vg90H21EOLACvtfcHk0ljylnMhvLCpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D&md5=25fcaa959dae5e8512b959936bcbb347</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc2109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2109%26sid%3Dliteratum%253Aachs%26aulast%3DSchubbert%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DHyperactive%2520Ras%2520in%2520Developmental%2520Disorders%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D4%26spage%3D295%26epage%3D308%26doi%3D10.1038%2Fnrc2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">(V600E)BRAF Is Associated with Disabled Feedback Inhibition of RAF-MEK Signaling and Elevated Transcriptional Output of the Pathway</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4519</span>– <span class="NLM_lpage">4524</span>, <span class="refDoi"> DOI: 10.1073/pnas.0900780106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.0900780106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=4519-4524&issue=11&author=C.%0AA.+Pratilasauthor=B.+S.+Taylorauthor=Q.+Yeauthor=A.+Vialeauthor=C.+Sanderauthor=D.+B.+Solitauthor=N.+Rosen&title=%28V600E%29BRAF+Is+Associated+with+Disabled+Feedback+Inhibition+of+RAF-MEK+Signaling+and+Elevated+Transcriptional+Output+of+the+Pathway&doi=10.1073%2Fpnas.0900780106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0900780106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0900780106%26sid%3Dliteratum%253Aachs%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3D%2528V600E%2529BRAF%2520Is%2520Associated%2520with%2520Disabled%2520Feedback%2520Inhibition%2520of%2520RAF-MEK%2520Signaling%2520and%2520Elevated%2520Transcriptional%2520Output%2520of%2520the%2520Pathway%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D11%26spage%3D4519%26epage%3D4524%26doi%3D10.1073%2Fpnas.0900780106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group">Cancer Genome Project.</span> <span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&issue=6&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Maraisauthor=Cancer+Genome+Project.&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lj0ga87Of7jjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3D%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26issue%3D6%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayfield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2016.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26996308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=477-493&issue=4&author=S.+A.+Fosterauthor=D.+M.+Whalenauthor=A.+%C3%96zenauthor=M.+J.+Wongchenkoauthor=J.+Yinauthor=I.+Yenauthor=G.+Schaeferauthor=J.+D.+Mayfieldauthor=J.+Chmieleckiauthor=P.+J.+Stephensauthor=L.+A.+Albackerauthor=Y.+Yanauthor=K.+Songauthor=G.+Hatzivassiliouauthor=C.+Eigenbrotauthor=C.+Yuauthor=A.+S.+Shawauthor=G.+Manningauthor=N.+J.+Skeltonauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Activation+Mechanism+of+Oncogenic+Deletion+Mutations+in+BRAF%2C+EGFR%2C+and+HER2&doi=10.1016%2Fj.ccell.2016.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2</span></div><div class="casAuthors">Foster, Scott A.; Whalen, Daniel M.; Ozen, Aysegul; Wongchenko, Matthew J.; Yin, Jian Ping; Yen, Ivana; Schaefer, Gabriele; Mayfield, John D.; Chmielecki, Juliann; Stephens, Philip J.; Albacker, Lee A.; Yan, Yibing; Song, Kyung; Hatzivassiliou, Georgia; Eigenbrot, Charles; Yu, Christine; Shaw, Andrey S.; Manning, Gerard; Skelton, Nicholas J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-493</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activating mutations in protein kinases drive many cancers.  While how recurring point mutations affect kinase activity has been described, the effect of in-frame deletions is not well understood.  We show that oncogenic deletions within the β3-αC loop of HER2 and BRAF are analogous to the recurrent EGFR exon 19 deletions.  We identify pancreatic carcinomas with BRAF deletions mutually exclusive with KRAS mutations.  Crystal structures of BRAF deletions reveal the truncated loop restrains αC in an active "in" conformation, imparting resistance to inhibitors like vemurafenib that bind the αC "out" conformation.  Characterization of loop length explains the prevalence of five amino acid deletions in BRAF, EGFR, and HER2 and highlights the importance of this region for kinase activity and inhibitor efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObiwE2cwFlbVg90H21EOLACvtfcHk0lj0ga87Of7jjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D&md5=7aad1cea6f17f2b74c42fbc3c1c9b0fd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DWhalen%26aufirst%3DD.%2BM.%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DMayfield%26aufirst%3DJ.%2BD.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DAlbacker%26aufirst%3DL.%2BA.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DManning%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DActivation%2520Mechanism%2520of%2520Oncogenic%2520Deletion%2520Mutations%2520in%2520BRAF%252C%2520EGFR%252C%2520and%2520HER2%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26issue%3D4%26spage%3D477%26epage%3D493%26doi%3D10.1016%2Fj.ccell.2016.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holderfield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuker, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, M.</span></span> <span> </span><span class="NLM_article-title">Targeting RAF Kinases for Cancer Therapy: BRAF-Mutated Melanoma and Beyond</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1038/nrc3760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc3760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24957944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=455-467&issue=7&author=M.+Holderfieldauthor=M.+M.+Deukerauthor=F.+McCormickauthor=M.+McMahon&title=Targeting+RAF+Kinases+for+Cancer+Therapy%3A+BRAF-Mutated+Melanoma+and+Beyond&doi=10.1038%2Fnrc3760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond</span></div><div class="casAuthors">Holderfield, Matthew; Deuker, Marian M.; McCormick, Frank; McMahon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of mutationally activated BRAF in many cancers altered our conception of the part played by the RAF family of protein kinases in oncogenesis.  In this Review, we describe the development of BRAF inhibitors and the results that have emerged from their anal. in both the lab. and the clinic.  We discuss the spectrum of RAF mutations in human cancer and the complex interplay between the tissue of origin and the response to RAF inhibition.  Finally, we enumerate mechanisms of resistance to BRAF inhibition that have been characterized and postulate how strategies of RAF pathway inhibition may be extended in scope to benefit not only the thousands of patients who are diagnosed annually with BRAF-mutated metastatic melanoma but also the larger patient population with malignancies harboring mutationally activated RAF genes that are ineffectively treated with the current generation of BRAF kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocz-DIK1jK5LVg90H21EOLACvtfcHk0lj0ga87Of7jjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M&md5=d7de7a5409dbb2aefaf3fc9ef6d8f944</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrc3760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3760%26sid%3Dliteratum%253Aachs%26aulast%3DHolderfield%26aufirst%3DM.%26aulast%3DDeuker%26aufirst%3DM.%2BM.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DMcMahon%26aufirst%3DM.%26atitle%3DTargeting%2520RAF%2520Kinases%2520for%2520Cancer%2520Therapy%253A%2520BRAF-Mutated%2520Melanoma%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D7%26spage%3D455%26epage%3D467%26doi%3D10.1038%2Fnrc3760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">BRAF Inhibitors: The Current and the Future</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.coph.2015.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26072431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=68-73&author=W.+Zhang&title=BRAF+Inhibitors%3A+The+Current+and+the+Future&doi=10.1016%2Fj.coph.2015.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF inhibitors: the current and the future</span></div><div class="casAuthors">Zhang, Weijiang</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The introduction of BRAF inhibitors (BRAFi), vemurafenib and dabrafenib, revolutionized BRAFV600-mutated metastatic melanoma treatment with improved response rate and overall survival compared to std. chemotherapy.  However, the mechanism related cutaneous toxicity remains a concern.  In addn., intrinsic and acquired resistance remain the key challenges in BRAFi therapy.  Extensive efforts to elucidate the mechanisms have led to an improved understanding of disease biol. and resulted in exploration of multiple new therapeutic options.  While the future looks bright with multiple new therapeutic strategies in exploration and possible new generations of BRAFi, there are questions remaining to be answered to enable more efficient use of BRAFi in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNC7oPN122rrVg90H21EOLACvtfcHk0lipBpNKWWMjZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtL%252FI&md5=8cd005e17d14da7a9a6ee00231fc0b58</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DBRAF%2520Inhibitors%253A%2520The%2520Current%2520and%2520the%2520Future%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D68%26epage%3D73%26doi%3D10.1016%2Fj.coph.2015.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barras, D.</span></span> <span> </span><span class="NLM_article-title">BRAF Mutation in Colorectal Cancer: An Update</span>. <i>Biomarkers Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.4137/BIC.S25248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.4137%2FBIC.S25248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26396549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsFegt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=9-12&issue=Suppl.+1&author=D.+Barras&title=BRAF+Mutation+in+Colorectal+Cancer%3A+An+Update&doi=10.4137%2FBIC.S25248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation in colorectal cancer: an update</span></div><div class="casAuthors">Barras, David</div><div class="citationInfo"><span class="NLM_cas:title">Biomarkers in Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">9-12</span>CODEN:
                <span class="NLM_cas:coden">BCIACZ</span>;
        ISSN:<span class="NLM_cas:issn">1179-299X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica Ltd.</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) is still one of the deadliest cancer-related diseases.  About 10% of CRC patients are characterized by a mutation in the B-Raf proto-oncogene serine/threonine kinase (BRAF) gene resulting in a valine-to-glutamate change at the residue 600 (V600E).  This mutation is also present in more than 60% of melanoma patients.  BRAF inhibitors were developed and found to improve patient survival; however, most patients at the end of the track ultimately develop resistance to these inhibitors.  Melanoma patients benefit from the combination of BRAF inhibitors with mitogen/ extracellular signal-regulated kinase (MEK) inhibitors, among others.  Unfortunately, colorectal patients do not respond much efficiently, which suggests different resistance mechanisms between the two cancer types.  This review aims at shedding light on recent discoveries that improve our understanding of the BRAF mutation biol. in CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpENU5EvBwYYrVg90H21EOLACvtfcHk0lipBpNKWWMjZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsFegt7k%253D&md5=1f075fc24c1a03fb8af91bfc6ff1c530</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4137%2FBIC.S25248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FBIC.S25248%26sid%3Dliteratum%253Aachs%26aulast%3DBarras%26aufirst%3DD.%26atitle%3DBRAF%2520Mutation%2520in%2520Colorectal%2520Cancer%253A%2520An%2520Update%26jtitle%3DBiomarkers%2520Cancer%26date%3D2015%26volume%3D7%26issue%3DSuppl.%25201%26spage%3D9%26epage%3D12%26doi%3D10.4137%2FBIC.S25248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paik, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Clinical Characteristics of Patients with Lung Adenocarcinomas Harboring BRAF Mutations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2046</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.33.1280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1200%2FJCO.2010.33.1280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=21483012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjtFOmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2046-2051&issue=15&author=P.+K.+Paikauthor=M.+E.+Arcilaauthor=M.+Faraauthor=C.+S.+Simaauthor=V.+A.+Millerauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Clinical+Characteristics+of+Patients+with+Lung+Adenocarcinomas+Harboring+BRAF+Mutations&doi=10.1200%2FJCO.2010.33.1280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations</span></div><div class="casAuthors">Paik Paul K; Arcila Maria E; Fara Michael; Sima Camelia S; Miller Vincent A; Kris Mark G; Ladanyi Marc; Riely Gregory J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2046-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  BRAF mutations occur in non-small-cell lung cancer.  Therapies targeting BRAF mutant tumors have recently been identified.  We undertook this study to determine the clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.  PATIENTS AND METHODS:  We reviewed data from consecutive patients with lung adenocarcinoma whose tumors underwent BRAF, EGFR, and KRAS mutation testing as well as fluorescence in situ hybridization for ALK rearrangements.  Patient characteristics including age, sex, race, performance status, smoking history, stage, treatment history, and overall survival were collected.  RESULTS:  Among 697 patients with lung adenocarcinoma, BRAF mutations were present in 18 patients (3%; 95% CI, 2% to 4%).  The BRAF mutations identified were V600E (50%), G469A (39%), and D594G (11%).  Mutations in EGFR were present in 24%, KRAS in 25%, and ALK translocations in 6%.  In contrast to patients with EGFR mutations and ALK rearrangements who were mostly never smokers, all patients with BRAF mutations were current or former smokers (P < .001).  The median overall survival of advanced-stage patients with BRAF mutations was not reached.  In comparison, the median overall survival of patients with EGFR mutations was 37 months (P = .73), with KRAS mutations was 18 months (P = .12), and with ALK rearrangements was not reached (P = .64).  CONCLUSION:  BRAF mutations occur in 3% of patients with lung adenocarcinoma and occur more commonly in current and former smokers.  The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbo-HEAKiAr1MGsG_HTXYFfW6udTcc2eZNRtt_ca1Y8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjtFOmsg%253D%253D&md5=f6d11ddad68bb7698db853a1ebb9431f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.1280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.1280%26sid%3Dliteratum%253Aachs%26aulast%3DPaik%26aufirst%3DP.%2BK.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DFara%26aufirst%3DM.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DClinical%2520Characteristics%2520of%2520Patients%2520with%2520Lung%2520Adenocarcinomas%2520Harboring%2520BRAF%2520Mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D15%26spage%3D2046%26epage%3D2051%26doi%3D10.1200%2FJCO.2010.33.1280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollaee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koduru, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yopp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">Whole-Exome Sequencing of Pancreatic Cancer Defines Genetic Diversity and Therapeutic Targets</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6744</span>, <span class="refDoi"> DOI: 10.1038/ncomms7744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fncomms7744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25855536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2lurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6744&author=A.+K.+Witkiewiczauthor=E.+A.+McMillanauthor=U.+Balajiauthor=G.+Baekauthor=W.-C.+Linauthor=J.+Mansourauthor=M.+Mollaeeauthor=K.-U.+Wagnerauthor=P.+Koduruauthor=A.+Yoppauthor=M.+A.+Chotiauthor=C.+J.+Yeoauthor=P.+McCueauthor=M.+A.+Whiteauthor=E.+S.+Knudsen&title=Whole-Exome+Sequencing+of+Pancreatic+Cancer+Defines+Genetic+Diversity+and+Therapeutic+Targets&doi=10.1038%2Fncomms7744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets</span></div><div class="casAuthors">Witkiewicz, Agnieszka K.; McMillan, Elizabeth A.; Balaji, Uthra; Baek, Guem Hee; Lin, Wan-Chi; Mansour, John; Mollaee, Mehri; Wagner, Kay-Uwe; Koduru, Prasad; Yopp, Adam; Choti, Michael A.; Yeo, Charles J.; McCue, Peter; White, Michael A.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6744</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and insights into both disease etiol. and targeted intervention are needed.  A total of 109 micro-dissected PDA cases were subjected to whole-exome sequencing.  Microdissection enriches tumor cellularity and enhances mutation calling.  Here we show that environmental stress and alterations in DNA repair genes assoc. with distinct mutation spectra.  Copy no. alterations target multiple tumor suppressive/oncogenic loci; however, amplification of MYC is uniquely assocd. with poor outcome and adenosquamous subtype.  We identify multiple novel mutated genes in PDA, with select genes harbouring prognostic significance.  RBM10 mutations assoc. with longer survival in spite of histol. features of aggressive disease.  KRAS mutations are obsd. in >90% of cases, but codon Q61 alleles are selectively assocd. with improved survival.  Oncogenic BRAF mutations are mutually exclusive with KRAS and define sensitivity to vemurafenib in PDA models.  High-frequency alterations in Wnt signalling, chromatin remodelling, Hedgehog signalling, DNA repair and cell cycle processes are obsd.  Together, these data delineate new genetic diversity of PDA and provide insights into prognostic determinants and therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0gY2GitPt7Vg90H21EOLACvtfcHk0lgBbBvTtQQpWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2lurvN&md5=0e578f8e3652284b47c1c74e87173de9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fncomms7744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7744%26sid%3Dliteratum%253Aachs%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DMcMillan%26aufirst%3DE.%2BA.%26aulast%3DBalaji%26aufirst%3DU.%26aulast%3DBaek%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DW.-C.%26aulast%3DMansour%26aufirst%3DJ.%26aulast%3DMollaee%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DK.-U.%26aulast%3DKoduru%26aufirst%3DP.%26aulast%3DYopp%26aufirst%3DA.%26aulast%3DChoti%26aufirst%3DM.%2BA.%26aulast%3DYeo%26aufirst%3DC.%2BJ.%26aulast%3DMcCue%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DWhole-Exome%2520Sequencing%2520of%2520Pancreatic%2520Cancer%2520Defines%2520Genetic%2520Diversity%2520and%2520Therapeutic%2520Targets%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6744%26doi%3D10.1038%2Fncomms7744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montagut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulkus, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4853</span>– <span class="NLM_lpage">4861</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-07-6787" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4853-4861&issue=12&author=C.+Montagutauthor=S.+V.+Sharmaauthor=T.+Shiodaauthor=U.+McDermottauthor=M.+Ulmanauthor=L.+E.+Ulkusauthor=D.+Dias-Santagataauthor=H.+Stubbsauthor=D.+Y.+Leeauthor=A.+Singhauthor=L.+Drewauthor=D.+A.+Haberauthor=J.+Settleman&title=Elevated+CRAF+as+a+Potential+Mechanism+of+Acquired+Resistance+to+BRAF+Inhibition+in+Melanoma&doi=10.1158%2F0008-5472.CAN-07-6787"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6787%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DUlman%26aufirst%3DM.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DElevated%2520CRAF%2520as%2520a%2520Potential%2520Mechanism%2520of%2520Acquired%2520Resistance%2520to%2520BRAF%2520Inhibition%2520in%2520Melanoma%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D12%26spage%3D4853%26epage%3D4861%26doi%3D10.1158%2F0008-5472.CAN-07-6787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prados, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaides, T.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.11882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.18632%2Foncotarget.11882" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=583-595&issue=1&author=T.-W.+Yaoauthor=J.+Zhangauthor=M.+Pradosauthor=W.+A.+Weissauthor=C.+D.+Jamesauthor=T.+Nicolaides&title=Acquired+Resistance+to+BRAF+Inhibition+in+BRAFV600E+Mutant+Gliomas&doi=10.18632%2Foncotarget.11882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11882%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DT.-W.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPrados%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DNicolaides%26aufirst%3DT.%26atitle%3DAcquired%2520Resistance%2520to%2520BRAF%2520Inhibition%2520in%2520BRAFV600E%2520Mutant%2520Gliomas%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D583%26epage%3D595%26doi%3D10.18632%2Foncotarget.11882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Path Forward for RAF Therapies: Inhibition of Monomers and Dimers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2015.08.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=279-281&issue=3&author=R.+L.+Kortumauthor=D.+K.+Morrison&title=Path+Forward+for+RAF+Therapies%3A+Inhibition+of+Monomers+and+Dimers&doi=10.1016%2Fj.ccell.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKortum%26aufirst%3DR.%2BL.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DPath%2520Forward%2520for%2520RAF%2520Therapies%253A%2520Inhibition%2520of%2520Monomers%2520and%2520Dimers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D279%26epage%3D281%26doi%3D10.1016%2Fj.ccell.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms That Determine Their Sensitivity to Pharmacologic Inhibition</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26343582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=370-383&issue=3&author=Z.+Yaoauthor=N.+M.+Torresauthor=A.+Taoauthor=Y.+Gaoauthor=L.+Luoauthor=Q.+Liauthor=E.+de+Stanchinaauthor=O.+Abdel-Wahabauthor=D.+B.+Solitauthor=P.+I.+Poulikakosauthor=N.+Rosen&title=BRAF+Mutants+Evade+ERK-Dependent+Feedback+by+Different+Mechanisms+That+Determine+Their+Sensitivity+to+Pharmacologic+Inhibition&doi=10.1016%2Fj.ccell.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition</span></div><div class="casAuthors">Yao, Zhan; Torres, Neilawattie M.; Tao, Anthony; Gao, Yijun; Luo, Lusong; Li, Qi; de Stanchina, Elisa; Abdel-Wahab, Omar; Solit, David B.; Poulikakos, Poulikos I.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-383</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">ERK signaling requires RAS-induced RAF dimerization and is limited by feedback.  Activated BRAF mutants evade feedback inhibition of RAS by either of two mechanisms.  BRAF V600 mutants are activated monomers when RAS activity is low; all other activating BRAF mutants function as constitutive RAS-independent dimers.  RAF inhibitors effectively inhibit mutant monomers, but not dimers; their binding to one site in the dimer significantly reduces their affinity for the second.  Tumors with non-V600E BRAF mutants are insensitive to these drugs, and increased expression of BRAF V600E dimers causes acquired resistance.  A compd. that equally inhibits both sites of mutant RAF dimers inhibits tumors driven by either class of mutants or those BRAF V600E tumors with dimer-dependent acquired resistance to monomer-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJvmOiNDvOO7Vg90H21EOLACvtfcHk0liCVxaUEH64PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7M&md5=60ebf55ede549e4dbc3a1481c4eea67c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DTorres%26aufirst%3DN.%2BM.%26aulast%3DTao%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520Mutants%2520Evade%2520ERK-Dependent%2520Feedback%2520by%2520Different%2520Mechanisms%2520That%2520Determine%2520Their%2520Sensitivity%2520to%2520Pharmacologic%2520Inhibition%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D370%26epage%3D383%26doi%3D10.1016%2Fj.ccell.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakiraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misteli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitor Resistance Is Mediated by Dimerization of Aberrantly Spliced BRAF(V600E)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span> (<span class="NLM_issue">7377</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/nature10662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&issue=7377&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+Inhibitor+Resistance+Is+Mediated+by+Dimerization+of+Aberrantly+Spliced+BRAF%28V600E%29&doi=10.1038%2Fnature10662"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520Inhibitor%2520Resistance%2520Is%2520Mediated%2520by%2520Dimerization%2520of%2520Aberrantly%2520Spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26issue%3D7377%26spage%3D387%26epage%3D390%26doi%3D10.1038%2Fnature10662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Transactivate RAF Dimers and ERK Signalling in Cells with Wild-Type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&issue=7287&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+Inhibitors+Transactivate+RAF+Dimers+and+ERK+Signalling+in+Cells+with+Wild-Type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0liCVxaUEH64PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520Inhibitors%2520Transactivate%2520RAF%2520Dimers%2520and%2520ERK%2520Signalling%2520in%2520Cells%2520with%2520Wild-Type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halilovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merghoub, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccr.2012.10.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=668-682&issue=5&author=P.+Litoauthor=C.+A.+Pratilasauthor=E.+W.+Josephauthor=M.+Tadiauthor=E.+Halilovicauthor=M.+Zubrowskiauthor=A.+Huangauthor=W.+L.+Wongauthor=M.+K.+Callahanauthor=T.+Merghoubauthor=J.+D.+Wolchokauthor=E.+de+Stanchinaauthor=S.+Chandarlapatyauthor=P.+I.+Poulikakosauthor=J.+A.+Faginauthor=N.+Rosen&title=Relief+of+Profound+Feedback+Inhibition+of+Mitogenic+Signaling+by+RAF+Inhibitors+Attenuates+Their+Activity+in+BRAFV600E+Melanomas&doi=10.1016%2Fj.ccr.2012.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DZubrowski%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DMerghoub%26aufirst%3DT.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRelief%2520of%2520Profound%2520Feedback%2520Inhibition%2520of%2520Mitogenic%2520Signaling%2520by%2520RAF%2520Inhibitors%2520Attenuates%2520Their%2520Activity%2520in%2520BRAFV600E%2520Melanomas%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26issue%3D5%26spage%3D668%26epage%3D682%26doi%3D10.1016%2Fj.ccr.2012.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaspy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-13-0642" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=80-93&issue=1&author=H.+Shiauthor=W.+Hugoauthor=X.+Kongauthor=A.+Hongauthor=R.+C.+Koyaauthor=G.+Moriceauauthor=T.+Chodonauthor=R.+Guoauthor=D.+B.+Johnsonauthor=K.+B.+Dahlmanauthor=M.+C.+Kelleyauthor=R.+F.+Keffordauthor=B.+Chmielowskiauthor=J.+A.+Glaspyauthor=J.+A.+Sosmanauthor=N.+van+Barenauthor=G.+V.+Longauthor=A.+Ribasauthor=R.+S.+Lo&title=Acquired+Resistance+and+Clonal+Evolution+in+Melanoma+during+BRAF+Inhibitor+Therapy&doi=10.1158%2F2159-8290.CD-13-0642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0642%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DGlaspy%26aufirst%3DJ.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DAcquired%2520Resistance%2520and%2520Clonal%2520Evolution%2520in%2520Melanoma%2520during%2520BRAF%2520Inhibitor%2520Therapy%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D1%26spage%3D80%26epage%3D93%26doi%3D10.1158%2F2159-8290.CD-13-0642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanlou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchalski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2014.11.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=240-256&issue=2&author=G.+Moriceauauthor=W.+Hugoauthor=A.+Hongauthor=H.+Shiauthor=X.+Kongauthor=C.+C.+Yuauthor=R.+C.+Koyaauthor=A.+A.+Samatarauthor=N.+Khanlouauthor=J.+Braunauthor=K.+Ruchalskiauthor=H.+Seifertauthor=J.+Larkinauthor=K.+B.+Dahlmanauthor=D.+B.+Johnsonauthor=A.+Algaziauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Tunable-Combinatorial+Mechanisms+of+Acquired+Resistance+Limit+the+Efficacy+of+BRAF%2FMEK+Cotargeting+but+Result+in+Melanoma+Drug+Addiction&doi=10.1016%2Fj.ccell.2014.11.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%2BC.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DKhanlou%26aufirst%3DN.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DRuchalski%26aufirst%3DK.%26aulast%3DSeifert%26aufirst%3DH.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DTunable-Combinatorial%2520Mechanisms%2520of%2520Acquired%2520Resistance%2520Limit%2520the%2520Efficacy%2520of%2520BRAF%252FMEK%2520Cotargeting%2520but%2520Result%2520in%2520Melanoma%2520Drug%2520Addiction%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26issue%3D2%26spage%3D240%26epage%3D256%26doi%3D10.1016%2Fj.ccell.2014.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescioli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bax, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynne, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilieva, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacy, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, S. N.</span></span> <span> </span><span class="NLM_article-title">BRAF Inhibitors: Resistance and the Promise of Combination Treatments for Melanoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">78174</span>– <span class="NLM_lpage">78192</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.18632%2Foncotarget.19836" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=78174-78192&issue=44&author=M.+Griffinauthor=D.+Scottoauthor=D.+H.+Josephsauthor=S.+Meleauthor=S.+Crescioliauthor=H.+J.+Baxauthor=G.+Pellizzariauthor=M.+D.+Wynneauthor=M.+Nakamuraauthor=R.+M.+Hoffmannauthor=K.+M.+Ilievaauthor=A.+Cheungauthor=J.+F.+Spicerauthor=S.+Papaauthor=K.+E.+Lacyauthor=S.+N.+Karagiannis&title=BRAF+Inhibitors%3A+Resistance+and+the+Promise+of+Combination+Treatments+for+Melanoma&doi=10.18632%2Foncotarget.19836"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19836%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DM.%26aulast%3DScotto%26aufirst%3DD.%26aulast%3DJosephs%26aufirst%3DD.%2BH.%26aulast%3DMele%26aufirst%3DS.%26aulast%3DCrescioli%26aufirst%3DS.%26aulast%3DBax%26aufirst%3DH.%2BJ.%26aulast%3DPellizzari%26aufirst%3DG.%26aulast%3DWynne%26aufirst%3DM.%2BD.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DR.%2BM.%26aulast%3DIlieva%26aufirst%3DK.%2BM.%26aulast%3DCheung%26aufirst%3DA.%26aulast%3DSpicer%26aufirst%3DJ.%2BF.%26aulast%3DPapa%26aufirst%3DS.%26aulast%3DLacy%26aufirst%3DK.%2BE.%26aulast%3DKaragiannis%26aufirst%3DS.%2BN.%26atitle%3DBRAF%2520Inhibitors%253A%2520Resistance%2520and%2520the%2520Promise%2520of%2520Combination%2520Treatments%2520for%2520Melanoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D44%26spage%3D78174%26epage%3D78192%26doi%3D10.18632%2Foncotarget.19836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meharena, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A.</span></span> <span> </span><span class="NLM_article-title">Pseudokinases from a Structural Perspective</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1042/BST20130120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1042%2FBST20130120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23863167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=981-986&issue=4&author=S.+S.+Taylorauthor=A.+Shawauthor=J.+Huauthor=H.+S.+Meharenaauthor=A.+Kornev&title=Pseudokinases+from+a+Structural+Perspective&doi=10.1042%2FBST20130120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudokinases from a structural perspective</span></div><div class="casAuthors">Taylor, Susan S.; Shaw, Andrey; Hu, Jiancheng; Meharena, Hiruy S.; Kornev, Alexandr</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">981-986</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The catalytic (C) subunit of PKA was the first protein kinase structure to be solved, and it continues to serve as the prototype for the protein kinase superfamily.  In contrast, by comparing many active and inactive kinases, the authors developed a novel spine' concept where every active kinase is composed of two hydrophobic spines anchored to a hydrophobic F-helix.  The R-spine (regulatory spine) is dynamically assembled, typically by activation loop phosphorylation, whereas the C-spine (catalytic spine) is completed by the adenine ring of ATP.  In the present paper, the authors show how the spine concept can be applied to B-Raf, specifically to engineer a kinase-dead pseudokinase.  To achieve this, the authors mutated one of the C-spine residues in the N-lobe (N-terminal lobe), Ala481, to phenylalanine.  This mutant cannot bind ATP and is thus kinase-dead, presumably because the phenylalanine ring fills the adenine-binding pocket.  The C-spine is thus fused.  However, the A481F mutant is still capable of binding wild-type B-Raf and wild-type C-Raf, and dimerization with a wild-type Raf leads to downstream activation of MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] and ERK.  The mutant requires dimerization, but is independent of Ras and does not require enzymic activity.  By distinguishing between catalytic and scaffold functions of B-Raf, the authors define kinases as being bifunctional and show that, at least in some cases, the scaffold function is sufficient for downstream signalling.  Since this alanine residue is one of the most highly conserved residues in the kinome, we suggest that this may be a general strategy for engineering kinase-dead pseudokinases and exploring biol. functions that are independent of catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHPvM-pkay6rVg90H21EOLACvtfcHk0liRV_pBEj8d8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrF&md5=cd6c66553f58a31e4afaa2734d675a0f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1042%2FBST20130120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130120%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DKornev%26aufirst%3DA.%26atitle%3DPseudokinases%2520from%2520a%2520Structural%2520Perspective%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2013%26volume%3D41%26issue%3D4%26spage%3D981%26epage%3D986%26doi%3D10.1042%2FBST20130120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masselot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccr.2014.07.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=402-413&issue=3&author=J.+R.+Halingauthor=J.+Sudhamsuauthor=I.+Yenauthor=S.+Siderisauthor=W.+Sandovalauthor=W.+Phungauthor=B.+J.+Bravoauthor=A.+M.+Giannettiauthor=A.+Peckauthor=A.+Masselotauthor=T.+Moralesauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Structure+of+the+BRAF-MEK+Complex+Reveals+a+Kinase+Activity+Independent+Role+for+BRAF+in+MAPK+Signaling&doi=10.1016%2Fj.ccr.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DPhung%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DMasselot%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520BRAF-MEK%2520Complex%2520Reveals%2520a%2520Kinase%2520Activity%2520Independent%2520Role%2520for%2520BRAF%2520in%2520MAPK%2520Signaling%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D3%26spage%3D402%26epage%3D413%26doi%3D10.1016%2Fj.ccr.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saracino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Autoregulation of the Raf-1 Serine/Threonine Kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">9214</span>– <span class="NLM_lpage">9219</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.16.9214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.95.16.9214" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=9214-9219&issue=16&author=R.+E.+Cutlerauthor=R.+M.+Stephensauthor=M.+R.+Saracinoauthor=D.+K.+Morrison&title=Autoregulation+of+the+Raf-1+Serine%2FThreonine+Kinase&doi=10.1073%2Fpnas.95.16.9214"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.16.9214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.16.9214%26sid%3Dliteratum%253Aachs%26aulast%3DCutler%26aufirst%3DR.%2BE.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DSaracino%26aufirst%3DM.%2BR.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DAutoregulation%2520of%2520the%2520Raf-1%2520Serine%252FThreonine%2520Kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26issue%3D16%26spage%3D9214%26epage%3D9219%26doi%3D10.1073%2Fpnas.95.16.9214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Kinases and Pseudokinases: Lessons from RAF</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1128/MCB.00057-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1128%2FMCB.00057-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24567368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1538-1546&issue=9&author=A.+S.+Shawauthor=A.+P.+Kornevauthor=J.+Huauthor=L.+G.+Ahujaauthor=S.+S.+Taylor&title=Kinases+and+Pseudokinases%3A+Lessons+from+RAF&doi=10.1128%2FMCB.00057-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases and pseudokinases: lessons from RAF</span></div><div class="casAuthors">Shaw, Andrey S.; Kornev, Alexandr P.; Hu, Jiancheng; Ahuja, Lalima G.; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1538-1546, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Protein kinases are thought to mediate their biol. effects through their catalytic activity.  The large no. of pseudokinases in the kinome and an increasing appreciation that they have crit. roles in signaling pathways, however, suggest that catalyzing protein phosphorylation may not be the only function of protein kinases.  Using the principle of hydrophobic spine assembly, we interpret how kinases are capable of performing a dual function in signaling.  Its first role is that of a signaling enzyme (classical kinases; canonical), while its second role is that of an allosteric activator of other kinases or as a scaffold protein for signaling in a manner that is independent of phosphoryl transfer (classical pseudokinases; noncanonical).  As the hydrophobic spines are a conserved feature of the kinase domain itself, all kinases carry an inherent potential to play both roles in signaling.  This review focuses on the recent lessons from the RAF kinases that effectively toggle between these roles and can be "frozen" by introducing mutations at their hydrophobic spines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMtbrpjoo1xrVg90H21EOLACvtfcHk0liRV_pBEj8d8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D&md5=9f883042d2619f33087c7605ac7f22e9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FMCB.00057-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00057-14%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAhuja%26aufirst%3DL.%2BG.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DKinases%2520and%2520Pseudokinases%253A%2520Lessons%2520from%2520RAF%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26issue%3D9%26spage%3D1538%26epage%3D1546%26doi%3D10.1128%2FMCB.00057-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span> <span> </span><span class="NLM_article-title">Dimerization-Induced Allostery in Protein Kinase Regulation</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2014.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.tibs.2014.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=475-486&issue=10&author=H.+Lavoieauthor=J.+J.+Liauthor=N.+Thevakumaranauthor=M.+Therrienauthor=F.+Sicheri&title=Dimerization-Induced+Allostery+in+Protein+Kinase+Regulation&doi=10.1016%2Fj.tibs.2014.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2014.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2014.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DTherrien%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26atitle%3DDimerization-Induced%2520Allostery%2520in%2520Protein%2520Kinase%2520Regulation%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2014%26volume%3D39%26issue%3D10%26spage%3D475%26epage%3D486%26doi%3D10.1016%2Fj.tibs.2014.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.molcel.2012.12.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=751-758&issue=4&author=A.+K.+Freemanauthor=D.+A.+Rittauthor=D.+K.+Morrison&title=Effects+of+Raf+Dimerization+and+Its+Inhibition+on+Normal+and+Disease-Associated+Raf+Signaling&doi=10.1016%2Fj.molcel.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DEffects%2520of%2520Raf%2520Dimerization%2520and%2520Its%2520Inhibition%2520on%2520Normal%2520and%2520Disease-Associated%2520Raf%2520Signaling%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26issue%3D4%26spage%3D751%26epage%3D758%26doi%3D10.1016%2Fj.molcel.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baljuls, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzenau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polzien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span> <span> </span><span class="NLM_article-title">Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">16491</span>– <span class="NLM_lpage">16503</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.194167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1074%2Fjbc.M110.194167" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=16491-16503&issue=18&author=A.+Baljulsauthor=R.+Mahrauthor=I.+Schwarzenauauthor=T.+M%C3%BCllerauthor=L.+Polzienauthor=M.+Hekmanauthor=U.+R.+Rapp&title=Single+Substitution+within+the+RKTR+Motif+Impairs+Kinase+Activity+but+Promotes+Dimerization+of+RAF+Kinase&doi=10.1074%2Fjbc.M110.194167"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.194167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.194167%26sid%3Dliteratum%253Aachs%26aulast%3DBaljuls%26aufirst%3DA.%26aulast%3DMahr%26aufirst%3DR.%26aulast%3DSchwarzenau%26aufirst%3DI.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DPolzien%26aufirst%3DL.%26aulast%3DHekman%26aufirst%3DM.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26atitle%3DSingle%2520Substitution%2520within%2520the%2520RKTR%2520Motif%2520Impairs%2520Kinase%2520Activity%2520but%2520Promotes%2520Dimerization%2520of%2520RAF%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D18%26spage%3D16491%26epage%3D16503%26doi%3D10.1074%2Fjbc.M110.194167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&issue=3&author=Z.+Karouliaauthor=Y.+Wuauthor=T.+A.+Ahmedauthor=Q.+Xinauthor=J.+Bollardauthor=C.+Kreplerauthor=X.+Wuauthor=C.+Zhangauthor=G.+Bollagauthor=M.+Herlynauthor=J.+A.+Faginauthor=A.+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+Integrated+Model+of+RAF+Inhibitor+Action+Predicts+Inhibitor+Activity+against+Oncogenic+BRAF+Signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DBollard%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520Integrated%2520Model%2520of%2520RAF%2520Inhibitor%2520Action%2520Predicts%2520Inhibitor%2520Activity%2520against%2520Oncogenic%2520BRAF%2520Signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26issue%3D3%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of a BRAF Kinase Domain Monomer Explains Basis for Allosteric Regulation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnsmb.2924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25437913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=37-43&issue=1&author=N.+Thevakumaranauthor=H.+Lavoieauthor=D.+A.+Crittonauthor=A.+Tebbenauthor=A.+Marinierauthor=F.+Sicheriauthor=M.+Therrien&title=Crystal+Structure+of+a+BRAF+Kinase+Domain+Monomer+Explains+Basis+for+Allosteric+Regulation&doi=10.1038%2Fnsmb.2924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation</span></div><div class="casAuthors">Thevakumaran, Neroshan; Lavoie, Hugo; Critton, David A.; Tebben, Andrew; Marinier, Anne; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reported RAF kinase domain structures adopt a side-to-side dimer configuration reflective of an 'on' state that underpins an allosteric mechanism of regulation.  Atomic details of the monomer 'off' state have been elusive.  Reinspection of the BRAF kinase domain structures revealed that sulfonamide inhibitors induce features of an off state, primarily a laterally displaced helix αC stabilized by the activation segment helix 1 (AS-H1).  These features correlated with the ability of sulfonamides to disrupt human BRAF homodimers in cells, in vitro and in crystals yielding a structure of BRAF in a monomer state.  The crystal structure revealed exaggerated, nonproductive positions of helix αC and AS-H1, the latter of which is the target of potent BRAF oncogenic mutations.  Together, this work provides formal proof of an allosteric link between the RAF dimer interface, the activation segment and the catalytic infrastructure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mmFDDNHIrLVg90H21EOLACvtfcHk0lgv3qSTR4u3Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I&md5=0417ca047f52f6a425a3925fec6b5e05</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2924%26sid%3Dliteratum%253Aachs%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DCritton%26aufirst%3DD.%2BA.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DCrystal%2520Structure%2520of%2520a%2520BRAF%2520Kinase%2520Domain%2520Monomer%2520Explains%2520Basis%2520for%2520Allosteric%2520Regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3D37%26epage%3D43%26doi%3D10.1038%2Fnsmb.2924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span> <span> </span><span class="NLM_article-title">Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-15-0896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=300-315&issue=3&author=S.-H.+Chenauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=S.+Buchananauthor=V.+Yadavauthor=I.+Mochalkinauthor=S.+S.+Wongauthor=Y.+G.+Yueauthor=L.+Huberauthor=I.+Contiauthor=J.+R.+Henryauthor=J.+J.+Starlingauthor=G.+D.+Plowmanauthor=S.-B.+Peng&title=Oncogenic+BRAF+Deletions+That+Function+as+Homodimers+and+Are+Sensitive+to+Inhibition+by+RAF+Dimer+Inhibitor+LY3009120&doi=10.1158%2F2159-8290.CD-15-0896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0896%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DYue%26aufirst%3DY.%2BG.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26atitle%3DOncogenic%2520BRAF%2520Deletions%2520That%2520Function%2520as%2520Homodimers%2520and%2520Are%2520Sensitive%2520to%2520Inhibition%2520by%2520RAF%2520Dimer%2520Inhibitor%2520LY3009120%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D3%26spage%3D300%26epage%3D315%26doi%3D10.1158%2F2159-8290.CD-15-0896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holderfield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallroth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, T. E.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccr.2013.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23680146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslantLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=594-602&issue=5&author=M.+Holderfieldauthor=H.+Merrittauthor=J.+Chanauthor=M.+Wallrothauthor=L.+Tandeskeauthor=H.+Zhaiauthor=J.+Tellewauthor=S.+Hardyauthor=M.+Hekmat-Nejadauthor=D.+D.+Stuartauthor=F.+McCormickauthor=T.+E.+Nagel&title=RAF+Inhibitors+Activate+the+MAPK+Pathway+by+Relieving+Inhibitory+Autophosphorylation&doi=10.1016%2Fj.ccr.2013.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation</span></div><div class="casAuthors">Holderfield, Matthew; Merritt, Hanne; Chan, John; Wallroth, Marco; Tandeske, Laura; Zhai, Huili; Tellew, John; Hardy, Stephen; Hekmat-Nejad, Mohammad; Stuart, Darrin D.; McCormick, Frank; Nagel, Tobi E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">594-602</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">ATP competitive inhibitors of the BRAFV600E oncogene paradoxically activate downstream signaling in cells bearing wild-type BRAF (BRAFWT).  In this study, we investigate the biochem. mechanism of wild-type RAF (RAFWT) activation by multiple catalytic inhibitors using kinetic anal. of purified BRAFV600E and RAFWT enzymes.  We show that activation of RAFWT is ATP dependent and directly linked to RAF kinase activity.  These data support a mechanism involving inhibitory autophosphorylation of RAF's phosphate-binding loop that, when disrupted either through pharmacol. or genetic alterations, results in activation of RAF and the mitogen-activated protein kinase (MAPK) pathway.  This mechanism accounts not only for compd.-mediated activation of the MAPK pathway in BRAFWT cells but also offers a biochem. mechanism for BRAF oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq54U_rGedYm7Vg90H21EOLACvtfcHk0ljuffkZZakbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslantLo%253D&md5=6fcb339de5bb8b23ea627a3945caa08a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DHolderfield%26aufirst%3DM.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DWallroth%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DH.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DHardy%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DNagel%26aufirst%3DT.%2BE.%26atitle%3DRAF%2520Inhibitors%2520Activate%2520the%2520MAPK%2520Pathway%2520by%2520Relieving%2520Inhibitory%2520Autophosphorylation%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26issue%3D5%26spage%3D594%26epage%3D602%26doi%3D10.1016%2Fj.ccr.2013.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban-Burgos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-López, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span> <span> </span><span class="NLM_article-title">A Braf Kinase-Inactive Mutant Induces Lung Adenocarcinoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>548</i></span> (<span class="NLM_issue">7666</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/nature23297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature23297" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2017&pages=239-243&issue=7666&author=P.+Nietoauthor=C.+Ambrogioauthor=L.+Esteban-Burgosauthor=G.+G%C3%B3mez-L%C3%B3pezauthor=M.+T.+Blascoauthor=Z.+Yaoauthor=R.+Maraisauthor=N.+Rosenauthor=R.+Chiarleauthor=D.+G.+Pisanoauthor=M.+Barbacidauthor=D.+Santamar%C3%ADa&title=A+Braf+Kinase-Inactive+Mutant+Induces+Lung+Adenocarcinoma&doi=10.1038%2Fnature23297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature23297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23297%26sid%3Dliteratum%253Aachs%26aulast%3DNieto%26aufirst%3DP.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DEsteban-Burgos%26aufirst%3DL.%26aulast%3DG%25C3%25B3mez-L%25C3%25B3pez%26aufirst%3DG.%26aulast%3DBlasco%26aufirst%3DM.%2BT.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DPisano%26aufirst%3DD.%2BG.%26aulast%3DBarbacid%26aufirst%3DM.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26atitle%3DA%2520Braf%2520Kinase-Inactive%2520Mutant%2520Induces%2520Lung%2520Adenocarcinoma%26jtitle%3DNature%26date%3D2017%26volume%3D548%26issue%3D7666%26spage%3D239%26epage%3D243%26doi%3D10.1038%2Fnature23297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaeger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrik-Outmezguine, V.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembrough, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Tumours with Class 3 BRAF Mutants Are Sensitive to the Inhibition of Activated RAS</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>548</i></span> (<span class="NLM_issue">7666</span>),  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1038/nature23291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature23291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28783719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OjsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2017&pages=234-238&issue=7666&author=Z.+Yaoauthor=R.+Yaegerauthor=V.%0AS.+Rodrik-Outmezguineauthor=A.+Taoauthor=N.+M.+Torresauthor=M.+T.+Changauthor=M.+Drostenauthor=H.+Zhaoauthor=F.+Cecchiauthor=T.+Hembroughauthor=J.+Michelsauthor=H.+Baumertauthor=L.+Milesauthor=N.+M.+Campbellauthor=E.+de+Stanchinaauthor=D.+B.+Solitauthor=M.+Barbacidauthor=B.+S.+Taylorauthor=N.+Rosen&title=Tumours+with+Class+3+BRAF+Mutants+Are+Sensitive+to+the+Inhibition+of+Activated+RAS&doi=10.1038%2Fnature23291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS</span></div><div class="casAuthors">Yao, Zhan; Yaeger, Rona; Rodrik-Outmezguine, Vanessa S.; Tao, Anthony; Torres, Neilawattie M.; Chang, Matthew T.; Drosten, Matthias; Zhao, Huiyong; Cecchi, Fabiola; Hembrough, Todd; Michels, Judith; Baumert, Herve; Miles, Linde; Campbell, Naomi M.; de Stanchina, Elisa; Solit, David B.; Barbacid, Mariano; Taylor, Barry S.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">7666</span>),
    <span class="NLM_cas:pages">234-238</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Approx. 200 BRAF mutant alleles have been identified in human tumors.  Activating BRAF mutants cause feedback inhibition of GTP-bound RAS, are RAS-independent and signal either as active monomers (class 1) or constitutively active dimers (class 2).  Here we characterize a third class of BRAF mutants-those that have impaired kinase activity or are kinase-dead.  These mutants are sensitive to ERK-mediated feedback and their activation of signalling is RAS-dependent.  The mutants bind more tightly than wild-type BRAF to RAS-GTP, and their binding to and activation of wild-type CRAF is enhanced, leading to increased ERK signalling.  The model suggests that dysregulation of signalling by these mutants in tumors requires coexistent mechanisms for maintaining RAS activation despite ERK-dependent feedback.  Consistent with this hypothesis, melanomas with these class 3 BRAF mutations also harbor RAS mutations or NF1 deletions.  By contrast, in lung and colorectal cancers with class 3 BRAF mutants, RAS is typically activated by receptor tyrosine kinase signalling.  These tumors are sensitive to the inhibition of RAS activation by inhibitors of receptor tyrosine kinases.  We have thus defined three distinct functional classes of BRAF mutants in human tumors.  The mutants activate ERK signalling by different mechanisms that dictate their sensitivity to therapeutic inhibitors of the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLEqr4hGX0YrVg90H21EOLACvtfcHk0lhyfmJKVLwZ1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OjsrvK&md5=126b9319928d55174f4b5c733394c880</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnature23291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23291%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DYaeger%26aufirst%3DR.%26aulast%3DRodrik-Outmezguine%26aufirst%3DV.%2BS.%26aulast%3DTao%26aufirst%3DA.%26aulast%3DTorres%26aufirst%3DN.%2BM.%26aulast%3DChang%26aufirst%3DM.%2BT.%26aulast%3DDrosten%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCecchi%26aufirst%3DF.%26aulast%3DHembrough%26aufirst%3DT.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DBaumert%26aufirst%3DH.%26aulast%3DMiles%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DN.%2BM.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DBarbacid%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DTumours%2520with%2520Class%25203%2520BRAF%2520Mutants%2520Are%2520Sensitive%2520to%2520the%2520Inhibition%2520of%2520Activated%2520RAS%26jtitle%3DNature%26date%3D2017%26volume%3D548%26issue%3D7666%26spage%3D234%26epage%3D238%26doi%3D10.1038%2Fnature23291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span> <span> </span><span class="NLM_article-title">Conformation-Specific Effects of Raf Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7332</span>– <span class="NLM_lpage">7341</span>, <span class="refDoi"> DOI: 10.1021/jm300613w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300613w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7332-7341&issue=17&author=X.+Wangauthor=J.+Kim&title=Conformation-Specific+Effects+of+Raf+Kinase+Inhibitors&doi=10.1021%2Fjm300613w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm300613w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300613w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DConformation-Specific%2520Effects%2520of%2520Raf%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7332%26epage%3D7341%26doi%3D10.1021%2Fjm300613w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlattl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalkuhl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-15-0617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26916115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=354-365&issue=3&author=I.+C.+Waizeneggerauthor=A.+Baumauthor=S.+Steurerauthor=H.+Stadtm%C3%BCllerauthor=G.+Baderauthor=O.+Schaafauthor=P.+Garin-Chesaauthor=A.+Schlattlauthor=N.+Schweiferauthor=C.+Haslingerauthor=F.+Colbatzkyauthor=S.+Mousaauthor=A.+Kalkuhlauthor=N.+Krautauthor=G.+R.+Adolf&title=A+Novel+RAF+Kinase+Inhibitor+with+DFG-Out-Binding+Mode%3A+High+Efficacy+in+BRAF-Mutant+Tumor+Xenograft+Models+in+the+Absence+of+Normal+Tissue+Hyperproliferation&doi=10.1158%2F1535-7163.MCT-15-0617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span></div><div class="casAuthors">Waizenegger, Irene C.; Baum, Anke; Steurer, Steffen; Stadtmuller, Heinz; Bader, Gerd; Schaaf, Otmar; Garin-Chesa, Pilar; Schlattl, Andreas; Schweifer, Norbert; Haslinger, Christian; Colbatzky, Florian; Mousa, Sien; Kalkuhl, Arno; Kraut, Norbert; Adolf, Gunther R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase.  The compd. inhibited proliferation of human BRAF-mutant melanoma cells with 100× higher potency (1-10 nmol/L) than vemurafenib, whereas wild-type cells were not affected at 1,000 nmol/L.  BI 882370 administered orally was efficacious in multiple mouse models of BRAF-mutant melanomas and colorectal carcinomas, and at 25 mg/kg twice daily showed superior efficacy compared with vemurafenib, dabrafenib, or trametinib (dosed to provide exposures reached in patients).  To model drug resistance, A375 melanoma-bearing mice were initially treated with vemurafenib; all tumors responded with regression, but the majority subsequently resumed growth.  Trametinib did not show any efficacy in this progressing population.  BI 882370 induced tumor regression; however, resistance developed within 3 wk.  BI 882370 in combination with trametinib resulted in more pronounced regressions, and resistance was not obsd. during 5 wk of second-line therapy.  Importantly, mice treated with BI 882370 did not show any body wt. loss or clin. signs of intolerability, and no pathol. changes were obsd. in several major organs investigated, including skin.  Furthermore, a pilot study in rats (up to 60 mg/kg daily for 2 wk) indicated lack of toxicity in terms of clin. chem., hematol., pathol., and toxicogenomics.  Our results indicate the feasibility of developing novel compds. that provide an improved therapeutic window compared with first-generation BRAF inhibitors, resulting in more pronounced and long-lasting pathway suppression and thus improved efficacy.  Mol Cancer Ther; 15(3); 354-65. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtRl_zbyDibVg90H21EOLACvtfcHk0lg2bZhNKr0jnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D&md5=e35140e31364622de51538b99618001a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0617%26sid%3Dliteratum%253Aachs%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSchaaf%26aufirst%3DO.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DSchlattl%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DMousa%26aufirst%3DS.%26aulast%3DKalkuhl%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DA%2520Novel%2520RAF%2520Kinase%2520Inhibitor%2520with%2520DFG-Out-Binding%2520Mode%253A%2520High%2520Efficacy%2520in%2520BRAF-Mutant%2520Tumor%2520Xenograft%2520Models%2520in%2520the%2520Absence%2520of%2520Normal%2520Tissue%2520Hyperproliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D3%26spage%3D354%26epage%3D365%26doi%3D10.1158%2F1535-7163.MCT-15-0617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Prime Wild-Type RAF to Activate the MAPK Pathway and Enhance Growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+Inhibitors+Prime+Wild-Type+RAF+to+Activate+the+MAPK+Pathway+and+Enhance+Growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0ljYBWEhslCqSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520Inhibitors%2520Prime%2520Wild-Type%2520RAF%2520to%2520Activate%2520the%2520MAPK%2520Pathway%2520and%2520Enhance%2520Growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavory, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padeganeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, D. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors That Stabilize a Closed RAF Kinase Domain Conformation Induce Dimerization</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&issue=7&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+L.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+That+Stabilize+a+Closed+RAF+Kinase+Domain+Conformation+Induce+Dimerization&doi=10.1038%2Fnchembio.1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0ljYBWEhslCqSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%2BL.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520That%2520Stabilize%2520a%2520Closed%2520RAF%2520Kinase%2520Domain%2520Conformation%2520Induce%2520Dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D7%26spage%3D428%26epage%3D436%26doi%3D10.1038%2Fnchembio.1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donelan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouitar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carideo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7043</span>– <span class="NLM_lpage">7055</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-13-1825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=7043-7055&issue=23&author=A.+Nakamuraauthor=T.+Aritaauthor=S.+Tsuchiyaauthor=J.+Donelanauthor=J.+Chouitarauthor=E.+Carideoauthor=K.+Galvinauthor=M.+Okaniwaauthor=T.+Ishikawaauthor=S.+Yoshida&title=Antitumor+Activity+of+the+Selective+Pan-RAF+Inhibitor+TAK-632+in+BRAF+Inhibitor-Resistant+Melanoma&doi=10.1158%2F0008-5472.CAN-13-1825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1825%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DDonelan%26aufirst%3DJ.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DCarideo%26aufirst%3DE.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DS.%26atitle%3DAntitumor%2520Activity%2520of%2520the%2520Selective%2520Pan-RAF%2520Inhibitor%2520TAK-632%2520in%2520BRAF%2520Inhibitor-Resistant%2520Melanoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D23%26spage%3D7043%26epage%3D7055%26doi%3D10.1158%2F0008-5472.CAN-13-1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girotti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suijkerbuijk, B. M. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejiama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Laorden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohloch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusiak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brognard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Paradox-Breaking RAF Inhibitors That Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2014.11.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=85-96&issue=1&author=M.+R.+Girottiauthor=F.+Lopesauthor=N.+Preeceauthor=D.+Niculescu-Duvazauthor=A.+Zambonauthor=L.+Daviesauthor=S.+Whittakerauthor=G.+Saturnoauthor=A.+Virosauthor=M.+Pedersenauthor=B.+M.+J.+M.+Suijkerbuijkauthor=D.+Menardauthor=R.+McLearyauthor=L.+Johnsonauthor=L.+Fishauthor=S.+Ejiamaauthor=B.+Sanchez-Laordenauthor=J.+Hohlochauthor=N.+Carragherauthor=K.+Macleodauthor=G.+Ashtonauthor=A.+A.+Marusiakauthor=A.+Fusiauthor=J.+Brognardauthor=M.+Frameauthor=P.+Loriganauthor=R.+Maraisauthor=C.+Springer&title=Paradox-Breaking+RAF+Inhibitors+That+Also+Target+SRC+Are+Effective+in+Drug-Resistant+BRAF+Mutant+Melanoma&doi=10.1016%2Fj.ccell.2014.11.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DSuijkerbuijk%26aufirst%3DB.%2BM.%2BJ.%2BM.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DFish%26aufirst%3DL.%26aulast%3DEjiama%26aufirst%3DS.%26aulast%3DSanchez-Laorden%26aufirst%3DB.%26aulast%3DHohloch%26aufirst%3DJ.%26aulast%3DCarragher%26aufirst%3DN.%26aulast%3DMacleod%26aufirst%3DK.%26aulast%3DAshton%26aufirst%3DG.%26aulast%3DMarusiak%26aufirst%3DA.%2BA.%26aulast%3DFusi%26aufirst%3DA.%26aulast%3DBrognard%26aufirst%3DJ.%26aulast%3DFrame%26aufirst%3DM.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DParadox-Breaking%2520RAF%2520Inhibitors%2520That%2520Also%2520Target%2520SRC%2520Are%2520Effective%2520in%2520Drug-Resistant%2520BRAF%2520Mutant%2520Melanoma%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26issue%3D1%26spage%3D85%26epage%3D96%26doi%3D10.1016%2Fj.ccell.2014.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-Tumor Activities in RAS or BRAF Mutant Cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2015.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26343583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=384-398&issue=3&author=S.-B.+Pengauthor=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=W.-P.+Luauthor=B.+D.+Smithauthor=S.+Vogetiauthor=T.+J.+Rutkoskiauthor=S.+Wiseauthor=L.+Chunauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=X.+Zhangauthor=V.+Yadavauthor=S.-H.+Chenauthor=X.+Gongauthor=X.+Maauthor=Y.+Websterauthor=S.+Buchananauthor=I.+Mochalkinauthor=L.+Huberauthor=L.+Kaysauthor=G.+P.+Donohoauthor=J.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=I.+Contiauthor=G.+D.+Plowmanauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Inhibition+of+RAF+Isoforms+and+Active+Dimers+by+LY3009120+Leads+to+Anti-Tumor+Activities+in+RAS+or+BRAF+Mutant+Cancers&doi=10.1016%2Fj.ccell.2015.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers</span></div><div class="casAuthors">Peng, Sheng-Bin; Henry, James R.; Kaufman, Michael D.; Lu, Wei-Ping; Smith, Bryan D.; Vogeti, Subha; Rutloski, Thomas J.; Wise, Scott; Chun, Lawrence; Zhang, Youyan; Van Horn, Robert D.; Yin, Tinggui; Zhang, Xiaoyi; Yadav, Vipin; Chen, Shih-Hsun; Gong, Xueqian; Ma, Xiwen; Webster, Yue; Buchanan, Sean; Mochalkin, Igor; Huber, Lysiane; Kays, Lisa; Donoho, Gregory P.; Walgren, Jennie; McCann, Denis; Patel, Phenil; Conti, Ilaria; Plowman, Gregory D.; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-398</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.  Biochem. and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.  LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.  Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.  Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJMiHK-Gub5bVg90H21EOLACvtfcHk0lh13zLRj26OCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O&md5=c167caa6e5a9b47a6ec1ee2ab6d9e0d1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWebster%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DInhibition%2520of%2520RAF%2520Isoforms%2520and%2520Active%2520Dimers%2520by%2520LY3009120%2520Leads%2520to%2520Anti-Tumor%2520Activities%2520in%2520RAS%2520or%2520BRAF%2520Mutant%2520Cancers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D384%26epage%3D398%26doi%3D10.1016%2Fj.ccell.2015.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuzumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitor Hijacking of Akt Activation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1038/nchembio.183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnchembio.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=19465931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=484-493&issue=7&author=T.+Okuzumiauthor=D.+Fiedlerauthor=C.+Zhangauthor=D.+C.+Grayauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=K.+M.+Shokat&title=Inhibitor+Hijacking+of+Akt+Activation&doi=10.1038%2Fnchembio.183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor hijacking of Akt activation</span></div><div class="casAuthors">Okuzumi, Tatsuya; Fiedler, Dorothea; Zhang, Chao; Gray, Daniel C.; Aizenstein, Brian; Hoffman, Randy; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">484-493</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase Akt plays a central role as a regulator of multiple growth factor input signals, thus making it an attractive anticancer drug target.  A-443654 is an ATP-competitive Akt inhibitor.  Unexpectedly, treatment of cells with A-443654 causes paradoxical hyperphosphorylation of Akt at its two regulatory sites (Thr308 and Ser473).  We explored whether inhibitor-induced hyperphosphorylation of Akt by A-443654 is a consequence of disrupted feedback regulation at a pathway level or whether it is a direct consequence of inhibitor binding to the ATP binding site of Akt.  Catalytically inactive mutants of Akt revealed that binding of an inhibitor to the ATP site of Akt is sufficient to directly cause hyperphosphorylation of the kinase in the absence of any pathway feedback effects.  We conclude that ATP-competitive Akt inhibitors impart regulatory phosphorylation of their target kinase Akt.  These results provide new insights into both natural regulation of Akt activation and Akt inhibitors entering the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWNjUB9YVue7Vg90H21EOLACvtfcHk0lg4eGA8plsL8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D&md5=4edb5a0457fd9378850102a6414bfdb5</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.183%26sid%3Dliteratum%253Aachs%26aulast%3DOkuzumi%26aufirst%3DT.%26aulast%3DFiedler%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DD.%2BC.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DInhibitor%2520Hijacking%2520of%2520Akt%2520Activation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D7%26spage%3D484%26epage%3D493%26doi%3D10.1038%2Fnchembio.183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurin, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostelecky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P. J.</span></span> <span> </span><span class="NLM_article-title">PKC Maturation Is Promoted by Nucleotide Pocket Occupation Independently of Intrinsic Kinase Activity</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnsmb.1606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=19465915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlars78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=624-630&issue=6&author=A.+J.+M.+Cameronauthor=C.+Escribanoauthor=A.+T.+Saurinauthor=B.+Kosteleckyauthor=P.+J.+Parker&title=PKC+Maturation+Is+Promoted+by+Nucleotide+Pocket+Occupation+Independently+of+Intrinsic+Kinase+Activity&doi=10.1038%2Fnsmb.1606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity</span></div><div class="casAuthors">Cameron, Angus J. M.; Escribano, Cristina; Saurin, Adrian T.; Kostelecky, Brenda; Parker, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">624-630</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein kinase C (PKC) Ser/Thr kinases account for ∼2% of the human kinome and regulate diverse cellular behaviors.  PKC catalytic activity requires priming phosphorylations at 3 conserved sites within the kinase domain.  Here, the authors demonstrate that priming of PKC is dependent on the conformation of the nucleotide-binding pocket, but not on its intrinsic kinase activity.  Inactive ATP-binding site mutants were unprimed, but they became phosphorylated upon occupancy of the ATP-binding pocket with inhibitors of PKC.  The authors exploited this property to screen for PKC inhibitors in vivo.  Further, the authors generated a distinct class of kinase-inactive mutants that maintained the integrity of the ATP-binding pocket; such mutants were constitutively primed and functionally distinct from ATP-binding site mutants.  These data demonstrated that autophosphorylation is not required for PKC priming and showed how ATP-pocket occupation could enable a kinase to mature as well as function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbLEzm35IJ6rVg90H21EOLACvtfcHk0lg4eGA8plsL8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlars78%253D&md5=ed8cdc844dbc79581fd8705e1298cb4c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1606%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DEscribano%26aufirst%3DC.%26aulast%3DSaurin%26aufirst%3DA.%2BT.%26aulast%3DKostelecky%26aufirst%3DB.%26aulast%3DParker%26aufirst%3DP.%2BJ.%26atitle%3DPKC%2520Maturation%2520Is%2520Promoted%2520by%2520Nucleotide%2520Pocket%2520Occupation%2520Independently%2520of%2520Intrinsic%2520Kinase%2520Activity%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26issue%3D6%26spage%3D624%26epage%3D630%26doi%3D10.1038%2Fnsmb.1606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andraos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonenfant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangrevelinghe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marque, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Régnier, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckelynck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baffert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pissot-Soldermann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voshol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span> <span> </span><span class="NLM_article-title">Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-11-0324" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=512-523&issue=6&author=R.+Andraosauthor=Z.+Qianauthor=D.+Bonenfantauthor=J.+Rubertauthor=E.+Vangrevelingheauthor=C.+Scheuflerauthor=F.+Marqueauthor=C.+H.+R%C3%A9gnierauthor=A.+De+Poverauthor=H.+Ryckelynckauthor=N.+Bhagwatauthor=P.+Koppikarauthor=A.+Goelauthor=L.+Wyderauthor=G.+Tavaresauthor=F.+Baffertauthor=C.+Pissot-Soldermannauthor=P.+W.+Manleyauthor=C.+Gaulauthor=H.+Vosholauthor=R.+L.+Levineauthor=W.+R.+Sellersauthor=F.+Hofmannauthor=T.+Radimerski&title=Modulation+of+Activation-Loop+Phosphorylation+by+JAK+Inhibitors+Is+Binding+Mode+Dependent&doi=10.1158%2F2159-8290.CD-11-0324"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0324%26sid%3Dliteratum%253Aachs%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DBonenfant%26aufirst%3DD.%26aulast%3DRubert%26aufirst%3DJ.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DMarque%26aufirst%3DF.%26aulast%3DR%25C3%25A9gnier%26aufirst%3DC.%2BH.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DRyckelynck%26aufirst%3DH.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DWyder%26aufirst%3DL.%26aulast%3DTavares%26aufirst%3DG.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DPissot-Soldermann%26aufirst%3DC.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DVoshol%26aufirst%3DH.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26atitle%3DModulation%2520of%2520Activation-Loop%2520Phosphorylation%2520by%2520JAK%2520Inhibitors%2520Is%2520Binding%2520Mode%2520Dependent%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D6%26spage%3D512%26epage%3D523%26doi%3D10.1158%2F2159-8290.CD-11-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, B. G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhhatarai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schürer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span> <span> </span><span class="NLM_article-title">Divergent Allosteric Control of the IRE1α Endoribonuclease Using Kinase Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnchembio.1094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23086298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOmtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=982-989&issue=12&author=L.+Wangauthor=B.+G.+K.+Pereraauthor=S.+B.+Hariauthor=B.+Bhhataraiauthor=B.+J.+Backesauthor=M.+A.+Seeligerauthor=S.+C.+Sch%C3%BCrerauthor=S.+A.+Oakesauthor=F.+R.+Papaauthor=D.+J.+Maly&title=Divergent+Allosteric+Control+of+the+IRE1%CE%B1+Endoribonuclease+Using+Kinase+Inhibitors&doi=10.1038%2Fnchembio.1094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors</span></div><div class="casAuthors">Wang, Likun; Perera, B. Gayani K.; Hari, Sanjay B.; Bhhatarai, Barun; Backes, Bradley J.; Seeliger, Markus A.; Schuerer, Stephan C.; Oakes, Scott A.; Papa, Feroz R.; Maly, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">982-989</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Under endoplasmic reticulum stress, unfolded protein accumulation leads to activation of the endoplasmic reticulum transmembrane kinase/endoRNase IRE1α.  IRE1α oligomerizes, autophosphorylates and initiates splicing of XBP1 mRNA, thus triggering the unfolded protein response (UPR).  Here we show that IRE1α's kinase-controlled RNase can be regulated in two distinct modes with kinase inhibitors: one class of ligands occupies IRE1α's kinase ATP-binding site to activate RNase-mediated XBP1 mRNA splicing even without upstream endoplasmic reticulum stress, whereas a second class can inhibit the RNase through the same ATP-binding site, even under endoplasmic reticulum stress.  Thus, alternative kinase conformations stabilized by distinct classes of ATP-competitive inhibitors can cause allosteric switching of IRE1α's RNase-either on or off.  As dysregulation of the UPR has been implicated in a variety of cell degenerative and neoplastic disorders, small-mol. control over IRE1α should advance efforts to understand the UPR's role in pathophysiol. and to develop drugs for endoplasmic reticulum stress-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5edxS7gfwNrVg90H21EOLACvtfcHk0li57LyFK8Gnmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOmtLbO&md5=a6daf1ddb2ccdec77035e2e3c70d674c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1094%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPerera%26aufirst%3DB.%2BG.%2BK.%26aulast%3DHari%26aufirst%3DS.%2BB.%26aulast%3DBhhatarai%26aufirst%3DB.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%2BC.%26aulast%3DOakes%26aufirst%3DS.%2BA.%26aulast%3DPapa%26aufirst%3DF.%2BR.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DDivergent%2520Allosteric%2520Control%2520of%2520the%2520IRE1%25CE%25B1%2520Endoribonuclease%2520Using%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D12%26spage%3D982%26epage%3D989%26doi%3D10.1038%2Fnchembio.1094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpivaara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hricik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marubayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>489</i></span> (<span class="NLM_issue">7414</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&issue=7414&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+G%C3%B6nenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+Activation+as+a+Mechanism+of+Persistence+to+JAK2+Inhibitor+Therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0lgAWb1aafNIPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DG%25C3%25B6nen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520Activation%2520as%2520a%2520Mechanism%2520of%2520Persistence%2520to%2520JAK2%2520Inhibitor%2520Therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26issue%3D7414%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanftner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors That Evade Paradoxical MAPK Pathway Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span> (<span class="NLM_issue">7574</span>),  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1038/nature14982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature14982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26466569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=583-586&issue=7574&author=C.+Zhangauthor=W.+Spevakauthor=Y.+Zhangauthor=E.+A.+Burtonauthor=Y.+Maauthor=G.+Habetsauthor=J.+Zhangauthor=J.+Linauthor=T.+Ewingauthor=B.+Matusowauthor=G.+Tsangauthor=A.+Marimuthuauthor=H.+Choauthor=G.+Wuauthor=W.+Wangauthor=D.+Fongauthor=H.+Nguyenauthor=S.+Shiauthor=P.+Womackauthor=M.+Nespiauthor=R.+Shellooeauthor=H.+Cariasauthor=B.+Powellauthor=E.+Lightauthor=L.+Sanftnerauthor=J.+Waltersauthor=J.+Tsaiauthor=B.+L.+Westauthor=G.+Visorauthor=H.+Rezaeiauthor=P.+S.+Linauthor=K.+Nolopauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=G.+Bollag&title=RAF+Inhibitors+That+Evade+Paradoxical+MAPK+Pathway+Activation&doi=10.1038%2Fnature14982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors that evade paradoxical MAPK pathway activation</span></div><div class="casAuthors">Zhang, Chao; Spevak, Wayne; Zhang, Ying; Burton, Elizabeth A.; Ma, Yan; Habets, Gaston; Zhang, Jiazhong; Lin, Jack; Ewing, Todd; Matusow, Bernice; Tsang, Garson; Marimuthu, Adhirai; Cho, Hanna; Wu, Guoxian; Wang, Weiru; Fong, Daniel; Nguyen, Hoa; Shi, Songyuan; Womack, Patrick; Nespi, Marika; Shellooe, Rafe; Carias, Heidi; Powell, Ben; Light, Emily; Sanftner, Laura; Walters, Jason; Tsai, James; West, Brian L.; Visor, Gary; Rezaei, Hamid; Lin, Paul S.; Nolop, Keith; Ibrahim, Prabha N.; Hirth, Peter; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7574</span>),
    <span class="NLM_cas:pages">583-586</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oncogenic activation of BRAF fuels cancer growth by constitutively promoting RAS-independent mitogen-activated protein kinase (MAPK) pathway signalling.  Accordingly, RAF inhibitors have brought substantially improved personalized treatment of metastatic melanoma.  However, these targeted agents have also revealed an unexpected consequence: stimulated growth of certain cancers.  Structurally diverse ATP-competitive RAF inhibitors can either inhibit or paradoxically activate the MAPK pathway, depending whether activation is by BRAF mutation or by an upstream event, such as RAS mutation or receptor tyrosine kinase activation.  Here we have identified next-generation RAF inhibitors (dubbed 'paradox breakers') that suppress mutant BRAF cells without activating the MAPK pathway in cells bearing upstream activation.  In cells that express the same HRAS mutation prevalent in squamous tumors from patients treated with RAF inhibitors, the first-generation RAF inhibitor vemurafenib stimulated in vitro and in vivo growth and induced expression of MAPK pathway response genes; by contrast the paradox breakers PLX7904 and PLX8394 had no effect.  Paradox breakers also overcame several known mechanisms of resistance to first-generation RAF inhibitors.  Dissocg. MAPK pathway inhibition from paradoxical activation might yield both improved safety and more durable efficacy than first-generation RAF inhibitors, a concept currently undergoing human clin. evaluation with PLX8394.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv_s6rL_GkBbVg90H21EOLACvtfcHk0ljc9Inun_0HZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN&md5=e5e4c5e11a6c54d442a4ed7a2f21d76a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnature14982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14982%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DEwing%26aufirst%3DT.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLight%26aufirst%3DE.%26aulast%3DSanftner%26aufirst%3DL.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DVisor%26aufirst%3DG.%26aulast%3DRezaei%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DRAF%2520Inhibitors%2520That%2520Evade%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%26jtitle%3DNature%26date%3D2015%26volume%3D526%26issue%3D7574%26spage%3D583%26epage%3D586%26doi%3D10.1038%2Fnature14982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Michele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermarliere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Heerde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span> <span> </span><span class="NLM_article-title">Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1818</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1021/jm501667n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501667n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1818-1831&issue=4&author=R.+Aroraauthor=M.+Di+Micheleauthor=E.+Stesauthor=E.+Vandermarliereauthor=L.+Martensauthor=K.+Gevaertauthor=E.+Van+Heerdeauthor=J.+T.+M.+Lindersauthor=D.+Brehmerauthor=E.+Jacobyauthor=P.+Bonnet&title=Structural+Investigation+of+B-Raf+Paradox+Breaker+and+Inducer+Inhibitors&doi=10.1021%2Fjm501667n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm501667n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501667n%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DR.%26aulast%3DDi%2BMichele%26aufirst%3DM.%26aulast%3DStes%26aufirst%3DE.%26aulast%3DVandermarliere%26aufirst%3DE.%26aulast%3DMartens%26aufirst%3DL.%26aulast%3DGevaert%26aufirst%3DK.%26aulast%3DVan%2BHeerde%26aufirst%3DE.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%2BM.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBonnet%26aufirst%3DP.%26atitle%3DStructural%2520Investigation%2520of%2520B-Raf%2520Paradox%2520Breaker%2520and%2520Inducer%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1818%26epage%3D1831%26doi%3D10.1021%2Fjm501667n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall-Jackson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedge, P.</span></span> <span> </span><span class="NLM_article-title">Paradoxical Activation of Raf by a Novel Raf Inhibitor</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(99)80088-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS1074-5521%2899%2980088-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10421767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=559-568&issue=8&author=C.+A.+Hall-Jacksonauthor=P.+A.+Eyersauthor=P.+Cohenauthor=M.+Goedertauthor=F.+T.+Boyleauthor=N.+Hewittauthor=H.+Plantauthor=P.+Hedge&title=Paradoxical+Activation+of+Raf+by+a+Novel+Raf+Inhibitor&doi=10.1016%2FS1074-5521%2899%2980088-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Paradoxical activation of raf by a novel raf inhibitor</span></div><div class="casAuthors">Hall-Jackson, Clare A.; Eyers, Patrick A.; Cohen, Philip; Goedert, Michel; Boyle, F. Tom; Hewitt, Neil; Plant, Helen; Hedge, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-568</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">Raf is a proto-oncogene that is activated in response to growth factors or phorbol esters, and is thought to activate MAP kinase kinase-1 (MKK1) and hence the classical MAP kinase (MAPK) cascade.  The compd. ZM 336372 is identified as a potent and specific inhibitor of Raf isoforms in vitro.  Paradoxically, exposure of cells to ZM 336372 induces > 100-fold activation of c-Raf (measured in the absence of compd.), but without triggering any activation of MKK1 or p42 MAPK/ERK2.  The ZM 336372-induced activation of c-Raf occurs without any increase in the GTP-loading of Ras and is not prevented by inhibition of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase.  ZM 336372 does not prevent growth factor or phorbol ester induced activation of MKK1 or p42 MAPK/ERK2, or reverse the phenotype of Ras- or Raf-transformed cell lines.  The only other protein kinase inhibited by ZM 336372 out of 20 tested was SAPK2/p38.  Although ZM 336372 is structurally unrelated to SB 203580, a potent inhibitor of SAPK2/p38, the mutation of Thr106→Met made SAPK2/p38 insensitive to ZM 336372 as well as to SB 203580.  Raf appears to suppress its own activation by a novel feedback loop, such that inhibition is always counterbalanced by reactivation.  These observations imply that some agonists reported to trigger the cellular activation of c-Raf might actually be inhibitors of this enzyme, and that compds. which inhibit the kinase activity of Raf might not be useful as anticancer drugs.  The binding sites for ZM 336372 and SB 203580 on Raf and SAPK2/p38 are likely to overlap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo23oQKXswmRbVg90H21EOLACvtfcHk0ljc9Inun_0HZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D&md5=93aa7dbc301a6f798be138df3e5a075c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980088-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980088-X%26sid%3Dliteratum%253Aachs%26aulast%3DHall-Jackson%26aufirst%3DC.%2BA.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DHewitt%26aufirst%3DN.%26aulast%3DPlant%26aufirst%3DH.%26aulast%3DHedge%26aufirst%3DP.%26atitle%3DParadoxical%2520Activation%2520of%2520Raf%2520by%2520a%2520Novel%2520Raf%2520Inhibitor%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26issue%3D8%26spage%3D559%26epage%3D568%26doi%3D10.1016%2FS1074-5521%2899%2980088-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Raf Kinase Inhibitor</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0080219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1677%2Ferc.0.0080219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=11566613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlCqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=219-225&issue=3&author=J.+F.+Lyonsauthor=S.+Wilhelmauthor=B.+Hibnerauthor=G.+Bollag&title=Discovery+of+a+Novel+Raf+Kinase+Inhibitor&doi=10.1677%2Ferc.0.0080219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel Raf kinase inhibitor</span></div><div class="casAuthors">Lyons, J. F.; Wilhelm, S.; Hibner, B.; Bollag, G.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-225</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  We discuss the biol. of Ras signal transduction and the epidemiol. of ras mutations in assocn. with disease as a background for the development of a Raf kinase inhibitor, BAY 43-9006.  Knowledge of Ras effector pathways has permitted genetic validation of numerous targets involved in the Ras signaling cascade.  A key Ras effector pathway involves the kinase cascade RAF/MEK/ERK (MEK: MAP/ERK kinase; ERK: extracellular signal related kinase).  Indeed, we present studies of cell lines stably expressing mutant MEK constructs, which point to Raf kinase as a target for therapeutics with selective anti-tumor activity.  Finally, a small mol. drug discovery program based on inhibition of Raf kinase activity is outlined and the initial pre-clin. development process of the Raf kinase inhibitor BAY 43-9006 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKQjOYAj8UXbVg90H21EOLACvtfcHk0ljO6-VEAQBe5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlCqsLc%253D&md5=ea4960d080e9cdef008a8a9bed7d5a42</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0080219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0080219%26sid%3Dliteratum%253Aachs%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DHibner%26aufirst%3DB.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Raf%2520Kinase%2520Inhibitor%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2001%26volume%3D8%26issue%3D3%26spage%3D219%26epage%3D225%26doi%3D10.1677%2Ferc.0.0080219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevreau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolland, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demkow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simantov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, R. M.</span></span> <span> </span><span class="NLM_article-title">TARGET Study Group. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa060655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa060655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=17215530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=125-134&issue=2&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Siebelsauthor=S.+Negrierauthor=C.+Chevreauauthor=E.+Solskaauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Freemanauthor=B.+Schwartzauthor=M.+Shanauthor=R.+Simantovauthor=R.+M.+Bukowski&title=TARGET+Study+Group.+Sorafenib+in+Advanced+Clear-Cell+Renal-Cell+Carcinoma&doi=10.1056%2FNEJMoa060655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced clear-cell renal-cell carcinoma</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael; Negrier, Sylvie; Chevreau, Christine; Solska, Ewa; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Freeman, Scott; Schwartz, Brian; Shan, Minghua; Simantov, Ronit; Bukowski, Ronald M.; Blajman, C.; Fein, L.; Martin, C.; Taber, R.; Boyer, M.; Davis, I.; Gurney, H.; Hovey, E.; Leong, D.; Steer, C.; DeGreve, J.; Gil, T.; Barrios, C.; David, W.; Skare, N. G.; Notari, A.; Schwartsmann, G.; Gunnar, N.; Ernst, S.; Hotte, S.; Miller, W.; Moore, M.; North, S.; Fodor, M.; Caty, A.; Chevreau, C.; Duclos, B.; Gravis, G.; Negrier, S.; Oudard, S.; Ravaud, A.; Rolland, F.; Sevin, E.; Grimm, M. O.; Gschwennd, J.; Heinzer, H.; Jager, E.; Krause, S.; Michel, M.-S.; Rohde, D.; Siebels, M.; Siegsmund, M.; Staehler, M.; Wirth, M.; Baki, M.; Bodrogi, I.; Cseh, J.; Ruzsa, A.; Toth, C.; Ben-Yosef, R.; Gez, E.; Bajetta, E.; Boni, C.; Bracarda, S.; Cognetti, F.; Conte, P.; Porta, C.; Spronsen, D. J.; Blasinka-Morawiec, M.; Dernkow, T.; Lorenz, J.; Mazurkiewicz, M.; Roslki, J.; Sikorski, A.; Solska, E.; Tomczak, P.; Bolotina, L.; Karlov, P.; Karyakin, O.; Khasanov, R.; Lichinitser, M.; Lubennikov, V.; Moiseenko, V.; Sherman, N.; Abratt, R.; Coetzee, L.; Cohen, G.; Heyns, C.; Jordaan, J.; Ruff, P.; Wentzel, S.; Bellmunt, J.; Climent, M. A.; Gonzalez, J. L.; Lopez, G.; Bashtan, V.; Dumamsky, Y.; Klimenko, I.; Pilipenko, N.; Shparik, Y.; Hawkins, R.; McMenemin, R.; Nathan, P.; Porfiri, E.; Savage, P.; White, J.; Anderson, C.; Bains, Y.; Bleickardt, E.; Bradof, J.; Brooks, D.; Cardi, G.; Cervera, A.; Davis, N.; Desai, A.; Drabkin, H.; Dudek, A.; Dutcher, J.; Formanek, G.; Gabrail, N.; Gorss, H.; Haung, Y.; Henderson, C.; Hutson, T.; Jonasch, E.; Lara, P.; McCracken, J.; McDermott, D.; Mena, R.; Middleton, R.; Petrylak, D.; Picus, D.; Quinn, D.; Rausch, P.; Rinaldi, D.; Ryan, C.; Tchekmedyian, N.; Vuky, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.  From Nov. 2003 to Mar. 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to std. therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo.  The primary end point was overall survival.  A single planned anal. of progression-free survival in Jan. 2005 showed a statistically significant benefit of sorafenib over placebo.  Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005.  At the Jan. 2005 cutoff, the median progression-free survival was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55).  The 1st interim anal. of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94), although this benefit was not statistically significant according to the O'Brien-Fleming threshold.  Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo.  Diarrhea, rash, fatigue, and hand-foot skin reactions were the most common adverse events assocd. with sorafenib.  Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.  As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is assocd. with increased toxic effects.  (ClinicalTrials.gov no., NCT00073307).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_8zTNHmXrLVg90H21EOLACvtfcHk0ljO6-VEAQBe5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D&md5=8f6da990729f8ff17587d71744b834f4</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa060655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa060655%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DSiebels%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DTARGET%2520Study%2520Group.%2520Sorafenib%2520in%2520Advanced%2520Clear-Cell%2520Renal-Cell%2520Carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26issue%3D2%26spage%3D125%26epage%3D134%26doi%3D10.1056%2FNEJMoa060655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzaferro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raoul, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolondi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbath, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häussinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannaris, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscovici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliotis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruix, J.</span></span> <span> </span><span class="NLM_article-title">SHARP Investigators Study Group. Sorafenib in Advanced Hepatocellular Carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0708857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa0708857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=18650514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFWjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=378-390&issue=4&author=J.+M.+Llovetauthor=S.+Ricciauthor=V.+Mazzaferroauthor=P.+Hilgardauthor=E.+Ganeauthor=J.-F.+Blancauthor=A.+C.+de+Oliveiraauthor=A.+Santoroauthor=J.-L.+Raoulauthor=A.+Fornerauthor=M.+Schwartzauthor=C.+Portaauthor=S.+Zeuzemauthor=L.+Bolondiauthor=T.+F.+Gretenauthor=P.+R.+Galleauthor=J.-F.+Seitzauthor=I.+Borbathauthor=D.+H%C3%A4ussingerauthor=T.+Giannarisauthor=M.+Shanauthor=M.+Moscoviciauthor=D.+Voliotisauthor=J.+Bruix&title=SHARP+Investigators+Study+Group.+Sorafenib+in+Advanced+Hepatocellular+Carcinoma&doi=10.1056%2FNEJMoa0708857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced hepatocellular carcinoma</span></div><div class="casAuthors">Llovet, Josep M.; Ricci, Sergio; Mazzaferro, Vincenzo; Hilgard, Philip; Gane, Edward; Blanc, Jean-Frederic; Cosme de Oliveira, Andre; Santoro, Armando; Raoul, Jean-Luc; Forner, Alejandro; Schwartz, Myron; Porta, Camillo; Zeuzem, Stefan; Bolondi, Luigi; Greten, Tim F.; Galle, Peter R.; Seitz, Jean-Francois; Borbath, Ivan; Haussinger, Dieter; Giannaris, Tom; Shan, Minghua; Moscovici, Marius; Voliotis, Dimitris; Bruix, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">378-390</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">No effective systemic therapy exists for patients with advanced hepatocellular carcinoma.  A preliminary study suggested that sorafenib, an oral multi-kinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma.  In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo.  Primary outcomes were overall survival and the time to symptomatic progression.  Secondary outcomes included the time to radiol. progression and safety.  At the second planned interim anal., 321 deaths had occurred, and the study was stopped.  Median overall survival was 10.7 mo in the sorafenib group and 7.9 mo in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P < 0.001).  There was no significant difference between the two groups in the median time to symptomatic progression (4.1 mo vs. 4.9 mo, resp., P = 0.77). The median time to radiol. progression was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (P < 0.001).  Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response.  Diarrhea, wt. loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group.  In patients with advanced hepatocellular carcinoma, median survival and the time to radiol. progression were nearly 3 mo longer for patients treated with sorafenib than for those given placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6mcSPrj1TibVg90H21EOLACvtfcHk0lj6bcquNlFunQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFWjsL8%253D&md5=579650dc323f35ad2415523c9827bf9a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0708857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0708857%26sid%3Dliteratum%253Aachs%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26aulast%3DRicci%26aufirst%3DS.%26aulast%3DMazzaferro%26aufirst%3DV.%26aulast%3DHilgard%26aufirst%3DP.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DBlanc%26aufirst%3DJ.-F.%26aulast%3Dde%2BOliveira%26aufirst%3DA.%2BC.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DRaoul%26aufirst%3DJ.-L.%26aulast%3DForner%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DM.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DBolondi%26aufirst%3DL.%26aulast%3DGreten%26aufirst%3DT.%2BF.%26aulast%3DGalle%26aufirst%3DP.%2BR.%26aulast%3DSeitz%26aufirst%3DJ.-F.%26aulast%3DBorbath%26aufirst%3DI.%26aulast%3DH%25C3%25A4ussinger%26aufirst%3DD.%26aulast%3DGiannaris%26aufirst%3DT.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DMoscovici%26aufirst%3DM.%26aulast%3DVoliotis%26aufirst%3DD.%26aulast%3DBruix%26aufirst%3DJ.%26atitle%3DSHARP%2520Investigators%2520Study%2520Group.%2520Sorafenib%2520in%2520Advanced%2520Hepatocellular%2520Carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26issue%3D4%26spage%3D378%26epage%3D390%26doi%3D10.1056%2FNEJMoa0708857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNabola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shujath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eveleigh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voznesensky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7099</span>– <span class="NLM_lpage">7109</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-04-1443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&issue=19&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+Exhibits+Broad+Spectrum+Oral+Antitumor+Activity+and+Targets+the+RAF%2FMEK%2FERK+Pathway+and+Receptor+Tyrosine+Kinases+Involved+in+Tumor+Progression+and+Angiogenesis&doi=10.1158%2F0008-5472.CAN-04-1443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520Exhibits%2520Broad%2520Spectrum%2520Oral%2520Antitumor%2520Activity%2520and%2520Targets%2520the%2520RAF%252FMEK%252FERK%2520Pathway%2520and%2520Receptor%2520Tyrosine%2520Kinases%2520Involved%2520in%2520Tumor%2520Progression%2520and%2520Angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D19%26spage%3D7099%26epage%3D7109%26doi%3D10.1158%2F0008-5472.CAN-04-1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moye, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steelman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blalock, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">Differential Effects of Kinase Cascade Inhibitors on Neoplastic and Cytokine-Mediated Cell Proliferation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1765</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2403052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fsj.leu.2403052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=1765-1782&issue=9&author=J.+G.+Sheltonauthor=P.+W.+Moyeauthor=L.+S.+Steelmanauthor=W.+L.+Blalockauthor=J.+T.+Leeauthor=R.+A.+Franklinauthor=M.+McMahonauthor=J.+A.+McCubrey&title=Differential+Effects+of+Kinase+Cascade+Inhibitors+on+Neoplastic+and+Cytokine-Mediated+Cell+Proliferation&doi=10.1038%2Fsj.leu.2403052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2403052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2403052%26sid%3Dliteratum%253Aachs%26aulast%3DShelton%26aufirst%3DJ.%2BG.%26aulast%3DMoye%26aufirst%3DP.%2BW.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DBlalock%26aufirst%3DW.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DFranklin%26aufirst%3DR.%2BA.%26aulast%3DMcMahon%26aufirst%3DM.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DDifferential%2520Effects%2520of%2520Kinase%2520Cascade%2520Inhibitors%2520on%2520Neoplastic%2520and%2520Cytokine-Mediated%2520Cell%2520Proliferation%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26issue%3D9%26spage%3D1765%26epage%3D1782%26doi%3D10.1038%2Fsj.leu.2403052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottiglieri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Mello, S. R.</span></span> <span> </span><span class="NLM_article-title">The C-Raf Inhibitor GW5074 Provides Neuroprotection in Vitro and in an Animal Model of Neurodegeneration through a MEK-ERK and Akt-Independent Mechanism</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2004.02530.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1111%2Fj.1471-4159.2004.02530.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=15255937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFersbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=595-608&issue=3&author=P.+C.+Chinauthor=L.+Liuauthor=B.+E.+Morrisonauthor=A.+Siddiqauthor=R.+R.+Ratanauthor=T.+Bottiglieriauthor=S.+R.+D%E2%80%99Mello&title=The+C-Raf+Inhibitor+GW5074+Provides+Neuroprotection+in+Vitro+and+in+an+Animal+Model+of+Neurodegeneration+through+a+MEK-ERK+and+Akt-Independent+Mechanism&doi=10.1111%2Fj.1471-4159.2004.02530.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism</span></div><div class="casAuthors">Chin, Paul C.; Liu, Li; Morrison, Bradley E.; Siddiq, Ambreena; Ratan, Rajiv R.; Bottiglieri, Teodoro; D'Mello, Santosh R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-608</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Cerebellar granule neurons undergo apoptosis when switched from a medium contg. high potassium (HK) to one that has low potassium (LK).  LK-induced cell death is blocked by GW5074 {5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}, a synthetic drug that inhibits c-Raf activity in vitro.  GW5074 has no direct effect on the activities of several apoptosis-assocd. kinases when assayed in vitro.  In contrast to its effect in vitro, treatment of neurons with GW5074 causes c-Raf activation (when measured in vitro in the absence of the drug) and stimulates the Raf-MEK-ERK pathway.  Treatment of neurons with GW5074 also leads to an increase in the activity of B-Raf, which is not inhibited by GW5074 in vitro at concns. at which the drug exerts its neuroprotective effect.  PD98059 and U0126, two distinct inhibitors of MEK, block the activation of ERK by GW5074 but have no effect on its ability to prevent cell death.  Overexpression of a dominant-neg. form of Akt does not reduce the efficacy of GW5074, demonstrating an Akt-independent mechanism of action.  Neuroprotection is inhibited by SN-50, a specific inhibitor of nuclear factor-kappa B (NF-κB) and by the Ras inhibitor S-trans, trans-famesylthiosalicylic acid (FTS) implicating NF-κB and Ras in the neuroprotective signaling pathway activated by GW5074.  In addn. to preventing LK-induced apoptosis, treatment with GW5074 protects against the neurotoxic effects of MPP+ and methylmercury in cerebellar granule neurons, and glutathione depletion-induced oxidative stress in cortical neurons.  Furthermore, GW5074 prevents neurodegeneration and improves behavioral outcome in an animal model of Huntington's disease.  Given its neuroprotective effect on distinct types of cultured neurons, in response to different neurotoxic stimuli, and in an animal model of neurodegeneration, GW5074 could have therapeutic value against neurodegenerative pathologies in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Fw56vPqc8LVg90H21EOLACvtfcHk0lhH2ymzeoZuLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFersbY%253D&md5=5cdc3bf26db26b5624567b62b2ae6bc4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2004.02530.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2004.02530.x%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DP.%2BC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMorrison%26aufirst%3DB.%2BE.%26aulast%3DSiddiq%26aufirst%3DA.%26aulast%3DRatan%26aufirst%3DR.%2BR.%26aulast%3DBottiglieri%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Mello%26aufirst%3DS.%2BR.%26atitle%3DThe%2520C-Raf%2520Inhibitor%2520GW5074%2520Provides%2520Neuroprotection%2520in%2520Vitro%2520and%2520in%2520an%2520Animal%2520Model%2520of%2520Neurodegeneration%2520through%2520a%2520MEK-ERK%2520and%2520Akt-Independent%2520Mechanism%26jtitle%3DJ.%2520Neurochem.%26date%3D2004%26volume%3D90%26issue%3D3%26spage%3D595%26epage%3D608%26doi%3D10.1111%2Fj.1471-4159.2004.02530.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batorsky, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takle, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karreth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contractor, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. S.</span></span> <span> </span><span class="NLM_article-title">Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">11100</span>– <span class="NLM_lpage">11105</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-06-2554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11100-11105&issue=23&author=A.+J.+Kingauthor=D.+R.+Patrickauthor=R.+S.+Batorskyauthor=M.+L.+Hoauthor=H.+T.+Doauthor=S.+Y.+Zhangauthor=R.+Kumarauthor=D.+W.+Rusnakauthor=A.+K.+Takleauthor=D.+M.+Wilsonauthor=E.+Huggerauthor=L.+Wangauthor=F.+Karrethauthor=J.+C.+Lougheedauthor=J.+Leeauthor=D.+Chauauthor=T.+J.+Stoutauthor=E.+W.+Mayauthor=C.+M.+Romingerauthor=M.+D.+Schaberauthor=L.+Luoauthor=A.+S.+Lakdawalaauthor=J.+L.+Adamsauthor=R.+G.+Contractorauthor=K.+S.+M.+Smalleyauthor=M.+Herlynauthor=M.+M.+Morrisseyauthor=D.+A.+Tuvesonauthor=P.+S.+Huang&title=Demonstration+of+a+Genetic+Therapeutic+Index+for+Tumors+Expressing+Oncogenic+BRAF+by+the+Kinase+Inhibitor+SB-590885&doi=10.1158%2F0008-5472.CAN-06-2554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2554%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DBatorsky%26aufirst%3DR.%2BS.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKarreth%26aufirst%3DF.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DContractor%26aufirst%3DR.%2BG.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DDemonstration%2520of%2520a%2520Genetic%2520Therapeutic%2520Index%2520for%2520Tumors%2520Expressing%2520Oncogenic%2520BRAF%2520by%2520the%2520Kinase%2520Inhibitor%2520SB-590885%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D23%26spage%3D11100%26epage%3D11105%26doi%3D10.1158%2F0008-5472.CAN-06-2554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span> <span> </span><span class="NLM_article-title">Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3042</span>– <span class="NLM_lpage">3051</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-3563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-08-3563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3042-3051&issue=7&author=K.+P.+Hoeflichauthor=S.+Herterauthor=J.+Tienauthor=L.+Wongauthor=L.+Berryauthor=J.+Chanauthor=C.+O%E2%80%99Brienauthor=Z.+Modrusanauthor=S.+Seshagiriauthor=M.+Lacknerauthor=H.+Sternauthor=E.+Chooauthor=L.+Murrayauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Antitumor+Efficacy+of+the+Novel+RAF+Inhibitor+GDC-0879+Is+Predicted+by+BRAFV600E+Mutational+Status+and+Sustained+Extracellular+Signal-Regulated+Kinase%2FMitogen-Activated+Protein+Kinase+Pathway+Suppression&doi=10.1158%2F0008-5472.CAN-08-3563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-3563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-3563%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DHerter%26aufirst%3DS.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DLackner%26aufirst%3DM.%26aulast%3DStern%26aufirst%3DH.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DAntitumor%2520Efficacy%2520of%2520the%2520Novel%2520RAF%2520Inhibitor%2520GDC-0879%2520Is%2520Predicted%2520by%2520BRAFV600E%2520Mutational%2520Status%2520and%2520Sustained%2520Extracellular%2520Signal-Regulated%2520Kinase%252FMitogen-Activated%2520Protein%2520Kinase%2520Pathway%2520Suppression%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D7%26spage%3D3042%26epage%3D3051%26doi%3D10.1158%2F0008-5472.CAN-08-3563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproesser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3046</span>, <span class="refDoi"> DOI: 10.1073/pnas.0711741105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&issue=8&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.-L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+Selective+Inhibitor+of+Oncogenic+B-Raf+Kinase+with+Potent+Antimelanoma+Activity&doi=10.1073%2Fpnas.0711741105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lhkP529-I-7eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.-L.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Inhibitor%2520of%2520Oncogenic%2520B-Raf%2520Kinase%2520with%2520Potent%2520Antimelanoma%2520Activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D8%26spage%3D3041%26epage%3D3046%26doi%3D10.1073%2Fpnas.0711741105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span> (<span class="NLM_issue">7315</span>),  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&issue=7315&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+Efficacy+of+a+RAF+Inhibitor+Needs+Broad+Target+Blockade+in+BRAF-Mutant+Melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lg2o7X5faKE2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520Efficacy%2520of%2520a%2520RAF%2520Inhibitor%2520Needs%2520Broad%2520Target%2520Blockade%2520in%2520BRAF-Mutant%2520Melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26issue%3D7315%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in Patients with Melanoma, Untreated Brain Metastases, and Other Solid Tumours: A Phase 1 Dose-Escalation Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">9829</span>),  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1901</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60398-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0140-6736%2812%2960398-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1893-1901&issue=9829&author=G.+S.+Falchookauthor=G.+V.+Longauthor=R.+Kurzrockauthor=K.+B.+Kimauthor=T.+H.+Arkenauauthor=M.+P.+Brownauthor=O.+Hamidauthor=J.+R.+Infanteauthor=M.+Millwardauthor=A.+C.+Pavlickauthor=S.+J.+O%E2%80%99Dayauthor=S.+C.+Blackmanauthor=C.+M.+Curtisauthor=P.+Lebowitzauthor=B.+Maauthor=D.+Ouelletauthor=R.+F.+Kefford&title=Dabrafenib+in+Patients+with+Melanoma%2C+Untreated+Brain+Metastases%2C+and+Other+Solid+Tumours%3A+A+Phase+1+Dose-Escalation+Trial&doi=10.1016%2FS0140-6736%2812%2960398-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960398-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960398-5%26sid%3Dliteratum%253Aachs%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DArkenau%26aufirst%3DT.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26aulast%3DCurtis%26aufirst%3DC.%2BM.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26atitle%3DDabrafenib%2520in%2520Patients%2520with%2520Melanoma%252C%2520Untreated%2520Brain%2520Metastases%252C%2520and%2520Other%2520Solid%2520Tumours%253A%2520A%2520Phase%25201%2520Dose-Escalation%2520Trial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26issue%3D9829%26spage%3D1893%26epage%3D1901%26doi%3D10.1016%2FS0140-6736%2812%2960398-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempgen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in BRAF-Mutated Metastatic Melanoma: A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">9839</span>),  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60868-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&issue=9839&author=A.+Hauschildauthor=J.-J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.-M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-Mutated+Metastatic+Melanoma%3A+A+Multicentre%2C+Open-Label%2C+Phase+3+Randomised+Controlled+Trial&doi=10.1016%2FS0140-6736%2812%2960868-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.-M.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-Mutated%2520Metastatic%2520Melanoma%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Phase%25203%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26issue%3D9839%26spage%3D358%26epage%3D365%26doi%3D10.1016%2FS0140-6736%2812%2960868-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spleiss, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kockx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1105358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa1105358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22256804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=207-215&issue=3&author=F.+Suauthor=A.+Virosauthor=C.+Milagreauthor=K.+Trunzerauthor=G.+Bollagauthor=O.+Spleissauthor=J.+S.+Reis-Filhoauthor=X.+Kongauthor=R.+C.+Koyaauthor=K.+T.+Flahertyauthor=P.+B.+Chapmanauthor=M.+J.+Kimauthor=R.+Haywardauthor=M.+Martinauthor=H.+Yangauthor=Q.+Wangauthor=H.+Hiltonauthor=J.+S.+Hangauthor=J.+Noeauthor=M.+Lambrosauthor=F.+Geyerauthor=N.+Dhomenauthor=I.+Niculescu-Duvazauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=N.+Preeceauthor=L.+Robertauthor=N.+J.+Otteauthor=S.+Mokauthor=D.+Keeauthor=Y.+Maauthor=C.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=H.+Nguyenauthor=M.+Kockxauthor=L.+Andriesauthor=B.+Lestiniauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=J.+L.+Troyauthor=R.+Gonzalezauthor=T.+E.+Hutsonauthor=I.+Puzanovauthor=B.+Chmielowskiauthor=C.+J.+Springerauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=R.+S.+Loauthor=A.+Ribasauthor=R.+Marais&title=RAS+Mutations+in+Cutaneous+Squamous-Cell+Carcinomas+in+Patients+Treated+with+BRAF+Inhibitors&doi=10.1056%2FNEJMoa1105358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span></div><div class="casAuthors">Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S.; Kong, Xiangju; Koya, Richard C.; Flaherty, Keith T.; Chapman, Paul B.; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Nguyen, Hoa; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Troy, James L.; Gonzalez, Rene; Hutson, Thomas E.; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J.; McArthur, Grant A.; Sosman, Jeffrey A.; Lo, Roger S.; Ribas, Antoni; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.  METHODS: We performed a mol. anal. to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.  An anal. of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed.  RESULTS: Among 21 tumor samples, 13 had RAS mutations (12 in HRAS).  In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS).  Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L.  Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was assocd. with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription.  In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analog PLX4720 was not an initiator or a.promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor.  CONCLUSIONS: Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib.  The mol. mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplrkvSEAdDG7Vg90H21EOLACvtfcHk0lgR1z6lnGo99w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D&md5=6c813dc23344a8eedcc7a289d2326f4f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105358%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DF.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DTrunzer%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSpleiss%26aufirst%3DO.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DHayward%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BS.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKockx%26aufirst%3DM.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DTroy%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DRAS%2520Mutations%2520in%2520Cutaneous%2520Squamous-Cell%2520Carcinomas%2520in%2520Patients%2520Treated%2520with%2520BRAF%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D3%26spage%3D207%26epage%3D215%26doi%3D10.1056%2FNEJMoa1105358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">B-Raf and the Inhibitors: From Bench to Bedside</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-6-30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1186%2F1756-8722-6-30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23617957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFWrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=30&author=T.+Huangauthor=M.+Karsyauthor=J.+Zhugeauthor=M.+Zhongauthor=D.+Liu&title=B-Raf+and+the+Inhibitors%3A+From+Bench+to+Bedside&doi=10.1186%2F1756-8722-6-30"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">B-Raf and the inhibitors: from bench to bedside</span></div><div class="casAuthors">Huang, Tiangui; Karsy, Michael; Zhuge, Jian; Zhong, Minghao; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The B-Raf protein is a key signaling mol. in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of cancers.  An important V600E mutation has been identified and can cause constitutive B-Raf activation.  Recent studies have evaluated a variety of small mol. inhibitors targeting B-Raf, including PLX4032/vemurafenib, dabrafenib, LGX818, GDC0879, XL281, ARQ736, PLX3603 (RO5212054), and RAF265.  Therapeutic resistance has been identified and various mechanisms described.  This review also discussed the current understanding of B-Raf signaling mechanism, methods of mutation detection, treatment strategies as well as potential methods of overcoming therapeutic resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW96ypSxw3MrVg90H21EOLACvtfcHk0lgBnJnvgTF1vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFWrsLw%253D&md5=62c83f28798a093cf4be76376020721b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-30%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DKarsy%26aufirst%3DM.%26aulast%3DZhuge%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DB-Raf%2520and%2520the%2520Inhibitors%253A%2520From%2520Bench%2520to%2520Bedside%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D30%26doi%3D10.1186%2F1756-8722-6-30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salangsang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoddusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryer, N.</span></span> <span> </span><span class="NLM_article-title">Abstract 3790: Preclinical Profile of LGX818: A Potent and Selective RAF Kinase Inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">8 Suppl.</span>),  <span class="NLM_fpage">3790</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2012-3790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1538-7445.AM2012-3790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3790-3790&issue=8+Suppl.&author=D.+D.+Stuartauthor=N.+Liauthor=D.+J.+Poonauthor=K.+Aardalenauthor=S.+Kaufmanauthor=H.+Merrittauthor=F.+Salangsangauthor=E.+Lorenzanaauthor=A.+Liauthor=M.+Ghoddusiauthor=G.+Caponigroauthor=F.+Sunauthor=S.+Kulkarniauthor=S.+Kakarauthor=N.+Turnerauthor=R.+Zangauthor=J.+Tellewauthor=N.+Pryer&title=Abstract+3790%3A+Preclinical+Profile+of+LGX818%3A+A+Potent+and+Selective+RAF+Kinase+Inhibitor&doi=10.1158%2F1538-7445.AM2012-3790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-3790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-3790%26sid%3Dliteratum%253Aachs%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DSalangsang%26aufirst%3DF.%26aulast%3DLorenzana%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGhoddusi%26aufirst%3DM.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DKakar%26aufirst%3DS.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DPryer%26aufirst%3DN.%26atitle%3DAbstract%25203790%253A%2520Preclinical%2520Profile%2520of%2520LGX818%253A%2520A%2520Potent%2520and%2520Selective%2520RAF%2520Kinase%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D8%2520Suppl%26spage%3D3790%26epage%3D3790%26doi%3D10.1158%2F1538-7445.AM2012-3790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span> <span> </span><span class="NLM_article-title">Encorafenib (LGX818), a Potent BRAF Inhibitor, Induces Senescence Accompanied by Autophagy in BRAFV600E Melanoma Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2015.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.canlet.2015.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26586345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKmt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2016&pages=332-344&issue=2&author=Z.+Liauthor=K.+Jiangauthor=X.+Zhuauthor=G.+Linauthor=F.+Songauthor=Y.+Zhaoauthor=Y.+Piaoauthor=J.+Liuauthor=W.+Chengauthor=X.+Biauthor=P.+Gongauthor=Z.+Songauthor=S.+Meng&title=Encorafenib+%28LGX818%29%2C+a+Potent+BRAF+Inhibitor%2C+Induces+Senescence+Accompanied+by+Autophagy+in+BRAFV600E+Melanoma+Cells&doi=10.1016%2Fj.canlet.2015.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells</span></div><div class="casAuthors">Li, Zhen; Jiang, Ke; Zhu, Xiaofang; Lin, Guibin; Song, Fei; Zhao, Yongfu; Piao, Yongjun; Liu, Jiwei; Cheng, Wei; Bi, Xiaolin; Gong, Peng; Song, Zhiqi; Meng, Songshu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-344</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clin. trials.  However, the underlying mechanism remains to be elucidated.  Here the authors show that LGX818 potently decreased ERK phosphorylation and inhibited proliferation in BRAFV600E melanoma cell lines.  Moreover, LGX818 downregulated Cyclin D1 in a glycogen synthase kinase 3β-independent manner and induced cell cycle arrest in the G1 phase.  Surprisingly, LGX818 triggered cellular senescence in BRAFV600E melanoma cells, as evidenced by increased β-galactosidase staining, while no appreciable induction of apoptosis was detected, as detd. by Annexin V and propidium iodide staining and immunoblot anal. of caspase-3 processing and poly (ADP-ribose) polymerase cleavage.  Increased p27KIP1 expression and retinoblastoma protein activation were detected during LGX818-induced senescence.  Addnl., inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 1B by AZ191 reversed LGX818-induced Cyclin D1 turnover and senescence.  Interestingly, autophagy is triggered through inhibition of the mTOR/70S6K pathway during LGX818-induced senescence.  Moreover, autophagy inhibition by pharmacol. and genetic regulation attenuates LGX818-induced senescence.  Notably, combining LGX818 with autophagy modulators has anti-proliferative effect in LGX818-resistant BRAF mutant melanoma cells.  Altogether, the authors uncovered a mechanism by which LGX818 exerts its anti-tumor activity in BRAFV600E melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu_EM8hUteQLVg90H21EOLACvtfcHk0lgBnJnvgTF1vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKmt73O&md5=c1b58e63bbaa50db4765ceb932f810d1</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2015.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2015.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DPiao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DBi%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DS.%26atitle%3DEncorafenib%2520%2528LGX818%2529%252C%2520a%2520Potent%2520BRAF%2520Inhibitor%252C%2520Induces%2520Senescence%2520Accompanied%2520by%2520Autophagy%2520in%2520BRAFV600E%2520Melanoma%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D370%26issue%3D2%26spage%3D332%26epage%3D344%26doi%3D10.1016%2Fj.canlet.2015.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span>Study
Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and
LGX818 Monotherapy in BRAF Mutant Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01909453" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01909453</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0AComparing+Combination+of+LGX818+Plus+MEK162+Versus+Vemurafenib+and%0ALGX818+Monotherapy+in+BRAF+Mutant+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01909453+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clary, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of XL281 (BMS-908662), a Potent Oral RAF Kinase Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0191-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1007%2Fs10637-014-0191-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=349-356&issue=2&author=M.+A.+Dicksonauthor=M.+S.+Gordonauthor=G.+Edelmanauthor=J.+C.+Bendellauthor=R.+R.+Kudchadkarauthor=P.+M.+LoRussoauthor=S.+H.+Johnstonauthor=D.+O.+Claryauthor=G.+K.+Schwartz&title=Phase+I+Study+of+XL281+%28BMS-908662%29%2C+a+Potent+Oral+RAF+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1007%2Fs10637-014-0191-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0191-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0191-5%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DEdelman%26aufirst%3DG.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DJohnston%26aufirst%3DS.%2BH.%26aulast%3DClary%26aufirst%3DD.%2BO.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DPhase%2520I%2520Study%2520of%2520XL281%2520%2528BMS-908662%2529%252C%2520a%2520Potent%2520Oral%2520RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D2%26spage%3D349%26epage%3D356%26doi%3D10.1007%2Fs10637-014-0191-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dials, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of XL281, a Selective Oral RAF Kinase Inhibitor, in Patients (Pts) with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">15S</span>),  <span class="NLM_fpage">3513</span>– <span class="NLM_lpage">3513</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3513-3513&issue=15S&author=G.+K.+Schwartzauthor=S.+Robertsonauthor=A.+Shenauthor=E.+Wangauthor=L.+Paceauthor=H.+Dialsauthor=D.+Mendelsonauthor=P.+Shannonauthor=M.+Gordon&title=A+Phase+I+Study+of+XL281%2C+a+Selective+Oral+RAF+Kinase+Inhibitor%2C+in+Patients+%28Pts%29+with+Advanced+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DRobertson%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DPace%26aufirst%3DL.%26aulast%3DDials%26aufirst%3DH.%26aulast%3DMendelson%26aufirst%3DD.%26aulast%3DShannon%26aufirst%3DP.%26aulast%3DGordon%26aufirst%3DM.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520XL281%252C%2520a%2520Selective%2520Oral%2520RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26issue%3D15S%26spage%3D3513%26epage%3D3513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clary, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of XL281 (BMS-908662), a Potent Oral RAF Kinase Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0191-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1007%2Fs10637-014-0191-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=349-356&issue=2&author=M.%0AA.+Dicksonauthor=M.+S.+Gordonauthor=G.+Edelmanauthor=J.+C.+Bendellauthor=R.+R.+Kudchadkarauthor=P.+M.+LoRussoauthor=S.+H.+Johnstonauthor=D.+O.+Claryauthor=G.+K.+Schwartz&title=Phase+I+Study+of+XL281+%28BMS-908662%29%2C+a+Potent+Oral+RAF+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1007%2Fs10637-014-0191-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0191-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0191-5%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DEdelman%26aufirst%3DG.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DJohnston%26aufirst%3DS.%2BH.%26aulast%3DClary%26aufirst%3DD.%2BO.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DPhase%2520I%2520Study%2520of%2520XL281%2520%2528BMS-908662%2529%252C%2520a%2520Potent%2520Oral%2520RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D2%26spage%3D349%26epage%3D356%26doi%3D10.1007%2Fs10637-014-0191-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltz, L.</span></span> <span> </span><span class="NLM_article-title">Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">4032</span>– <span class="NLM_lpage">4038</span>, <span class="refDoi"> DOI: 10.1200/JCO.2015.63.2497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1200%2FJCO.2015.63.2497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26460303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvV2gtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=4032-4038&issue=34&author=S.+Kopetzauthor=J.+Desaiauthor=E.+Chanauthor=J.+R.+Hechtauthor=P.+J.+O%E2%80%99Dwyerauthor=D.+Maruauthor=V.+Morrisauthor=F.+Jankuauthor=A.+Dasariauthor=W.+Chungauthor=J.-P.+J.+Issaauthor=P.+Gibbsauthor=B.+Jamesauthor=G.+Powisauthor=K.+B.+Nolopauthor=S.+Bhattacharyaauthor=L.+Saltz&title=Phase+II+Pilot+Study+of+Vemurafenib+in+Patients+With+Metastatic+BRAF-Mutated+Colorectal+Cancer&doi=10.1200%2FJCO.2015.63.2497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer</span></div><div class="casAuthors">Kopetz, Scott; Desai, Jayesh; Chan, Emily; Hecht, Joel Randolph; O'Dwyer, Peter J.; Maru, Dipen; Morris, Van; Janku, Filip; Dasari, Arvind; Chung, Woonbook; Issa, Jean-Pierre J.; Gibbs, Peter; James, Brian; Powis, Garth; Nolop, Keith B.; Bhattacharya, Suman; Saltz, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4032-4038</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is assocd. with poor prognosis.  Vemurafenib, an oralBRAF V600 inhibitor, has pronounced activity in patients with metastatic melanoma, but its activity in patients with BRAF V600E-pos. metastatic CRC was unknown.  In this multi-institutional, open-label study, patients with metastatic CRC with BRAF V600 mutations were recruited to an expansion cohort at the previously detd. max.-tolerated dose of 960 mg orally twice a day.  Twenty-one patients were enrolled, of whom 20 had received at least one prior metastatic chemotherapy regimen.  Grade 3 toxicities included keratoacanthomas, rash, fatigue, and arthralgia.  Of the 21 patients treated, one patient had a confirmed partial response (5%; 95% CI, 1% to 24%) and seven other patients had stable disease by RECIST criteria.  Median progression-free survival was 2.1 mo.  Patterns of concurrent mutations, microsatellite instability status, CpG island methylation status, PTEN loss, EGFR expression, and copy no. alterations were not assocd. with clin. benefit.  In contrast to prior expectations, concurrent KRAS and NRAS mutations were detected at low allele frequency in a subset of the patients' tumors (median, 0.21% allele frequency) and were apparent mechanisms of acquired resistance in vemurafenib-sensitive patient-derived xenograft models.  In marked contrast to the results seen in patients with BRAF V600E-mutant melanoma, single-agent vemurafenib did not show meaningful clin. activity in patients with BRAF V600E mutant CRC.  Combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYRSTz4lRinbVg90H21EOLACvtfcHk0lg7p04-Z78Ciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvV2gtr8%253D&md5=0486caf26220c2b1fe93ec73ac84ee37</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.63.2497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.63.2497%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DHecht%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DMaru%26aufirst%3DD.%26aulast%3DMorris%26aufirst%3DV.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DDasari%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DIssa%26aufirst%3DJ.-P.%2BJ.%26aulast%3DGibbs%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DB.%26aulast%3DPowis%26aufirst%3DG.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DSaltz%26aufirst%3DL.%26atitle%3DPhase%2520II%2520Pilot%2520Study%2520of%2520Vemurafenib%2520in%2520Patients%2520With%2520Metastatic%2520BRAF-Mutated%2520Colorectal%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D34%26spage%3D4032%26epage%3D4038%26doi%3D10.1200%2FJCO.2015.63.2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faris, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elez-Fernandez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofheinz, R.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasserre, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makrutzki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirzen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1502309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa1502309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26287849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFWrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=726-736&issue=8&author=D.+M.+Hymanauthor=I.+Puzanovauthor=V.+Subbiahauthor=J.+E.+Farisauthor=I.+Chauauthor=J.-Y.+Blayauthor=J.+Wolfauthor=N.+S.+Rajeauthor=E.+L.+Diamondauthor=A.+Hollebecqueauthor=R.+Gervaisauthor=M.+E.+Elez-Fernandezauthor=A.+Italianoauthor=R.-D.+Hofheinzauthor=M.+Hidalgoauthor=E.+Chanauthor=M.+Schulerauthor=S.+F.+Lasserreauthor=M.+Makrutzkiauthor=F.+Sirzenauthor=M.+L.+Veroneseauthor=J.+Taberneroauthor=J.+Baselga&title=Vemurafenib+in+Multiple+Nonmelanoma+Cancers+with+BRAF+V600+Mutations&doi=10.1056%2FNEJMoa1502309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations</span></div><div class="casAuthors">Hyman, David M.; Puzanov, Igor; Subbiah, Vivek; Faris, Jason E.; Chau, Ian; Blay, Jean-Yves; Wolf, Jurgen; Raje, Noopur S.; Diamond, Eli L.; Hollebecque, Antoine; Gervais, Radj; Elez-Fernandez, Maria Elena; Italiano, Antoine; Hofheinz, Ralf-Dieter; Hidalgo, Manuel; Chan, Emily; Schuler, Martin; Lasserre, Susan Frances; Makrutzki, Martina; Sirzen, Florin; Veronese, Maria Luisa; Tabernero, Josep; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">726-736</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers.  We undertook a histol.-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation- pos. nonmelanoma cancers.  METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort.  A total of 122 patients with BRAF V600 mutation-pos. cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab.  The primary end point was the response rate; secondary end points included progression-free and overall survival.  RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 mo (95% CI, 3.5 to 10.8).  In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 mo (range, 0.6 to 18.6), and no patients had disease progression during therapy.  There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab.  Safety was similar to that in prior studies of vemurafenib for melanoma.  CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers.  Preliminary vemurafenib activity was obsd. in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.  The histol. context is an important determinant of response in BRAF V600-mutated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov1cskwNZrtLVg90H21EOLACvtfcHk0lgizd6GN6xbsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFWrtg%253D%253D&md5=a91d4ce875a05e4bbec36e69dfb08b80</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1502309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1502309%26sid%3Dliteratum%253Aachs%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DFaris%26aufirst%3DJ.%2BE.%26aulast%3DChau%26aufirst%3DI.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DRaje%26aufirst%3DN.%2BS.%26aulast%3DDiamond%26aufirst%3DE.%2BL.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DGervais%26aufirst%3DR.%26aulast%3DElez-Fernandez%26aufirst%3DM.%2BE.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DHofheinz%26aufirst%3DR.-D.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DLasserre%26aufirst%3DS.%2BF.%26aulast%3DMakrutzki%26aufirst%3DM.%26aulast%3DSirzen%26aufirst%3DF.%26aulast%3DVeronese%26aufirst%3DM.%2BL.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DVemurafenib%2520in%2520Multiple%2520Nonmelanoma%2520Cancers%2520with%2520BRAF%2520V600%2520Mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D8%26spage%3D726%26epage%3D736%26doi%3D10.1056%2FNEJMoa1502309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecchin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition through Feedback Activation of EGFR</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>483</i></span> (<span class="NLM_issue">7387</span>),  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1038/nature10868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature10868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=100-103&issue=7387&author=A.+Prahalladauthor=C.+Sunauthor=S.+Huangauthor=F.+Di+Nicolantonioauthor=R.+Salazarauthor=D.+Zecchinauthor=R.+L.+Beijersbergenauthor=A.+Bardelliauthor=R.+Bernards&title=Unresponsiveness+of+Colon+Cancer+to+BRAF%28V600E%29+Inhibition+through+Feedback+Activation+of+EGFR&doi=10.1038%2Fnature10868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnature10868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10868%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DSalazar%26aufirst%3DR.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DUnresponsiveness%2520of%2520Colon%2520Cancer%2520to%2520BRAF%2528V600E%2529%2520Inhibition%2520through%2520Feedback%2520Activation%2520of%2520EGFR%26jtitle%3DNature%26date%3D2012%26volume%3D483%26issue%3D7387%26spage%3D100%26epage%3D103%26doi%3D10.1038%2Fnature10868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turke, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogdill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pelle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">EGFR-Mediated Re-Activation of MAPK Signaling Contributes to Insensitivity of BRAF Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-11-0341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22448344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=227-235&issue=3&author=R.+B.+Corcoranauthor=H.+Ebiauthor=A.+B.+Turkeauthor=E.+M.+Coffeeauthor=M.+Nishinoauthor=A.+P.+Cogdillauthor=R.+D.+Brownauthor=P.+Della+Pelleauthor=D.+Dias-Santagataauthor=K.+E.+Hungauthor=K.+T.+Flahertyauthor=A.+Pirisauthor=J.+A.+Wargoauthor=J.+Settlemanauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=EGFR-Mediated+Re-Activation+of+MAPK+Signaling+Contributes+to+Insensitivity+of+BRAF+Mutant+Colorectal+Cancers+to+RAF+Inhibition+with+Vemurafenib&doi=10.1158%2F2159-8290.CD-11-0341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib</span></div><div class="casAuthors">Corcoran, Ryan B.; Ebi, Hiromichi; Turke, Alexa B.; Coffee, Erin M.; Nishino, Michiya; Cogdill, Alexandria P.; Brown, Ronald D.; Della Pelle, Patricia; Dias-Santagata, Dora; Hung, Kenneth E.; Flaherty, Keith T.; Piris, Adriano; Wargo, Jennifer A.; Settleman, Jeffrey; Mino-Kenudson, Mari; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">227-235</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in the metastatic setting.  Although RAF inhibitors such as vemurafenib (PLX4032) have proven effective in the treatment of BRAF-mutant melanoma, they are surprisingly ineffective in BRAF-mutant colorectal cancers, and the reason for this disparity remains unclear.  Compared with BRAF-mutant melanoma cells, BRAF-mutant colorectal cancer cells were less sensitive to vemurafenib, and phospho-extracellular signal-regulated kinase (P-ERK) suppression was not sustained in response to treatment.  Although transient inhibition of P-ERK by vemurafenib was obsd. in colorectal cancer, rapid ERK reactivation occurred through epidermal growth factor receptor (EGFR)-mediated activation of RAS and CRAF.  BRAF-mutant colorectal cancers expressed greater levels of phospho-EGFR than BRAF-mutant melanomas, suggesting that colorectal cancers are specifically poised for EGFR-mediated resistance.  Combined RAF and EGFR inhibition blocked reactivation of mitogen-activated protein kinase (MAPK) signaling in BRAF-mutant colorectal cancer cells and markedly improved efficacy in vitro and in vivo.  These findings support the evaluation of combined RAF and EGFR inhibition in patients with BRAF-mutant colorectal cancer.  SIGNIFICANCE: BRAF valine 600 (V600) mutations occur in 10% to 15% of colorectal cancers, yet these tumors show a surprisingly low clin. response rate (∼5%) to selective RAF inhibitors such as vemurafenib, which have produced dramatic response rates (60%-80%) in melanomas harboring the identical BRAF V600 mutation.  We found that EGFR-mediated MAPK pathway reactivation leads to resistance to vemurafenib in BRAF-mutant colorectal cancers and that combined RAF and EGFR inhibition can lead to sustained MAPK pathway suppression and improved efficacy in vitro and in tumor xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFZt8toXDqQrVg90H21EOLACvtfcHk0likGcqW5QVvpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGntbs%253D&md5=8de601cad959e7ad51ff4a6f96e183f4</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0341%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DCoffee%26aufirst%3DE.%2BM.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DCogdill%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DR.%2BD.%26aulast%3DDella%2BPelle%26aufirst%3DP.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DHung%26aufirst%3DK.%2BE.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPiris%26aufirst%3DA.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DEGFR-Mediated%2520Re-Activation%2520of%2520MAPK%2520Signaling%2520Contributes%2520to%2520Insensitivity%2520of%2520BRAF%2520Mutant%2520Colorectal%2520Cancers%2520to%2520RAF%2520Inhibition%2520with%2520Vemurafenib%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D3%26spage%3D227%26epage%3D235%26doi%3D10.1158%2F2159-8290.CD-11-0341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahrendt, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrigo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, G.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 3: An Increase in Aqueous Solubility via the Disruption of Crystal Packing</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bmcl.2011.12.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=912-915&issue=2&author=S.+Wenglowskyauthor=D.+Morenoauthor=J.+Rudolphauthor=Y.+Ranauthor=K.+A.+Ahrendtauthor=A.+Arrigoauthor=B.+Colsonauthor=S.+L.+Gloorauthor=G.+Hastings&title=Pyrazolopyridine+Inhibitors+of+B-Raf%28V600E%29.+Part+3%3A+An+Increase+in+Aqueous+Solubility+via+the+Disruption+of+Crystal+Packing&doi=10.1016%2Fj.bmcl.2011.12.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DAhrendt%26aufirst%3DK.%2BA.%26aulast%3DArrigo%26aufirst%3DA.%26aulast%3DColson%26aufirst%3DB.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DHastings%26aufirst%3DG.%26atitle%3DPyrazolopyridine%2520Inhibitors%2520of%2520B-Raf%2528V600E%2529.%2520Part%25203%253A%2520An%2520Increase%2520in%2520Aqueous%2520Solubility%2520via%2520the%2520Disruption%2520of%2520Crystal%2520Packing%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D912%26epage%3D915%26doi%3D10.1016%2Fj.bmcl.2011.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telikepalli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobb, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglicmot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(3,3-Dimethylbutyl)-3-(2-Fluoro-4-Methyl-5-(7-Methyl-2-(Methylamino)Pyrido[2,3-d]Pyrimidin-6-Yl)Phenyl)Urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4165</span>– <span class="NLM_lpage">4179</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4165-4179&issue=10&author=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=S.-B.+Pengauthor=Y.+M.+Ahnauthor=T.+M.+Caldwellauthor=L.+Vogetiauthor=H.+Telikepalliauthor=W.-P.+Luauthor=M.+M.+Hoodauthor=T.+J.+Rutkoskiauthor=B.+D.+Smithauthor=S.+Vogetiauthor=D.+Millerauthor=S.+C.+Wiseauthor=L.+Chunauthor=X.+Zhangauthor=Y.+Zhangauthor=L.+Kaysauthor=P.+A.+Hipskindauthor=A.+D.+Wrobleskiauthor=K.+L.+Lobbauthor=J.+M.+Clayauthor=J.+D.+Cohenauthor=J.+L.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=D.+K.+Clawsonauthor=S.+Guoauthor=D.+Manglicmotauthor=C.+Groshongauthor=C.+Loganauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Discovery+of+1-%283%2C3-Dimethylbutyl%29-3-%282-Fluoro-4-Methyl-5-%287-Methyl-2-%28Methylamino%29Pyrido%5B2%2C3-d%5DPyrimidin-6-Yl%29Phenyl%29Urea+%28LY3009120%29+as+a+Pan-RAF+Inhibitor+with+Minimal+Paradoxical+Activation+and+Activity+against+BRAF+or+RAS+Mutant+Tumor+Cells&doi=10.1021%2Facs.jmedchem.5b00067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00067%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DHipskind%26aufirst%3DP.%2BA.%26aulast%3DWrobleski%26aufirst%3DA.%2BD.%26aulast%3DLobb%26aufirst%3DK.%2BL.%26aulast%3DClay%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BD.%26aulast%3DWalgren%26aufirst%3DJ.%2BL.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DClawson%26aufirst%3DD.%2BK.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DManglicmot%26aufirst%3DD.%26aulast%3DGroshong%26aufirst%3DC.%26aulast%3DLogan%26aufirst%3DC.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DDiscovery%2520of%25201-%25283%252C3-Dimethylbutyl%2529-3-%25282-Fluoro-4-Methyl-5-%25287-Methyl-2-%2528Methylamino%2529Pyrido%255B2%252C3-d%255DPyrimidin-6-Yl%2529Phenyl%2529Urea%2520%2528LY3009120%2529%2520as%2520a%2520Pan-RAF%2520Inhibitor%2520with%2520Minimal%2520Paradoxical%2520Activation%2520and%2520Activity%2520against%2520BRAF%2520or%2520RAS%2520Mutant%2520Tumor%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D10%26spage%3D4165%26epage%3D4179%26doi%3D10.1021%2Facs.jmedchem.5b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blosser, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowless, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stancato, L. F.</span></span> <span> </span><span class="NLM_article-title">LY3009120, a PanRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">9251</span>– <span class="NLM_lpage">9266</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.18632%2Foncotarget.14002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=9251-9266&issue=6&author=E.+Vakanaauthor=S.+Prattauthor=W.+Blosserauthor=M.+Dowlessauthor=N.+Simpsonauthor=X.-J.+Yuanauthor=S.+Jakenauthor=J.+Manroauthor=J.+Stephensauthor=Y.+Zhangauthor=L.+Huberauthor=S.-B.+Pengauthor=L.+F.+Stancato&title=LY3009120%2C+a+PanRAF+Inhibitor%2C+Has+Significant+Anti-Tumor+Activity+in+BRAF+and+KRAS+Mutant+Preclinical+Models+of+Colorectal+Cancer&doi=10.18632%2Foncotarget.14002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14002%26sid%3Dliteratum%253Aachs%26aulast%3DVakana%26aufirst%3DE.%26aulast%3DPratt%26aufirst%3DS.%26aulast%3DBlosser%26aufirst%3DW.%26aulast%3DDowless%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DX.-J.%26aulast%3DJaken%26aufirst%3DS.%26aulast%3DManro%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DStancato%26aufirst%3DL.%2BF.%26atitle%3DLY3009120%252C%2520a%2520PanRAF%2520Inhibitor%252C%2520Has%2520Significant%2520Anti-Tumor%2520Activity%2520in%2520BRAF%2520and%2520KRAS%2520Mutant%2520Preclinical%2520Models%2520of%2520Colorectal%2520Cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D6%26spage%3D9251%26epage%3D9266%26doi%3D10.18632%2Foncotarget.14002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span>A Study
of LY3009120 in Participants With Advanced Cancer or Cancer That Has
Spread to Other Parts of Their Body. <a href="https://clinicaltrials.gov/ct2/show/NCT02014116" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02014116</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+LY3009120+in+Participants+With+Advanced+Cancer+or+Cancer+That+Has%0ASpread+to+Other+Parts+of+Their+Body.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02014116+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tottori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">6478</span>– <span class="NLM_lpage">6494</span>, <span class="refDoi"> DOI: 10.1021/jm400778d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400778d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6478-6494&issue=16&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Nakamuraauthor=T.+Takagiauthor=T.+Kawamotoauthor=N.+Uchiyamaauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=Y.+Inuiauthor=B.-C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Discovery+of+a+Selective+Kinase+Inhibitor+%28TAK-632%29+Targeting+Pan-RAF+Inhibition%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+C-7-Substituted+1%2C3-Benzothiazole+Derivatives&doi=10.1021%2Fjm400778d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400778d%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DB.-C.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Kinase%2520Inhibitor%2520%2528TAK-632%2529%2520Targeting%2520Pan-RAF%2520Inhibition%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520C-7-Substituted%25201%252C3-Benzothiazole%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D16%26spage%3D6478%26epage%3D6494%26doi%3D10.1021%2Fjm400778d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberta, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramkissoon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramkissoon, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goumnerova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agar, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, C. D.</span></span> <span> </span><span class="NLM_article-title">A Brain-Penetrant RAF Dimer Antagonist for the Noncanonical BRAF Oncoprotein of Pediatric Low-Grade Astrocytomas</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1093/neuonc/now261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1093%2Fneuonc%2Fnow261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28082416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A280%3ADC%252BC1c7lt1Cjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=774-785&issue=6&author=Y.+Sunauthor=J.+A.+Albertaauthor=C.+Pilarzauthor=D.+Calligarisauthor=E.+J.+Chadwickauthor=S.+H.+Ramkissoonauthor=L.+A.+Ramkissoonauthor=V.+M.+Garciaauthor=E.+Mazzolaauthor=L.+Goumnerovaauthor=M.+Kaneauthor=Z.+Yaoauthor=M.+W.+Kieranauthor=K.+L.+Ligonauthor=W.+C.+Hahnauthor=L.+A.+Garrawayauthor=N.+Rosenauthor=N.+S.+Grayauthor=N.+Y.+Agarauthor=S.+J.+Buhrlageauthor=R.+A.+Segalauthor=C.+D.+Stiles&title=A+Brain-Penetrant+RAF+Dimer+Antagonist+for+the+Noncanonical+BRAF+Oncoprotein+of+Pediatric+Low-Grade+Astrocytomas&doi=10.1093%2Fneuonc%2Fnow261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas</span></div><div class="casAuthors">Sun Yu; Alberta John A; Pilarz Catherine; Chadwick Emily J; Garcia Veronica Matia; Kane Michael; Segal Rosalind A; Stiles Charles D; Sun Yu; Alberta John A; Pilarz Catherine; Chadwick Emily J; Garcia Veronica Matia; Kane Michael; Gray Nathanael S; Buhrlage Sara J; Segal Rosalind A; Stiles Charles D; Calligaris David; Agar Nathalie Y; Ramkissoon Shakti H; Ramkissoon Lori A; Ligon Keith L; Ramkissoon Shakti H; Ligon Keith L; Mazzola Emanuele; Goumnerova Liliana; Yao Zhan; Rosen Neal; Kieran Mark W; Kieran Mark W; Segal Rosalind A; Hahn William C; Garraway Levi A; Hahn William C; Garraway Levi A; Gray Nathanael S; Buhrlage Sara J; Agar Nathalie Y; Agar Nathalie Y</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">774-785</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade astrocytomas (PLGAs).  However, first-generation RAF inhibitors approved for adult melanoma have poor blood-brain penetrance and are only effective on tumors that express the canonical BRAFV600E oncoprotein, which functions as a monomer.  These drugs (type I antagonists that target the "DFG-in" conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA.  Methods:  A panel of small molecule RAF inhibitors (including type II inhibitors, targeting the "DFG-out" conformation of the kinase) was screened for drugs showing efficacy on murine models of PLGA and on authentic human PLGA cells expressing KIAA1549:BRAF.  Results:  We identify a type II RAF inhibitor that serves as an equipotent antagonist of BRAFV600E, KIAA1549:BRAF, and other noncanonical BRAF oncoproteins that function as dimers.  This drug (MLN2480, also known as TAK-580) has good brain penetrance and is active on authentic human PLGA cells in brain organotypic cultures.  Conclusion:  MLN2480 may be an effective therapeutic for BRAF mutant pediatric astrocytomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSShg7-DV6mnENHe_gFldTbfW6udTcc2eZNalc3J-7Dirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7lt1Cjtw%253D%253D&md5=557c01e0e2fa68750e24b8e863b67fc2</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnow261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnow261%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAlberta%26aufirst%3DJ.%2BA.%26aulast%3DPilarz%26aufirst%3DC.%26aulast%3DCalligaris%26aufirst%3DD.%26aulast%3DChadwick%26aufirst%3DE.%2BJ.%26aulast%3DRamkissoon%26aufirst%3DS.%2BH.%26aulast%3DRamkissoon%26aufirst%3DL.%2BA.%26aulast%3DGarcia%26aufirst%3DV.%2BM.%26aulast%3DMazzola%26aufirst%3DE.%26aulast%3DGoumnerova%26aufirst%3DL.%26aulast%3DKane%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DAgar%26aufirst%3DN.%2BY.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26aulast%3DStiles%26aufirst%3DC.%2BD.%26atitle%3DA%2520Brain-Penetrant%2520RAF%2520Dimer%2520Antagonist%2520for%2520the%2520Noncanonical%2520BRAF%2520Oncoprotein%2520of%2520Pediatric%2520Low-Grade%2520Astrocytomas%26jtitle%3DNeuro-Oncol.%26date%3D2017%26volume%3D19%26issue%3D6%26spage%3D774%26epage%3D785%26doi%3D10.1093%2Fneuonc%2Fnow261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holovanchuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Efficacy of the Paradox-Breaking PanRAF and SRC Drug CCT3833/BAL3833 in KRAS-Driven Cancer Models</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">S199</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)61703-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0959-8049%2816%2961703-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=S199&author=G.+Saturnoauthor=F.+Lopesauthor=M.+R.+Girottiauthor=I.+Niculescu-Duvazauthor=D.+Niculescu-Duvazauthor=A.+Zambonauthor=L.+Daviesauthor=L.+Johnsonauthor=N.+Preeceauthor=A.+Virosauthor=M.+Pedersenauthor=R.+McLearyauthor=R.+Knightauthor=R.+Leeauthor=D.+Holovanchukauthor=A.+Fusiauthor=P.+Loriganauthor=N.+Dhomenauthor=R.+Maraisauthor=C.+Springer&title=Therapeutic+Efficacy+of+the+Paradox-Breaking+PanRAF+and+SRC+Drug+CCT3833%2FBAL3833+in+KRAS-Driven+Cancer+Models&doi=10.1016%2FS0959-8049%2816%2961703-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2961703-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252961703-3%26sid%3Dliteratum%253Aachs%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DHolovanchuk%26aufirst%3DD.%26aulast%3DFusi%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DTherapeutic%2520Efficacy%2520of%2520the%2520Paradox-Breaking%2520PanRAF%2520and%2520SRC%2520Drug%2520CCT3833%252FBAL3833%2520in%2520KRAS-Driven%2520Cancer%2520Models%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D61%26spage%3DS199%26doi%3D10.1016%2FS0959-8049%2816%2961703-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span>A Phase
I, First in Man Study to Evaluate the Safety and Tolerability of a
panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours. <a href="https://clinicaltrials.gov/ct2/show/NCT02437227" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02437227</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Phase%0AI%2C+First+in+Man+Study+to+Evaluate+the+Safety+and+Tolerability+of+a%0ApanRAF+Inhibitor+%28CCT3833%2FBAL3833%29in+Patients+With+Solid+Tumours.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02437227+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span>Study
of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed
by a Dose Expansion in Patients With Metastatic Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01425008" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01425008</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+MLN2480+in+Patients+With+Relapsed+or+Refractory+Solid+Tumors+Followed%0Aby+a+Dose+Expansion+in+Patients+With+Metastatic+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01425008+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuwirth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargfrede, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangolli, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozon, V.</span></span> <span> </span><span class="NLM_article-title">MLN2480, an Investigational Oral Pan-RAF Kinase Inhibitor, in Patients (Pts) with Relapsed or Refractory Solid Tumors: Phase I Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">Suppl.</span>),  <span class="NLM_fpage">2547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2547&issue=Suppl.&author=D.+W.+Rascoauthor=A.+J.+Olszanskiauthor=A.+Patnaikauthor=G.+Espinoauthor=R.+Neuwirthauthor=S.+Faucetteauthor=M.+Bargfredeauthor=E.+A.+Gangolliauthor=R.+M.+Walkerauthor=M.+Kneisslauthor=V.+Bozon&title=MLN2480%2C+an+Investigational+Oral+Pan-RAF+Kinase+Inhibitor%2C+in+Patients+%28Pts%29+with+Relapsed+or+Refractory+Solid+Tumors%3A+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DEspino%26aufirst%3DG.%26aulast%3DNeuwirth%26aufirst%3DR.%26aulast%3DFaucette%26aufirst%3DS.%26aulast%3DBargfrede%26aufirst%3DM.%26aulast%3DGangolli%26aufirst%3DE.%2BA.%26aulast%3DWalker%26aufirst%3DR.%2BM.%26aulast%3DKneissl%26aufirst%3DM.%26aulast%3DBozon%26aufirst%3DV.%26atitle%3DMLN2480%252C%2520an%2520Investigational%2520Oral%2520Pan-RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Relapsed%2520or%2520Refractory%2520Solid%2520Tumors%253A%2520Phase%2520I%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3DSuppl%26spage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span>A Phase
1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel,
or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic
Malignancies. <a href="https://clinicaltrials.gov/ct2/show/NCT02327169" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02327169</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Phase%0A1B+Study+of+MLN2480+in+Combination+With+MLN0128+or+Alisertib%2C+or+Paclitaxel%2C%0Aor+Cetuximab%2C+or+Irinotecan+in+Adult+Patients+With+Advanced+Nonhematologic%0AMalignancies.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02327169+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holovanchuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Abstract LB-212: Therapeutic Efficacy of the Paradox-Breaking PanRAF and SRC Drug CCT3833/BAL3833 in KRAS-Driven Cancer Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">14 Suppl.</span>),  <span class="NLM_fpage">LB-212</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-LB-212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1538-7445.AM2016-LB-212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=LB-212&issue=14+Suppl.&author=G.+Saturnoauthor=F.+Lopesauthor=M.+R.+Girottiauthor=I.+Niculescu-Duvazauthor=D.+Niculescu-Duvazauthor=A.+Zambonauthor=L.+Daviesauthor=L.+Johnsonauthor=N.+Preeceauthor=A.+Virosauthor=M.+Pedersenauthor=R.+McLearyauthor=R.+Knightauthor=R.+Leeauthor=D.+Holovanchukauthor=P.+Loriganauthor=N.+Dhomenauthor=R.+Maraisauthor=C.+Springer&title=Abstract+LB-212%3A+Therapeutic+Efficacy+of+the+Paradox-Breaking+PanRAF+and+SRC+Drug+CCT3833%2FBAL3833+in+KRAS-Driven+Cancer+Models&doi=10.1158%2F1538-7445.AM2016-LB-212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-LB-212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-LB-212%26sid%3Dliteratum%253Aachs%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DHolovanchuk%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DAbstract%2520LB-212%253A%2520Therapeutic%2520Efficacy%2520of%2520the%2520Paradox-Breaking%2520PanRAF%2520and%2520SRC%2520Drug%2520CCT3833%252FBAL3833%2520in%2520KRAS-Driven%2520Cancer%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%2520Suppl%26spage%3DLB-212%26doi%3D10.1158%2F1538-7445.AM2016-LB-212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gould, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afroze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouitar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffey, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iartchouk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paske, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renou, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tregay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K. M.</span></span> <span> </span><span class="NLM_article-title">Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1021/jm101479y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101479y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1836-1846&issue=6&author=A.+E.+Gouldauthor=R.+Adamsauthor=S.+Adhikariauthor=K.+Aertgeertsauthor=R.+Afrozeauthor=C.+Blackburnauthor=E.+F.+Calderwoodauthor=R.+Chauauthor=J.+Chouitarauthor=M.+O.+Duffeyauthor=D.+B.+Englandauthor=C.+Farrerauthor=N.+Forsythauthor=K.+Garciaauthor=J.+Gaulinauthor=P.+D.+Greenspanauthor=R.+Guoauthor=S.+J.+Harrisonauthor=S.-C.+Huangauthor=N.+Iartchoukauthor=D.+Janowickauthor=M.-S.+Kimauthor=B.+Kulkarniauthor=S.+P.+Langstonauthor=J.+X.+Liuauthor=L.-T.+Maauthor=S.+Menonauthor=H.+Mizutaniauthor=E.+Paskeauthor=C.+C.+Renouauthor=M.+Rezaeiauthor=R.+S.+Rowlandauthor=M.+D.+Sintchakauthor=M.+D.+Smithauthor=S.+G.+Stroudauthor=M.+Tregayauthor=Y.+Tianauthor=O.+P.+Veibyauthor=T.+J.+Vosauthor=S.+Vyskocilauthor=J.+Williamsauthor=T.+Xuauthor=J.+J.+Yangauthor=J.+Yanoauthor=H.+Zengauthor=D.+M.+Zhangauthor=Q.+Zhangauthor=K.+M.+Galvin&title=Design+and+Optimization+of+Potent+and+Orally+Bioavailable+Tetrahydronaphthalene+Raf+Inhibitors&doi=10.1021%2Fjm101479y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm101479y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101479y%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%2BE.%26aulast%3DAdams%26aufirst%3DR.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DAfroze%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DCalderwood%26aufirst%3DE.%2BF.%26aulast%3DChau%26aufirst%3DR.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DDuffey%26aufirst%3DM.%2BO.%26aulast%3DEngland%26aufirst%3DD.%2BB.%26aulast%3DFarrer%26aufirst%3DC.%26aulast%3DForsyth%26aufirst%3DN.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DGaulin%26aufirst%3DJ.%26aulast%3DGreenspan%26aufirst%3DP.%2BD.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DHarrison%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DS.-C.%26aulast%3DIartchouk%26aufirst%3DN.%26aulast%3DJanowick%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DKulkarni%26aufirst%3DB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DMa%26aufirst%3DL.-T.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DPaske%26aufirst%3DE.%26aulast%3DRenou%26aufirst%3DC.%2BC.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DR.%2BS.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DStroud%26aufirst%3DS.%2BG.%26aulast%3DTregay%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DVeiby%26aufirst%3DO.%2BP.%26aulast%3DVos%26aufirst%3DT.%2BJ.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGalvin%26aufirst%3DK.%2BM.%26atitle%3DDesign%2520and%2520Optimization%2520of%2520Potent%2520and%2520Orally%2520Bioavailable%2520Tetrahydronaphthalene%2520Raf%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D6%26spage%3D1836%26epage%3D1846%26doi%3D10.1021%2Fjm101479y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span> <span> </span><span class="NLM_article-title">BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2187</span>– <span class="NLM_lpage">2197</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-15-0262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26208524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2187-2197&issue=10&author=Z.+Tangauthor=X.+Yuanauthor=R.+Duauthor=S.-H.+Cheungauthor=G.+Zhangauthor=J.+Weiauthor=Y.+Zhaoauthor=Y.+Fengauthor=H.+Pengauthor=Y.+Zhangauthor=Y.+Duauthor=X.+Huauthor=W.+Gongauthor=Y.+Liuauthor=Y.+Gaoauthor=Y.+Liuauthor=R.+Haoauthor=S.+Liauthor=S.+Wangauthor=J.+Jiauthor=L.+Zhangauthor=S.+Liauthor=D.+Suttonauthor=M.+Weiauthor=C.+Zhouauthor=L.+Wangauthor=L.+Luo&title=BGB-283%2C+a+Novel+RAF+Kinase+and+EGFR+Inhibitor%2C+Displays+Potent+Antitumor+Activity+in+BRAF-Mutated+Colorectal+Cancers&doi=10.1158%2F1535-7163.MCT-15-0262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers</span></div><div class="casAuthors">Tang, Zhiyu; Yuan, Xi; Du, Rong; Cheung, Shing-Hu; Zhang, Guoliang; Wei, Jing; Zhao, Yuan; Feng, Yingcai; Peng, Hao; Zhang, Yi; Du, Yunguang; Hu, Xiaoxia; Gong, Wenfeng; Liu, Yong; Gao, Yajuan; Liu, Ye; Hao, Rui; Li, Shengjian; Wang, Shaohui; Ji, Jiafu; Zhang, Lianhai; Li, Shuangxi; Sutton, David; Wei, Min; Zhou, Changyou; Wang, Lai; Luo, Lusong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2187-2197</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approx. 50% of human malignant melanomas and 5% to 15% of colorectal cancers.  Despite the remarkable clin. activities achieved by vemurafenib and dabrafenib in treating BRAFV600E metastatic melanoma, their clin. efficacy in BRAFV600E colorectal cancer is far less impressive.  Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors.  Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clin. investigation.  In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation.  It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAFV600E and EGFR mutation/amplification.  In BRAFV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation.  In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAFV600E mutation.  These findings support BGB-283 as a potent antitumor drug candidate with clin. potential for treating colorectal cancer harboring BRAFV600E mutation.  Mol Cancer Ther; 14(10); 2187-97. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreLelFO0aG27Vg90H21EOLACvtfcHk0ljBQP_VN_X8UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsL7L&md5=45f62fb276bd364ece47dd04ecd7bfb3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0262%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DCheung%26aufirst%3DS.-H.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DL.%26atitle%3DBGB-283%252C%2520a%2520Novel%2520RAF%2520Kinase%2520and%2520EGFR%2520Inhibitor%252C%2520Displays%2520Potent%2520Antitumor%2520Activity%2520in%2520BRAF-Mutated%2520Colorectal%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D10%26spage%3D2187%26epage%3D2197%26doi%3D10.1158%2F1535-7163.MCT-15-0262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span>Study
of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid
Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02610361" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02610361</a> (accessed Aug
31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+the+Safety+and+Pharmacokinetics+of+BGB-283+in+Patients+With+Solid%0ATumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02610361+%28accessed+Aug%0A31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">7049</span>– <span class="NLM_lpage">7052</span>, <span class="refDoi"> DOI: 10.1021/jm801050k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801050k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7049-7052&issue=22&author=S.+Ramurthyauthor=S.+Subramanianauthor=M.+Aikawaauthor=P.+Amiriauthor=A.+Costalesauthor=J.+Doveauthor=S.+Fongauthor=J.+M.+Jansenauthor=B.+Levineauthor=S.+Maauthor=C.+M.+McBrideauthor=J.+Michaelianauthor=T.+Pickauthor=D.+J.+Poonauthor=S.+Girishauthor=C.+M.+Shaferauthor=D.+Stuartauthor=L.+Sungauthor=P.+A.+Renhowe&title=Design+and+Synthesis+of+Orally+Bioavailable+Benzimidazoles+as+Raf+Kinase+Inhibitors&doi=10.1021%2Fjm801050k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm801050k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801050k%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DDove%26aufirst%3DJ.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DLevine%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DMichaelian%26aufirst%3DJ.%26aulast%3DPick%26aufirst%3DT.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Orally%2520Bioavailable%2520Benzimidazoles%2520as%2520Raf%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D22%26spage%3D7049%26epage%3D7052%26doi%3D10.1021%2Fjm801050k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span> <span> </span><span class="NLM_article-title">Design and Discovery of of N-(2-Methyl-5′-Morpholino-6′-((Tetrahydro-2H-Pyran-4-Yl)Oxy)-[3,3′-Bipyridin]-5-Yl)-3-(Trifluoromethyl)Benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4881</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4869-4881&issue=12&author=G.+A.+Nishiguchiauthor=A.+Ricoauthor=H.+Tannerauthor=R.+J.+Aversaauthor=B.+R.+Taftauthor=S.+Subramanianauthor=L.+Settiauthor=M.+T.+Burgerauthor=L.+Wanauthor=V.+Tamezauthor=A.+Smithauthor=Y.+Louauthor=P.+A.+Barsantiauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=I.+Dixauthor=J.+E.+Tellewauthor=S.+Huangauthor=L.+A.+Mathews+Grinerauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=S.+Maauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=J.+M.+Jansenauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=E.+Leesauthor=W.+Shaoauthor=D.+D.+Stuartauthor=M.+P.+Dillonauthor=S.+Ramurthy&title=Design+and+Discovery+of+of+N-%282-Methyl-5%E2%80%B2-Morpholino-6%E2%80%B2-%28%28Tetrahydro-2H-Pyran-4-Yl%29Oxy%29-%5B3%2C3%E2%80%B2-Bipyridin%5D-5-Yl%29-3-%28Trifluoromethyl%29Benzamide+%28RAF709%29%3A+A+Potent%2C+Selective%2C+and+Efficacious+RAF+Inhibitor+Targeting+RAS+Mutant+Cancers&doi=10.1021%2Facs.jmedchem.6b01862"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01862%26sid%3Dliteratum%253Aachs%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DRamurthy%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Discovery%2520of%2520of%2520N-%25282-Methyl-5%25E2%2580%25B2-Morpholino-6%25E2%2580%25B2-%2528%2528Tetrahydro-2H-Pyran-4-Yl%2529Oxy%2529-%255B3%252C3%25E2%2580%25B2-Bipyridin%255D-5-Yl%2529-3-%2528Trifluoromethyl%2529Benzamide%2520%2528RAF709%2529%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520RAF%2520Inhibitor%2520Targeting%2520RAS%2520Mutant%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D4869%26epage%3D4881%26doi%3D10.1021%2Facs.jmedchem.6b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonios-McCrea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machajewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of RAF265: A Potent Mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1021/ml500526p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500526p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=961-965&issue=9&author=T.+E.+Williamsauthor=S.+Subramanianauthor=J.+Verhagenauthor=C.+M.+McBrideauthor=A.+Costalesauthor=L.+Sungauthor=W.+Antonios-McCreaauthor=M.+McKennaauthor=A.+K.+Louieauthor=S.+Ramurthyauthor=B.+Levineauthor=C.+M.+Shaferauthor=T.+Machajewskiauthor=P.+A.+Renhoweauthor=B.+A.+Appletonauthor=P.+Amiriauthor=J.+Chouauthor=D.+Stuartauthor=K.+Aardalenauthor=D.+Poon&title=Discovery+of+RAF265%3A+A+Potent+Mut-B-RAF+Inhibitor+for+the+Treatment+of+Metastatic+Melanoma&doi=10.1021%2Fml500526p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fml500526p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500526p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DT.%2BE.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcKenna%26aufirst%3DM.%26aulast%3DLouie%26aufirst%3DA.%2BK.%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DB.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DChou%26aufirst%3DJ.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DPoon%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520RAF265%253A%2520A%2520Potent%2520Mut-B-RAF%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Melanoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D961%26epage%3D965%26doi%3D10.1021%2Fml500526p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span>A Study
to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally
Advanced or Metastatic Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT00304525?term=raf265&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT00304525?term=raf265&rank=1</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Ato+Evaluate+RAF265%2C+an+Oral+Drug+Administered+to+Subjects+With+Locally%0AAdvanced+or+Metastatic+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00304525%3Fterm%3Draf265%26rank%3D1+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markegard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rymar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Efficacy of a RAF Inhibitor That Evades Paradoxical MAPK Pathway Activation in Protein Kinase BRAF-Mutant Lung Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">13456</span>– <span class="NLM_lpage">13461</span>, <span class="refDoi"> DOI: 10.1073/pnas.1610456113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.1610456113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=13456-13461&issue=47&author=R.+A.+Okimotoauthor=L.+Linauthor=V.+Olivasauthor=E.+Chanauthor=E.+Markegardauthor=A.+Rymarauthor=D.+Neelauthor=X.+Chenauthor=G.+Hemmatiauthor=G.+Bollagauthor=T.+G.+Bivona&title=Preclinical+Efficacy+of+a+RAF+Inhibitor+That+Evades+Paradoxical+MAPK+Pathway+Activation+in+Protein+Kinase+BRAF-Mutant+Lung+Cancer&doi=10.1073%2Fpnas.1610456113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1610456113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1610456113%26sid%3Dliteratum%253Aachs%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMarkegard%26aufirst%3DE.%26aulast%3DRymar%26aufirst%3DA.%26aulast%3DNeel%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DPreclinical%2520Efficacy%2520of%2520a%2520RAF%2520Inhibitor%2520That%2520Evades%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%2520in%2520Protein%2520Kinase%2520BRAF-Mutant%2520Lung%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D47%26spage%3D13456%26epage%3D13461%26doi%3D10.1073%2Fpnas.1610456113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaunwhite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, A. C.</span></span> <span> </span><span class="NLM_article-title">Paradoxical Activation and RAF Inhibitor Resistance of BRAF Protein Kinase Fusions Characterizing Pediatric Astrocytomas</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5957</span>– <span class="NLM_lpage">5962</span>, <span class="refDoi"> DOI: 10.1073/pnas.1219232110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.1219232110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=5957-5962&issue=15&author=A.+J.+Sievertauthor=S.-S.+Langauthor=K.+L.+Boucherauthor=P.+J.+Madsenauthor=E.+Slaunwhiteauthor=N.+Choudhariauthor=M.+Kelletauthor=P.+B.+Stormauthor=A.+C.+Resnick&title=Paradoxical+Activation+and+RAF+Inhibitor+Resistance+of+BRAF+Protein+Kinase+Fusions+Characterizing+Pediatric+Astrocytomas&doi=10.1073%2Fpnas.1219232110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1219232110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1219232110%26sid%3Dliteratum%253Aachs%26aulast%3DSievert%26aufirst%3DA.%2BJ.%26aulast%3DLang%26aufirst%3DS.-S.%26aulast%3DBoucher%26aufirst%3DK.%2BL.%26aulast%3DMadsen%26aufirst%3DP.%2BJ.%26aulast%3DSlaunwhite%26aufirst%3DE.%26aulast%3DChoudhari%26aufirst%3DN.%26aulast%3DKellet%26aufirst%3DM.%26aulast%3DStorm%26aufirst%3DP.%2BB.%26aulast%3DResnick%26aufirst%3DA.%2BC.%26atitle%3DParadoxical%2520Activation%2520and%2520RAF%2520Inhibitor%2520Resistance%2520of%2520BRAF%2520Protein%2520Kinase%2520Fusions%2520Characterizing%2520Pediatric%2520Astrocytomas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D15%26spage%3D5957%26epage%3D5962%26doi%3D10.1073%2Fpnas.1219232110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basile, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartsough, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplin, A. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutant BRAF Splice Variant Signaling by Next-Generation, Selective RAF Inhibitors</span>. <i>Pigm. Cell Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/pcmr.12218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1111%2Fpcmr.12218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24422853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=479-484&issue=3&author=K.+J.+Basileauthor=K.+Leauthor=E.+J.+Hartsoughauthor=A.+E.+Aplin&title=Inhibition+of+Mutant+BRAF+Splice+Variant+Signaling+by+Next-Generation%2C+Selective+RAF+Inhibitors&doi=10.1111%2Fpcmr.12218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors</span></div><div class="casAuthors">Basile, Kevin J.; Le, Kaitlyn; Hartsough, Edward J.; Aplin, Andrew E.</div><div class="citationInfo"><span class="NLM_cas:title">Pigment Cell & Melanoma Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">PCMRCM</span>;
        ISSN:<span class="NLM_cas:issn">1755-1471</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Vemurafenib and dabrafenib block MEK-ERK1/2 signaling and cause tumor regression in the majority of advanced-stage BRAFV600E melanoma patients; however, acquired resistance and paradoxical signaling have driven efforts for more potent and selective RAF inhibitors.  Next-generation RAF inhibitors, such as PLX7904 (PB04), effectively inhibit RAF signaling in BRAFV600E melanoma cells without paradoxical effects in wild-type cells.  Furthermore, PLX7904 blocks the growth of vemurafenib-resistant BRAFV600E cells that express mutant NRAS.  Acquired resistance to vemurafenib and dabrafenib is also frequently driven by expression of mutation BRAF splice variants; thus, we tested the effects of PLX7904 and its clin. analog, PLX8394 (PB03), in BRAFV600E splice variant-mediated vemurafenib-resistant cells.  We show that paradox-breaker RAF inhibitors potently block MEK-ERK1/2 signaling, G1/S cell cycle events, survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAFV600E splice variants.  These data support the further investigation of paradox-breaker RAF inhibitors as a second-line treatment option for patients failing on vemurafenib or dabrafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovvoDjV1fbw7Vg90H21EOLACvtfcHk0liBAsnD7fkkmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D&md5=e9d363cc4fff1821674569c31b8980ee</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1111%2Fpcmr.12218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcmr.12218%26sid%3Dliteratum%253Aachs%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DHartsough%26aufirst%3DE.%2BJ.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DInhibition%2520of%2520Mutant%2520BRAF%2520Splice%2520Variant%2520Signaling%2520by%2520Next-Generation%252C%2520Selective%2520RAF%2520Inhibitors%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2014%26volume%3D27%26issue%3D3%26spage%3D479%26epage%3D484%26doi%3D10.1111%2Fpcmr.12218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span>A Study
of PLX8394 as a Single Agent in Patients With Advanced Unresectable
Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02428712" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02428712</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+PLX8394+as+a+Single+Agent+in+Patients+With+Advanced+Unresectable%0ASolid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02428712+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holladay, M. W.</span></span> <span> </span><span class="NLM_article-title">CEP-32496: A Novel Orally Active BRAF(V600E) Inhibitor with Selective Cellular and in Vivo Antitumor Activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-11-0645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22319199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=930-941&issue=4&author=J.+Jamesauthor=B.+Ruggeriauthor=R.+C.+Armstrongauthor=M.+W.+Rowbottomauthor=S.+Jones-Bolinauthor=R.+N.+Gunawardaneauthor=P.+Dobrzanskiauthor=M.+F.+Gardnerauthor=H.+Zhaoauthor=M.+D.+Cramerauthor=K.+Hunterauthor=R.+R.+Nepomucenoauthor=M.+Chengauthor=D.+Gitnickauthor=M.+Yazdanianauthor=D.+E.+Inskoauthor=M.+A.+Atorauthor=J.+L.+Apuyauthor=R.+Faraoniauthor=B.+D.+Dorseyauthor=M.+Williamsauthor=S.+S.+Bhagwatauthor=M.+W.+Holladay&title=CEP-32496%3A+A+Novel+Orally+Active+BRAF%28V600E%29+Inhibitor+with+Selective+Cellular+and+in+Vivo+Antitumor+Activity&doi=10.1158%2F1535-7163.MCT-11-0645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity</span></div><div class="casAuthors">James, Joyce; Ruggeri, Bruce; Armstrong, Robert C.; Rowbottom, Martin W.; Jones-Bolin, Susan; Gunawardane, Ruwanthi N.; Dobrzanski, Pawel; Gardner, Michael F.; Zhao, Hugh; Cramer, Merryl D.; Hunter, Kathryn; Nepomuceno, Ronald R.; Cheng, Mangeng; Gitnick, Dana; Yazdanian, Mehran; Insko, Darren E.; Ator, Mark A.; Apuy, Julius L.; Faraoni, Raffaella; Dorsey, Bruce D.; Williams, Michael; Bhagwat, Shripad S.; Holladay, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">930-941</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations in the BRAF gene have been identified in approx. 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of papillary thyroid carcinomas, 4% to 16% colorectal cancers, and a lesser extent in serous ovarian and non-small cell lung cancers.  The V600E mutation is found in the vast majority of cases and is an activating mutation, conferring transforming and immortalization potential to cells.  CEP-32496 is a potent BRAF inhibitor in an in vitro binding assay for mutated BRAFV600E (Kd BRAFV600E = 14 nmol/L) and in a mitogen-activated protein (MAP)/extracellular signal-regulated (ER) kinase (MEK) phosphorylation (pMEK) inhibition assay in human melanoma (A375) and colorectal cancer (Colo-205) cell lines (IC50 = 78 and 60 nmol/L).  In vitro, CEP-32496 has multikinase binding activity at other cancer targets of interest; however, it exhibits selective cellular cytotoxicity for BRAFV600E vs. wild-type cells.  CEP-32496 is orally bioavailable in multiple preclin. species (>95% in rats, dogs, and monkeys) and has single oral dose pharmacodynamic inhibition (10-55 mg/kg) of both pMEK and pERK in BRAFV600E colon carcinoma xenografts in nude mice.  Sustained tumor stasis and regressions are obsd. with oral administration (30-100 mg/kg twice daily) against BRAFV600E melanoma and colon carcinoma xenografts, with no adverse effects.  Little or no epithelial hyperplasia was obsd. in rodents and primates with prolonged oral administration and sustained exposure.  CEP-32496 benchmarks favorably with respect to other kinase inhibitors, including RAF-265 (phase I), sorafenib, (approved), and vemurafenib (PLX4032/RG7204, approved).  CEP-32496 represents a novel and pharmacol. active BRAF inhibitor with a favorable side effect profile currently in clin. development.  Mol Cancer Ther; 11(4); 930-41.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozSMo-ZE8g-7Vg90H21EOLACvtfcHk0lifplz5-XhEhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nur4%253D&md5=4a27d41e3b140027cd9b17ede9087cb6</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0645%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DApuy%26aufirst%3DJ.%2BL.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DCEP-32496%253A%2520A%2520Novel%2520Orally%2520Active%2520BRAF%2528V600E%2529%2520Inhibitor%2520with%2520Selective%2520Cellular%2520and%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D930%26epage%3D941%26doi%3D10.1158%2F1535-7163.MCT-11-0645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holladay, M. W.</span></span> <span> </span><span class="NLM_article-title">Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-Yloxy)Phenyl)-3-(5-(1,1,1-Trifluoro-2-Methylpropan-2-Yl)Isoxazol-3-Yl)Urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1105</span>, <span class="refDoi"> DOI: 10.1021/jm2009925</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1082-1105&issue=3&author=M.+W.+Rowbottomauthor=R.+Faraoniauthor=Q.+Chaoauthor=B.+T.+Campbellauthor=A.+G.+Laiauthor=E.+Settiauthor=M.+Ezawaauthor=K.+G.+Sprankleauthor=S.+Abrahamauthor=L.+Tranauthor=B.+Strussauthor=M.+Gibneyauthor=R.+C.+Armstrongauthor=R.+N.+Gunawardaneauthor=R.+R.+Nepomucenoauthor=I.+Valentaauthor=H.+Huaauthor=M.+F.+Gardnerauthor=M.+D.+Cramerauthor=D.+Gitnickauthor=D.+E.+Inskoauthor=J.+L.+Apuyauthor=S.+Jones-Bolinauthor=A.+K.+Ghoseauthor=T.+Herbertzauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=B.+Ruggeriauthor=M.+Williamsauthor=S.+Bhagwatauthor=J.+Jamesauthor=M.+W.+Holladay&title=Identification+of+1-%283-%286%2C7-Dimethoxyquinazolin-4-Yloxy%29Phenyl%29-3-%285-%281%2C1%2C1-Trifluoro-2-Methylpropan-2-Yl%29Isoxazol-3-Yl%29Urea+Hydrochloride+%28CEP-32496%29%2C+a+Highly+Potent+and+Orally+Efficacious+Inhibitor+of+V-RAF+Murine+Sarcoma+Viral+Oncogene+Homologue+B1+%28BRAF%29+V600E&doi=10.1021%2Fjm2009925"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fjm2009925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009925%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DEzawa%26aufirst%3DM.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DStruss%26aufirst%3DB.%26aulast%3DGibney%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DApuy%26aufirst%3DJ.%2BL.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DIdentification%2520of%25201-%25283-%25286%252C7-Dimethoxyquinazolin-4-Yloxy%2529Phenyl%2529-3-%25285-%25281%252C1%252C1-Trifluoro-2-Methylpropan-2-Yl%2529Isoxazol-3-Yl%2529Urea%2520Hydrochloride%2520%2528CEP-32496%2529%252C%2520a%2520Highly%2520Potent%2520and%2520Orally%2520Efficacious%2520Inhibitor%2520of%2520V-RAF%2520Murine%2520Sarcoma%2520Viral%2520Oncogene%2520Homologue%2520B1%2520%2528BRAF%2529%2520V600E%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D3%26spage%3D1082%26epage%3D1105%26doi%3D10.1021%2Fjm2009925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span>Study
of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer
and Other Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT01877811" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01877811</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+RXDX-105%2C+Potent+RET+Inhibitor+in+Patients+With+Advanced+Lung+Cancer%0Aand+Other+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01877811+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Abstract 2607: Antitumor Activity of the Selective RAF Inhibitor HM95573 in Solid Tumors and Hematologic Malignancies</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">15 Suppl.</span>),  <span class="NLM_fpage">2607</span>– <span class="NLM_lpage">2607</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-2607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1538-7445.AM2015-2607" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2607-2607&issue=15+Suppl.&author=Y.-M.+Leeauthor=I.+Baeauthor=N.+G.+Moauthor=J.+H.+Leeauthor=S.+Kimauthor=J.+Y.+Songauthor=K.+H.+Leeauthor=T.+H.+Songauthor=Y.+G.+Ahnauthor=Y.+H.+Kimauthor=K.+H.+Suh&title=Abstract+2607%3A+Antitumor+Activity+of+the+Selective+RAF+Inhibitor+HM95573+in+Solid+Tumors+and+Hematologic+Malignancies&doi=10.1158%2F1538-7445.AM2015-2607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-2607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-2607%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DBae%26aufirst%3DI.%26aulast%3DMo%26aufirst%3DN.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DSong%26aufirst%3DT.%2BH.%26aulast%3DAhn%26aufirst%3DY.%2BG.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26atitle%3DAbstract%25202607%253A%2520Antitumor%2520Activity%2520of%2520the%2520Selective%2520RAF%2520Inhibitor%2520HM95573%2520in%2520Solid%2520Tumors%2520and%2520Hematologic%2520Malignancies%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D15%2520Suppl%26spage%3D2607%26epage%3D2607%26doi%3D10.1158%2F1538-7445.AM2015-2607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span>Expansion
Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS
or NRAS Mutant Solid Cancers. <a href="https://clinicaltrials.gov/ct2/show/NCT03118817" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03118817</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Expansion%0AStudy+to+Evaluate+the+Efficacy+and+Safety+of+HM95573+in+BRAF%2C+KRAS%0Aor+NRAS+Mutant+Solid+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03118817+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span>Clinical
Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor
Activity of HM95573. <a href="https://clinicaltrials.gov/ct2/show/NCT02405065" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02405065</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0ATrial+to+Evaluate+Safety%2C+Tolerability+and+Pharmacokinetics+and+Anti-tumor%0AActivity+of+HM95573.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02405065+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span>Phase
I Study of LXH254 in Patients With Advanced Solid Tumors Haboring
MAPK Pathway Alterations. <a href="https://clinicaltrials.gov/ct2/show/NCT02607813" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02607813</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase%0AI+Study+of+LXH254+in+Patients+With+Advanced+Solid+Tumors+Haboring%0AMAPK+Pathway+Alterations.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02607813+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babij, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Purinylpyridinylamino-Based DFG-in/AC-Helix-out B-Raf Inhibitors: Applying Mutant versus Wild-Type B-Raf Selectivity Indices for Compound Profiling</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2215</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bmc.2016.03.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2215-2234&issue=10&author=L.+Liuauthor=M.+R.+Leeauthor=J.+L.+Kimauthor=D.+A.+Whittingtonauthor=H.+Bregmanauthor=Z.+Huaauthor=R.+T.+Lewisauthor=M.+W.+Martinauthor=N.+Nishimuraauthor=M.+Potashmanauthor=K.+Yangauthor=S.+Yiauthor=K.+R.+Vaidaauthor=L.+F.+Epsteinauthor=C.+Babijauthor=M.+Fernandoauthor=J.+Carnahanauthor=M.+H.+Norman&title=Purinylpyridinylamino-Based+DFG-in%2FAC-Helix-out+B-Raf+Inhibitors%3A+Applying+Mutant+versus+Wild-Type+B-Raf+Selectivity+Indices+for+Compound+Profiling&doi=10.1016%2Fj.bmc.2016.03.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.055%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DBregman%26aufirst%3DH.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DPurinylpyridinylamino-Based%2520DFG-in%252FAC-Helix-out%2520B-Raf%2520Inhibitors%253A%2520Applying%2520Mutant%2520versus%2520Wild-Type%2520B-Raf%2520Selectivity%2520Indices%2520for%2520Compound%2520Profiling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D10%26spage%3D2215%26epage%3D2234%26doi%3D10.1016%2Fj.bmc.2016.03.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traquandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modugno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated HERG Inhibition, and Low Paradoxical Effect</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1002%2Fcmdc.201402424" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=276-295&issue=2&author=M.+Puliciauthor=G.+Traquandiauthor=C.+Marchionniauthor=M.+Modugnoauthor=R.+Lupiauthor=N.+Amboldiauthor=E.+Casaleauthor=N.+Colomboauthor=L.+Cortiauthor=M.+Fasoliniauthor=F.+Gasparriauthor=W.+Pastoriauthor=A.+Scolaroauthor=D.+Donatiauthor=E.+Felderauthor=A.+Galvaniauthor=A.+Isacchiauthor=E.+Pesentiauthor=M.+Ciomei&title=Optimization+of+Diarylthiazole+B-Raf+Inhibitors%3A+Identification+of+a+Compound+Endowed+with+High+Oral+Antitumor+Activity%2C+Mitigated+HERG+Inhibition%2C+and+Low+Paradoxical+Effect&doi=10.1002%2Fcmdc.201402424"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402424%26sid%3Dliteratum%253Aachs%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DColombo%26aufirst%3DN.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520Diarylthiazole%2520B-Raf%2520Inhibitors%253A%2520Identification%2520of%2520a%2520Compound%2520Endowed%2520with%2520High%2520Oral%2520Antitumor%2520Activity%252C%2520Mitigated%2520HERG%2520Inhibition%252C%2520and%2520Low%2520Paradoxical%2520Effect%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3D276%26epage%3D295%26doi%3D10.1002%2Fcmdc.201402424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciszewski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frommer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowicz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span> <span> </span><span class="NLM_article-title">Non-Hinge-Binding Pyrazolo[1,5-a]Pyrimidines as Potent B-Raf Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6519</span>– <span class="NLM_lpage">6523</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bmcl.2009.10.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6519-6523&issue=23&author=D.+M.+Bergerauthor=N.+Torresauthor=M.+Dutiaauthor=D.+Powellauthor=G.+Ciszewskiauthor=A.+Gopalsamyauthor=J.+I.+Levinauthor=K.-H.+Kimauthor=W.+Xuauthor=J.+Wilhelmauthor=Y.+Huauthor=K.+Collinsauthor=L.+Feldbergauthor=S.+Kimauthor=E.+Frommerauthor=D.+Wojciechowiczauthor=R.+Mallon&title=Non-Hinge-Binding+Pyrazolo%5B1%2C5-a%5DPyrimidines+as+Potent+B-Raf+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2009.10.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DTorres%26aufirst%3DN.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DCiszewski%26aufirst%3DG.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWilhelm%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DFrommer%26aufirst%3DE.%26aulast%3DWojciechowicz%26aufirst%3DD.%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DNon-Hinge-Binding%2520Pyrazolo%255B1%252C5-a%255DPyrimidines%2520as%2520Potent%2520B-Raf%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D23%26spage%3D6519%26epage%3D6523%26doi%3D10.1016%2Fj.bmcl.2009.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B. a. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraresi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probachai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib plus Trametinib versus Dabrafenib Monotherapy in Patients with Metastatic BRAF V600E/K-Mutant Melanoma: Long-Term Survival and Safety Analysis of a Phase 3 Study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1631</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1093%2Fannonc%2Fmdx176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28475671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A280%3ADC%252BC1crksVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1631-1639&issue=7&author=G.+V.+Longauthor=K.+T.+Flahertyauthor=D.+Stroyakovskiyauthor=H.+Gogasauthor=E.+Levchenkoauthor=F.+de+Braudauthor=J.+Larkinauthor=C.+Garbeauthor=T.+Jouaryauthor=A.+Hauschildauthor=V.+Chiarion-Sileniauthor=C.+Lebbeauthor=M.+Mandal%C3%A0author=M.+Millwardauthor=A.+Aranceauthor=I.+Bondarenkoauthor=J.+B.+a.+G.+Haanenauthor=J.+Hanssonauthor=J.+Utikalauthor=V.+Ferraresiauthor=P.+Mohrauthor=V.+Probachaiauthor=D.+Schadendorfauthor=P.+Nathanauthor=C.+Robertauthor=A.+Ribasauthor=M.+A.+Daviesauthor=S.+R.+Laneauthor=J.+J.+Legosauthor=B.+Mookerjeeauthor=J.-J.+Grob&title=Dabrafenib+plus+Trametinib+versus+Dabrafenib+Monotherapy+in+Patients+with+Metastatic+BRAF+V600E%2FK-Mutant+Melanoma%3A+Long-Term+Survival+and+Safety+Analysis+of+a+Phase+3+Study&doi=10.1093%2Fannonc%2Fmdx176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study</span></div><div class="casAuthors">Long G V; Flaherty K T; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandala M; Millward M; Arance A; Bondarenko I; Haanen J B A G; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Schadendorf D; Nathan P; Robert C; Ribas A; Davies M A; Lane S R; Legos J J; Mookerjee B; Grob J-J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1631-1639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma.  This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients.  Patients and methods:  This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma.  Patients were randomized to receive dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or dabrafenib plus placebo.  The primary endpoint was PFS; secondary endpoints were OS, overall response, duration of response, safety, and pharmacokinetics.  Results:  Between 4 May and 30 November 2012, a total of 423 of 947 screened patients were randomly assigned to receive dabrafenib plus trametinib (n = 211) or dabrafenib monotherapy (n = 212).  At data cut-off (15 February 2016), outcomes remained superior with the combination: 3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively.  Twenty-five patients receiving monotherapy crossed over to combination therapy, with continued follow-up under the monotherapy arm (per intent-to-treat principle).  Of combination-arm patients alive at 3 years, 58% remained on dabrafenib plus trametinib.  Three-year OS with the combination reached 62% in the most favourable subgroup (normal lactate dehydrogenase and <3 organ sites with metastasis) versus only 25% in the unfavourable subgroup (elevated lactate dehydrogenase).  The dabrafenib plus trametinib safety profile was consistent with previous clinical trial observations, and no new safety signals were detected with long-term use.  Conclusions:  These data demonstrate that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoYeNFf5RK-c25P7XSLhESfW6udTcc2eYsnRDEF0yBQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crksVartw%253D%253D&md5=9bdf87626d5e107825a3caf99cc19bca</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx176%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DMandal%25C3%25A0%26aufirst%3DM.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%2Ba.%2BG.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DFerraresi%26aufirst%3DV.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DProbachai%26aufirst%3DV.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DLane%26aufirst%3DS.%2BR.%26aulast%3DLegos%26aufirst%3DJ.%2BJ.%26aulast%3DMookerjee%26aufirst%3DB.%26aulast%3DGrob%26aufirst%3DJ.-J.%26atitle%3DDabrafenib%2520plus%2520Trametinib%2520versus%2520Dabrafenib%2520Monotherapy%2520in%2520Patients%2520with%2520Metastatic%2520BRAF%2520V600E%252FK-Mutant%2520Melanoma%253A%2520Long-Term%2520Survival%2520and%2520Safety%2520Analysis%2520of%2520a%2520Phase%25203%2520Study%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26issue%3D7%26spage%3D1631%26epage%3D1639%26doi%3D10.1093%2Fannonc%2Fmdx176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dréno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hack, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&issue=20&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Dr%C3%A9noauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandal%C3%A0author=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+Vemurafenib+and+Cobimetinib+in+BRAF-Mutated+Melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0ljsOpcYdpgoww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDr%25C3%25A9no%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandal%25C3%25A0%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520Vemurafenib%2520and%2520Cobimetinib%2520in%2520BRAF-Mutated%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D20%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span>Study
Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and
LGX818 Monotherapy in BRAF Mutant Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01909453" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01909453</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0AComparing+Combination+of+LGX818+Plus+MEK162+Versus+Vemurafenib+and%0ALGX818+Monotherapy+in+BRAF+Mutant+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01909453+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span>Study
of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant
Metastatic Colorectal Cancer. <a href="https://clinicaltrials.gov/ct2/show/NCT01719380" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01719380</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+LGX818+and+Cetuximab+or+LGX818%2C+BYL719%2C+and+Cetuximab+in+BRAF+Mutant%0AMetastatic+Colorectal+Cancer.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01719380+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span>LGX818
and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398
or INC280) in Advanced BRAF Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT02159066" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02159066</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LGX818%0Aand+MEK162+in+Combination+With+a+Third+Agent+%28BKM120%2C+LEE011%2C+BGJ398%0Aor+INC280%29+in+Advanced+BRAF+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02159066+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e0155217</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0155217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1371%2Fjournal.pone.0155217" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0155217&issue=5&author=Y.+Xiaauthor=Y.+Liauthor=K.+D.+Westoverauthor=J.+Sunauthor=H.+Chenauthor=J.+Zhangauthor=D.+E.+Fisher&title=Inhibition+of+Cell+Proliferation+in+an+NRAS+Mutant+Melanoma+Cell+Line+by+Combining+Sorafenib+and+%CE%B1-Mangostin&doi=10.1371%2Fjournal.pone.0155217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0155217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0155217%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26atitle%3DInhibition%2520of%2520Cell%2520Proliferation%2520in%2520an%2520NRAS%2520Mutant%2520Melanoma%2520Cell%2520Line%2520by%2520Combining%2520Sorafenib%2520and%2520%25CE%25B1-Mangostin%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D5%26spage%3De0155217%26doi%3D10.1371%2Fjournal.pone.0155217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halilovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">The RAF Inhibitor PLX4032 Inhibits ERK Signaling and Tumor Cell Proliferation in a V600E BRAF-Selective Manner</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">14903</span>– <span class="NLM_lpage">14908</span>, <span class="refDoi"> DOI: 10.1073/pnas.1008990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&issue=33&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+Inhibitor+PLX4032+Inhibits+ERK+Signaling+and+Tumor+Cell+Proliferation+in+a+V600E+BRAF-Selective+Manner&doi=10.1073%2Fpnas.1008990107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520Inhibitor%2520PLX4032%2520Inhibits%2520ERK%2520Signaling%2520and%2520Tumor%2520Cell%2520Proliferation%2520in%2520a%2520V600E%2520BRAF-Selective%2520Manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D33%26spage%3D14903%26epage%3D14908%26doi%3D10.1073%2Fpnas.1008990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleam, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span> <span> </span><span class="NLM_article-title">Combinations of BRAF, MEK, and PI3K/MTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-11-0989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22389471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-920&issue=4&author=J.+G.+Gregerauthor=S.+D.+Eastmanauthor=V.+Zhangauthor=M.+R.+Bleamauthor=A.+M.+Hughesauthor=K.+N.+Smithemanauthor=S.+H.+Dickersonauthor=S.+G.+Laquerreauthor=L.+Liuauthor=T.+M.+Gilmer&title=Combinations+of+BRAF%2C+MEK%2C+and+PI3K%2FMTOR+Inhibitors+Overcome+Acquired+Resistance+to+the+BRAF+Inhibitor+GSK2118436+Dabrafenib%2C+Mediated+by+NRAS+or+MEK+Mutations&doi=10.1158%2F1535-7163.MCT-11-0989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations</span></div><div class="casAuthors">Greger, James G.; Eastman, Stephen D.; Zhang, Vivian; Bleam, Maureen R.; Hughes, Ashley M.; Smitheman, Kimberly N.; Dickerson, Scott H.; Laquerre, Sylvie G.; Liu, Li; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-920</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent results from clin. trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown encouraging response rates; however, the duration of response has been limited.  To identify determinants of acquired resistance to GSK2118436 and strategies to overcome the resistance, we isolated GSK2118436 drug-resistant clones from the A375 BRAFV600E and the YUSIT1 BRAFV600K melanoma cell lines.  These clones also showed reduced sensitivity to the allosteric mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor GSK1120212 (trametinib).  Genetic characterization of these clones identified an in-frame deletion in MEK1 (MEK1K59del) or NRAS mutation (NRASQ61K and/or NRASA146T) with and without MEK1P387S in the BRAFV600E background and NRASQ61K in the BRAFV600K background.  Stable knockdown of NRAS with short hairpin RNA partially restored GSK2118436 sensitivity in mutant NRAS clones, whereas expression of NRASQ61K or NRASA146T in the A375 parental cells decreased sensitivity to GSK2118436.  Similarly, expression of MEK1K59del, but not MEK1P387S, decreased sensitivity of A375 cells to GSK2118436.  The combination of GSK2118436 and GSK1120212 effectively inhibited cell growth, decreased ERK phosphorylation, decreased cyclin D1 protein, and increased p27kip1 protein in the resistant clones.  Moreover, the combination of GSK2118436 or GSK1120212 with the phosphoinositide 3-kinase/mTOR inhibitor GSK2126458 enhanced cell growth inhibition and decreased S6 ribosomal protein phosphorylation in these clones.  Our results show that NRAS and/or MEK mutations contribute to BRAF inhibitor resistance in vitro, and the combination of GSK2118436 and GSK1120212 overcomes this resistance.  In addn., these resistant clones respond to the combination of GSK2126458 with GSK2118436 or GSK1120212.  Clin. trials are ongoing or planned to test these combinations.  Mol Cancer Ther; 11(4); 909-20.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-aBjkeaBsgLVg90H21EOLACvtfcHk0lhqz-WlB6IGMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbY%253D&md5=416c0679440a16f76f3622e0b26cf3a2</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0989%26sid%3Dliteratum%253Aachs%26aulast%3DGreger%26aufirst%3DJ.%2BG.%26aulast%3DEastman%26aufirst%3DS.%2BD.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DBleam%26aufirst%3DM.%2BR.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DCombinations%2520of%2520BRAF%252C%2520MEK%252C%2520and%2520PI3K%252FMTOR%2520Inhibitors%2520Overcome%2520Acquired%2520Resistance%2520to%2520the%2520BRAF%2520Inhibitor%2520GSK2118436%2520Dabrafenib%252C%2520Mediated%2520by%2520NRAS%2520or%2520MEK%2520Mutations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D909%26epage%3D920%26doi%3D10.1158%2F1535-7163.MCT-11-0989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">BRAF Targeted Therapy Changes the Treatment Paradigm in Melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2011.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrclinonc.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=21606968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=426-433&issue=7&author=A.+Ribasauthor=K.+T.+Flaherty&title=BRAF+Targeted+Therapy+Changes+the+Treatment+Paradigm+in+Melanoma&doi=10.1038%2Fnrclinonc.2011.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF targeted therapy changes the treatment paradigm in melanoma</span></div><div class="casAuthors">Ribas, Antoni; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">426-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target.  The authors describe the scientific basis for the targeting of BRAF mutations in cancer, the early clin. data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.  After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon.  The discovery of the genetic underpinnings of this historically refractory disease has exposed potential targets for therapy, BRAF mutations being principal among them.  In the 8 years following the discovery of BRAF mutations in 50-60% of advanced melanomas, only recently have potent and selective inhibitors of this intracellular signaling mol. shown efficacy from early clin. testing.  Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their resp. phase I, II, and III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJ5nnopldxbVg90H21EOLACvtfcHk0lg8a47OH8ZtWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D&md5=710ef1d3ccb02a0c80bf7f9b3fe935a7</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DBRAF%2520Targeted%2520Therapy%2520Changes%2520the%2520Treatment%2520Paradigm%2520in%2520Melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26issue%3D7%26spage%3D426%26epage%3D433%26doi%3D10.1038%2Fnrclinonc.2011.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariyan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merghoub, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-13-0160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2326-6066.CIR-13-0160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24416731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=70-79&issue=1&author=M.+K.+Callahanauthor=G.+Mastersauthor=C.+A.+Pratilasauthor=C.+Ariyanauthor=J.+Katzauthor=S.+Kitanoauthor=V.+Russellauthor=R.+A.+Gordonauthor=S.+Vyasauthor=J.+Yuanauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=N.+Rosenauthor=T.+Merghoubauthor=M.+Jure-Kunkelauthor=J.+D.+Wolchok&title=Paradoxical+Activation+of+T+Cells+via+Augmented+ERK+Signaling+Mediated+by+a+RAF+Inhibitor&doi=10.1158%2F2326-6066.CIR-13-0160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor</span></div><div class="casAuthors">Callahan, Margaret K.; Masters, Gregg; Pratilas, Christine A.; Ariyan, Charlotte; Katz, Jessica; Kitano, Shigehisa; Russell, Valerie; Gordon, Ruth Ann; Vyas, Shachi; Yuan, Jianda; Gupta, Ashok; Wigginton, Jon M.; Rosen, Neal; Merghoub, Taha; Jure-Kunkel, Maria; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RAF inhibitors selectively block extracellular signal-regulated kinase (ERK) signaling in BRAF-mutant melanomas and have defined a genotype-guided approach to care for this disease.  RAF inhibitors have the opposite effect in BRAF wild-type tumor cells, where they cause hyperactivation of ERK signaling.  Here, we predict that RAF inhibitors can enhance T-cell activation, based on the observation that these agents paradoxically activate ERK signaling in BRAF wild-type cells.  To test this hypothesis, we have evaluated the effects of the RAF inhibitor BMS908662 on T-cell activation and signaling in vitro and in vivo.  We observe that T-cell activation is enhanced in a concn.-dependent manner and that this effect corresponds with increased ERK signaling, consistent with paradoxical activation of the pathway.  Furthermore, we find that the combination of BMS908662 with cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockade in vivo potentiates T-cell expansion, corresponding with hyperactivation of ERK signaling in T cells detectable ex vivo.  Finally, this combination demonstrates superior antitumor activity, compared with either agent alone, in two transplantable tumor models.  This study provides clear evidence that RAF inhibitors can modulate T-cell function by potentiating T-cell activation in vitro and in vivo.  Paradoxical activation of ERK signaling in T cells offers one mechanism to explain the enhanced antitumor activity seen when RAF inhibitors are combined with CTLA-4 blockade in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr53PahaKZ3ZrVg90H21EOLACvtfcHk0lg8a47OH8ZtWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ls70%253D&md5=b4c9ea6f475ae79d053577c7eacc22d8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-13-0160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-13-0160%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DMasters%26aufirst%3DG.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DAriyan%26aufirst%3DC.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DKitano%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DV.%26aulast%3DGordon%26aufirst%3DR.%2BA.%26aulast%3DVyas%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DMerghoub%26aufirst%3DT.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DParadoxical%2520Activation%2520of%2520T%2520Cells%2520via%2520Augmented%2520ERK%2520Signaling%2520Mediated%2520by%2520a%2520RAF%2520Inhibitor%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2%26issue%3D1%26spage%3D70%26epage%3D79%26doi%3D10.1158%2F2326-6066.CIR-13-0160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span> <span> </span><span class="NLM_article-title">MLN2480: A Novel Pan-RAF Inhibitor for Treatment of BRAF Mutant and Wild-Type Tumors</span>. Presented at the 103rd Annual Meeting of the AACR, Chicago, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=K.+Galvin&title=MLN2480%3A+A+Novel+Pan-RAF+Inhibitor+for+Treatment+of+BRAF+Mutant+and+Wild-Type+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGalvin%26aufirst%3DK.%26atitle%3DMLN2480%253A%2520A%2520Novel%2520Pan-RAF%2520Inhibitor%2520for%2520Treatment%2520of%2520BRAF%2520Mutant%2520and%2520Wild-Type%2520Tumors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 35 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Malcolm P. Huestis, Darlene Dela Cruz, Antonio G. DiPasquale, Matthew R. Durk, Charles Eigenbrot, Paul Gibbons, Alberto Gobbi, Thomas L. Hunsaker, Hank La, Dennis H. Leung, Wendy Liu, Shiva Malek, Mark Merchant, John G. Moffat, Christine S. Muli, Christine J. Orr, Brendan T. Parr, Frances Shanahan, Christopher J. Sneeringer, Weiru Wang, Ivana Yen, Jianping Yin, Michael Siu, <span class="NLM_string-name hlFld-ContribAuthor">Joachim Rudolph</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3940-3955. <a href="https://doi.org/10.1021/acs.jmedchem.0c02085" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02085%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BKRAS%252BMutant%252BCancers%252Bvia%252BCombination%252BTreatment%25253A%252BDiscovery%252Bof%252Ba%252B5-Fluoro-4-%2525283H%252529-quinazolinone%252BAryl%252BUrea%252Bpan-RAF%252BKinase%252BInhibitor%26aulast%3DHuestis%26aufirst%3DMalcolm%2BP.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D01122020%26date%3D29032021%26volume%3D64%26issue%3D7%26spage%3D3940%26epage%3D3955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiao-Ran Han, Liqun Chen, Yuanqi Wei, Weihua Yu, Yanke Chen, Chunyan Zhang, Bingyang Jiao, Tingting Shi, Lei Sun, Chao Zhang, Yang Xu, Matthew R. Lee, Ying Luo, Michael B. Plewe, <span class="NLM_string-name hlFld-ContribAuthor">Jialiang Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Selective Small Molecule Degraders of BRAF-V600E. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4069-4080. <a href="https://doi.org/10.1021/acs.jmedchem.9b02083" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02083%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSelective%252BSmall%252BMolecule%252BDegraders%252Bof%252BBRAF-V600E%26aulast%3DHan%26aufirst%3DXiao-Ran%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14122019%26date%3D10042020%26date%3D30032020%26volume%3D63%26issue%3D8%26spage%3D4069%26epage%3D4080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xingye Chen, Haichun Liu, Wuchen Xie, Yan Yang, Yuchen Wang, Yuanrong Fan, Yi Hua, Lu Zhu, Junnan Zhao, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Yanmin Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of Crystal Structures in Structure-Based Virtual Screening for Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5244-5262. <a href="https://doi.org/10.1021/acs.jcim.9b00684" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00684%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DInvestigation%252Bof%252BCrystal%252BStructures%252Bin%252BStructure-Based%252BVirtual%252BScreening%252Bfor%252BProtein%252BKinase%252BInhibitors%26aulast%3DChen%26aufirst%3DXingye%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17082019%26date%3D15112019%26date%3D05112019%26volume%3D59%26issue%3D12%26spage%3D5244%26epage%3D5262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chad M. Beneker, Magdalini Rovoli, George Kontopidis, Michael Röring, Simeon Galda, Sandra Braun, Tilman Brummer, <span class="NLM_string-name hlFld-ContribAuthor">Campbell McInnes</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 3886-3897. <a href="https://doi.org/10.1021/acs.jmedchem.8b01288" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01288%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BType-IV%252BInhibitors%252Bof%252BBRAF%252BKinase%252BThat%252BBlock%252BDimerization%252Band%252BOvercome%252BParadoxical%252BMEK%25252FERK%252BActivation%26aulast%3DBeneker%26aufirst%3DChad%2BM.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14082018%26date%3D12042019%26volume%3D62%26issue%3D8%26spage%3D3886%26epage%3D3897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramona  Rudalska</span>, <span class="hlFld-ContribAuthor ">Lars  Zender</span>, <span class="hlFld-ContribAuthor ">Daniel  Dauch</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting lipotoxicity for the treatment of liver cancer. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Cancer</span><span> <strong>2021,</strong> <em>491 </em><a href="https://doi.org/10.1038/s41416-021-01479-7" title="DOI URL">https://doi.org/10.1038/s41416-021-01479-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41416-021-01479-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41416-021-01479-7%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Cancer%26atitle%3DExploiting%252Blipotoxicity%252Bfor%252Bthe%252Btreatment%252Bof%252Bliver%252Bcancer%26aulast%3DRudalska%26aufirst%3DRamona%26date%3D2021%26date%3D2021%26volume%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingzhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Zhigang  Li</span>, <span class="hlFld-ContribAuthor ">David B.  Sacks</span>, <span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>. </span><span class="cited-content_cbyCitation_article-title">B-Raf autoinhibition in the presence and absence of 14-3-3. </span><span class="cited-content_cbyCitation_journal-name">Structure</span><span> <strong>2021,</strong> <em>29 </em>
                                    (7)
                                     , 768-777.e2. <a href="https://doi.org/10.1016/j.str.2021.02.005" title="DOI URL">https://doi.org/10.1016/j.str.2021.02.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.str.2021.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.str.2021.02.005%26sid%3Dliteratum%253Aachs%26jtitle%3DStructure%26atitle%3DB-Raf%252Bautoinhibition%252Bin%252Bthe%252Bpresence%252Band%252Babsence%252Bof%252B14-3-3%26aulast%3DZhang%26aufirst%3DMingzhen%26date%3D2021%26volume%3D29%26issue%3D7%26spage%3D768%26epage%3D777.e2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  He</span>, <span class="hlFld-ContribAuthor ">Wenxing  Lv</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.685106" title="DOI URL">https://doi.org/10.3389/fcell.2021.685106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.685106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.685106%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DOpportunities%252Band%252BChallenges%252Bof%252BSmall%252BMolecule%252BInduced%252BTargeted%252BProtein%252BDegradation%26aulast%3DHe%26aufirst%3DMing%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kassandra  Koumaki</span>, <span class="hlFld-ContribAuthor ">Georgia  Kontogianni</span>, <span class="hlFld-ContribAuthor ">Vivian  Kosmidou</span>, <span class="hlFld-ContribAuthor ">Fani  Pahitsa</span>, <span class="hlFld-ContribAuthor ">Eftichia  Kritsi</span>, <span class="hlFld-ContribAuthor ">Maria  Zervou</span>, <span class="hlFld-ContribAuthor ">Aristotelis  Chatziioannou</span>, <span class="hlFld-ContribAuthor ">Vassilis L.  Souliotis</span>, <span class="hlFld-ContribAuthor ">Olga  Papadodima</span>, <span class="hlFld-ContribAuthor ">Alexander  Pintzas</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</span><span> <strong>2021,</strong> <em>1867 </em>
                                    (4)
                                     , 166061. <a href="https://doi.org/10.1016/j.bbadis.2020.166061" title="DOI URL">https://doi.org/10.1016/j.bbadis.2020.166061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbadis.2020.166061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbadis.2020.166061%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Molecular%2520Basis%2520of%2520Disease%26atitle%3DBRAF%252Bparadox%252Bbreakers%252BPLX8394%25252C%252BPLX7904%252Bare%252Bmore%252Beffective%252Bagainst%252BBRAFV600%2525CE%252595%252BCRC%252Bcells%252Bcompared%252Bwith%252Bthe%252BBRAF%252Binhibitor%252BPLX4720%252Band%252Bshown%252Bby%252Bdetailed%252Bpathway%252Banalysis%26aulast%3DKoumaki%26aufirst%3DKassandra%26date%3D2021%26volume%3D1867%26issue%3D4%26spage%3D166061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-I  Lee</span>, <span class="hlFld-ContribAuthor ">Chu-Bin  Liao</span>, <span class="hlFld-ContribAuthor ">Chih-Shang  Chen</span>, <span class="hlFld-ContribAuthor ">Fen-Ying  Cheng</span>, <span class="hlFld-ContribAuthor ">Yu-Hsuan  Chung</span>, <span class="hlFld-ContribAuthor ">Yu-Chuan  Wang</span>, <span class="hlFld-ContribAuthor ">Sian-Yi  Ciou</span>, <span class="hlFld-ContribAuthor ">Wen-Yun  Hsueh</span>, <span class="hlFld-ContribAuthor ">Tzu-Hao  Lo</span>, <span class="hlFld-ContribAuthor ">Guan-Ru  Huang</span>, <span class="hlFld-ContribAuthor ">Hsin-Yi  Huang</span>, <span class="hlFld-ContribAuthor ">Chia-Shen  Tsai</span>, <span class="hlFld-ContribAuthor ">Yu-Jung  Lu</span>, <span class="hlFld-ContribAuthor ">Shih-Hsien  Chuang</span>, <span class="hlFld-ContribAuthor ">Jiann-Jyh  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104715. <a href="https://doi.org/10.1016/j.bioorg.2021.104715" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104715</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104715%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B4-anilinoquinazolines%252Bas%252BRaf%252Bkinase%252Binhibitors.%252BPart%252B1.%252BSelective%252BB-Raf%25252FB-RafV600E%252Band%252Bpotent%252BEGFR%25252FVEGFR2%252Binhibitory%252B4-%2525283-hydroxyanilino%252529-6-%2525281H-1%25252C2%25252C3-triazol-4-yl%252529quinazolines%26aulast%3DLee%26aufirst%3DCheng-I%26date%3D2021%26volume%3D109%26spage%3D104715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeehoon  Ham</span>, <span class="hlFld-ContribAuthor ">Bin  Wang</span>, <span class="hlFld-ContribAuthor ">Joseph William  Po</span>, <span class="hlFld-ContribAuthor ">Amandeep  Singh</span>, <span class="hlFld-ContribAuthor ">Navin  Niles</span>, <span class="hlFld-ContribAuthor ">Cheok Soon  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Cancer-associated fibroblasts (CAFs) in thyroid papillary carcinoma: molecular networks and interactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Pathology</span><span> <strong>2021,</strong> <em>25 </em>, jclinpath-2020-207357. <a href="https://doi.org/10.1136/jclinpath-2020-207357" title="DOI URL">https://doi.org/10.1136/jclinpath-2020-207357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/jclinpath-2020-207357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fjclinpath-2020-207357%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Pathology%26atitle%3DCancer-associated%252Bfibroblasts%252B%252528CAFs%252529%252Bin%252Bthyroid%252Bpapillary%252Bcarcinoma%25253A%252Bmolecular%252Bnetworks%252Band%252Binteractions%26aulast%3DHam%26aufirst%3DJeehoon%26date%3D2021%26date%3D2021%26volume%3D25%26spage%3Djclinpath-2020-207357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">G.  Kirishnamaline</span>, <span class="hlFld-ContribAuthor ">J. Daisy  Magdaline</span>, <span class="hlFld-ContribAuthor ">T.  Chithambarathanu</span>, <span class="hlFld-ContribAuthor ">D.  Aruldhas</span>, <span class="hlFld-ContribAuthor ">A. Ronaldo  Anuf</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical investigation of structure, anticancer activity and molecular docking of thiourea derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1225 </em>, 129118. <a href="https://doi.org/10.1016/j.molstruc.2020.129118" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.129118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.129118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.129118%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DTheoretical%252Binvestigation%252Bof%252Bstructure%25252C%252Banticancer%252Bactivity%252Band%252Bmolecular%252Bdocking%252Bof%252Bthiourea%252Bderivatives%26aulast%3DKirishnamaline%26aufirst%3DG.%26date%3D2021%26volume%3D1225%26spage%3D129118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramona  Rudalska</span>, <span class="hlFld-ContribAuthor ">Jule  Harbig</span>, <span class="hlFld-ContribAuthor ">Marteinn T.  Snaebjornsson</span>, <span class="hlFld-ContribAuthor ">Sabrina  Klotz</span>, <span class="hlFld-ContribAuthor ">Stefan  Zwirner</span>, <span class="hlFld-ContribAuthor ">Liudmyla  Taranets</span>, <span class="hlFld-ContribAuthor ">Florian  Heinzmann</span>, <span class="hlFld-ContribAuthor ">Thales  Kronenberger</span>, <span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Wei  Cui</span>, <span class="hlFld-ContribAuthor ">Luana  D’Artista</span>, <span class="hlFld-ContribAuthor ">Elias  Einig</span>, <span class="hlFld-ContribAuthor ">Martina  Hinterleitner</span>, <span class="hlFld-ContribAuthor ">Werner  Schmitz</span>, <span class="hlFld-ContribAuthor ">Agata  Dylawerska</span>, <span class="hlFld-ContribAuthor ">Tae-Won  Kang</span>, <span class="hlFld-ContribAuthor ">Antti  Poso</span>, <span class="hlFld-ContribAuthor ">Mathias T.  Rosenfeldt</span>, <span class="hlFld-ContribAuthor ">Nisar P.  Malek</span>, <span class="hlFld-ContribAuthor ">Michael  Bitzer</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Bernd J.  Pichler</span>, <span class="hlFld-ContribAuthor ">Nikita  Popov</span>, <span class="hlFld-ContribAuthor ">Almut  Schulze</span>, <span class="hlFld-ContribAuthor ">Lars  Zender</span>, <span class="hlFld-ContribAuthor ">Daniel  Dauch</span>. </span><span class="cited-content_cbyCitation_article-title">LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Cancer</span><span> <strong>2021,</strong> <em>2 </em>
                                    (2)
                                     , 201-217. <a href="https://doi.org/10.1038/s43018-020-00168-3" title="DOI URL">https://doi.org/10.1038/s43018-020-00168-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s43018-020-00168-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs43018-020-00168-3%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Cancer%26atitle%3DLXR%2525CE%2525B1%252Bactivation%252Band%252BRaf%252Binhibition%252Btrigger%252Blethal%252Blipotoxicity%252Bin%252Bliver%252Bcancer%26aulast%3DRudalska%26aufirst%3DRamona%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D2%26spage%3D201%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiomaris M.  Cotto-Rios</span>, <span class="hlFld-ContribAuthor ">Bogos  Agianian</span>, <span class="hlFld-ContribAuthor ">Nadege  Gitego</span>, <span class="hlFld-ContribAuthor ">Emmanouil  Zacharioudakis</span>, <span class="hlFld-ContribAuthor ">Orsi  Giricz</span>, <span class="hlFld-ContribAuthor ">Yang  Wu</span>, <span class="hlFld-ContribAuthor ">Yiyu  Zou</span>, <span class="hlFld-ContribAuthor ">Amit  Verma</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>, <span class="hlFld-ContribAuthor ">Evripidis  Gavathiotis</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of BRAF dimers using an allosteric site. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-18123-2" title="DOI URL">https://doi.org/10.1038/s41467-020-18123-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-18123-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-18123-2%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DInhibitors%252Bof%252BBRAF%252Bdimers%252Busing%252Ban%252Ballosteric%252Bsite%26aulast%3DCotto-Rios%26aufirst%3DXiomaris%2BM.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lior  Zimmerman</span>, <span class="hlFld-ContribAuthor ">Ori  Zelichov</span>, <span class="hlFld-ContribAuthor ">Arie  Aizenmann</span>, <span class="hlFld-ContribAuthor ">Zohar  Barbash</span>, <span class="hlFld-ContribAuthor ">Michael  Vidne</span>, <span class="hlFld-ContribAuthor ">Gabi  Tarcic</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-61173-1" title="DOI URL">https://doi.org/10.1038/s41598-020-61173-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-61173-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-61173-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252BNovel%252BSystem%252Bfor%252BFunctional%252BDetermination%252Bof%252BVariants%252Bof%252BUncertain%252BSignificance%252Busing%252BDeep%252BConvolutional%252BNeural%252BNetworks%26aulast%3DZimmerman%26aufirst%3DLior%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Viola  Previtali</span>, <span class="hlFld-ContribAuthor ">Helene B.  Mihigo</span>, <span class="hlFld-ContribAuthor ">Rebecca  Amet</span>, <span class="hlFld-ContribAuthor ">Anthony M.  McElligott</span>, <span class="hlFld-ContribAuthor ">Daniela M.  Zisterer</span>, <span class="hlFld-ContribAuthor ">Isabel  Rozas</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the Anti-Cancer Mechanism of Novel 3,4′-Substituted Diaryl Guanidinium Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (12)
                                     , 485. <a href="https://doi.org/10.3390/ph13120485" title="DOI URL">https://doi.org/10.3390/ph13120485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13120485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13120485%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DExploring%252Bthe%252BAnti-Cancer%252BMechanism%252Bof%252BNovel%252B3%25252C4%2525E2%252580%2525B2-Substituted%252BDiaryl%252BGuanidinium%252BDerivatives%26aulast%3DPrevitali%26aufirst%3DViola%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D12%26spage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed Karam  Farag</span>, <span class="hlFld-ContribAuthor ">Ahmed H.E.  Hassan</span>, <span class="hlFld-ContribAuthor ">Kyung-Sook  Chung</span>, <span class="hlFld-ContribAuthor ">Jeong-Hun  Lee</span>, <span class="hlFld-ContribAuthor ">Hyo-Sun  Gil</span>, <span class="hlFld-ContribAuthor ">Kyung-Tae  Lee</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Diarylurea derivatives comprising 2,4-diarylpyrimidines: Discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>103 </em>, 104121. <a href="https://doi.org/10.1016/j.bioorg.2020.104121" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104121%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiarylurea%252Bderivatives%252Bcomprising%252B2%25252C4-diarylpyrimidines%25253A%252BDiscovery%252Bof%252Bnovel%252Bpotential%252Banticancer%252Bagents%252Bvia%252Bcombined%252Bfailed-ligands%252Brepurposing%252Band%252Bmolecular%252Bhybridization%252Bapproaches%26aulast%3DFarag%26aufirst%3DAhmed%2BKaram%26date%3D2020%26volume%3D103%26spage%3D104121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ludmila E.  Campos</span>, <span class="hlFld-ContribAuthor ">Francisco  Garibotto</span>, <span class="hlFld-ContribAuthor ">Emilio  Angelina</span>, <span class="hlFld-ContribAuthor ">Jiri  Kos</span>, <span class="hlFld-ContribAuthor ">Tomas  Gonec</span>, <span class="hlFld-ContribAuthor ">Pavlina  Marvanova</span>, <span class="hlFld-ContribAuthor ">Marcela  Vettorazzi</span>, <span class="hlFld-ContribAuthor ">Michal  Oravec</span>, <span class="hlFld-ContribAuthor ">Izabela  Jendrzejewska</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Sergio E.  Alvarez</span>, <span class="hlFld-ContribAuthor ">Ricardo D.  Enriz</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxynaphthalenecarboxamides and substituted piperazinylpropandiols, two new series of BRAF inhibitors. A theoretical and experimental study. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>103 </em>, 104145. <a href="https://doi.org/10.1016/j.bioorg.2020.104145" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104145%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DHydroxynaphthalenecarboxamides%252Band%252Bsubstituted%252Bpiperazinylpropandiols%25252C%252Btwo%252Bnew%252Bseries%252Bof%252BBRAF%252Binhibitors.%252BA%252Btheoretical%252Band%252Bexperimental%252Bstudy%26aulast%3DCampos%26aufirst%3DLudmila%2BE.%26date%3D2020%26volume%3D103%26spage%3D104145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hechuan  Wang</span>, <span class="hlFld-ContribAuthor ">Janel  Long‐Boyle</span>, <span class="hlFld-ContribAuthor ">Beth Apsel  Winger</span>, <span class="hlFld-ContribAuthor ">Theodore  Nicolaides</span>, <span class="hlFld-ContribAuthor ">Sabine  Mueller</span>, <span class="hlFld-ContribAuthor ">Michael  Prados</span>, <span class="hlFld-ContribAuthor ">Vijay  Ivaturi</span>. </span><span class="cited-content_cbyCitation_article-title">Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory
              BRAF
              Gene V600E‐Mutant Astrocytomas. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Clinical Pharmacology</span><span> <strong>2020,</strong> <em>60 </em>
                                    (9)
                                     , 1209-1219. <a href="https://doi.org/10.1002/jcph.1617" title="DOI URL">https://doi.org/10.1002/jcph.1617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcph.1617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcph.1617%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DPopulation%252BPharmacokinetics%252Bof%252BVemurafenib%252Bin%252BChildren%252BWith%252BRecurrent%25252FRefractory%252BBRAF%252BGene%252BV600E%2525E2%252580%252590Mutant%252BAstrocytomas%26aulast%3DWang%26aufirst%3DHechuan%26date%3D2020%26date%3D2020%26volume%3D60%26issue%3D9%26spage%3D1209%26epage%3D1219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evgeni  Pisarevsky</span>, <span class="hlFld-ContribAuthor ">Rachel  Blau</span>, <span class="hlFld-ContribAuthor ">Yana  Epshtein</span>, <span class="hlFld-ContribAuthor ">Dikla  Ben‐Shushan</span>, <span class="hlFld-ContribAuthor ">Anat  Eldar‐Boock</span>, <span class="hlFld-ContribAuthor ">Galia  Tiram</span>, <span class="hlFld-ContribAuthor ">Shani  Koshrovski‐Michael</span>, <span class="hlFld-ContribAuthor ">Anna  Scomparin</span>, <span class="hlFld-ContribAuthor ">Sabina  Pozzi</span>, <span class="hlFld-ContribAuthor ">Adva  Krivitsky</span>, <span class="hlFld-ContribAuthor ">Gal  Shenbach‐Koltin</span>, <span class="hlFld-ContribAuthor ">Eilam  Yeini</span>, <span class="hlFld-ContribAuthor ">Lidar  Fridrich</span>, <span class="hlFld-ContribAuthor ">Richard  White</span>, <span class="hlFld-ContribAuthor ">Ronit  Satchi‐Fainaro</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Advanced Therapeutics</span><span> <strong>2020,</strong> <em>3 </em>
                                    (8)
                                     , 2000028. <a href="https://doi.org/10.1002/adtp.202000028" title="DOI URL">https://doi.org/10.1002/adtp.202000028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adtp.202000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadtp.202000028%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Therapeutics%26atitle%3DRational%252BDesign%252Bof%252BPolyglutamic%252BAcid%252BDelivering%252Ban%252BOptimized%252BCombination%252Bof%252BDrugs%252BTargeting%252BMutated%252BBRAF%252Band%252BMEK%252Bin%252BMelanoma%26aulast%3DPisarevsky%26aufirst%3DEvgeni%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D8%26spage%3D2000028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diren  Usta</span>, <span class="hlFld-ContribAuthor ">Romain  Sigaud</span>, <span class="hlFld-ContribAuthor ">Juliane L.  Buhl</span>, <span class="hlFld-ContribAuthor ">Florian  Selt</span>, <span class="hlFld-ContribAuthor ">Viktoria  Marquardt</span>, <span class="hlFld-ContribAuthor ">David  Pauck</span>, <span class="hlFld-ContribAuthor ">Jennifer  Jansen</span>, <span class="hlFld-ContribAuthor ">Stefan  Pusch</span>, <span class="hlFld-ContribAuthor ">Jonas  Ecker</span>, <span class="hlFld-ContribAuthor ">Thomas  Hielscher</span>, <span class="hlFld-ContribAuthor ">Johanna  Vollmer</span>, <span class="hlFld-ContribAuthor ">Alexander C.  Sommerkamp</span>, <span class="hlFld-ContribAuthor ">Tobias  Rubner</span>, <span class="hlFld-ContribAuthor ">Darren  Hargrave</span>, <span class="hlFld-ContribAuthor ">Cornelis M.  van Tilburg</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Pfister</span>, <span class="hlFld-ContribAuthor ">David T.W.  Jones</span>, <span class="hlFld-ContribAuthor ">Marc  Remke</span>, <span class="hlFld-ContribAuthor ">Tilman  Brummer</span>, <span class="hlFld-ContribAuthor ">Olaf  Witt</span>, <span class="hlFld-ContribAuthor ">Till  Milde</span>. </span><span class="cited-content_cbyCitation_article-title">A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
              BRAF
              -Driven Pediatric Low-Grade Glioma Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (8)
                                     , 1736-1750. <a href="https://doi.org/10.1158/1535-7163.MCT-19-1021" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-1021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-1021%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DA%252BCell-Based%252BMAPK%252BReporter%252BAssay%252BReveals%252BSynergistic%252BMAPK%252BPathway%252BActivity%252BSuppression%252Bby%252BMAPK%252BInhibitor%252BCombination%252Bin%252BBRAF%252B-Driven%252BPediatric%252BLow-Grade%252BGlioma%252BCells%26aulast%3DUsta%26aufirst%3DDiren%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D8%26spage%3D1736%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veronika  Palušová</span>, <span class="hlFld-ContribAuthor ">Tereza  Renzová</span>, <span class="hlFld-ContribAuthor ">Amandine  Verlande</span>, <span class="hlFld-ContribAuthor ">Tereza  Vaclová</span>, <span class="hlFld-ContribAuthor ">Michaela  Medková</span>, <span class="hlFld-ContribAuthor ">Linda  Cetlová</span>, <span class="hlFld-ContribAuthor ">Miroslava  Sedláčková</span>, <span class="hlFld-ContribAuthor ">Hana  Hříbková</span>, <span class="hlFld-ContribAuthor ">Iva  Slaninová</span>, <span class="hlFld-ContribAuthor ">Miriama  Krutá</span>, <span class="hlFld-ContribAuthor ">Vladimír  Rotrekl</span>, <span class="hlFld-ContribAuthor ">Hana  Uhlířová</span>, <span class="hlFld-ContribAuthor ">Aneta  Křížová</span>, <span class="hlFld-ContribAuthor ">Radim  Chmelík</span>, <span class="hlFld-ContribAuthor ">Pavel  Veselý</span>, <span class="hlFld-ContribAuthor ">Michaela  Krafčíková</span>, <span class="hlFld-ContribAuthor ">Lukáš  Trantírek</span>, <span class="hlFld-ContribAuthor ">Kay Oliver  Schink</span>, <span class="hlFld-ContribAuthor ">Stjepan  Uldrijan</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (6)
                                     , 1516. <a href="https://doi.org/10.3390/cancers12061516" title="DOI URL">https://doi.org/10.3390/cancers12061516</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12061516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12061516%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDual%252BTargeting%252Bof%252BBRAF%252Band%252BmTOR%252BSignaling%252Bin%252BMelanoma%252BCells%252Bwith%252BPyridinyl%252BImidazole%252BCompounds%26aulast%3DPalu%25C5%25A1ov%25C3%25A1%26aufirst%3DVeronika%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tilman  Brummer</span>, <span class="hlFld-ContribAuthor ">Campbell  McInnes</span>. </span><span class="cited-content_cbyCitation_article-title">RAF kinase dimerization: implications for drug discovery and clinical outcomes. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2020,</strong> <em>39 </em>
                                    (21)
                                     , 4155-4169. <a href="https://doi.org/10.1038/s41388-020-1263-y" title="DOI URL">https://doi.org/10.1038/s41388-020-1263-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-020-1263-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-020-1263-y%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DRAF%252Bkinase%252Bdimerization%25253A%252Bimplications%252Bfor%252Bdrug%252Bdiscovery%252Band%252Bclinical%252Boutcomes%26aulast%3DBrummer%26aufirst%3DTilman%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D21%26spage%3D4155%26epage%3D4169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John D.  Westbrook</span>, <span class="hlFld-ContribAuthor ">Rose  Soskind</span>, <span class="hlFld-ContribAuthor ">Brian P.  Hudson</span>, <span class="hlFld-ContribAuthor ">Stephen K.  Burley</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of the Protein Data Bank on antineoplastic approvals. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (5)
                                     , 837-850. <a href="https://doi.org/10.1016/j.drudis.2020.02.002" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DImpact%252Bof%252Bthe%252BProtein%252BData%252BBank%252Bon%252Bantineoplastic%252Bapprovals%26aulast%3DWestbrook%26aufirst%3DJohn%2BD.%26date%3D2020%26volume%3D25%26issue%3D5%26spage%3D837%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepika  Sirohi</span>, <span class="hlFld-ContribAuthor ">Robert L.  Schmidt</span>, <span class="hlFld-ContribAuthor ">Dara L.  Aisner</span>, <span class="hlFld-ContribAuthor ">Amir  Behdad</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Betz</span>, <span class="hlFld-ContribAuthor ">Noah  Brown</span>, <span class="hlFld-ContribAuthor ">Joshua F.  Coleman</span>, <span class="hlFld-ContribAuthor ">Christopher L.  Corless</span>, <span class="hlFld-ContribAuthor ">Georgios  Deftereos</span>, <span class="hlFld-ContribAuthor ">Mark D.  Ewalt</span>, <span class="hlFld-ContribAuthor ">Helen  Fernandes</span>, <span class="hlFld-ContribAuthor ">Susan J.  Hsiao</span>, <span class="hlFld-ContribAuthor ">Mahesh M.  Mansukhani</span>, <span class="hlFld-ContribAuthor ">Sarah S.  Murray</span>, <span class="hlFld-ContribAuthor ">Nifang  Niu</span>, <span class="hlFld-ContribAuthor ">Lauren L.  Ritterhouse</span>, <span class="hlFld-ContribAuthor ">Carlos J.  Suarez</span>, <span class="hlFld-ContribAuthor ">Laura J.  Tafe</span>, <span class="hlFld-ContribAuthor ">John A.  Thorson</span>, <span class="hlFld-ContribAuthor ">Jeremy P.  Segal</span>, <span class="hlFld-ContribAuthor ">Larissa V.  Furtado</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Molecular Diagnostics</span><span> <strong>2020,</strong> <em>22 </em>
                                    (2)
                                     , 284-293. <a href="https://doi.org/10.1016/j.jmoldx.2019.10.010" title="DOI URL">https://doi.org/10.1016/j.jmoldx.2019.10.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmoldx.2019.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmoldx.2019.10.010%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Molecular%2520Diagnostics%26atitle%3DMulti-Institutional%252BEvaluation%252Bof%252BInterrater%252BAgreement%252Bof%252BVariant%252BClassification%252BBased%252Bon%252Bthe%252B2017%252BAssociation%252Bfor%252BMolecular%252BPathology%25252C%252BAmerican%252BSociety%252Bof%252BClinical%252BOncology%25252C%252Band%252BCollege%252Bof%252BAmerican%252BPathologists%252BStandards%252Band%252BGuidelines%252Bfor%252Bthe%252BInterpretation%252Band%252BReporting%252Bof%252BSequence%252BVariants%252Bin%252BCancer%26aulast%3DSirohi%26aufirst%3DDeepika%26date%3D2020%26volume%3D22%26issue%3D2%26spage%3D284%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Athina  Moschopoulou</span>, <span class="hlFld-ContribAuthor ">Stefan  Zwirner</span>, <span class="hlFld-ContribAuthor ">Lars  Zender</span>, <span class="hlFld-ContribAuthor ">Daniel  Dauch</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 125-153. <a href="https://doi.org/10.1007/7355_2020_100" title="DOI URL">https://doi.org/10.1007/7355_2020_100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_100%26sid%3Dliteratum%253Aachs%26atitle%3DExploiting%252BKinase%252BInhibitors%252Bfor%252BCancer%252BTreatment%25253A%252BAn%252BOverview%252Bof%252BClinical%252BResults%252Band%252BOutlook%26aulast%3DMoschopoulou%26aufirst%3DAthina%26date%3D2020%26date%3D2020%26spage%3D125%26epage%3D153%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rona  Yaeger</span>, <span class="hlFld-ContribAuthor ">Daisuke  Kotani</span>, <span class="hlFld-ContribAuthor ">Sebastián  Mondaca</span>, <span class="hlFld-ContribAuthor ">Aparna R.  Parikh</span>, <span class="hlFld-ContribAuthor ">Hideaki  Bando</span>, <span class="hlFld-ContribAuthor ">Emily E.  Van Seventer</span>, <span class="hlFld-ContribAuthor ">Hiroya  Taniguchi</span>, <span class="hlFld-ContribAuthor ">HuiYong  Zhao</span>, <span class="hlFld-ContribAuthor ">Claire N.  Thant</span>, <span class="hlFld-ContribAuthor ">Elisa  de Stanchina</span>, <span class="hlFld-ContribAuthor ">Neal  Rosen</span>, <span class="hlFld-ContribAuthor ">Ryan B.  Corcoran</span>, <span class="hlFld-ContribAuthor ">Takayuki  Yoshino</span>, <span class="hlFld-ContribAuthor ">Zhan  Yao</span>, <span class="hlFld-ContribAuthor ">Hiromichi  Ebi</span>. </span><span class="cited-content_cbyCitation_article-title">Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2019,</strong> <em>25 </em>
                                    (23)
                                     , 7089-7097. <a href="https://doi.org/10.1158/1078-0432.CCR-19-2004" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-19-2004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-19-2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-19-2004%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DResponse%252Bto%252BAnti-EGFR%252BTherapy%252Bin%252BPatients%252Bwith%252BBRAF%252Bnon-V600%2525E2%252580%252593Mutant%252BMetastatic%252BColorectal%252BCancer%26aulast%3DYaeger%26aufirst%3DRona%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D23%26spage%3D7089%26epage%3D7097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krissie  Lenting</span>, <span class="hlFld-ContribAuthor ">Corina N. A. M.  van den Heuvel</span>, <span class="hlFld-ContribAuthor ">Anne  van Ewijk</span>, <span class="hlFld-ContribAuthor ">Duaa  ElMelik</span>, <span class="hlFld-ContribAuthor ">Remco  de Boer</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Tindall</span>, <span class="hlFld-ContribAuthor ">Ge  Wei</span>, <span class="hlFld-ContribAuthor ">Benno  Kusters</span>, <span class="hlFld-ContribAuthor ">Maarten  te Dorsthorst</span>, <span class="hlFld-ContribAuthor ">Mark  ter Laan</span>, <span class="hlFld-ContribAuthor ">Martijn A.  Huynen</span>, <span class="hlFld-ContribAuthor ">William P.  Leenders</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing. </span><span class="cited-content_cbyCitation_journal-name">Acta Neuropathologica Communications</span><span> <strong>2019,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s40478-019-0826-z" title="DOI URL">https://doi.org/10.1186/s40478-019-0826-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s40478-019-0826-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs40478-019-0826-z%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Neuropathologica%2520Communications%26atitle%3DMapping%252Bactionable%252Bpathways%252Band%252Bmutations%252Bin%252Bbrain%252Btumours%252Busing%252Btargeted%252BRNA%252Bnext%252Bgeneration%252Bsequencing%26aulast%3DLenting%26aufirst%3DKrissie%26date%3D2019%26date%3D2019%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas  Cope</span>, <span class="hlFld-ContribAuthor ">Borna  Novak</span>, <span class="hlFld-ContribAuthor ">Christine  Candelora</span>, <span class="hlFld-ContribAuthor ">Kenneth  Wong</span>, <span class="hlFld-ContribAuthor ">Maria  Cavallo</span>, <span class="hlFld-ContribAuthor ">Amber  Gunderwala</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Liu</span>, <span class="hlFld-ContribAuthor ">Yana  Li</span>, <span class="hlFld-ContribAuthor ">Zhihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Biochemical Characterization of Full‐Length Oncogenic BRAF
              V600E
              together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2019,</strong> <em>20 </em>
                                    (22)
                                     , 2850-2861. <a href="https://doi.org/10.1002/cbic.201900266" title="DOI URL">https://doi.org/10.1002/cbic.201900266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201900266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201900266%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DBiochemical%252BCharacterization%252Bof%252BFull%2525E2%252580%252590Length%252BOncogenic%252BBRAF%252BV600E%252Btogether%252Bwith%252BMolecular%252BDynamics%252BSimulations%252BProvide%252BInsight%252Binto%252Bthe%252BActivation%252Band%252BInhibition%252BMechanisms%252Bof%252BRAF%252BKinases%26aulast%3DCope%26aufirst%3DNicholas%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D2850%26epage%3D2861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasushi  Kondo</span>, <span class="hlFld-ContribAuthor ">Jana  Ognjenović</span>, <span class="hlFld-ContribAuthor ">Saikat  Banerjee</span>, <span class="hlFld-ContribAuthor ">Deepti  Karandur</span>, <span class="hlFld-ContribAuthor ">Alan  Merk</span>, <span class="hlFld-ContribAuthor ">Kayla  Kulhanek</span>, <span class="hlFld-ContribAuthor ">Kathryn  Wong</span>, <span class="hlFld-ContribAuthor ">Jeroen P.  Roose</span>, <span class="hlFld-ContribAuthor ">Sriram  Subramaniam</span>, <span class="hlFld-ContribAuthor ">John  Kuriyan</span>. </span><span class="cited-content_cbyCitation_article-title">Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases. </span><span class="cited-content_cbyCitation_journal-name">Science</span><span> <strong>2019,</strong> <em>366 </em>
                                    (6461)
                                     , 109-115. <a href="https://doi.org/10.1126/science.aay0543" title="DOI URL">https://doi.org/10.1126/science.aay0543</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/science.aay0543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscience.aay0543%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%26atitle%3DCryo-EM%252Bstructure%252Bof%252Ba%252Bdimeric%252BB-Raf%25253A14-3-3%252Bcomplex%252Breveals%252Basymmetry%252Bin%252Bthe%252Bactive%252Bsites%252Bof%252BB-Raf%252Bkinases%26aulast%3DKondo%26aufirst%3DYasushi%26date%3D2019%26date%3D2019%26volume%3D366%26issue%3D6461%26spage%3D109%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ludmila E.  Campos</span>, <span class="hlFld-ContribAuthor ">Francisco M.  Garibotto</span>, <span class="hlFld-ContribAuthor ">Emilio  Angelina</span>, <span class="hlFld-ContribAuthor ">Jiri  Kos</span>, <span class="hlFld-ContribAuthor ">Tihomir  Tomašič</span>, <span class="hlFld-ContribAuthor ">Nace  Zidar</span>, <span class="hlFld-ContribAuthor ">Danijel  Kikelj</span>, <span class="hlFld-ContribAuthor ">Tomas  Gonec</span>, <span class="hlFld-ContribAuthor ">Pavlina  Marvanova</span>, <span class="hlFld-ContribAuthor ">Petr  Mokry</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Sergio E.  Alvarez</span>, <span class="hlFld-ContribAuthor ">Ricardo D.  Enriz</span>. </span><span class="cited-content_cbyCitation_article-title">Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>91 </em>, 103125. <a href="https://doi.org/10.1016/j.bioorg.2019.103125" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103125%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSearching%252Bnew%252Bstructural%252Bscaffolds%252Bfor%252BBRAF%252Binhibitors.%252BAn%252Bintegrative%252Bstudy%252Busing%252Btheoretical%252Band%252Bexperimental%252Btechniques%26aulast%3DCampos%26aufirst%3DLudmila%2BE.%26date%3D2019%26volume%3D91%26spage%3D103125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Guoliang  Gong</span>, <span class="hlFld-ContribAuthor ">Xinyang  Chen</span>, <span class="hlFld-ContribAuthor ">Ruihu  Song</span>, <span class="hlFld-ContribAuthor ">Mei  Duan</span>, <span class="hlFld-ContribAuthor ">Ruizhi  Qiao</span>, <span class="hlFld-ContribAuthor ">Yu  Jiao</span>, <span class="hlFld-ContribAuthor ">Jianzhao  Qi</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Yong  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2019,</strong> <em>67 </em>
                                    (10)
                                     , 1116-1122. <a href="https://doi.org/10.1248/cpb.c19-00425" title="DOI URL">https://doi.org/10.1248/cpb.c19-00425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c19-00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c19-00425%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BBenzoylimidazole%252BDerivatives%252Bas%252BRaf%252Band%252BHistone%252BDeacetylases%252BDual%252BInhibitors%26aulast%3DChen%26aufirst%3DXin%26date%3D2019%26volume%3D67%26issue%3D10%26spage%3D1116%26epage%3D1122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Yang  Yu</span>, <span class="hlFld-ContribAuthor ">Yanling  Zhao</span>, <span class="hlFld-ContribAuthor ">Deanna  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaoman  Yu</span>, <span class="hlFld-ContribAuthor ">Jiaxiong  Lu</span>, <span class="hlFld-ContribAuthor ">Zhenghu  Chen</span>, <span class="hlFld-ContribAuthor ">Huiyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongguang  Hu</span>, <span class="hlFld-ContribAuthor ">Yuanfen  Zhai</span>, <span class="hlFld-ContribAuthor ">Jun  Su</span>, <span class="hlFld-ContribAuthor ">Ayinuer  Aheman</span>, <span class="hlFld-ContribAuthor ">Augusto  De las Casas</span>, <span class="hlFld-ContribAuthor ">Jingling  Jin</span>, <span class="hlFld-ContribAuthor ">Xin  Xu</span>, <span class="hlFld-ContribAuthor ">Zhongcheng  Shi</span>, <span class="hlFld-ContribAuthor ">Sarah E.  Woodfield</span>, <span class="hlFld-ContribAuthor ">Sanjeev A.  Vasudevan</span>, <span class="hlFld-ContribAuthor ">Saurabh  Agarwal</span>, <span class="hlFld-ContribAuthor ">Yusheng  Yan</span>, <span class="hlFld-ContribAuthor ">Jianhua  Yang</span>, <span class="hlFld-ContribAuthor ">Jennifer H.  Foster</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>457 </em>, 129-141. <a href="https://doi.org/10.1016/j.canlet.2019.05.011" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.05.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.05.011%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DSmall%252Bmolecule%252Binhibitor%252Bagerafenib%252Beffectively%252Bsuppresses%252Bneuroblastoma%252Btumor%252Bgrowth%252Bin%252Bmouse%252Bmodels%252Bvia%252Binhibiting%252BERK%252BMAPK%252Bsignaling%26aulast%3DLi%26aufirst%3DHui%26date%3D2019%26volume%3D457%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun-Ho  Ahn</span>, <span class="hlFld-ContribAuthor ">Sung-Hee  Hwang</span>, <span class="hlFld-ContribAuthor ">Hyun-Soo  Cho</span>, <span class="hlFld-ContribAuthor ">Michael  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules & Therapeutics</span><span> <strong>2019,</strong> <em>27 </em>
                                    (3)
                                     , 302-310. <a href="https://doi.org/10.4062/biomolther.2018.133" title="DOI URL">https://doi.org/10.4062/biomolther.2018.133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4062/biomolther.2018.133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4062%2Fbiomolther.2018.133%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%2520%2526%2520Therapeutics%26atitle%3DDifferential%252BGene%252BExpression%252BCommon%252Bto%252BAcquired%252Band%252BIntrinsic%252BResistance%252Bto%252BBRAF%252BInhibitor%252BRevealed%252Bby%252BRNA-Seq%252BAnalysis%26aulast%3DAhn%26aufirst%3DJun-Ho%26date%3D2019%26volume%3D27%26issue%3D3%26spage%3D302%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinwoong  Kim</span>, <span class="hlFld-ContribAuthor ">Byeongha  Choi</span>, <span class="hlFld-ContribAuthor ">Daseul  Im</span>, <span class="hlFld-ContribAuthor ">Hoyong  Jung</span>, <span class="hlFld-ContribAuthor ">Hyungwoo  Moon</span>, <span class="hlFld-ContribAuthor ">Waqar  Aman</span>, <span class="hlFld-ContribAuthor ">Jung-Mi  Hah</span>. </span><span class="cited-content_cbyCitation_article-title">Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1
              H
              -pyrazole as highly selective and potent BRAFV600E and CRAF inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1314-1320. <a href="https://doi.org/10.1080/14756366.2019.1599366" title="DOI URL">https://doi.org/10.1080/14756366.2019.1599366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1599366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1599366%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DComputer-aided%252Bdesign%252Band%252Bsynthesis%252Bof%252B3-carbonyl-5-phenyl-1%252BH%252B-pyrazole%252Bas%252Bhighly%252Bselective%252Band%252Bpotent%252BBRAFV600E%252Band%252BCRAF%252Binhibitor%26aulast%3DKim%26aufirst%3DJinwoong%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1314%26epage%3D1320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong-Lin  Li</span>, <span class="hlFld-ContribAuthor ">Mi-Mi  Su</span>, <span class="hlFld-ContribAuthor ">Yun-Jie  Xu</span>, <span class="hlFld-ContribAuthor ">Chen  Xu</span>, <span class="hlFld-ContribAuthor ">Yu-Shun  Yang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAFV600E inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 725-735. <a href="https://doi.org/10.1016/j.ejmech.2018.06.043" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.06.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.06.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.06.043%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Btriaryl%252Bpyrazoline%252Bderivatives%252Bwith%252Bdioxane%252Bmoiety%252Bfor%252Bselective%252BBRAFV600E%252Binhibition%26aulast%3DLi%26aufirst%3DHong-Lin%26date%3D2018%26volume%3D155%26spage%3D725%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. BRAF structure. (a) Ribbon representation of a BRAF protomer kinase domain structure bound to inhibitor <b>18</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VAM">5VAM</a>). The kinase consists of the N-lobe (salmon) and the C-lobe (blue) linked by a short flexible linker (hinge). The key structural elements for kinase activation, p-loop (yellow),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> αC-helix (magenta), and activation loop (α-loop, green) are highlighted. The regulatory F595 residue of the DFG motif (orange) adopts the DFG-OUT conformation, the αC-helix is in the IN position, and the α-loop is disordered. The floor of the inhibitor binding pocket (gray) is depicted in surface and the bound inhibitor in sticks. (b) Close-up view of BRAF active site illustrating schematically its ribose (pink), adenine (orange), hydrophobic (blue), type I (brown), and type II (green) subpockets (see text for details). The “gatekeeper” residue T529 and the catalytic residues E501 and D594 (DFG motif) are shown. A salt-bridge between catalytic E501 and K483, a hallmark of active kinase,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> is also shown. (c) The BRAF dimer (ribbons) demonstrates the spatial arrangement of protomers. Packing of residues R509 (ball-and-sticks, green) from each protomer, at the dimer interface, is essential for dimerization. αC-helix residue R506 (ball-and-sticks, yellow) can move toward OUT (red arrow) or IN (green arrow) conformations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0011.jpeg" id="rightTab-GRAPHIC-d7e364-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inactive and active BRAF conformations. Ribbon representations of three representative inactive BRAF protomers and a monomer BRAF structure. Residues forming the C-spine (brown) and R-spine (white) (see text for details) are shown in Corey–Pauling–Koltun (CPK) representation. DFG residue F595 is part of the R-spine and is colored magenta. Fully assembled R-spine is depicted schematically with a straight red line, while a fully disassembled R-spine is depicted with a dashed red line. (a, b) BRAF-inhibitor inactive protomer structures showing disordered (part a, complex with <b>1</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH">1UWH</a>) or ordered (part b, β3αC-deletion mutant in complex with <b>10</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HID">5HID</a>) α-loop. In both structures, the, inactive DFG-OUT position of F595 prevents full alignment of the R-spines. (c) A monomeric BRAF structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>) demonstrates an inactive kinase conformation in which the α-loop is folded into a helical conformation. The AS forms a short helix that stabilizes αC-helix in the inactive OUT position. The R-spine is assembled but kinked (kinked red line), indicative of inactive kinase.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (d) Protomer of the active BRAF dimer (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNE">4MNE</a>). The active kinase conformation is illustrated by the αC-IN position, the unfolding and full extension of the α-loop (including the AS) and the full assembly of the R-spine residues into a straight line (red line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural mapping of BRAF activating mutations. Structural mapping of common cancer activation point mutations on inactive BRAF monomer (panel a, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZV">4RZV</a>), an inactive protomer (panel b, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HID">5HID</a>), and active protomers (panel c, BRAFWT/MEK1 complex structure, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNE">4MNE</a>; panel d, BRAFV600E, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a>). Most mutations are concentrated at the AS of the α-loop and the p-loop. Mutations shown are the following: p-loop, G464, G466, S467, G469; α-loop, D594, G596, L597, T599, V600, K601; other locations, L485 and deletions in the 486–490 loop. Cα atoms of mutated residues are shown schematically as gold and magenta spheres, respectively, and F595 of DFG motif in sticks (orange). Residue V600 (pink) participates in a cluster of van der Waals contacts with p-loop or αC-helix residues (molecular surface) which stabilize inactive BRAF conformations (see text). In the inactive BRAF monomer (a) the cluster involves L597, L485, and αC-helix residue F498. In an inactive protomer (b) which comprise an in-frame deletion of BRAF<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> positioned at the short segment connecting αC-helix to β3-strand of the N-lobe (β3αC), it involves T599 and the p-loop residue S467. In active BRAF structures, release of steric V600 contacts upon MEK complexation (c) or mutation (d) leads to α-loop extension and positions V600 (or E600) within interaction distance to K507 at the base of αC-helix, which adopts the “active” IN position.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitor binding to BRAF structure impacts aC-helix conformation. 3D-superposition of protomers from BRAF dimers illustrate allosteric movements of αC-helix upon inhibitor binding. (a) Binding of type I<sup>1</sup>/<sub>2</sub> inhibitor <b>5</b> induces the OUT position of αC-helix (magenta) in one protomer, while the αC-IN position is observed in the inhibitor-free second protomer (cyan). PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a>. (b) Type II inhibitor <b>10</b> binds to both protomers of a BRAF dimer (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>). αC-helices of both protomers are stabilized in the αC-IN position (within some variation). (c) The position of DFG motif is not priming the conformation of αC-helix. DFG-IN or DFG-OUT conformations are sterically compatible with either IN or OUT αC-helix positions. The corresponding inhibitors and the conformations of BRAF-inhibitor crystal structures are noted. β-Sheets are represented in ribbons and helices as cylinders. Some protein parts of the C-lobe are not shown for clarity. Inhibitors and F595 (part c) are shown in sticks and molecular surface representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitors induce asymmetric BRAF dimers. Illustration of a BRAF dimer showing the two protomers in a molecular surface representation (brown, blue). OUT and IN positions of αC-helices of inhibitor bound protomers A from different BRAF dimers in complex with <b>5</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OG7">5OG7</a>), <b>9</b> (magenta, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX">5CSX</a>), <b>10</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>), and <b>2</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FB8">2FB8</a>) are shown after structural superposition. F595 residues (in sticks) adopt either the IN (yellow, cyan) or OUT (magenta, green) positions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of BRAF inhibitors. First (a), second (b), and third (c) generation BRAF inhibitors. Inhibitor moieties interacting with subpockets of BRAF active site are highlighted in different colors as in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. Coloring key of subpockets: ribose (pink), adenine (orange), hydrophobic (blue), type I (brown), and type II (green). Groups exposed to solvent are colored in gray.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Recognition of BRAF active site by type I and I<sup>1</sup>/<sub>2</sub> BRAF inhibitors. Close-up on the active site of BRAF showing binding mode of various type I or I<sup>1</sup>/<sub>2</sub> inhibitors: (a) <b>5</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a>); (b) <b>6</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSW">5CSW</a>); (c) <b>9</b>, a mixed type (I/II, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) inhibitor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX">5CSX</a>); (d) <b>20</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV1">4XV1</a>). Active-site subpockets are colored according to <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. Key H-bonds are shown (see text for details). In all complexes the terminal sulfonamide of the inhibitors is recognized by specific H-bonds. The E501-K483 salt-bridge is broken, and the αC-helix adopts the OUT position.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/medium/jm-2017-01306t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Recognition of BRAF active site by type II BRAF inhibitors. Close-up on the active site of BRAF showing binding mode of various type II inhibitors: (a) <b>11</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C9C">5C9C</a>); (b) <b>12</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>); (c) <b>18</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VAM">5VAM</a>); (d) <b>17</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R5Y">4R5Y</a>). Active-site subpockets are colored according to <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. The αC-helix adopts the IN position, typical for type II inhibitors complexes. The catalytic E501 recognizes linker or ring nitrogens of the inhibitors, and in some cases (see panels b and c) the salt-bridge to K483 is maintained.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.7b01306/20180719/images/large/jm-2017-01306t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01306&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 128 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wellbrock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasarides, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">The RAF Proteins Take Centre Stage</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1038/nrm1498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrm1498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=15520807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=875-885&issue=11&author=C.+Wellbrockauthor=M.+Karasaridesauthor=R.+Marais&title=The+RAF+Proteins+Take+Centre+Stage&doi=10.1038%2Fnrm1498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF proteins take center stage</span></div><div class="casAuthors">Wellbrock, Claudia; Karasarides, Maria; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">875-885</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their discovery over 20 years ago, the RAF proteins have been intensely studied.  For most of that time, the focus of the field has been the C-RAF isoform and its role as an effector of the RAS proteins.  However, a report that implicates B-RAF in human cancer has highlighted the importance of all members of this protein kinase family and recent studies have uncovered intriguing new data relating to their complex regulation and biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvN4GggcdfU7Vg90H21EOLACvtfcHk0li7Dt6RHeKL0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D&md5=95f0a579b4c852fbe80a54befb88b052</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm1498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1498%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DKarasarides%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DThe%2520RAF%2520Proteins%2520Take%2520Centre%2520Stage%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26issue%3D11%26spage%3D875%26epage%3D885%26doi%3D10.1038%2Fnrm1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">New Perspectives for Targeting RAF Kinase in Human Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28984291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=676-691&issue=11&author=Z.+Karouliaauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=New+Perspectives+for+Targeting+RAF+Kinase+in+Human+Cancer&doi=10.1038%2Fnrc.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives for targeting RAF kinase in human cancer</span></div><div class="casAuthors">Karoulia, Zoi; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">676-691</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The discovery that a subset of human tumors is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics.  The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and improved survival of patients with BRAF-V600E/K melanoma, but their effectiveness is limited by resistance.  Beyond melanoma, current clin. RAF inhibitors show modest efficacy when used for colorectal and thyroid BRAF-V600E tumors or for tumors harboring BRAF alterations other than the V600 mutation.  Accumulated exptl. and clin. evidence indicates that the complex biochem. mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumor resistance to them.  Recently, a no. of next-generation RAF inhibitors, with diverse structural and biochem. properties, have entered preclin. and clin. development.  In this Review, we discuss the current understanding of RAF kinase regulation, mechanisms of inhibitor action and related clin. resistance to these drugs.  The recent elucidation of crit. structural and biochem. aspects of RAF inhibitor action, combined with the availability of a no. of structurally diverse RAF inhibitors currently in preclin. and clin. development, will enable the design of more effective RAF inhibitors and RAF-inhibitor-based therapeutic strategies, tailored to different clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUrKAljS7SrVg90H21EOLACvtfcHk0ljc8rEdAqU5eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN&md5=7e8ee4222467a2d5c12b23ccce99fc62</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DNew%2520Perspectives%2520for%2520Targeting%2520RAF%2520Kinase%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D11%26spage%3D676%26epage%3D691%26doi%3D10.1038%2Fnrc.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Regulation of RAF Protein Kinases in ERK Signalling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/nrm3979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrm3979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25907612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=281-298&issue=5&author=H.+Lavoieauthor=M.+Therrien&title=Regulation+of+RAF+Protein+Kinases+in+ERK+Signalling&doi=10.1038%2Fnrm3979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of RAF protein kinases in ERK signalling</span></div><div class="casAuthors">Lavoie, Hugo; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">281-298</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF family kinases were among the first oncoproteins to be described more than 30 years ago.  They primarily act as signalling relays downstream of RAS, and their close ties to cancer have fuelled a large no. of studies.  However, we still lack a systems-level understanding of their regulation and mode of action.  The recent discovery that the catalytic activity of RAF depends on an allosteric mechanism driven by kinase domain dimerization is providing a vital new piece of information towards a comprehensive model of RAF function.  The fact that current RAF inhibitors unexpectedly induce ERK signalling by stimulating RAF dimerization also calls for a deeper structural characterization of this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzK227mPD3rVg90H21EOLACvtfcHk0ljc8rEdAqU5eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D&md5=1f4c4fbbacb1e3d790b81dbb027520b9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3979%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520RAF%2520Protein%2520Kinases%2520in%2520ERK%2520Signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26issue%3D5%26spage%3D281%26epage%3D298%26doi%3D10.1038%2Fnrm3979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS-ERK Signalling in Cancer: Promises and Challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1038/nrd4281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&issue=12&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS-ERK+Signalling+in+Cancer%3A+Promises+and+Challenges&doi=10.1038%2Fnrd4281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0ljc8rEdAqU5eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS-ERK%2520Signalling%2520in%2520Cancer%253A%2520Promises%2520and%2520Challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D12%26spage%3D928%26epage%3D942%26doi%3D10.1038%2Fnrd4281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3291</span>– <span class="NLM_lpage">3310</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&issue=22&author=P.%0AJ.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+Mitogen-Activated+Protein+Kinase+Cascade+for+the+Treatment+of+Cancer&doi=10.1038%2Fsj.onc.1210422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0li7IID2NWSXkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520Mitogen-Activated%2520Protein%2520Kinase%2520Cascade%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D22%26spage%3D3291%26epage%3D3310%26doi%3D10.1038%2Fsj.onc.1210422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woffendin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayatilake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusterson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard-Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevix-Trench, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigler, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations of the BRAF Gene in Human Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span> (<span class="NLM_issue">6892</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&issue=6892&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+Gene+in+Human+Cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0li7IID2NWSXkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520Gene%2520in%2520Human%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26issue%3D6892%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucek, L.</span></span> <span> </span><span class="NLM_article-title">Drugging the “undruggable” Cancer Targets</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc.2017.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28643779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVChu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=502-508&issue=8&author=C.+V.+Dangauthor=E.+P.+Reddyauthor=K.+M.+Shokatauthor=L.+Soucek&title=Drugging+the+%E2%80%9Cundruggable%E2%80%9D+Cancer+Targets&doi=10.1038%2Fnrc.2017.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the 'undruggable' cancer targets</span></div><div class="casAuthors">Dang, Chi V.; Reddy, E. Premkumar; Shokat, Kevan M.; Soucek, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">502-508</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The term 'undruggable' was coined to describe proteins that could not be targeted pharmacol.  However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'.  Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacol. targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies.  In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoElcMCmqGx_rVg90H21EOLACvtfcHk0li9EfWthqZ5eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVChu7jP&md5=774da7ed04931a3fd3689eb9acea594a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.36%26sid%3Dliteratum%253Aachs%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSoucek%26aufirst%3DL.%26atitle%3DDrugging%2520the%2520%25E2%2580%259Cundruggable%25E2%2580%259D%2520Cancer%2520Targets%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D8%26spage%3D502%26epage%3D508%26doi%3D10.1038%2Fnrc.2017.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajakulendran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefrançois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">A Dimerization-Dependent Mechanism Drives RAF Catalytic Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span> (<span class="NLM_issue">7263</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/nature08314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature08314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=19727074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=542-545&issue=7263&author=T.+Rajakulendranauthor=M.+Sahmiauthor=M.+Lefran%C3%A7oisauthor=F.+Sicheriauthor=M.+Therrien&title=A+Dimerization-Dependent+Mechanism+Drives+RAF+Catalytic+Activation&doi=10.1038%2Fnature08314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A dimerization-dependent mechanism drives RAF catalytic activation</span></div><div class="casAuthors">Rajakulendran, Thanashan; Sahmi, Malha; Lefrancois, Martin; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7263</span>),
    <span class="NLM_cas:pages">542-545</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ERK (extracellular signal-regulated kinase) pathway is an evolutionarily conserved signal transduction module that controls cellular growth, differentiation and survival.  Activation of receptor tyrosine kinases (RTKs) by the binding of growth factors initiates GTP loading of RAS, which triggers the initial steps in the activation of the ERK pathway by modulating RAF family kinase function.  Once activated, RAF participates in a sequential cascade of phosphorylation events that activate MEK, and in turn ERK.  Unbridled signalling through the ERK pathway caused by activating mutations in RTKs, RAS or RAF has been linked to several human cancers.  Of note, one member of the RAF family, BRAF, is the most frequently mutated oncogene in the kinase superfamily.  Not surprisingly, there has been a colossal effort to understand the underlying regulation of this family of kinases.  In particular, the process by which the RAF kinase domain becomes activated towards its substrate MEK remains of topical interest.  Here, using Drosophila Schneider S2 cells, we demonstrate that RAF catalytic function is regulated in response to a specific mode of dimerization of its kinase domain, which we term the side-to-side dimer.  Moreover, we find that the RAF-related pseudo-kinase KSR (kinase suppressor of Ras) also participates in forming side-to-side heterodimers with RAF and can thereby trigger RAF activation.  This mechanism provides an elegant explanation for the longstanding conundrum about RAF catalytic activation and also provides an explanation for the capacity of KSR, despite lacking catalytic function, to directly mediate RAF activation.  We also show that RAF side-to-side dimer formation is essential for aberrant signalling by oncogenic BRAF mutants, and identify an oncogenic mutation that acts specifically by promoting side-to-side dimerization.  Together, our data identify the side-to-side dimer interface of RAF as a potential therapeutic target for intervention in BRAF-dependent tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbnxNSbvudjbVg90H21EOLACvtfcHk0li9EfWthqZ5eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI&md5=2248d71ce37a2bac4e508a1097e95cba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08314%26sid%3Dliteratum%253Aachs%26aulast%3DRajakulendran%26aufirst%3DT.%26aulast%3DSahmi%26aufirst%3DM.%26aulast%3DLefran%25C3%25A7ois%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DA%2520Dimerization-Dependent%2520Mechanism%2520Drives%2520RAF%2520Catalytic%2520Activation%26jtitle%3DNature%26date%3D2009%26volume%3D461%26issue%3D7263%26spage%3D542%26epage%3D545%26doi%3D10.1038%2Fnature08314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&issue=2&author=S.%0AJ.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-Dead+BRAF+and+Oncogenic+RAS+Cooperate+to+Drive+Tumor+Progression+through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0ljAm4lL02BA2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-Dead%2520BRAF%2520and%2520Oncogenic%2520RAS%2520Cooperate%2520to%2520Drive%2520Tumor%2520Progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D2%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiala, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhardt, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummer, T.</span></span> <span> </span><span class="NLM_article-title">Distinct Requirement for an Intact Dimer Interface in Wild-Type, V600E and Kinase-Dead B-Raf Signalling</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2629</span>– <span class="NLM_lpage">2647</span>, <span class="refDoi"> DOI: 10.1038/emboj.2012.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Femboj.2012.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=2629-2647&issue=11&author=M.+R%C3%B6ringauthor=R.+Herrauthor=G.+J.+Fialaauthor=K.+Heilmannauthor=S.+Braunauthor=A.+E.+Eisenhardtauthor=S.+Halbachauthor=D.+Capperauthor=A.+von+Deimlingauthor=W.+W.+Schamelauthor=D.+N.+Saundersauthor=T.+Brummer&title=Distinct+Requirement+for+an+Intact+Dimer+Interface+in+Wild-Type%2C+V600E+and+Kinase-Dead+B-Raf+Signalling&doi=10.1038%2Femboj.2012.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.100%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6ring%26aufirst%3DM.%26aulast%3DHerr%26aufirst%3DR.%26aulast%3DFiala%26aufirst%3DG.%2BJ.%26aulast%3DHeilmann%26aufirst%3DK.%26aulast%3DBraun%26aufirst%3DS.%26aulast%3DEisenhardt%26aufirst%3DA.%2BE.%26aulast%3DHalbach%26aufirst%3DS.%26aulast%3DCapper%26aufirst%3DD.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DSchamel%26aufirst%3DW.%2BW.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26aulast%3DBrummer%26aufirst%3DT.%26atitle%3DDistinct%2520Requirement%2520for%2520an%2520Intact%2520Dimer%2520Interface%2520in%2520Wild-Type%252C%2520V600E%2520and%2520Kinase-Dead%2520B-Raf%2520Signalling%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D31%26issue%3D11%26spage%3D2629%26epage%3D2647%26doi%3D10.1038%2Femboj.2012.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.molcel.2005.10.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=963-969&issue=6&author=M.+J.+Garnettauthor=S.+Ranaauthor=H.+Patersonauthor=D.+Barfordauthor=R.+Marais&title=Wild-Type+and+Mutant+B-RAF+Activate+C-RAF+through+Distinct+Mechanisms+Involving+Heterodimerization&doi=10.1016%2Fj.molcel.2005.10.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DWild-Type%2520and%2520Mutant%2520B-RAF%2520Activate%2520C-RAF%2520through%2520Distinct%2520Mechanisms%2520Involving%2520Heterodimerization%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26issue%3D6%26spage%3D963%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2005.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">RAF Protein-Serine/Threonine Kinases: Structure and Regulation</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>399</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2010.07.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bbrc.2010.07.092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=399&publication_year=2010&pages=313-317&issue=3&author=R.+Roskoski&title=RAF+Protein-Serine%2FThreonine+Kinases%3A+Structure+and+Regulation&doi=10.1016%2Fj.bbrc.2010.07.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2010.07.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2010.07.092%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DRAF%2520Protein-Serine%252FThreonine%2520Kinases%253A%2520Structure%2520and%2520Regulation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2010%26volume%3D399%26issue%3D3%26spage%3D313%26epage%3D317%26doi%3D10.1016%2Fj.bbrc.2010.07.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiello, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergameno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normanno, N.</span></span> <span> </span><span class="NLM_article-title">The RAS/RAF/MEK/ERK and the PI3K/AKT Signalling Pathways: Role in Cancer Pathogenesis and Implications for Therapeutic Approaches</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">Suppl. 2</span>),  <span class="NLM_fpage">S17</span>– <span class="NLM_lpage">S27</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.639361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1517%2F14728222.2011.639361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22443084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XksFWmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=S17-S27&issue=Suppl.+2&author=A.+De%0ALucaauthor=M.+R.+Maielloauthor=A.+D%E2%80%99Alessioauthor=M.+Pergamenoauthor=N.+Normanno&title=The+RAS%2FRAF%2FMEK%2FERK+and+the+PI3K%2FAKT+Signalling+Pathways%3A+Role+in+Cancer+Pathogenesis+and+Implications+for+Therapeutic+Approaches&doi=10.1517%2F14728222.2011.639361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches</span></div><div class="casAuthors">De Luca, Antonella; Maiello, Monica R.; D'Alessio, Amelia; Pergameno, Maria; Normanno, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">S2</span>),
    <span class="NLM_cas:pages">S17-S27</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The RAS/RAF/MAP kinase-ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) (MAPK) and the PI3K/AKT/mammalian target of rapamycin (mTOR) (PI3K) pathways are frequently deregulated in human cancer as a result of genetic alterations in their components or upstream activation of cell-surface receptors.  These signalling cascades are regulated by complex feedback and cross-talk mechanisms.Areas covered: In this review the key components of the MAPK and AKT pathways and their mol. alterations are described.  The complex interactions between these signalling cascades are also analyzed.Expert opinion: The observation that the MAPK and the PI3K pathways are often deregulated in human cancer makes the components of these signalling cascades interesting targets for therapeutic intervention.  Recently, the presence of compensatory loops that activate one pathway following the blockade of the other signalling cascade has been demonstrated.  Therefore, the blockade of both pathways with combinations of signalling inhibitors might result in a more efficient anti-tumor effect as compared with a single agent.  In addn., the MAPK and PI3K pathways are activated by mutations that coexist or can be mutually exclusive.  In this regard, a large-scale characterization of the cancer genome might offer personalized cancer genomic information, which may improve the anti-tumor efficacy of signalling inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2jyP6LXY3vrVg90H21EOLACvtfcHk0lhfWkH0dvLK0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksFWmt70%253D&md5=4a83930e8d8554a97e33eec64f76a814</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.639361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.639361%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DMaiello%26aufirst%3DM.%2BR.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DA.%26aulast%3DPergameno%26aufirst%3DM.%26aulast%3DNormanno%26aufirst%3DN.%26atitle%3DThe%2520RAS%252FRAF%252FMEK%252FERK%2520and%2520the%2520PI3K%252FAKT%2520Signalling%2520Pathways%253A%2520Role%2520in%2520Cancer%2520Pathogenesis%2520and%2520Implications%2520for%2520Therapeutic%2520Approaches%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26issue%3DSuppl.%25202%26spage%3DS17%26epage%3DS27%26doi%3D10.1517%2F14728222.2011.639361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Hyperactive Ras in Developmental Disorders and Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1038/nrc2109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc2109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=17384584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=295-308&issue=4&author=S.+Schubbertauthor=K.+Shannonauthor=G.+Bollag&title=Hyperactive+Ras+in+Developmental+Disorders+and+Cancer&doi=10.1038%2Fnrc2109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactive Ras in developmental disorders and cancer</span></div><div class="casAuthors">Schubbert, Suzanne; Shannon, Kevin; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-308</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ras genes are the most common targets for somatic gain-of-function mutations in human cancer.  Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Nonan, Costello and cardio-facio-cutaneous syndromes.  Many of these mutant alleles encode proteins with aberrant biochem. and functional properties.  Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRvjqrp1ho7Vg90H21EOLACvtfcHk0lhfWkH0dvLK0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D&md5=25fcaa959dae5e8512b959936bcbb347</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc2109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2109%26sid%3Dliteratum%253Aachs%26aulast%3DSchubbert%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DHyperactive%2520Ras%2520in%2520Developmental%2520Disorders%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D4%26spage%3D295%26epage%3D308%26doi%3D10.1038%2Fnrc2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">(V600E)BRAF Is Associated with Disabled Feedback Inhibition of RAF-MEK Signaling and Elevated Transcriptional Output of the Pathway</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4519</span>– <span class="NLM_lpage">4524</span>, <span class="refDoi"> DOI: 10.1073/pnas.0900780106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.0900780106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=4519-4524&issue=11&author=C.%0AA.+Pratilasauthor=B.+S.+Taylorauthor=Q.+Yeauthor=A.+Vialeauthor=C.+Sanderauthor=D.+B.+Solitauthor=N.+Rosen&title=%28V600E%29BRAF+Is+Associated+with+Disabled+Feedback+Inhibition+of+RAF-MEK+Signaling+and+Elevated+Transcriptional+Output+of+the+Pathway&doi=10.1073%2Fpnas.0900780106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0900780106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0900780106%26sid%3Dliteratum%253Aachs%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3D%2528V600E%2529BRAF%2520Is%2520Associated%2520with%2520Disabled%2520Feedback%2520Inhibition%2520of%2520RAF-MEK%2520Signaling%2520and%2520Elevated%2520Transcriptional%2520Output%2520of%2520the%2520Pathway%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D11%26spage%3D4519%26epage%3D4524%26doi%3D10.1073%2Fpnas.0900780106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group">Cancer Genome Project.</span> <span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&issue=6&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Maraisauthor=Cancer+Genome+Project.&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lhfWkH0dvLK0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3D%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26issue%3D6%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayfield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2016.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26996308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=477-493&issue=4&author=S.+A.+Fosterauthor=D.+M.+Whalenauthor=A.+%C3%96zenauthor=M.+J.+Wongchenkoauthor=J.+Yinauthor=I.+Yenauthor=G.+Schaeferauthor=J.+D.+Mayfieldauthor=J.+Chmieleckiauthor=P.+J.+Stephensauthor=L.+A.+Albackerauthor=Y.+Yanauthor=K.+Songauthor=G.+Hatzivassiliouauthor=C.+Eigenbrotauthor=C.+Yuauthor=A.+S.+Shawauthor=G.+Manningauthor=N.+J.+Skeltonauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Activation+Mechanism+of+Oncogenic+Deletion+Mutations+in+BRAF%2C+EGFR%2C+and+HER2&doi=10.1016%2Fj.ccell.2016.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2</span></div><div class="casAuthors">Foster, Scott A.; Whalen, Daniel M.; Ozen, Aysegul; Wongchenko, Matthew J.; Yin, Jian Ping; Yen, Ivana; Schaefer, Gabriele; Mayfield, John D.; Chmielecki, Juliann; Stephens, Philip J.; Albacker, Lee A.; Yan, Yibing; Song, Kyung; Hatzivassiliou, Georgia; Eigenbrot, Charles; Yu, Christine; Shaw, Andrey S.; Manning, Gerard; Skelton, Nicholas J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-493</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activating mutations in protein kinases drive many cancers.  While how recurring point mutations affect kinase activity has been described, the effect of in-frame deletions is not well understood.  We show that oncogenic deletions within the β3-αC loop of HER2 and BRAF are analogous to the recurrent EGFR exon 19 deletions.  We identify pancreatic carcinomas with BRAF deletions mutually exclusive with KRAS mutations.  Crystal structures of BRAF deletions reveal the truncated loop restrains αC in an active "in" conformation, imparting resistance to inhibitors like vemurafenib that bind the αC "out" conformation.  Characterization of loop length explains the prevalence of five amino acid deletions in BRAF, EGFR, and HER2 and highlights the importance of this region for kinase activity and inhibitor efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObiwE2cwFlbVg90H21EOLACvtfcHk0liz7gz806wrlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D&md5=7aad1cea6f17f2b74c42fbc3c1c9b0fd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DWhalen%26aufirst%3DD.%2BM.%26aulast%3D%25C3%2596zen%26aufirst%3DA.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DMayfield%26aufirst%3DJ.%2BD.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DAlbacker%26aufirst%3DL.%2BA.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DManning%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DActivation%2520Mechanism%2520of%2520Oncogenic%2520Deletion%2520Mutations%2520in%2520BRAF%252C%2520EGFR%252C%2520and%2520HER2%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26issue%3D4%26spage%3D477%26epage%3D493%26doi%3D10.1016%2Fj.ccell.2016.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holderfield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuker, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, M.</span></span> <span> </span><span class="NLM_article-title">Targeting RAF Kinases for Cancer Therapy: BRAF-Mutated Melanoma and Beyond</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1038/nrc3760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrc3760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24957944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=455-467&issue=7&author=M.+Holderfieldauthor=M.+M.+Deukerauthor=F.+McCormickauthor=M.+McMahon&title=Targeting+RAF+Kinases+for+Cancer+Therapy%3A+BRAF-Mutated+Melanoma+and+Beyond&doi=10.1038%2Fnrc3760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond</span></div><div class="casAuthors">Holderfield, Matthew; Deuker, Marian M.; McCormick, Frank; McMahon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of mutationally activated BRAF in many cancers altered our conception of the part played by the RAF family of protein kinases in oncogenesis.  In this Review, we describe the development of BRAF inhibitors and the results that have emerged from their anal. in both the lab. and the clinic.  We discuss the spectrum of RAF mutations in human cancer and the complex interplay between the tissue of origin and the response to RAF inhibition.  Finally, we enumerate mechanisms of resistance to BRAF inhibition that have been characterized and postulate how strategies of RAF pathway inhibition may be extended in scope to benefit not only the thousands of patients who are diagnosed annually with BRAF-mutated metastatic melanoma but also the larger patient population with malignancies harboring mutationally activated RAF genes that are ineffectively treated with the current generation of BRAF kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocz-DIK1jK5LVg90H21EOLACvtfcHk0liz7gz806wrlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M&md5=d7de7a5409dbb2aefaf3fc9ef6d8f944</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrc3760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3760%26sid%3Dliteratum%253Aachs%26aulast%3DHolderfield%26aufirst%3DM.%26aulast%3DDeuker%26aufirst%3DM.%2BM.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DMcMahon%26aufirst%3DM.%26atitle%3DTargeting%2520RAF%2520Kinases%2520for%2520Cancer%2520Therapy%253A%2520BRAF-Mutated%2520Melanoma%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D7%26spage%3D455%26epage%3D467%26doi%3D10.1038%2Fnrc3760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">BRAF Inhibitors: The Current and the Future</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.coph.2015.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26072431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=68-73&author=W.+Zhang&title=BRAF+Inhibitors%3A+The+Current+and+the+Future&doi=10.1016%2Fj.coph.2015.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF inhibitors: the current and the future</span></div><div class="casAuthors">Zhang, Weijiang</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The introduction of BRAF inhibitors (BRAFi), vemurafenib and dabrafenib, revolutionized BRAFV600-mutated metastatic melanoma treatment with improved response rate and overall survival compared to std. chemotherapy.  However, the mechanism related cutaneous toxicity remains a concern.  In addn., intrinsic and acquired resistance remain the key challenges in BRAFi therapy.  Extensive efforts to elucidate the mechanisms have led to an improved understanding of disease biol. and resulted in exploration of multiple new therapeutic options.  While the future looks bright with multiple new therapeutic strategies in exploration and possible new generations of BRAFi, there are questions remaining to be answered to enable more efficient use of BRAFi in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNC7oPN122rrVg90H21EOLACvtfcHk0liz7gz806wrlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtL%252FI&md5=8cd005e17d14da7a9a6ee00231fc0b58</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DBRAF%2520Inhibitors%253A%2520The%2520Current%2520and%2520the%2520Future%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D68%26epage%3D73%26doi%3D10.1016%2Fj.coph.2015.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barras, D.</span></span> <span> </span><span class="NLM_article-title">BRAF Mutation in Colorectal Cancer: An Update</span>. <i>Biomarkers Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.4137/BIC.S25248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.4137%2FBIC.S25248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26396549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsFegt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=9-12&issue=Suppl.+1&author=D.+Barras&title=BRAF+Mutation+in+Colorectal+Cancer%3A+An+Update&doi=10.4137%2FBIC.S25248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation in colorectal cancer: an update</span></div><div class="casAuthors">Barras, David</div><div class="citationInfo"><span class="NLM_cas:title">Biomarkers in Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">9-12</span>CODEN:
                <span class="NLM_cas:coden">BCIACZ</span>;
        ISSN:<span class="NLM_cas:issn">1179-299X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica Ltd.</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) is still one of the deadliest cancer-related diseases.  About 10% of CRC patients are characterized by a mutation in the B-Raf proto-oncogene serine/threonine kinase (BRAF) gene resulting in a valine-to-glutamate change at the residue 600 (V600E).  This mutation is also present in more than 60% of melanoma patients.  BRAF inhibitors were developed and found to improve patient survival; however, most patients at the end of the track ultimately develop resistance to these inhibitors.  Melanoma patients benefit from the combination of BRAF inhibitors with mitogen/ extracellular signal-regulated kinase (MEK) inhibitors, among others.  Unfortunately, colorectal patients do not respond much efficiently, which suggests different resistance mechanisms between the two cancer types.  This review aims at shedding light on recent discoveries that improve our understanding of the BRAF mutation biol. in CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpENU5EvBwYYrVg90H21EOLACvtfcHk0lj5OEVesaiTDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsFegt7k%253D&md5=1f075fc24c1a03fb8af91bfc6ff1c530</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4137%2FBIC.S25248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FBIC.S25248%26sid%3Dliteratum%253Aachs%26aulast%3DBarras%26aufirst%3DD.%26atitle%3DBRAF%2520Mutation%2520in%2520Colorectal%2520Cancer%253A%2520An%2520Update%26jtitle%3DBiomarkers%2520Cancer%26date%3D2015%26volume%3D7%26issue%3DSuppl.%25201%26spage%3D9%26epage%3D12%26doi%3D10.4137%2FBIC.S25248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paik, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Clinical Characteristics of Patients with Lung Adenocarcinomas Harboring BRAF Mutations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2046</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.33.1280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1200%2FJCO.2010.33.1280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=21483012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjtFOmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2046-2051&issue=15&author=P.+K.+Paikauthor=M.+E.+Arcilaauthor=M.+Faraauthor=C.+S.+Simaauthor=V.+A.+Millerauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Clinical+Characteristics+of+Patients+with+Lung+Adenocarcinomas+Harboring+BRAF+Mutations&doi=10.1200%2FJCO.2010.33.1280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations</span></div><div class="casAuthors">Paik Paul K; Arcila Maria E; Fara Michael; Sima Camelia S; Miller Vincent A; Kris Mark G; Ladanyi Marc; Riely Gregory J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2046-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  BRAF mutations occur in non-small-cell lung cancer.  Therapies targeting BRAF mutant tumors have recently been identified.  We undertook this study to determine the clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.  PATIENTS AND METHODS:  We reviewed data from consecutive patients with lung adenocarcinoma whose tumors underwent BRAF, EGFR, and KRAS mutation testing as well as fluorescence in situ hybridization for ALK rearrangements.  Patient characteristics including age, sex, race, performance status, smoking history, stage, treatment history, and overall survival were collected.  RESULTS:  Among 697 patients with lung adenocarcinoma, BRAF mutations were present in 18 patients (3%; 95% CI, 2% to 4%).  The BRAF mutations identified were V600E (50%), G469A (39%), and D594G (11%).  Mutations in EGFR were present in 24%, KRAS in 25%, and ALK translocations in 6%.  In contrast to patients with EGFR mutations and ALK rearrangements who were mostly never smokers, all patients with BRAF mutations were current or former smokers (P < .001).  The median overall survival of advanced-stage patients with BRAF mutations was not reached.  In comparison, the median overall survival of patients with EGFR mutations was 37 months (P = .73), with KRAS mutations was 18 months (P = .12), and with ALK rearrangements was not reached (P = .64).  CONCLUSION:  BRAF mutations occur in 3% of patients with lung adenocarcinoma and occur more commonly in current and former smokers.  The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbo-HEAKiAr1MGsG_HTXYFfW6udTcc2eZWfRHzye_QRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjtFOmsg%253D%253D&md5=f6d11ddad68bb7698db853a1ebb9431f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.1280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.1280%26sid%3Dliteratum%253Aachs%26aulast%3DPaik%26aufirst%3DP.%2BK.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DFara%26aufirst%3DM.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DClinical%2520Characteristics%2520of%2520Patients%2520with%2520Lung%2520Adenocarcinomas%2520Harboring%2520BRAF%2520Mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D15%26spage%3D2046%26epage%3D2051%26doi%3D10.1200%2FJCO.2010.33.1280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollaee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koduru, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yopp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">Whole-Exome Sequencing of Pancreatic Cancer Defines Genetic Diversity and Therapeutic Targets</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6744</span>, <span class="refDoi"> DOI: 10.1038/ncomms7744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fncomms7744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25855536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2lurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6744&author=A.+K.+Witkiewiczauthor=E.+A.+McMillanauthor=U.+Balajiauthor=G.+Baekauthor=W.-C.+Linauthor=J.+Mansourauthor=M.+Mollaeeauthor=K.-U.+Wagnerauthor=P.+Koduruauthor=A.+Yoppauthor=M.+A.+Chotiauthor=C.+J.+Yeoauthor=P.+McCueauthor=M.+A.+Whiteauthor=E.+S.+Knudsen&title=Whole-Exome+Sequencing+of+Pancreatic+Cancer+Defines+Genetic+Diversity+and+Therapeutic+Targets&doi=10.1038%2Fncomms7744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets</span></div><div class="casAuthors">Witkiewicz, Agnieszka K.; McMillan, Elizabeth A.; Balaji, Uthra; Baek, Guem Hee; Lin, Wan-Chi; Mansour, John; Mollaee, Mehri; Wagner, Kay-Uwe; Koduru, Prasad; Yopp, Adam; Choti, Michael A.; Yeo, Charles J.; McCue, Peter; White, Michael A.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6744</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and insights into both disease etiol. and targeted intervention are needed.  A total of 109 micro-dissected PDA cases were subjected to whole-exome sequencing.  Microdissection enriches tumor cellularity and enhances mutation calling.  Here we show that environmental stress and alterations in DNA repair genes assoc. with distinct mutation spectra.  Copy no. alterations target multiple tumor suppressive/oncogenic loci; however, amplification of MYC is uniquely assocd. with poor outcome and adenosquamous subtype.  We identify multiple novel mutated genes in PDA, with select genes harbouring prognostic significance.  RBM10 mutations assoc. with longer survival in spite of histol. features of aggressive disease.  KRAS mutations are obsd. in >90% of cases, but codon Q61 alleles are selectively assocd. with improved survival.  Oncogenic BRAF mutations are mutually exclusive with KRAS and define sensitivity to vemurafenib in PDA models.  High-frequency alterations in Wnt signalling, chromatin remodelling, Hedgehog signalling, DNA repair and cell cycle processes are obsd.  Together, these data delineate new genetic diversity of PDA and provide insights into prognostic determinants and therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0gY2GitPt7Vg90H21EOLACvtfcHk0liQwBRRQdR09w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2lurvN&md5=0e578f8e3652284b47c1c74e87173de9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fncomms7744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7744%26sid%3Dliteratum%253Aachs%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DMcMillan%26aufirst%3DE.%2BA.%26aulast%3DBalaji%26aufirst%3DU.%26aulast%3DBaek%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DW.-C.%26aulast%3DMansour%26aufirst%3DJ.%26aulast%3DMollaee%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DK.-U.%26aulast%3DKoduru%26aufirst%3DP.%26aulast%3DYopp%26aufirst%3DA.%26aulast%3DChoti%26aufirst%3DM.%2BA.%26aulast%3DYeo%26aufirst%3DC.%2BJ.%26aulast%3DMcCue%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DWhole-Exome%2520Sequencing%2520of%2520Pancreatic%2520Cancer%2520Defines%2520Genetic%2520Diversity%2520and%2520Therapeutic%2520Targets%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6744%26doi%3D10.1038%2Fncomms7744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montagut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulkus, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4853</span>– <span class="NLM_lpage">4861</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-07-6787" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4853-4861&issue=12&author=C.+Montagutauthor=S.+V.+Sharmaauthor=T.+Shiodaauthor=U.+McDermottauthor=M.+Ulmanauthor=L.+E.+Ulkusauthor=D.+Dias-Santagataauthor=H.+Stubbsauthor=D.+Y.+Leeauthor=A.+Singhauthor=L.+Drewauthor=D.+A.+Haberauthor=J.+Settleman&title=Elevated+CRAF+as+a+Potential+Mechanism+of+Acquired+Resistance+to+BRAF+Inhibition+in+Melanoma&doi=10.1158%2F0008-5472.CAN-07-6787"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6787%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DUlman%26aufirst%3DM.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DElevated%2520CRAF%2520as%2520a%2520Potential%2520Mechanism%2520of%2520Acquired%2520Resistance%2520to%2520BRAF%2520Inhibition%2520in%2520Melanoma%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D12%26spage%3D4853%26epage%3D4861%26doi%3D10.1158%2F0008-5472.CAN-07-6787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prados, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaides, T.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.11882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.18632%2Foncotarget.11882" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=583-595&issue=1&author=T.-W.+Yaoauthor=J.+Zhangauthor=M.+Pradosauthor=W.+A.+Weissauthor=C.+D.+Jamesauthor=T.+Nicolaides&title=Acquired+Resistance+to+BRAF+Inhibition+in+BRAFV600E+Mutant+Gliomas&doi=10.18632%2Foncotarget.11882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11882%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DT.-W.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPrados%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DNicolaides%26aufirst%3DT.%26atitle%3DAcquired%2520Resistance%2520to%2520BRAF%2520Inhibition%2520in%2520BRAFV600E%2520Mutant%2520Gliomas%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D583%26epage%3D595%26doi%3D10.18632%2Foncotarget.11882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Path Forward for RAF Therapies: Inhibition of Monomers and Dimers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2015.08.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=279-281&issue=3&author=R.+L.+Kortumauthor=D.+K.+Morrison&title=Path+Forward+for+RAF+Therapies%3A+Inhibition+of+Monomers+and+Dimers&doi=10.1016%2Fj.ccell.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKortum%26aufirst%3DR.%2BL.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DPath%2520Forward%2520for%2520RAF%2520Therapies%253A%2520Inhibition%2520of%2520Monomers%2520and%2520Dimers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D279%26epage%3D281%26doi%3D10.1016%2Fj.ccell.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms That Determine Their Sensitivity to Pharmacologic Inhibition</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26343582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=370-383&issue=3&author=Z.+Yaoauthor=N.+M.+Torresauthor=A.+Taoauthor=Y.+Gaoauthor=L.+Luoauthor=Q.+Liauthor=E.+de+Stanchinaauthor=O.+Abdel-Wahabauthor=D.+B.+Solitauthor=P.+I.+Poulikakosauthor=N.+Rosen&title=BRAF+Mutants+Evade+ERK-Dependent+Feedback+by+Different+Mechanisms+That+Determine+Their+Sensitivity+to+Pharmacologic+Inhibition&doi=10.1016%2Fj.ccell.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition</span></div><div class="casAuthors">Yao, Zhan; Torres, Neilawattie M.; Tao, Anthony; Gao, Yijun; Luo, Lusong; Li, Qi; de Stanchina, Elisa; Abdel-Wahab, Omar; Solit, David B.; Poulikakos, Poulikos I.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-383</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">ERK signaling requires RAS-induced RAF dimerization and is limited by feedback.  Activated BRAF mutants evade feedback inhibition of RAS by either of two mechanisms.  BRAF V600 mutants are activated monomers when RAS activity is low; all other activating BRAF mutants function as constitutive RAS-independent dimers.  RAF inhibitors effectively inhibit mutant monomers, but not dimers; their binding to one site in the dimer significantly reduces their affinity for the second.  Tumors with non-V600E BRAF mutants are insensitive to these drugs, and increased expression of BRAF V600E dimers causes acquired resistance.  A compd. that equally inhibits both sites of mutant RAF dimers inhibits tumors driven by either class of mutants or those BRAF V600E tumors with dimer-dependent acquired resistance to monomer-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJvmOiNDvOO7Vg90H21EOLACvtfcHk0lhUqWgxzZD29w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7M&md5=60ebf55ede549e4dbc3a1481c4eea67c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DTorres%26aufirst%3DN.%2BM.%26aulast%3DTao%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520Mutants%2520Evade%2520ERK-Dependent%2520Feedback%2520by%2520Different%2520Mechanisms%2520That%2520Determine%2520Their%2520Sensitivity%2520to%2520Pharmacologic%2520Inhibition%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D370%26epage%3D383%26doi%3D10.1016%2Fj.ccell.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakiraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misteli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitor Resistance Is Mediated by Dimerization of Aberrantly Spliced BRAF(V600E)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span> (<span class="NLM_issue">7377</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/nature10662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&issue=7377&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+Inhibitor+Resistance+Is+Mediated+by+Dimerization+of+Aberrantly+Spliced+BRAF%28V600E%29&doi=10.1038%2Fnature10662"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520Inhibitor%2520Resistance%2520Is%2520Mediated%2520by%2520Dimerization%2520of%2520Aberrantly%2520Spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26issue%3D7377%26spage%3D387%26epage%3D390%26doi%3D10.1038%2Fnature10662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Transactivate RAF Dimers and ERK Signalling in Cells with Wild-Type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&issue=7287&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+Inhibitors+Transactivate+RAF+Dimers+and+ERK+Signalling+in+Cells+with+Wild-Type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0lhUqWgxzZD29w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520Inhibitors%2520Transactivate%2520RAF%2520Dimers%2520and%2520ERK%2520Signalling%2520in%2520Cells%2520with%2520Wild-Type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halilovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merghoub, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccr.2012.10.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=668-682&issue=5&author=P.+Litoauthor=C.+A.+Pratilasauthor=E.+W.+Josephauthor=M.+Tadiauthor=E.+Halilovicauthor=M.+Zubrowskiauthor=A.+Huangauthor=W.+L.+Wongauthor=M.+K.+Callahanauthor=T.+Merghoubauthor=J.+D.+Wolchokauthor=E.+de+Stanchinaauthor=S.+Chandarlapatyauthor=P.+I.+Poulikakosauthor=J.+A.+Faginauthor=N.+Rosen&title=Relief+of+Profound+Feedback+Inhibition+of+Mitogenic+Signaling+by+RAF+Inhibitors+Attenuates+Their+Activity+in+BRAFV600E+Melanomas&doi=10.1016%2Fj.ccr.2012.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DZubrowski%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DMerghoub%26aufirst%3DT.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRelief%2520of%2520Profound%2520Feedback%2520Inhibition%2520of%2520Mitogenic%2520Signaling%2520by%2520RAF%2520Inhibitors%2520Attenuates%2520Their%2520Activity%2520in%2520BRAFV600E%2520Melanomas%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26issue%3D5%26spage%3D668%26epage%3D682%26doi%3D10.1016%2Fj.ccr.2012.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaspy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-13-0642" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=80-93&issue=1&author=H.+Shiauthor=W.+Hugoauthor=X.+Kongauthor=A.+Hongauthor=R.+C.+Koyaauthor=G.+Moriceauauthor=T.+Chodonauthor=R.+Guoauthor=D.+B.+Johnsonauthor=K.+B.+Dahlmanauthor=M.+C.+Kelleyauthor=R.+F.+Keffordauthor=B.+Chmielowskiauthor=J.+A.+Glaspyauthor=J.+A.+Sosmanauthor=N.+van+Barenauthor=G.+V.+Longauthor=A.+Ribasauthor=R.+S.+Lo&title=Acquired+Resistance+and+Clonal+Evolution+in+Melanoma+during+BRAF+Inhibitor+Therapy&doi=10.1158%2F2159-8290.CD-13-0642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0642%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DGlaspy%26aufirst%3DJ.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DAcquired%2520Resistance%2520and%2520Clonal%2520Evolution%2520in%2520Melanoma%2520during%2520BRAF%2520Inhibitor%2520Therapy%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D1%26spage%3D80%26epage%3D93%26doi%3D10.1158%2F2159-8290.CD-13-0642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanlou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchalski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2014.11.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=240-256&issue=2&author=G.+Moriceauauthor=W.+Hugoauthor=A.+Hongauthor=H.+Shiauthor=X.+Kongauthor=C.+C.+Yuauthor=R.+C.+Koyaauthor=A.+A.+Samatarauthor=N.+Khanlouauthor=J.+Braunauthor=K.+Ruchalskiauthor=H.+Seifertauthor=J.+Larkinauthor=K.+B.+Dahlmanauthor=D.+B.+Johnsonauthor=A.+Algaziauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Tunable-Combinatorial+Mechanisms+of+Acquired+Resistance+Limit+the+Efficacy+of+BRAF%2FMEK+Cotargeting+but+Result+in+Melanoma+Drug+Addiction&doi=10.1016%2Fj.ccell.2014.11.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%2BC.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DKhanlou%26aufirst%3DN.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DRuchalski%26aufirst%3DK.%26aulast%3DSeifert%26aufirst%3DH.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DTunable-Combinatorial%2520Mechanisms%2520of%2520Acquired%2520Resistance%2520Limit%2520the%2520Efficacy%2520of%2520BRAF%252FMEK%2520Cotargeting%2520but%2520Result%2520in%2520Melanoma%2520Drug%2520Addiction%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26issue%3D2%26spage%3D240%26epage%3D256%26doi%3D10.1016%2Fj.ccell.2014.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescioli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bax, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynne, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilieva, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacy, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, S. N.</span></span> <span> </span><span class="NLM_article-title">BRAF Inhibitors: Resistance and the Promise of Combination Treatments for Melanoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">78174</span>– <span class="NLM_lpage">78192</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.18632%2Foncotarget.19836" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=78174-78192&issue=44&author=M.+Griffinauthor=D.+Scottoauthor=D.+H.+Josephsauthor=S.+Meleauthor=S.+Crescioliauthor=H.+J.+Baxauthor=G.+Pellizzariauthor=M.+D.+Wynneauthor=M.+Nakamuraauthor=R.+M.+Hoffmannauthor=K.+M.+Ilievaauthor=A.+Cheungauthor=J.+F.+Spicerauthor=S.+Papaauthor=K.+E.+Lacyauthor=S.+N.+Karagiannis&title=BRAF+Inhibitors%3A+Resistance+and+the+Promise+of+Combination+Treatments+for+Melanoma&doi=10.18632%2Foncotarget.19836"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19836%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DM.%26aulast%3DScotto%26aufirst%3DD.%26aulast%3DJosephs%26aufirst%3DD.%2BH.%26aulast%3DMele%26aufirst%3DS.%26aulast%3DCrescioli%26aufirst%3DS.%26aulast%3DBax%26aufirst%3DH.%2BJ.%26aulast%3DPellizzari%26aufirst%3DG.%26aulast%3DWynne%26aufirst%3DM.%2BD.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DR.%2BM.%26aulast%3DIlieva%26aufirst%3DK.%2BM.%26aulast%3DCheung%26aufirst%3DA.%26aulast%3DSpicer%26aufirst%3DJ.%2BF.%26aulast%3DPapa%26aufirst%3DS.%26aulast%3DLacy%26aufirst%3DK.%2BE.%26aulast%3DKaragiannis%26aufirst%3DS.%2BN.%26atitle%3DBRAF%2520Inhibitors%253A%2520Resistance%2520and%2520the%2520Promise%2520of%2520Combination%2520Treatments%2520for%2520Melanoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D44%26spage%3D78174%26epage%3D78192%26doi%3D10.18632%2Foncotarget.19836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meharena, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A.</span></span> <span> </span><span class="NLM_article-title">Pseudokinases from a Structural Perspective</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1042/BST20130120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1042%2FBST20130120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23863167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=981-986&issue=4&author=S.+S.+Taylorauthor=A.+Shawauthor=J.+Huauthor=H.+S.+Meharenaauthor=A.+Kornev&title=Pseudokinases+from+a+Structural+Perspective&doi=10.1042%2FBST20130120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudokinases from a structural perspective</span></div><div class="casAuthors">Taylor, Susan S.; Shaw, Andrey; Hu, Jiancheng; Meharena, Hiruy S.; Kornev, Alexandr</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">981-986</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The catalytic (C) subunit of PKA was the first protein kinase structure to be solved, and it continues to serve as the prototype for the protein kinase superfamily.  In contrast, by comparing many active and inactive kinases, the authors developed a novel spine' concept where every active kinase is composed of two hydrophobic spines anchored to a hydrophobic F-helix.  The R-spine (regulatory spine) is dynamically assembled, typically by activation loop phosphorylation, whereas the C-spine (catalytic spine) is completed by the adenine ring of ATP.  In the present paper, the authors show how the spine concept can be applied to B-Raf, specifically to engineer a kinase-dead pseudokinase.  To achieve this, the authors mutated one of the C-spine residues in the N-lobe (N-terminal lobe), Ala481, to phenylalanine.  This mutant cannot bind ATP and is thus kinase-dead, presumably because the phenylalanine ring fills the adenine-binding pocket.  The C-spine is thus fused.  However, the A481F mutant is still capable of binding wild-type B-Raf and wild-type C-Raf, and dimerization with a wild-type Raf leads to downstream activation of MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] and ERK.  The mutant requires dimerization, but is independent of Ras and does not require enzymic activity.  By distinguishing between catalytic and scaffold functions of B-Raf, the authors define kinases as being bifunctional and show that, at least in some cases, the scaffold function is sufficient for downstream signalling.  Since this alanine residue is one of the most highly conserved residues in the kinome, we suggest that this may be a general strategy for engineering kinase-dead pseudokinases and exploring biol. functions that are independent of catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHPvM-pkay6rVg90H21EOLACvtfcHk0lgAQMZl7KOz5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrF&md5=cd6c66553f58a31e4afaa2734d675a0f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1042%2FBST20130120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130120%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DKornev%26aufirst%3DA.%26atitle%3DPseudokinases%2520from%2520a%2520Structural%2520Perspective%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2013%26volume%3D41%26issue%3D4%26spage%3D981%26epage%3D986%26doi%3D10.1042%2FBST20130120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masselot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccr.2014.07.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=402-413&issue=3&author=J.+R.+Halingauthor=J.+Sudhamsuauthor=I.+Yenauthor=S.+Siderisauthor=W.+Sandovalauthor=W.+Phungauthor=B.+J.+Bravoauthor=A.+M.+Giannettiauthor=A.+Peckauthor=A.+Masselotauthor=T.+Moralesauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Structure+of+the+BRAF-MEK+Complex+Reveals+a+Kinase+Activity+Independent+Role+for+BRAF+in+MAPK+Signaling&doi=10.1016%2Fj.ccr.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DPhung%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DMasselot%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520BRAF-MEK%2520Complex%2520Reveals%2520a%2520Kinase%2520Activity%2520Independent%2520Role%2520for%2520BRAF%2520in%2520MAPK%2520Signaling%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D3%26spage%3D402%26epage%3D413%26doi%3D10.1016%2Fj.ccr.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saracino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Autoregulation of the Raf-1 Serine/Threonine Kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">9214</span>– <span class="NLM_lpage">9219</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.16.9214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.95.16.9214" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=9214-9219&issue=16&author=R.+E.+Cutlerauthor=R.+M.+Stephensauthor=M.+R.+Saracinoauthor=D.+K.+Morrison&title=Autoregulation+of+the+Raf-1+Serine%2FThreonine+Kinase&doi=10.1073%2Fpnas.95.16.9214"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.16.9214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.16.9214%26sid%3Dliteratum%253Aachs%26aulast%3DCutler%26aufirst%3DR.%2BE.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DSaracino%26aufirst%3DM.%2BR.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DAutoregulation%2520of%2520the%2520Raf-1%2520Serine%252FThreonine%2520Kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26issue%3D16%26spage%3D9214%26epage%3D9219%26doi%3D10.1073%2Fpnas.95.16.9214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Kinases and Pseudokinases: Lessons from RAF</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1128/MCB.00057-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1128%2FMCB.00057-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24567368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1538-1546&issue=9&author=A.+S.+Shawauthor=A.+P.+Kornevauthor=J.+Huauthor=L.+G.+Ahujaauthor=S.+S.+Taylor&title=Kinases+and+Pseudokinases%3A+Lessons+from+RAF&doi=10.1128%2FMCB.00057-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases and pseudokinases: lessons from RAF</span></div><div class="casAuthors">Shaw, Andrey S.; Kornev, Alexandr P.; Hu, Jiancheng; Ahuja, Lalima G.; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1538-1546, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Protein kinases are thought to mediate their biol. effects through their catalytic activity.  The large no. of pseudokinases in the kinome and an increasing appreciation that they have crit. roles in signaling pathways, however, suggest that catalyzing protein phosphorylation may not be the only function of protein kinases.  Using the principle of hydrophobic spine assembly, we interpret how kinases are capable of performing a dual function in signaling.  Its first role is that of a signaling enzyme (classical kinases; canonical), while its second role is that of an allosteric activator of other kinases or as a scaffold protein for signaling in a manner that is independent of phosphoryl transfer (classical pseudokinases; noncanonical).  As the hydrophobic spines are a conserved feature of the kinase domain itself, all kinases carry an inherent potential to play both roles in signaling.  This review focuses on the recent lessons from the RAF kinases that effectively toggle between these roles and can be "frozen" by introducing mutations at their hydrophobic spines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMtbrpjoo1xrVg90H21EOLACvtfcHk0li6BwrjzcXQuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D&md5=9f883042d2619f33087c7605ac7f22e9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FMCB.00057-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00057-14%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAhuja%26aufirst%3DL.%2BG.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DKinases%2520and%2520Pseudokinases%253A%2520Lessons%2520from%2520RAF%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26issue%3D9%26spage%3D1538%26epage%3D1546%26doi%3D10.1128%2FMCB.00057-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span> <span> </span><span class="NLM_article-title">Dimerization-Induced Allostery in Protein Kinase Regulation</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2014.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.tibs.2014.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=475-486&issue=10&author=H.+Lavoieauthor=J.+J.+Liauthor=N.+Thevakumaranauthor=M.+Therrienauthor=F.+Sicheri&title=Dimerization-Induced+Allostery+in+Protein+Kinase+Regulation&doi=10.1016%2Fj.tibs.2014.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2014.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2014.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DTherrien%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26atitle%3DDimerization-Induced%2520Allostery%2520in%2520Protein%2520Kinase%2520Regulation%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2014%26volume%3D39%26issue%3D10%26spage%3D475%26epage%3D486%26doi%3D10.1016%2Fj.tibs.2014.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.molcel.2012.12.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=751-758&issue=4&author=A.+K.+Freemanauthor=D.+A.+Rittauthor=D.+K.+Morrison&title=Effects+of+Raf+Dimerization+and+Its+Inhibition+on+Normal+and+Disease-Associated+Raf+Signaling&doi=10.1016%2Fj.molcel.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DEffects%2520of%2520Raf%2520Dimerization%2520and%2520Its%2520Inhibition%2520on%2520Normal%2520and%2520Disease-Associated%2520Raf%2520Signaling%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26issue%3D4%26spage%3D751%26epage%3D758%26doi%3D10.1016%2Fj.molcel.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baljuls, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzenau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polzien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span> <span> </span><span class="NLM_article-title">Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">16491</span>– <span class="NLM_lpage">16503</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.194167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1074%2Fjbc.M110.194167" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=16491-16503&issue=18&author=A.+Baljulsauthor=R.+Mahrauthor=I.+Schwarzenauauthor=T.+M%C3%BCllerauthor=L.+Polzienauthor=M.+Hekmanauthor=U.+R.+Rapp&title=Single+Substitution+within+the+RKTR+Motif+Impairs+Kinase+Activity+but+Promotes+Dimerization+of+RAF+Kinase&doi=10.1074%2Fjbc.M110.194167"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.194167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.194167%26sid%3Dliteratum%253Aachs%26aulast%3DBaljuls%26aufirst%3DA.%26aulast%3DMahr%26aufirst%3DR.%26aulast%3DSchwarzenau%26aufirst%3DI.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DPolzien%26aufirst%3DL.%26aulast%3DHekman%26aufirst%3DM.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26atitle%3DSingle%2520Substitution%2520within%2520the%2520RKTR%2520Motif%2520Impairs%2520Kinase%2520Activity%2520but%2520Promotes%2520Dimerization%2520of%2520RAF%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D18%26spage%3D16491%26epage%3D16503%26doi%3D10.1074%2Fjbc.M110.194167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&issue=3&author=Z.+Karouliaauthor=Y.+Wuauthor=T.+A.+Ahmedauthor=Q.+Xinauthor=J.+Bollardauthor=C.+Kreplerauthor=X.+Wuauthor=C.+Zhangauthor=G.+Bollagauthor=M.+Herlynauthor=J.+A.+Faginauthor=A.+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+Integrated+Model+of+RAF+Inhibitor+Action+Predicts+Inhibitor+Activity+against+Oncogenic+BRAF+Signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DBollard%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520Integrated%2520Model%2520of%2520RAF%2520Inhibitor%2520Action%2520Predicts%2520Inhibitor%2520Activity%2520against%2520Oncogenic%2520BRAF%2520Signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26issue%3D3%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of a BRAF Kinase Domain Monomer Explains Basis for Allosteric Regulation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnsmb.2924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25437913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=37-43&issue=1&author=N.+Thevakumaranauthor=H.+Lavoieauthor=D.+A.+Crittonauthor=A.+Tebbenauthor=A.+Marinierauthor=F.+Sicheriauthor=M.+Therrien&title=Crystal+Structure+of+a+BRAF+Kinase+Domain+Monomer+Explains+Basis+for+Allosteric+Regulation&doi=10.1038%2Fnsmb.2924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation</span></div><div class="casAuthors">Thevakumaran, Neroshan; Lavoie, Hugo; Critton, David A.; Tebben, Andrew; Marinier, Anne; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reported RAF kinase domain structures adopt a side-to-side dimer configuration reflective of an 'on' state that underpins an allosteric mechanism of regulation.  Atomic details of the monomer 'off' state have been elusive.  Reinspection of the BRAF kinase domain structures revealed that sulfonamide inhibitors induce features of an off state, primarily a laterally displaced helix αC stabilized by the activation segment helix 1 (AS-H1).  These features correlated with the ability of sulfonamides to disrupt human BRAF homodimers in cells, in vitro and in crystals yielding a structure of BRAF in a monomer state.  The crystal structure revealed exaggerated, nonproductive positions of helix αC and AS-H1, the latter of which is the target of potent BRAF oncogenic mutations.  Together, this work provides formal proof of an allosteric link between the RAF dimer interface, the activation segment and the catalytic infrastructure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mmFDDNHIrLVg90H21EOLACvtfcHk0ljvJlJ62QR4ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I&md5=0417ca047f52f6a425a3925fec6b5e05</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2924%26sid%3Dliteratum%253Aachs%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DCritton%26aufirst%3DD.%2BA.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DCrystal%2520Structure%2520of%2520a%2520BRAF%2520Kinase%2520Domain%2520Monomer%2520Explains%2520Basis%2520for%2520Allosteric%2520Regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3D37%26epage%3D43%26doi%3D10.1038%2Fnsmb.2924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span> <span> </span><span class="NLM_article-title">Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-15-0896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=300-315&issue=3&author=S.-H.+Chenauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=S.+Buchananauthor=V.+Yadavauthor=I.+Mochalkinauthor=S.+S.+Wongauthor=Y.+G.+Yueauthor=L.+Huberauthor=I.+Contiauthor=J.+R.+Henryauthor=J.+J.+Starlingauthor=G.+D.+Plowmanauthor=S.-B.+Peng&title=Oncogenic+BRAF+Deletions+That+Function+as+Homodimers+and+Are+Sensitive+to+Inhibition+by+RAF+Dimer+Inhibitor+LY3009120&doi=10.1158%2F2159-8290.CD-15-0896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0896%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DYue%26aufirst%3DY.%2BG.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26atitle%3DOncogenic%2520BRAF%2520Deletions%2520That%2520Function%2520as%2520Homodimers%2520and%2520Are%2520Sensitive%2520to%2520Inhibition%2520by%2520RAF%2520Dimer%2520Inhibitor%2520LY3009120%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D3%26spage%3D300%26epage%3D315%26doi%3D10.1158%2F2159-8290.CD-15-0896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holderfield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallroth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, T. E.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccr.2013.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23680146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslantLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=594-602&issue=5&author=M.+Holderfieldauthor=H.+Merrittauthor=J.+Chanauthor=M.+Wallrothauthor=L.+Tandeskeauthor=H.+Zhaiauthor=J.+Tellewauthor=S.+Hardyauthor=M.+Hekmat-Nejadauthor=D.+D.+Stuartauthor=F.+McCormickauthor=T.+E.+Nagel&title=RAF+Inhibitors+Activate+the+MAPK+Pathway+by+Relieving+Inhibitory+Autophosphorylation&doi=10.1016%2Fj.ccr.2013.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation</span></div><div class="casAuthors">Holderfield, Matthew; Merritt, Hanne; Chan, John; Wallroth, Marco; Tandeske, Laura; Zhai, Huili; Tellew, John; Hardy, Stephen; Hekmat-Nejad, Mohammad; Stuart, Darrin D.; McCormick, Frank; Nagel, Tobi E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">594-602</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">ATP competitive inhibitors of the BRAFV600E oncogene paradoxically activate downstream signaling in cells bearing wild-type BRAF (BRAFWT).  In this study, we investigate the biochem. mechanism of wild-type RAF (RAFWT) activation by multiple catalytic inhibitors using kinetic anal. of purified BRAFV600E and RAFWT enzymes.  We show that activation of RAFWT is ATP dependent and directly linked to RAF kinase activity.  These data support a mechanism involving inhibitory autophosphorylation of RAF's phosphate-binding loop that, when disrupted either through pharmacol. or genetic alterations, results in activation of RAF and the mitogen-activated protein kinase (MAPK) pathway.  This mechanism accounts not only for compd.-mediated activation of the MAPK pathway in BRAFWT cells but also offers a biochem. mechanism for BRAF oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq54U_rGedYm7Vg90H21EOLACvtfcHk0lgF4WSnIjeMFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslantLo%253D&md5=6fcb339de5bb8b23ea627a3945caa08a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DHolderfield%26aufirst%3DM.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DWallroth%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DH.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DHardy%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DNagel%26aufirst%3DT.%2BE.%26atitle%3DRAF%2520Inhibitors%2520Activate%2520the%2520MAPK%2520Pathway%2520by%2520Relieving%2520Inhibitory%2520Autophosphorylation%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26issue%3D5%26spage%3D594%26epage%3D602%26doi%3D10.1016%2Fj.ccr.2013.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban-Burgos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-López, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span> <span> </span><span class="NLM_article-title">A Braf Kinase-Inactive Mutant Induces Lung Adenocarcinoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>548</i></span> (<span class="NLM_issue">7666</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/nature23297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature23297" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2017&pages=239-243&issue=7666&author=P.+Nietoauthor=C.+Ambrogioauthor=L.+Esteban-Burgosauthor=G.+G%C3%B3mez-L%C3%B3pezauthor=M.+T.+Blascoauthor=Z.+Yaoauthor=R.+Maraisauthor=N.+Rosenauthor=R.+Chiarleauthor=D.+G.+Pisanoauthor=M.+Barbacidauthor=D.+Santamar%C3%ADa&title=A+Braf+Kinase-Inactive+Mutant+Induces+Lung+Adenocarcinoma&doi=10.1038%2Fnature23297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature23297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23297%26sid%3Dliteratum%253Aachs%26aulast%3DNieto%26aufirst%3DP.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DEsteban-Burgos%26aufirst%3DL.%26aulast%3DG%25C3%25B3mez-L%25C3%25B3pez%26aufirst%3DG.%26aulast%3DBlasco%26aufirst%3DM.%2BT.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DPisano%26aufirst%3DD.%2BG.%26aulast%3DBarbacid%26aufirst%3DM.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26atitle%3DA%2520Braf%2520Kinase-Inactive%2520Mutant%2520Induces%2520Lung%2520Adenocarcinoma%26jtitle%3DNature%26date%3D2017%26volume%3D548%26issue%3D7666%26spage%3D239%26epage%3D243%26doi%3D10.1038%2Fnature23297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaeger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrik-Outmezguine, V.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembrough, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Tumours with Class 3 BRAF Mutants Are Sensitive to the Inhibition of Activated RAS</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>548</i></span> (<span class="NLM_issue">7666</span>),  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1038/nature23291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature23291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28783719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OjsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2017&pages=234-238&issue=7666&author=Z.+Yaoauthor=R.+Yaegerauthor=V.%0AS.+Rodrik-Outmezguineauthor=A.+Taoauthor=N.+M.+Torresauthor=M.+T.+Changauthor=M.+Drostenauthor=H.+Zhaoauthor=F.+Cecchiauthor=T.+Hembroughauthor=J.+Michelsauthor=H.+Baumertauthor=L.+Milesauthor=N.+M.+Campbellauthor=E.+de+Stanchinaauthor=D.+B.+Solitauthor=M.+Barbacidauthor=B.+S.+Taylorauthor=N.+Rosen&title=Tumours+with+Class+3+BRAF+Mutants+Are+Sensitive+to+the+Inhibition+of+Activated+RAS&doi=10.1038%2Fnature23291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS</span></div><div class="casAuthors">Yao, Zhan; Yaeger, Rona; Rodrik-Outmezguine, Vanessa S.; Tao, Anthony; Torres, Neilawattie M.; Chang, Matthew T.; Drosten, Matthias; Zhao, Huiyong; Cecchi, Fabiola; Hembrough, Todd; Michels, Judith; Baumert, Herve; Miles, Linde; Campbell, Naomi M.; de Stanchina, Elisa; Solit, David B.; Barbacid, Mariano; Taylor, Barry S.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">7666</span>),
    <span class="NLM_cas:pages">234-238</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Approx. 200 BRAF mutant alleles have been identified in human tumors.  Activating BRAF mutants cause feedback inhibition of GTP-bound RAS, are RAS-independent and signal either as active monomers (class 1) or constitutively active dimers (class 2).  Here we characterize a third class of BRAF mutants-those that have impaired kinase activity or are kinase-dead.  These mutants are sensitive to ERK-mediated feedback and their activation of signalling is RAS-dependent.  The mutants bind more tightly than wild-type BRAF to RAS-GTP, and their binding to and activation of wild-type CRAF is enhanced, leading to increased ERK signalling.  The model suggests that dysregulation of signalling by these mutants in tumors requires coexistent mechanisms for maintaining RAS activation despite ERK-dependent feedback.  Consistent with this hypothesis, melanomas with these class 3 BRAF mutations also harbor RAS mutations or NF1 deletions.  By contrast, in lung and colorectal cancers with class 3 BRAF mutants, RAS is typically activated by receptor tyrosine kinase signalling.  These tumors are sensitive to the inhibition of RAS activation by inhibitors of receptor tyrosine kinases.  We have thus defined three distinct functional classes of BRAF mutants in human tumors.  The mutants activate ERK signalling by different mechanisms that dictate their sensitivity to therapeutic inhibitors of the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLEqr4hGX0YrVg90H21EOLACvtfcHk0lgF4WSnIjeMFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OjsrvK&md5=126b9319928d55174f4b5c733394c880</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnature23291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23291%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DYaeger%26aufirst%3DR.%26aulast%3DRodrik-Outmezguine%26aufirst%3DV.%2BS.%26aulast%3DTao%26aufirst%3DA.%26aulast%3DTorres%26aufirst%3DN.%2BM.%26aulast%3DChang%26aufirst%3DM.%2BT.%26aulast%3DDrosten%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCecchi%26aufirst%3DF.%26aulast%3DHembrough%26aufirst%3DT.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DBaumert%26aufirst%3DH.%26aulast%3DMiles%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DN.%2BM.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DBarbacid%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DTumours%2520with%2520Class%25203%2520BRAF%2520Mutants%2520Are%2520Sensitive%2520to%2520the%2520Inhibition%2520of%2520Activated%2520RAS%26jtitle%3DNature%26date%3D2017%26volume%3D548%26issue%3D7666%26spage%3D234%26epage%3D238%26doi%3D10.1038%2Fnature23291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span> <span> </span><span class="NLM_article-title">Conformation-Specific Effects of Raf Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7332</span>– <span class="NLM_lpage">7341</span>, <span class="refDoi"> DOI: 10.1021/jm300613w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300613w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7332-7341&issue=17&author=X.+Wangauthor=J.+Kim&title=Conformation-Specific+Effects+of+Raf+Kinase+Inhibitors&doi=10.1021%2Fjm300613w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm300613w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300613w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DConformation-Specific%2520Effects%2520of%2520Raf%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7332%26epage%3D7341%26doi%3D10.1021%2Fjm300613w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlattl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalkuhl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-15-0617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26916115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=354-365&issue=3&author=I.+C.+Waizeneggerauthor=A.+Baumauthor=S.+Steurerauthor=H.+Stadtm%C3%BCllerauthor=G.+Baderauthor=O.+Schaafauthor=P.+Garin-Chesaauthor=A.+Schlattlauthor=N.+Schweiferauthor=C.+Haslingerauthor=F.+Colbatzkyauthor=S.+Mousaauthor=A.+Kalkuhlauthor=N.+Krautauthor=G.+R.+Adolf&title=A+Novel+RAF+Kinase+Inhibitor+with+DFG-Out-Binding+Mode%3A+High+Efficacy+in+BRAF-Mutant+Tumor+Xenograft+Models+in+the+Absence+of+Normal+Tissue+Hyperproliferation&doi=10.1158%2F1535-7163.MCT-15-0617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span></div><div class="casAuthors">Waizenegger, Irene C.; Baum, Anke; Steurer, Steffen; Stadtmuller, Heinz; Bader, Gerd; Schaaf, Otmar; Garin-Chesa, Pilar; Schlattl, Andreas; Schweifer, Norbert; Haslinger, Christian; Colbatzky, Florian; Mousa, Sien; Kalkuhl, Arno; Kraut, Norbert; Adolf, Gunther R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase.  The compd. inhibited proliferation of human BRAF-mutant melanoma cells with 100× higher potency (1-10 nmol/L) than vemurafenib, whereas wild-type cells were not affected at 1,000 nmol/L.  BI 882370 administered orally was efficacious in multiple mouse models of BRAF-mutant melanomas and colorectal carcinomas, and at 25 mg/kg twice daily showed superior efficacy compared with vemurafenib, dabrafenib, or trametinib (dosed to provide exposures reached in patients).  To model drug resistance, A375 melanoma-bearing mice were initially treated with vemurafenib; all tumors responded with regression, but the majority subsequently resumed growth.  Trametinib did not show any efficacy in this progressing population.  BI 882370 induced tumor regression; however, resistance developed within 3 wk.  BI 882370 in combination with trametinib resulted in more pronounced regressions, and resistance was not obsd. during 5 wk of second-line therapy.  Importantly, mice treated with BI 882370 did not show any body wt. loss or clin. signs of intolerability, and no pathol. changes were obsd. in several major organs investigated, including skin.  Furthermore, a pilot study in rats (up to 60 mg/kg daily for 2 wk) indicated lack of toxicity in terms of clin. chem., hematol., pathol., and toxicogenomics.  Our results indicate the feasibility of developing novel compds. that provide an improved therapeutic window compared with first-generation BRAF inhibitors, resulting in more pronounced and long-lasting pathway suppression and thus improved efficacy.  Mol Cancer Ther; 15(3); 354-65. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtRl_zbyDibVg90H21EOLACvtfcHk0lh3cSSPCbbbIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D&md5=e35140e31364622de51538b99618001a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0617%26sid%3Dliteratum%253Aachs%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSchaaf%26aufirst%3DO.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DSchlattl%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DMousa%26aufirst%3DS.%26aulast%3DKalkuhl%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DA%2520Novel%2520RAF%2520Kinase%2520Inhibitor%2520with%2520DFG-Out-Binding%2520Mode%253A%2520High%2520Efficacy%2520in%2520BRAF-Mutant%2520Tumor%2520Xenograft%2520Models%2520in%2520the%2520Absence%2520of%2520Normal%2520Tissue%2520Hyperproliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D3%26spage%3D354%26epage%3D365%26doi%3D10.1158%2F1535-7163.MCT-15-0617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Prime Wild-Type RAF to Activate the MAPK Pathway and Enhance Growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+Inhibitors+Prime+Wild-Type+RAF+to+Activate+the+MAPK+Pathway+and+Enhance+Growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0lh3cSSPCbbbIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520Inhibitors%2520Prime%2520Wild-Type%2520RAF%2520to%2520Activate%2520the%2520MAPK%2520Pathway%2520and%2520Enhance%2520Growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavory, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padeganeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, D. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors That Stabilize a Closed RAF Kinase Domain Conformation Induce Dimerization</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&issue=7&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+L.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+That+Stabilize+a+Closed+RAF+Kinase+Domain+Conformation+Induce+Dimerization&doi=10.1038%2Fnchembio.1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0ljS3xAhi-jVCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%2BL.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520That%2520Stabilize%2520a%2520Closed%2520RAF%2520Kinase%2520Domain%2520Conformation%2520Induce%2520Dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D7%26spage%3D428%26epage%3D436%26doi%3D10.1038%2Fnchembio.1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donelan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouitar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carideo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7043</span>– <span class="NLM_lpage">7055</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-13-1825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=7043-7055&issue=23&author=A.+Nakamuraauthor=T.+Aritaauthor=S.+Tsuchiyaauthor=J.+Donelanauthor=J.+Chouitarauthor=E.+Carideoauthor=K.+Galvinauthor=M.+Okaniwaauthor=T.+Ishikawaauthor=S.+Yoshida&title=Antitumor+Activity+of+the+Selective+Pan-RAF+Inhibitor+TAK-632+in+BRAF+Inhibitor-Resistant+Melanoma&doi=10.1158%2F0008-5472.CAN-13-1825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1825%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DDonelan%26aufirst%3DJ.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DCarideo%26aufirst%3DE.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DS.%26atitle%3DAntitumor%2520Activity%2520of%2520the%2520Selective%2520Pan-RAF%2520Inhibitor%2520TAK-632%2520in%2520BRAF%2520Inhibitor-Resistant%2520Melanoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D23%26spage%3D7043%26epage%3D7055%26doi%3D10.1158%2F0008-5472.CAN-13-1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girotti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suijkerbuijk, B. M. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejiama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Laorden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohloch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusiak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brognard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Paradox-Breaking RAF Inhibitors That Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2014.11.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=85-96&issue=1&author=M.+R.+Girottiauthor=F.+Lopesauthor=N.+Preeceauthor=D.+Niculescu-Duvazauthor=A.+Zambonauthor=L.+Daviesauthor=S.+Whittakerauthor=G.+Saturnoauthor=A.+Virosauthor=M.+Pedersenauthor=B.+M.+J.+M.+Suijkerbuijkauthor=D.+Menardauthor=R.+McLearyauthor=L.+Johnsonauthor=L.+Fishauthor=S.+Ejiamaauthor=B.+Sanchez-Laordenauthor=J.+Hohlochauthor=N.+Carragherauthor=K.+Macleodauthor=G.+Ashtonauthor=A.+A.+Marusiakauthor=A.+Fusiauthor=J.+Brognardauthor=M.+Frameauthor=P.+Loriganauthor=R.+Maraisauthor=C.+Springer&title=Paradox-Breaking+RAF+Inhibitors+That+Also+Target+SRC+Are+Effective+in+Drug-Resistant+BRAF+Mutant+Melanoma&doi=10.1016%2Fj.ccell.2014.11.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DSuijkerbuijk%26aufirst%3DB.%2BM.%2BJ.%2BM.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DFish%26aufirst%3DL.%26aulast%3DEjiama%26aufirst%3DS.%26aulast%3DSanchez-Laorden%26aufirst%3DB.%26aulast%3DHohloch%26aufirst%3DJ.%26aulast%3DCarragher%26aufirst%3DN.%26aulast%3DMacleod%26aufirst%3DK.%26aulast%3DAshton%26aufirst%3DG.%26aulast%3DMarusiak%26aufirst%3DA.%2BA.%26aulast%3DFusi%26aufirst%3DA.%26aulast%3DBrognard%26aufirst%3DJ.%26aulast%3DFrame%26aufirst%3DM.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DParadox-Breaking%2520RAF%2520Inhibitors%2520That%2520Also%2520Target%2520SRC%2520Are%2520Effective%2520in%2520Drug-Resistant%2520BRAF%2520Mutant%2520Melanoma%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26issue%3D1%26spage%3D85%26epage%3D96%26doi%3D10.1016%2Fj.ccell.2014.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-Tumor Activities in RAS or BRAF Mutant Cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.ccell.2015.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26343583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=384-398&issue=3&author=S.-B.+Pengauthor=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=W.-P.+Luauthor=B.+D.+Smithauthor=S.+Vogetiauthor=T.+J.+Rutkoskiauthor=S.+Wiseauthor=L.+Chunauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=X.+Zhangauthor=V.+Yadavauthor=S.-H.+Chenauthor=X.+Gongauthor=X.+Maauthor=Y.+Websterauthor=S.+Buchananauthor=I.+Mochalkinauthor=L.+Huberauthor=L.+Kaysauthor=G.+P.+Donohoauthor=J.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=I.+Contiauthor=G.+D.+Plowmanauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Inhibition+of+RAF+Isoforms+and+Active+Dimers+by+LY3009120+Leads+to+Anti-Tumor+Activities+in+RAS+or+BRAF+Mutant+Cancers&doi=10.1016%2Fj.ccell.2015.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers</span></div><div class="casAuthors">Peng, Sheng-Bin; Henry, James R.; Kaufman, Michael D.; Lu, Wei-Ping; Smith, Bryan D.; Vogeti, Subha; Rutloski, Thomas J.; Wise, Scott; Chun, Lawrence; Zhang, Youyan; Van Horn, Robert D.; Yin, Tinggui; Zhang, Xiaoyi; Yadav, Vipin; Chen, Shih-Hsun; Gong, Xueqian; Ma, Xiwen; Webster, Yue; Buchanan, Sean; Mochalkin, Igor; Huber, Lysiane; Kays, Lisa; Donoho, Gregory P.; Walgren, Jennie; McCann, Denis; Patel, Phenil; Conti, Ilaria; Plowman, Gregory D.; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-398</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.  Biochem. and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.  LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.  Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.  Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJMiHK-Gub5bVg90H21EOLACvtfcHk0ljKn4_zzVa2Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O&md5=c167caa6e5a9b47a6ec1ee2ab6d9e0d1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWebster%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DInhibition%2520of%2520RAF%2520Isoforms%2520and%2520Active%2520Dimers%2520by%2520LY3009120%2520Leads%2520to%2520Anti-Tumor%2520Activities%2520in%2520RAS%2520or%2520BRAF%2520Mutant%2520Cancers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D384%26epage%3D398%26doi%3D10.1016%2Fj.ccell.2015.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuzumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitor Hijacking of Akt Activation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1038/nchembio.183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnchembio.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=19465931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=484-493&issue=7&author=T.+Okuzumiauthor=D.+Fiedlerauthor=C.+Zhangauthor=D.+C.+Grayauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=K.+M.+Shokat&title=Inhibitor+Hijacking+of+Akt+Activation&doi=10.1038%2Fnchembio.183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor hijacking of Akt activation</span></div><div class="casAuthors">Okuzumi, Tatsuya; Fiedler, Dorothea; Zhang, Chao; Gray, Daniel C.; Aizenstein, Brian; Hoffman, Randy; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">484-493</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase Akt plays a central role as a regulator of multiple growth factor input signals, thus making it an attractive anticancer drug target.  A-443654 is an ATP-competitive Akt inhibitor.  Unexpectedly, treatment of cells with A-443654 causes paradoxical hyperphosphorylation of Akt at its two regulatory sites (Thr308 and Ser473).  We explored whether inhibitor-induced hyperphosphorylation of Akt by A-443654 is a consequence of disrupted feedback regulation at a pathway level or whether it is a direct consequence of inhibitor binding to the ATP binding site of Akt.  Catalytically inactive mutants of Akt revealed that binding of an inhibitor to the ATP site of Akt is sufficient to directly cause hyperphosphorylation of the kinase in the absence of any pathway feedback effects.  We conclude that ATP-competitive Akt inhibitors impart regulatory phosphorylation of their target kinase Akt.  These results provide new insights into both natural regulation of Akt activation and Akt inhibitors entering the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWNjUB9YVue7Vg90H21EOLACvtfcHk0ljKn4_zzVa2Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D&md5=4edb5a0457fd9378850102a6414bfdb5</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.183%26sid%3Dliteratum%253Aachs%26aulast%3DOkuzumi%26aufirst%3DT.%26aulast%3DFiedler%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DD.%2BC.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DInhibitor%2520Hijacking%2520of%2520Akt%2520Activation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D7%26spage%3D484%26epage%3D493%26doi%3D10.1038%2Fnchembio.183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurin, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostelecky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P. J.</span></span> <span> </span><span class="NLM_article-title">PKC Maturation Is Promoted by Nucleotide Pocket Occupation Independently of Intrinsic Kinase Activity</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnsmb.1606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=19465915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlars78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=624-630&issue=6&author=A.+J.+M.+Cameronauthor=C.+Escribanoauthor=A.+T.+Saurinauthor=B.+Kosteleckyauthor=P.+J.+Parker&title=PKC+Maturation+Is+Promoted+by+Nucleotide+Pocket+Occupation+Independently+of+Intrinsic+Kinase+Activity&doi=10.1038%2Fnsmb.1606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity</span></div><div class="casAuthors">Cameron, Angus J. M.; Escribano, Cristina; Saurin, Adrian T.; Kostelecky, Brenda; Parker, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">624-630</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein kinase C (PKC) Ser/Thr kinases account for ∼2% of the human kinome and regulate diverse cellular behaviors.  PKC catalytic activity requires priming phosphorylations at 3 conserved sites within the kinase domain.  Here, the authors demonstrate that priming of PKC is dependent on the conformation of the nucleotide-binding pocket, but not on its intrinsic kinase activity.  Inactive ATP-binding site mutants were unprimed, but they became phosphorylated upon occupancy of the ATP-binding pocket with inhibitors of PKC.  The authors exploited this property to screen for PKC inhibitors in vivo.  Further, the authors generated a distinct class of kinase-inactive mutants that maintained the integrity of the ATP-binding pocket; such mutants were constitutively primed and functionally distinct from ATP-binding site mutants.  These data demonstrated that autophosphorylation is not required for PKC priming and showed how ATP-pocket occupation could enable a kinase to mature as well as function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbLEzm35IJ6rVg90H21EOLACvtfcHk0lhBkCOGldQKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlars78%253D&md5=ed8cdc844dbc79581fd8705e1298cb4c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1606%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DEscribano%26aufirst%3DC.%26aulast%3DSaurin%26aufirst%3DA.%2BT.%26aulast%3DKostelecky%26aufirst%3DB.%26aulast%3DParker%26aufirst%3DP.%2BJ.%26atitle%3DPKC%2520Maturation%2520Is%2520Promoted%2520by%2520Nucleotide%2520Pocket%2520Occupation%2520Independently%2520of%2520Intrinsic%2520Kinase%2520Activity%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26issue%3D6%26spage%3D624%26epage%3D630%26doi%3D10.1038%2Fnsmb.1606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andraos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonenfant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangrevelinghe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marque, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Régnier, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckelynck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baffert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pissot-Soldermann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voshol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span> <span> </span><span class="NLM_article-title">Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-11-0324" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=512-523&issue=6&author=R.+Andraosauthor=Z.+Qianauthor=D.+Bonenfantauthor=J.+Rubertauthor=E.+Vangrevelingheauthor=C.+Scheuflerauthor=F.+Marqueauthor=C.+H.+R%C3%A9gnierauthor=A.+De+Poverauthor=H.+Ryckelynckauthor=N.+Bhagwatauthor=P.+Koppikarauthor=A.+Goelauthor=L.+Wyderauthor=G.+Tavaresauthor=F.+Baffertauthor=C.+Pissot-Soldermannauthor=P.+W.+Manleyauthor=C.+Gaulauthor=H.+Vosholauthor=R.+L.+Levineauthor=W.+R.+Sellersauthor=F.+Hofmannauthor=T.+Radimerski&title=Modulation+of+Activation-Loop+Phosphorylation+by+JAK+Inhibitors+Is+Binding+Mode+Dependent&doi=10.1158%2F2159-8290.CD-11-0324"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0324%26sid%3Dliteratum%253Aachs%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DBonenfant%26aufirst%3DD.%26aulast%3DRubert%26aufirst%3DJ.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DMarque%26aufirst%3DF.%26aulast%3DR%25C3%25A9gnier%26aufirst%3DC.%2BH.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DRyckelynck%26aufirst%3DH.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DWyder%26aufirst%3DL.%26aulast%3DTavares%26aufirst%3DG.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DPissot-Soldermann%26aufirst%3DC.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DVoshol%26aufirst%3DH.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26atitle%3DModulation%2520of%2520Activation-Loop%2520Phosphorylation%2520by%2520JAK%2520Inhibitors%2520Is%2520Binding%2520Mode%2520Dependent%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D6%26spage%3D512%26epage%3D523%26doi%3D10.1158%2F2159-8290.CD-11-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, B. G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhhatarai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schürer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span> <span> </span><span class="NLM_article-title">Divergent Allosteric Control of the IRE1α Endoribonuclease Using Kinase Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnchembio.1094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23086298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOmtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=982-989&issue=12&author=L.+Wangauthor=B.+G.+K.+Pereraauthor=S.+B.+Hariauthor=B.+Bhhataraiauthor=B.+J.+Backesauthor=M.+A.+Seeligerauthor=S.+C.+Sch%C3%BCrerauthor=S.+A.+Oakesauthor=F.+R.+Papaauthor=D.+J.+Maly&title=Divergent+Allosteric+Control+of+the+IRE1%CE%B1+Endoribonuclease+Using+Kinase+Inhibitors&doi=10.1038%2Fnchembio.1094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors</span></div><div class="casAuthors">Wang, Likun; Perera, B. Gayani K.; Hari, Sanjay B.; Bhhatarai, Barun; Backes, Bradley J.; Seeliger, Markus A.; Schuerer, Stephan C.; Oakes, Scott A.; Papa, Feroz R.; Maly, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">982-989</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Under endoplasmic reticulum stress, unfolded protein accumulation leads to activation of the endoplasmic reticulum transmembrane kinase/endoRNase IRE1α.  IRE1α oligomerizes, autophosphorylates and initiates splicing of XBP1 mRNA, thus triggering the unfolded protein response (UPR).  Here we show that IRE1α's kinase-controlled RNase can be regulated in two distinct modes with kinase inhibitors: one class of ligands occupies IRE1α's kinase ATP-binding site to activate RNase-mediated XBP1 mRNA splicing even without upstream endoplasmic reticulum stress, whereas a second class can inhibit the RNase through the same ATP-binding site, even under endoplasmic reticulum stress.  Thus, alternative kinase conformations stabilized by distinct classes of ATP-competitive inhibitors can cause allosteric switching of IRE1α's RNase-either on or off.  As dysregulation of the UPR has been implicated in a variety of cell degenerative and neoplastic disorders, small-mol. control over IRE1α should advance efforts to understand the UPR's role in pathophysiol. and to develop drugs for endoplasmic reticulum stress-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5edxS7gfwNrVg90H21EOLACvtfcHk0lhBkCOGldQKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOmtLbO&md5=a6daf1ddb2ccdec77035e2e3c70d674c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1094%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPerera%26aufirst%3DB.%2BG.%2BK.%26aulast%3DHari%26aufirst%3DS.%2BB.%26aulast%3DBhhatarai%26aufirst%3DB.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%2BC.%26aulast%3DOakes%26aufirst%3DS.%2BA.%26aulast%3DPapa%26aufirst%3DF.%2BR.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DDivergent%2520Allosteric%2520Control%2520of%2520the%2520IRE1%25CE%25B1%2520Endoribonuclease%2520Using%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D12%26spage%3D982%26epage%3D989%26doi%3D10.1038%2Fnchembio.1094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpivaara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hricik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marubayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>489</i></span> (<span class="NLM_issue">7414</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&issue=7414&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+G%C3%B6nenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+Activation+as+a+Mechanism+of+Persistence+to+JAK2+Inhibitor+Therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0lg8_vESvHI_Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DG%25C3%25B6nen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520Activation%2520as%2520a%2520Mechanism%2520of%2520Persistence%2520to%2520JAK2%2520Inhibitor%2520Therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26issue%3D7414%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanftner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors That Evade Paradoxical MAPK Pathway Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span> (<span class="NLM_issue">7574</span>),  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1038/nature14982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature14982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26466569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=583-586&issue=7574&author=C.+Zhangauthor=W.+Spevakauthor=Y.+Zhangauthor=E.+A.+Burtonauthor=Y.+Maauthor=G.+Habetsauthor=J.+Zhangauthor=J.+Linauthor=T.+Ewingauthor=B.+Matusowauthor=G.+Tsangauthor=A.+Marimuthuauthor=H.+Choauthor=G.+Wuauthor=W.+Wangauthor=D.+Fongauthor=H.+Nguyenauthor=S.+Shiauthor=P.+Womackauthor=M.+Nespiauthor=R.+Shellooeauthor=H.+Cariasauthor=B.+Powellauthor=E.+Lightauthor=L.+Sanftnerauthor=J.+Waltersauthor=J.+Tsaiauthor=B.+L.+Westauthor=G.+Visorauthor=H.+Rezaeiauthor=P.+S.+Linauthor=K.+Nolopauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=G.+Bollag&title=RAF+Inhibitors+That+Evade+Paradoxical+MAPK+Pathway+Activation&doi=10.1038%2Fnature14982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors that evade paradoxical MAPK pathway activation</span></div><div class="casAuthors">Zhang, Chao; Spevak, Wayne; Zhang, Ying; Burton, Elizabeth A.; Ma, Yan; Habets, Gaston; Zhang, Jiazhong; Lin, Jack; Ewing, Todd; Matusow, Bernice; Tsang, Garson; Marimuthu, Adhirai; Cho, Hanna; Wu, Guoxian; Wang, Weiru; Fong, Daniel; Nguyen, Hoa; Shi, Songyuan; Womack, Patrick; Nespi, Marika; Shellooe, Rafe; Carias, Heidi; Powell, Ben; Light, Emily; Sanftner, Laura; Walters, Jason; Tsai, James; West, Brian L.; Visor, Gary; Rezaei, Hamid; Lin, Paul S.; Nolop, Keith; Ibrahim, Prabha N.; Hirth, Peter; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7574</span>),
    <span class="NLM_cas:pages">583-586</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oncogenic activation of BRAF fuels cancer growth by constitutively promoting RAS-independent mitogen-activated protein kinase (MAPK) pathway signalling.  Accordingly, RAF inhibitors have brought substantially improved personalized treatment of metastatic melanoma.  However, these targeted agents have also revealed an unexpected consequence: stimulated growth of certain cancers.  Structurally diverse ATP-competitive RAF inhibitors can either inhibit or paradoxically activate the MAPK pathway, depending whether activation is by BRAF mutation or by an upstream event, such as RAS mutation or receptor tyrosine kinase activation.  Here we have identified next-generation RAF inhibitors (dubbed 'paradox breakers') that suppress mutant BRAF cells without activating the MAPK pathway in cells bearing upstream activation.  In cells that express the same HRAS mutation prevalent in squamous tumors from patients treated with RAF inhibitors, the first-generation RAF inhibitor vemurafenib stimulated in vitro and in vivo growth and induced expression of MAPK pathway response genes; by contrast the paradox breakers PLX7904 and PLX8394 had no effect.  Paradox breakers also overcame several known mechanisms of resistance to first-generation RAF inhibitors.  Dissocg. MAPK pathway inhibition from paradoxical activation might yield both improved safety and more durable efficacy than first-generation RAF inhibitors, a concept currently undergoing human clin. evaluation with PLX8394.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv_s6rL_GkBbVg90H21EOLACvtfcHk0lg8_vESvHI_Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN&md5=e5e4c5e11a6c54d442a4ed7a2f21d76a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnature14982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14982%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DEwing%26aufirst%3DT.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLight%26aufirst%3DE.%26aulast%3DSanftner%26aufirst%3DL.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DVisor%26aufirst%3DG.%26aulast%3DRezaei%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DRAF%2520Inhibitors%2520That%2520Evade%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%26jtitle%3DNature%26date%3D2015%26volume%3D526%26issue%3D7574%26spage%3D583%26epage%3D586%26doi%3D10.1038%2Fnature14982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Michele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermarliere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Heerde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span> <span> </span><span class="NLM_article-title">Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1818</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1021/jm501667n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501667n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1818-1831&issue=4&author=R.+Aroraauthor=M.+Di+Micheleauthor=E.+Stesauthor=E.+Vandermarliereauthor=L.+Martensauthor=K.+Gevaertauthor=E.+Van+Heerdeauthor=J.+T.+M.+Lindersauthor=D.+Brehmerauthor=E.+Jacobyauthor=P.+Bonnet&title=Structural+Investigation+of+B-Raf+Paradox+Breaker+and+Inducer+Inhibitors&doi=10.1021%2Fjm501667n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm501667n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501667n%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DR.%26aulast%3DDi%2BMichele%26aufirst%3DM.%26aulast%3DStes%26aufirst%3DE.%26aulast%3DVandermarliere%26aufirst%3DE.%26aulast%3DMartens%26aufirst%3DL.%26aulast%3DGevaert%26aufirst%3DK.%26aulast%3DVan%2BHeerde%26aufirst%3DE.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%2BM.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBonnet%26aufirst%3DP.%26atitle%3DStructural%2520Investigation%2520of%2520B-Raf%2520Paradox%2520Breaker%2520and%2520Inducer%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1818%26epage%3D1831%26doi%3D10.1021%2Fjm501667n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall-Jackson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedge, P.</span></span> <span> </span><span class="NLM_article-title">Paradoxical Activation of Raf by a Novel Raf Inhibitor</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(99)80088-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS1074-5521%2899%2980088-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10421767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=559-568&issue=8&author=C.+A.+Hall-Jacksonauthor=P.+A.+Eyersauthor=P.+Cohenauthor=M.+Goedertauthor=F.+T.+Boyleauthor=N.+Hewittauthor=H.+Plantauthor=P.+Hedge&title=Paradoxical+Activation+of+Raf+by+a+Novel+Raf+Inhibitor&doi=10.1016%2FS1074-5521%2899%2980088-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Paradoxical activation of raf by a novel raf inhibitor</span></div><div class="casAuthors">Hall-Jackson, Clare A.; Eyers, Patrick A.; Cohen, Philip; Goedert, Michel; Boyle, F. Tom; Hewitt, Neil; Plant, Helen; Hedge, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-568</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">Raf is a proto-oncogene that is activated in response to growth factors or phorbol esters, and is thought to activate MAP kinase kinase-1 (MKK1) and hence the classical MAP kinase (MAPK) cascade.  The compd. ZM 336372 is identified as a potent and specific inhibitor of Raf isoforms in vitro.  Paradoxically, exposure of cells to ZM 336372 induces > 100-fold activation of c-Raf (measured in the absence of compd.), but without triggering any activation of MKK1 or p42 MAPK/ERK2.  The ZM 336372-induced activation of c-Raf occurs without any increase in the GTP-loading of Ras and is not prevented by inhibition of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase.  ZM 336372 does not prevent growth factor or phorbol ester induced activation of MKK1 or p42 MAPK/ERK2, or reverse the phenotype of Ras- or Raf-transformed cell lines.  The only other protein kinase inhibited by ZM 336372 out of 20 tested was SAPK2/p38.  Although ZM 336372 is structurally unrelated to SB 203580, a potent inhibitor of SAPK2/p38, the mutation of Thr106→Met made SAPK2/p38 insensitive to ZM 336372 as well as to SB 203580.  Raf appears to suppress its own activation by a novel feedback loop, such that inhibition is always counterbalanced by reactivation.  These observations imply that some agonists reported to trigger the cellular activation of c-Raf might actually be inhibitors of this enzyme, and that compds. which inhibit the kinase activity of Raf might not be useful as anticancer drugs.  The binding sites for ZM 336372 and SB 203580 on Raf and SAPK2/p38 are likely to overlap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo23oQKXswmRbVg90H21EOLACvtfcHk0lgdWEfUQj9AkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVynsbo%253D&md5=93aa7dbc301a6f798be138df3e5a075c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980088-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980088-X%26sid%3Dliteratum%253Aachs%26aulast%3DHall-Jackson%26aufirst%3DC.%2BA.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DHewitt%26aufirst%3DN.%26aulast%3DPlant%26aufirst%3DH.%26aulast%3DHedge%26aufirst%3DP.%26atitle%3DParadoxical%2520Activation%2520of%2520Raf%2520by%2520a%2520Novel%2520Raf%2520Inhibitor%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26issue%3D8%26spage%3D559%26epage%3D568%26doi%3D10.1016%2FS1074-5521%2899%2980088-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Raf Kinase Inhibitor</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0080219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1677%2Ferc.0.0080219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=11566613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlCqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=219-225&issue=3&author=J.+F.+Lyonsauthor=S.+Wilhelmauthor=B.+Hibnerauthor=G.+Bollag&title=Discovery+of+a+Novel+Raf+Kinase+Inhibitor&doi=10.1677%2Ferc.0.0080219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel Raf kinase inhibitor</span></div><div class="casAuthors">Lyons, J. F.; Wilhelm, S.; Hibner, B.; Bollag, G.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-225</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  We discuss the biol. of Ras signal transduction and the epidemiol. of ras mutations in assocn. with disease as a background for the development of a Raf kinase inhibitor, BAY 43-9006.  Knowledge of Ras effector pathways has permitted genetic validation of numerous targets involved in the Ras signaling cascade.  A key Ras effector pathway involves the kinase cascade RAF/MEK/ERK (MEK: MAP/ERK kinase; ERK: extracellular signal related kinase).  Indeed, we present studies of cell lines stably expressing mutant MEK constructs, which point to Raf kinase as a target for therapeutics with selective anti-tumor activity.  Finally, a small mol. drug discovery program based on inhibition of Raf kinase activity is outlined and the initial pre-clin. development process of the Raf kinase inhibitor BAY 43-9006 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKQjOYAj8UXbVg90H21EOLACvtfcHk0lgdWEfUQj9AkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlCqsLc%253D&md5=ea4960d080e9cdef008a8a9bed7d5a42</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0080219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0080219%26sid%3Dliteratum%253Aachs%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DHibner%26aufirst%3DB.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Raf%2520Kinase%2520Inhibitor%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2001%26volume%3D8%26issue%3D3%26spage%3D219%26epage%3D225%26doi%3D10.1677%2Ferc.0.0080219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevreau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolland, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demkow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simantov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, R. M.</span></span> <span> </span><span class="NLM_article-title">TARGET Study Group. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa060655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa060655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=17215530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=125-134&issue=2&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Siebelsauthor=S.+Negrierauthor=C.+Chevreauauthor=E.+Solskaauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Freemanauthor=B.+Schwartzauthor=M.+Shanauthor=R.+Simantovauthor=R.+M.+Bukowski&title=TARGET+Study+Group.+Sorafenib+in+Advanced+Clear-Cell+Renal-Cell+Carcinoma&doi=10.1056%2FNEJMoa060655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced clear-cell renal-cell carcinoma</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael; Negrier, Sylvie; Chevreau, Christine; Solska, Ewa; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Freeman, Scott; Schwartz, Brian; Shan, Minghua; Simantov, Ronit; Bukowski, Ronald M.; Blajman, C.; Fein, L.; Martin, C.; Taber, R.; Boyer, M.; Davis, I.; Gurney, H.; Hovey, E.; Leong, D.; Steer, C.; DeGreve, J.; Gil, T.; Barrios, C.; David, W.; Skare, N. G.; Notari, A.; Schwartsmann, G.; Gunnar, N.; Ernst, S.; Hotte, S.; Miller, W.; Moore, M.; North, S.; Fodor, M.; Caty, A.; Chevreau, C.; Duclos, B.; Gravis, G.; Negrier, S.; Oudard, S.; Ravaud, A.; Rolland, F.; Sevin, E.; Grimm, M. O.; Gschwennd, J.; Heinzer, H.; Jager, E.; Krause, S.; Michel, M.-S.; Rohde, D.; Siebels, M.; Siegsmund, M.; Staehler, M.; Wirth, M.; Baki, M.; Bodrogi, I.; Cseh, J.; Ruzsa, A.; Toth, C.; Ben-Yosef, R.; Gez, E.; Bajetta, E.; Boni, C.; Bracarda, S.; Cognetti, F.; Conte, P.; Porta, C.; Spronsen, D. J.; Blasinka-Morawiec, M.; Dernkow, T.; Lorenz, J.; Mazurkiewicz, M.; Roslki, J.; Sikorski, A.; Solska, E.; Tomczak, P.; Bolotina, L.; Karlov, P.; Karyakin, O.; Khasanov, R.; Lichinitser, M.; Lubennikov, V.; Moiseenko, V.; Sherman, N.; Abratt, R.; Coetzee, L.; Cohen, G.; Heyns, C.; Jordaan, J.; Ruff, P.; Wentzel, S.; Bellmunt, J.; Climent, M. A.; Gonzalez, J. L.; Lopez, G.; Bashtan, V.; Dumamsky, Y.; Klimenko, I.; Pilipenko, N.; Shparik, Y.; Hawkins, R.; McMenemin, R.; Nathan, P.; Porfiri, E.; Savage, P.; White, J.; Anderson, C.; Bains, Y.; Bleickardt, E.; Bradof, J.; Brooks, D.; Cardi, G.; Cervera, A.; Davis, N.; Desai, A.; Drabkin, H.; Dudek, A.; Dutcher, J.; Formanek, G.; Gabrail, N.; Gorss, H.; Haung, Y.; Henderson, C.; Hutson, T.; Jonasch, E.; Lara, P.; McCracken, J.; McDermott, D.; Mena, R.; Middleton, R.; Petrylak, D.; Picus, D.; Quinn, D.; Rausch, P.; Rinaldi, D.; Ryan, C.; Tchekmedyian, N.; Vuky, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.  From Nov. 2003 to Mar. 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to std. therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo.  The primary end point was overall survival.  A single planned anal. of progression-free survival in Jan. 2005 showed a statistically significant benefit of sorafenib over placebo.  Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005.  At the Jan. 2005 cutoff, the median progression-free survival was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55).  The 1st interim anal. of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94), although this benefit was not statistically significant according to the O'Brien-Fleming threshold.  Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo.  Diarrhea, rash, fatigue, and hand-foot skin reactions were the most common adverse events assocd. with sorafenib.  Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.  As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is assocd. with increased toxic effects.  (ClinicalTrials.gov no., NCT00073307).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_8zTNHmXrLVg90H21EOLACvtfcHk0lgqepFwZD6eMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D&md5=8f6da990729f8ff17587d71744b834f4</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa060655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa060655%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DSiebels%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DTARGET%2520Study%2520Group.%2520Sorafenib%2520in%2520Advanced%2520Clear-Cell%2520Renal-Cell%2520Carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26issue%3D2%26spage%3D125%26epage%3D134%26doi%3D10.1056%2FNEJMoa060655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llovet, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzaferro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raoul, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolondi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbath, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häussinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannaris, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscovici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliotis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruix, J.</span></span> <span> </span><span class="NLM_article-title">SHARP Investigators Study Group. Sorafenib in Advanced Hepatocellular Carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0708857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa0708857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=18650514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFWjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=378-390&issue=4&author=J.+M.+Llovetauthor=S.+Ricciauthor=V.+Mazzaferroauthor=P.+Hilgardauthor=E.+Ganeauthor=J.-F.+Blancauthor=A.+C.+de+Oliveiraauthor=A.+Santoroauthor=J.-L.+Raoulauthor=A.+Fornerauthor=M.+Schwartzauthor=C.+Portaauthor=S.+Zeuzemauthor=L.+Bolondiauthor=T.+F.+Gretenauthor=P.+R.+Galleauthor=J.-F.+Seitzauthor=I.+Borbathauthor=D.+H%C3%A4ussingerauthor=T.+Giannarisauthor=M.+Shanauthor=M.+Moscoviciauthor=D.+Voliotisauthor=J.+Bruix&title=SHARP+Investigators+Study+Group.+Sorafenib+in+Advanced+Hepatocellular+Carcinoma&doi=10.1056%2FNEJMoa0708857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced hepatocellular carcinoma</span></div><div class="casAuthors">Llovet, Josep M.; Ricci, Sergio; Mazzaferro, Vincenzo; Hilgard, Philip; Gane, Edward; Blanc, Jean-Frederic; Cosme de Oliveira, Andre; Santoro, Armando; Raoul, Jean-Luc; Forner, Alejandro; Schwartz, Myron; Porta, Camillo; Zeuzem, Stefan; Bolondi, Luigi; Greten, Tim F.; Galle, Peter R.; Seitz, Jean-Francois; Borbath, Ivan; Haussinger, Dieter; Giannaris, Tom; Shan, Minghua; Moscovici, Marius; Voliotis, Dimitris; Bruix, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">378-390</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">No effective systemic therapy exists for patients with advanced hepatocellular carcinoma.  A preliminary study suggested that sorafenib, an oral multi-kinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma.  In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo.  Primary outcomes were overall survival and the time to symptomatic progression.  Secondary outcomes included the time to radiol. progression and safety.  At the second planned interim anal., 321 deaths had occurred, and the study was stopped.  Median overall survival was 10.7 mo in the sorafenib group and 7.9 mo in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P < 0.001).  There was no significant difference between the two groups in the median time to symptomatic progression (4.1 mo vs. 4.9 mo, resp., P = 0.77). The median time to radiol. progression was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (P < 0.001).  Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response.  Diarrhea, wt. loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group.  In patients with advanced hepatocellular carcinoma, median survival and the time to radiol. progression were nearly 3 mo longer for patients treated with sorafenib than for those given placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6mcSPrj1TibVg90H21EOLACvtfcHk0lgqepFwZD6eMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFWjsL8%253D&md5=579650dc323f35ad2415523c9827bf9a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0708857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0708857%26sid%3Dliteratum%253Aachs%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26aulast%3DRicci%26aufirst%3DS.%26aulast%3DMazzaferro%26aufirst%3DV.%26aulast%3DHilgard%26aufirst%3DP.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DBlanc%26aufirst%3DJ.-F.%26aulast%3Dde%2BOliveira%26aufirst%3DA.%2BC.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DRaoul%26aufirst%3DJ.-L.%26aulast%3DForner%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DM.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DBolondi%26aufirst%3DL.%26aulast%3DGreten%26aufirst%3DT.%2BF.%26aulast%3DGalle%26aufirst%3DP.%2BR.%26aulast%3DSeitz%26aufirst%3DJ.-F.%26aulast%3DBorbath%26aufirst%3DI.%26aulast%3DH%25C3%25A4ussinger%26aufirst%3DD.%26aulast%3DGiannaris%26aufirst%3DT.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DMoscovici%26aufirst%3DM.%26aulast%3DVoliotis%26aufirst%3DD.%26aulast%3DBruix%26aufirst%3DJ.%26atitle%3DSHARP%2520Investigators%2520Study%2520Group.%2520Sorafenib%2520in%2520Advanced%2520Hepatocellular%2520Carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26issue%3D4%26spage%3D378%26epage%3D390%26doi%3D10.1056%2FNEJMoa0708857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNabola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shujath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eveleigh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voznesensky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7099</span>– <span class="NLM_lpage">7109</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-04-1443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&issue=19&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+Exhibits+Broad+Spectrum+Oral+Antitumor+Activity+and+Targets+the+RAF%2FMEK%2FERK+Pathway+and+Receptor+Tyrosine+Kinases+Involved+in+Tumor+Progression+and+Angiogenesis&doi=10.1158%2F0008-5472.CAN-04-1443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520Exhibits%2520Broad%2520Spectrum%2520Oral%2520Antitumor%2520Activity%2520and%2520Targets%2520the%2520RAF%252FMEK%252FERK%2520Pathway%2520and%2520Receptor%2520Tyrosine%2520Kinases%2520Involved%2520in%2520Tumor%2520Progression%2520and%2520Angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D19%26spage%3D7099%26epage%3D7109%26doi%3D10.1158%2F0008-5472.CAN-04-1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moye, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steelman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blalock, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">Differential Effects of Kinase Cascade Inhibitors on Neoplastic and Cytokine-Mediated Cell Proliferation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1765</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2403052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fsj.leu.2403052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=1765-1782&issue=9&author=J.+G.+Sheltonauthor=P.+W.+Moyeauthor=L.+S.+Steelmanauthor=W.+L.+Blalockauthor=J.+T.+Leeauthor=R.+A.+Franklinauthor=M.+McMahonauthor=J.+A.+McCubrey&title=Differential+Effects+of+Kinase+Cascade+Inhibitors+on+Neoplastic+and+Cytokine-Mediated+Cell+Proliferation&doi=10.1038%2Fsj.leu.2403052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2403052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2403052%26sid%3Dliteratum%253Aachs%26aulast%3DShelton%26aufirst%3DJ.%2BG.%26aulast%3DMoye%26aufirst%3DP.%2BW.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DBlalock%26aufirst%3DW.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DFranklin%26aufirst%3DR.%2BA.%26aulast%3DMcMahon%26aufirst%3DM.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DDifferential%2520Effects%2520of%2520Kinase%2520Cascade%2520Inhibitors%2520on%2520Neoplastic%2520and%2520Cytokine-Mediated%2520Cell%2520Proliferation%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26issue%3D9%26spage%3D1765%26epage%3D1782%26doi%3D10.1038%2Fsj.leu.2403052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottiglieri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Mello, S. R.</span></span> <span> </span><span class="NLM_article-title">The C-Raf Inhibitor GW5074 Provides Neuroprotection in Vitro and in an Animal Model of Neurodegeneration through a MEK-ERK and Akt-Independent Mechanism</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2004.02530.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1111%2Fj.1471-4159.2004.02530.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=15255937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFersbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=595-608&issue=3&author=P.+C.+Chinauthor=L.+Liuauthor=B.+E.+Morrisonauthor=A.+Siddiqauthor=R.+R.+Ratanauthor=T.+Bottiglieriauthor=S.+R.+D%E2%80%99Mello&title=The+C-Raf+Inhibitor+GW5074+Provides+Neuroprotection+in+Vitro+and+in+an+Animal+Model+of+Neurodegeneration+through+a+MEK-ERK+and+Akt-Independent+Mechanism&doi=10.1111%2Fj.1471-4159.2004.02530.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism</span></div><div class="casAuthors">Chin, Paul C.; Liu, Li; Morrison, Bradley E.; Siddiq, Ambreena; Ratan, Rajiv R.; Bottiglieri, Teodoro; D'Mello, Santosh R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-608</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Cerebellar granule neurons undergo apoptosis when switched from a medium contg. high potassium (HK) to one that has low potassium (LK).  LK-induced cell death is blocked by GW5074 {5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}, a synthetic drug that inhibits c-Raf activity in vitro.  GW5074 has no direct effect on the activities of several apoptosis-assocd. kinases when assayed in vitro.  In contrast to its effect in vitro, treatment of neurons with GW5074 causes c-Raf activation (when measured in vitro in the absence of the drug) and stimulates the Raf-MEK-ERK pathway.  Treatment of neurons with GW5074 also leads to an increase in the activity of B-Raf, which is not inhibited by GW5074 in vitro at concns. at which the drug exerts its neuroprotective effect.  PD98059 and U0126, two distinct inhibitors of MEK, block the activation of ERK by GW5074 but have no effect on its ability to prevent cell death.  Overexpression of a dominant-neg. form of Akt does not reduce the efficacy of GW5074, demonstrating an Akt-independent mechanism of action.  Neuroprotection is inhibited by SN-50, a specific inhibitor of nuclear factor-kappa B (NF-κB) and by the Ras inhibitor S-trans, trans-famesylthiosalicylic acid (FTS) implicating NF-κB and Ras in the neuroprotective signaling pathway activated by GW5074.  In addn. to preventing LK-induced apoptosis, treatment with GW5074 protects against the neurotoxic effects of MPP+ and methylmercury in cerebellar granule neurons, and glutathione depletion-induced oxidative stress in cortical neurons.  Furthermore, GW5074 prevents neurodegeneration and improves behavioral outcome in an animal model of Huntington's disease.  Given its neuroprotective effect on distinct types of cultured neurons, in response to different neurotoxic stimuli, and in an animal model of neurodegeneration, GW5074 could have therapeutic value against neurodegenerative pathologies in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Fw56vPqc8LVg90H21EOLACvtfcHk0lgZSlQLmgn-AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFersbY%253D&md5=5cdc3bf26db26b5624567b62b2ae6bc4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2004.02530.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2004.02530.x%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DP.%2BC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMorrison%26aufirst%3DB.%2BE.%26aulast%3DSiddiq%26aufirst%3DA.%26aulast%3DRatan%26aufirst%3DR.%2BR.%26aulast%3DBottiglieri%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Mello%26aufirst%3DS.%2BR.%26atitle%3DThe%2520C-Raf%2520Inhibitor%2520GW5074%2520Provides%2520Neuroprotection%2520in%2520Vitro%2520and%2520in%2520an%2520Animal%2520Model%2520of%2520Neurodegeneration%2520through%2520a%2520MEK-ERK%2520and%2520Akt-Independent%2520Mechanism%26jtitle%3DJ.%2520Neurochem.%26date%3D2004%26volume%3D90%26issue%3D3%26spage%3D595%26epage%3D608%26doi%3D10.1111%2Fj.1471-4159.2004.02530.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batorsky, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takle, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karreth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contractor, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. S.</span></span> <span> </span><span class="NLM_article-title">Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">11100</span>– <span class="NLM_lpage">11105</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-06-2554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11100-11105&issue=23&author=A.+J.+Kingauthor=D.+R.+Patrickauthor=R.+S.+Batorskyauthor=M.+L.+Hoauthor=H.+T.+Doauthor=S.+Y.+Zhangauthor=R.+Kumarauthor=D.+W.+Rusnakauthor=A.+K.+Takleauthor=D.+M.+Wilsonauthor=E.+Huggerauthor=L.+Wangauthor=F.+Karrethauthor=J.+C.+Lougheedauthor=J.+Leeauthor=D.+Chauauthor=T.+J.+Stoutauthor=E.+W.+Mayauthor=C.+M.+Romingerauthor=M.+D.+Schaberauthor=L.+Luoauthor=A.+S.+Lakdawalaauthor=J.+L.+Adamsauthor=R.+G.+Contractorauthor=K.+S.+M.+Smalleyauthor=M.+Herlynauthor=M.+M.+Morrisseyauthor=D.+A.+Tuvesonauthor=P.+S.+Huang&title=Demonstration+of+a+Genetic+Therapeutic+Index+for+Tumors+Expressing+Oncogenic+BRAF+by+the+Kinase+Inhibitor+SB-590885&doi=10.1158%2F0008-5472.CAN-06-2554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2554%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DBatorsky%26aufirst%3DR.%2BS.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKarreth%26aufirst%3DF.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DContractor%26aufirst%3DR.%2BG.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DDemonstration%2520of%2520a%2520Genetic%2520Therapeutic%2520Index%2520for%2520Tumors%2520Expressing%2520Oncogenic%2520BRAF%2520by%2520the%2520Kinase%2520Inhibitor%2520SB-590885%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D23%26spage%3D11100%26epage%3D11105%26doi%3D10.1158%2F0008-5472.CAN-06-2554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span> <span> </span><span class="NLM_article-title">Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3042</span>– <span class="NLM_lpage">3051</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-3563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F0008-5472.CAN-08-3563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3042-3051&issue=7&author=K.+P.+Hoeflichauthor=S.+Herterauthor=J.+Tienauthor=L.+Wongauthor=L.+Berryauthor=J.+Chanauthor=C.+O%E2%80%99Brienauthor=Z.+Modrusanauthor=S.+Seshagiriauthor=M.+Lacknerauthor=H.+Sternauthor=E.+Chooauthor=L.+Murrayauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Antitumor+Efficacy+of+the+Novel+RAF+Inhibitor+GDC-0879+Is+Predicted+by+BRAFV600E+Mutational+Status+and+Sustained+Extracellular+Signal-Regulated+Kinase%2FMitogen-Activated+Protein+Kinase+Pathway+Suppression&doi=10.1158%2F0008-5472.CAN-08-3563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-3563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-3563%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DHerter%26aufirst%3DS.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DLackner%26aufirst%3DM.%26aulast%3DStern%26aufirst%3DH.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DAntitumor%2520Efficacy%2520of%2520the%2520Novel%2520RAF%2520Inhibitor%2520GDC-0879%2520Is%2520Predicted%2520by%2520BRAFV600E%2520Mutational%2520Status%2520and%2520Sustained%2520Extracellular%2520Signal-Regulated%2520Kinase%252FMitogen-Activated%2520Protein%2520Kinase%2520Pathway%2520Suppression%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D7%26spage%3D3042%26epage%3D3051%26doi%3D10.1158%2F0008-5472.CAN-08-3563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproesser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3046</span>, <span class="refDoi"> DOI: 10.1073/pnas.0711741105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&issue=8&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.-L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+Selective+Inhibitor+of+Oncogenic+B-Raf+Kinase+with+Potent+Antimelanoma+Activity&doi=10.1073%2Fpnas.0711741105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lgp0TEH2Dhhew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.-L.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Inhibitor%2520of%2520Oncogenic%2520B-Raf%2520Kinase%2520with%2520Potent%2520Antimelanoma%2520Activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D8%26spage%3D3041%26epage%3D3046%26doi%3D10.1073%2Fpnas.0711741105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span> (<span class="NLM_issue">7315</span>),  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&issue=7315&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+Efficacy+of+a+RAF+Inhibitor+Needs+Broad+Target+Blockade+in+BRAF-Mutant+Melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lgp0TEH2Dhhew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520Efficacy%2520of%2520a%2520RAF%2520Inhibitor%2520Needs%2520Broad%2520Target%2520Blockade%2520in%2520BRAF-Mutant%2520Melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26issue%3D7315%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in Patients with Melanoma, Untreated Brain Metastases, and Other Solid Tumours: A Phase 1 Dose-Escalation Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">9829</span>),  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1901</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60398-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0140-6736%2812%2960398-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1893-1901&issue=9829&author=G.+S.+Falchookauthor=G.+V.+Longauthor=R.+Kurzrockauthor=K.+B.+Kimauthor=T.+H.+Arkenauauthor=M.+P.+Brownauthor=O.+Hamidauthor=J.+R.+Infanteauthor=M.+Millwardauthor=A.+C.+Pavlickauthor=S.+J.+O%E2%80%99Dayauthor=S.+C.+Blackmanauthor=C.+M.+Curtisauthor=P.+Lebowitzauthor=B.+Maauthor=D.+Ouelletauthor=R.+F.+Kefford&title=Dabrafenib+in+Patients+with+Melanoma%2C+Untreated+Brain+Metastases%2C+and+Other+Solid+Tumours%3A+A+Phase+1+Dose-Escalation+Trial&doi=10.1016%2FS0140-6736%2812%2960398-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960398-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960398-5%26sid%3Dliteratum%253Aachs%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DArkenau%26aufirst%3DT.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26aulast%3DCurtis%26aufirst%3DC.%2BM.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26atitle%3DDabrafenib%2520in%2520Patients%2520with%2520Melanoma%252C%2520Untreated%2520Brain%2520Metastases%252C%2520and%2520Other%2520Solid%2520Tumours%253A%2520A%2520Phase%25201%2520Dose-Escalation%2520Trial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26issue%3D9829%26spage%3D1893%26epage%3D1901%26doi%3D10.1016%2FS0140-6736%2812%2960398-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempgen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in BRAF-Mutated Metastatic Melanoma: A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">9839</span>),  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60868-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&issue=9839&author=A.+Hauschildauthor=J.-J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.-M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-Mutated+Metastatic+Melanoma%3A+A+Multicentre%2C+Open-Label%2C+Phase+3+Randomised+Controlled+Trial&doi=10.1016%2FS0140-6736%2812%2960868-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.-M.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-Mutated%2520Metastatic%2520Melanoma%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Phase%25203%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26issue%3D9839%26spage%3D358%26epage%3D365%26doi%3D10.1016%2FS0140-6736%2812%2960868-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spleiss, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kockx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1105358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa1105358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22256804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=207-215&issue=3&author=F.+Suauthor=A.+Virosauthor=C.+Milagreauthor=K.+Trunzerauthor=G.+Bollagauthor=O.+Spleissauthor=J.+S.+Reis-Filhoauthor=X.+Kongauthor=R.+C.+Koyaauthor=K.+T.+Flahertyauthor=P.+B.+Chapmanauthor=M.+J.+Kimauthor=R.+Haywardauthor=M.+Martinauthor=H.+Yangauthor=Q.+Wangauthor=H.+Hiltonauthor=J.+S.+Hangauthor=J.+Noeauthor=M.+Lambrosauthor=F.+Geyerauthor=N.+Dhomenauthor=I.+Niculescu-Duvazauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=N.+Preeceauthor=L.+Robertauthor=N.+J.+Otteauthor=S.+Mokauthor=D.+Keeauthor=Y.+Maauthor=C.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=H.+Nguyenauthor=M.+Kockxauthor=L.+Andriesauthor=B.+Lestiniauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=J.+L.+Troyauthor=R.+Gonzalezauthor=T.+E.+Hutsonauthor=I.+Puzanovauthor=B.+Chmielowskiauthor=C.+J.+Springerauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=R.+S.+Loauthor=A.+Ribasauthor=R.+Marais&title=RAS+Mutations+in+Cutaneous+Squamous-Cell+Carcinomas+in+Patients+Treated+with+BRAF+Inhibitors&doi=10.1056%2FNEJMoa1105358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span></div><div class="casAuthors">Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S.; Kong, Xiangju; Koya, Richard C.; Flaherty, Keith T.; Chapman, Paul B.; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Nguyen, Hoa; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Troy, James L.; Gonzalez, Rene; Hutson, Thomas E.; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J.; McArthur, Grant A.; Sosman, Jeffrey A.; Lo, Roger S.; Ribas, Antoni; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.  METHODS: We performed a mol. anal. to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.  An anal. of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed.  RESULTS: Among 21 tumor samples, 13 had RAS mutations (12 in HRAS).  In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS).  Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L.  Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was assocd. with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription.  In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analog PLX4720 was not an initiator or a.promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor.  CONCLUSIONS: Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib.  The mol. mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplrkvSEAdDG7Vg90H21EOLACvtfcHk0liyE_92a3fRFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D&md5=6c813dc23344a8eedcc7a289d2326f4f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105358%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DF.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DTrunzer%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSpleiss%26aufirst%3DO.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DHayward%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BS.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKockx%26aufirst%3DM.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DTroy%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DRAS%2520Mutations%2520in%2520Cutaneous%2520Squamous-Cell%2520Carcinomas%2520in%2520Patients%2520Treated%2520with%2520BRAF%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D3%26spage%3D207%26epage%3D215%26doi%3D10.1056%2FNEJMoa1105358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">B-Raf and the Inhibitors: From Bench to Bedside</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-6-30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1186%2F1756-8722-6-30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=23617957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFWrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=30&author=T.+Huangauthor=M.+Karsyauthor=J.+Zhugeauthor=M.+Zhongauthor=D.+Liu&title=B-Raf+and+the+Inhibitors%3A+From+Bench+to+Bedside&doi=10.1186%2F1756-8722-6-30"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">B-Raf and the inhibitors: from bench to bedside</span></div><div class="casAuthors">Huang, Tiangui; Karsy, Michael; Zhuge, Jian; Zhong, Minghao; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The B-Raf protein is a key signaling mol. in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of cancers.  An important V600E mutation has been identified and can cause constitutive B-Raf activation.  Recent studies have evaluated a variety of small mol. inhibitors targeting B-Raf, including PLX4032/vemurafenib, dabrafenib, LGX818, GDC0879, XL281, ARQ736, PLX3603 (RO5212054), and RAF265.  Therapeutic resistance has been identified and various mechanisms described.  This review also discussed the current understanding of B-Raf signaling mechanism, methods of mutation detection, treatment strategies as well as potential methods of overcoming therapeutic resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW96ypSxw3MrVg90H21EOLACvtfcHk0liyE_92a3fRFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFWrsLw%253D&md5=62c83f28798a093cf4be76376020721b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-30%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DKarsy%26aufirst%3DM.%26aulast%3DZhuge%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DB-Raf%2520and%2520the%2520Inhibitors%253A%2520From%2520Bench%2520to%2520Bedside%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D30%26doi%3D10.1186%2F1756-8722-6-30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salangsang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoddusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryer, N.</span></span> <span> </span><span class="NLM_article-title">Abstract 3790: Preclinical Profile of LGX818: A Potent and Selective RAF Kinase Inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">8 Suppl.</span>),  <span class="NLM_fpage">3790</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2012-3790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1538-7445.AM2012-3790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3790-3790&issue=8+Suppl.&author=D.+D.+Stuartauthor=N.+Liauthor=D.+J.+Poonauthor=K.+Aardalenauthor=S.+Kaufmanauthor=H.+Merrittauthor=F.+Salangsangauthor=E.+Lorenzanaauthor=A.+Liauthor=M.+Ghoddusiauthor=G.+Caponigroauthor=F.+Sunauthor=S.+Kulkarniauthor=S.+Kakarauthor=N.+Turnerauthor=R.+Zangauthor=J.+Tellewauthor=N.+Pryer&title=Abstract+3790%3A+Preclinical+Profile+of+LGX818%3A+A+Potent+and+Selective+RAF+Kinase+Inhibitor&doi=10.1158%2F1538-7445.AM2012-3790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-3790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-3790%26sid%3Dliteratum%253Aachs%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DSalangsang%26aufirst%3DF.%26aulast%3DLorenzana%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGhoddusi%26aufirst%3DM.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DKakar%26aufirst%3DS.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DPryer%26aufirst%3DN.%26atitle%3DAbstract%25203790%253A%2520Preclinical%2520Profile%2520of%2520LGX818%253A%2520A%2520Potent%2520and%2520Selective%2520RAF%2520Kinase%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D8%2520Suppl%26spage%3D3790%26epage%3D3790%26doi%3D10.1158%2F1538-7445.AM2012-3790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span> <span> </span><span class="NLM_article-title">Encorafenib (LGX818), a Potent BRAF Inhibitor, Induces Senescence Accompanied by Autophagy in BRAFV600E Melanoma Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2015.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.canlet.2015.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26586345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKmt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2016&pages=332-344&issue=2&author=Z.+Liauthor=K.+Jiangauthor=X.+Zhuauthor=G.+Linauthor=F.+Songauthor=Y.+Zhaoauthor=Y.+Piaoauthor=J.+Liuauthor=W.+Chengauthor=X.+Biauthor=P.+Gongauthor=Z.+Songauthor=S.+Meng&title=Encorafenib+%28LGX818%29%2C+a+Potent+BRAF+Inhibitor%2C+Induces+Senescence+Accompanied+by+Autophagy+in+BRAFV600E+Melanoma+Cells&doi=10.1016%2Fj.canlet.2015.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells</span></div><div class="casAuthors">Li, Zhen; Jiang, Ke; Zhu, Xiaofang; Lin, Guibin; Song, Fei; Zhao, Yongfu; Piao, Yongjun; Liu, Jiwei; Cheng, Wei; Bi, Xiaolin; Gong, Peng; Song, Zhiqi; Meng, Songshu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-344</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clin. trials.  However, the underlying mechanism remains to be elucidated.  Here the authors show that LGX818 potently decreased ERK phosphorylation and inhibited proliferation in BRAFV600E melanoma cell lines.  Moreover, LGX818 downregulated Cyclin D1 in a glycogen synthase kinase 3β-independent manner and induced cell cycle arrest in the G1 phase.  Surprisingly, LGX818 triggered cellular senescence in BRAFV600E melanoma cells, as evidenced by increased β-galactosidase staining, while no appreciable induction of apoptosis was detected, as detd. by Annexin V and propidium iodide staining and immunoblot anal. of caspase-3 processing and poly (ADP-ribose) polymerase cleavage.  Increased p27KIP1 expression and retinoblastoma protein activation were detected during LGX818-induced senescence.  Addnl., inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 1B by AZ191 reversed LGX818-induced Cyclin D1 turnover and senescence.  Interestingly, autophagy is triggered through inhibition of the mTOR/70S6K pathway during LGX818-induced senescence.  Moreover, autophagy inhibition by pharmacol. and genetic regulation attenuates LGX818-induced senescence.  Notably, combining LGX818 with autophagy modulators has anti-proliferative effect in LGX818-resistant BRAF mutant melanoma cells.  Altogether, the authors uncovered a mechanism by which LGX818 exerts its anti-tumor activity in BRAFV600E melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu_EM8hUteQLVg90H21EOLACvtfcHk0lh1UZySj7K0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKmt73O&md5=c1b58e63bbaa50db4765ceb932f810d1</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2015.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2015.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DPiao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DBi%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DS.%26atitle%3DEncorafenib%2520%2528LGX818%2529%252C%2520a%2520Potent%2520BRAF%2520Inhibitor%252C%2520Induces%2520Senescence%2520Accompanied%2520by%2520Autophagy%2520in%2520BRAFV600E%2520Melanoma%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D370%26issue%3D2%26spage%3D332%26epage%3D344%26doi%3D10.1016%2Fj.canlet.2015.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span>Study
Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and
LGX818 Monotherapy in BRAF Mutant Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01909453" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01909453</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0AComparing+Combination+of+LGX818+Plus+MEK162+Versus+Vemurafenib+and%0ALGX818+Monotherapy+in+BRAF+Mutant+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01909453+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clary, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of XL281 (BMS-908662), a Potent Oral RAF Kinase Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0191-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1007%2Fs10637-014-0191-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=349-356&issue=2&author=M.+A.+Dicksonauthor=M.+S.+Gordonauthor=G.+Edelmanauthor=J.+C.+Bendellauthor=R.+R.+Kudchadkarauthor=P.+M.+LoRussoauthor=S.+H.+Johnstonauthor=D.+O.+Claryauthor=G.+K.+Schwartz&title=Phase+I+Study+of+XL281+%28BMS-908662%29%2C+a+Potent+Oral+RAF+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1007%2Fs10637-014-0191-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0191-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0191-5%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DEdelman%26aufirst%3DG.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DJohnston%26aufirst%3DS.%2BH.%26aulast%3DClary%26aufirst%3DD.%2BO.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DPhase%2520I%2520Study%2520of%2520XL281%2520%2528BMS-908662%2529%252C%2520a%2520Potent%2520Oral%2520RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D2%26spage%3D349%26epage%3D356%26doi%3D10.1007%2Fs10637-014-0191-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dials, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of XL281, a Selective Oral RAF Kinase Inhibitor, in Patients (Pts) with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">15S</span>),  <span class="NLM_fpage">3513</span>– <span class="NLM_lpage">3513</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3513-3513&issue=15S&author=G.+K.+Schwartzauthor=S.+Robertsonauthor=A.+Shenauthor=E.+Wangauthor=L.+Paceauthor=H.+Dialsauthor=D.+Mendelsonauthor=P.+Shannonauthor=M.+Gordon&title=A+Phase+I+Study+of+XL281%2C+a+Selective+Oral+RAF+Kinase+Inhibitor%2C+in+Patients+%28Pts%29+with+Advanced+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DRobertson%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DPace%26aufirst%3DL.%26aulast%3DDials%26aufirst%3DH.%26aulast%3DMendelson%26aufirst%3DD.%26aulast%3DShannon%26aufirst%3DP.%26aulast%3DGordon%26aufirst%3DM.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520XL281%252C%2520a%2520Selective%2520Oral%2520RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26issue%3D15S%26spage%3D3513%26epage%3D3513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clary, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of XL281 (BMS-908662), a Potent Oral RAF Kinase Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0191-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1007%2Fs10637-014-0191-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=349-356&issue=2&author=M.%0AA.+Dicksonauthor=M.+S.+Gordonauthor=G.+Edelmanauthor=J.+C.+Bendellauthor=R.+R.+Kudchadkarauthor=P.+M.+LoRussoauthor=S.+H.+Johnstonauthor=D.+O.+Claryauthor=G.+K.+Schwartz&title=Phase+I+Study+of+XL281+%28BMS-908662%29%2C+a+Potent+Oral+RAF+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1007%2Fs10637-014-0191-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0191-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0191-5%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DEdelman%26aufirst%3DG.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DJohnston%26aufirst%3DS.%2BH.%26aulast%3DClary%26aufirst%3DD.%2BO.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DPhase%2520I%2520Study%2520of%2520XL281%2520%2528BMS-908662%2529%252C%2520a%2520Potent%2520Oral%2520RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D2%26spage%3D349%26epage%3D356%26doi%3D10.1007%2Fs10637-014-0191-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltz, L.</span></span> <span> </span><span class="NLM_article-title">Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">4032</span>– <span class="NLM_lpage">4038</span>, <span class="refDoi"> DOI: 10.1200/JCO.2015.63.2497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1200%2FJCO.2015.63.2497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26460303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvV2gtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=4032-4038&issue=34&author=S.+Kopetzauthor=J.+Desaiauthor=E.+Chanauthor=J.+R.+Hechtauthor=P.+J.+O%E2%80%99Dwyerauthor=D.+Maruauthor=V.+Morrisauthor=F.+Jankuauthor=A.+Dasariauthor=W.+Chungauthor=J.-P.+J.+Issaauthor=P.+Gibbsauthor=B.+Jamesauthor=G.+Powisauthor=K.+B.+Nolopauthor=S.+Bhattacharyaauthor=L.+Saltz&title=Phase+II+Pilot+Study+of+Vemurafenib+in+Patients+With+Metastatic+BRAF-Mutated+Colorectal+Cancer&doi=10.1200%2FJCO.2015.63.2497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer</span></div><div class="casAuthors">Kopetz, Scott; Desai, Jayesh; Chan, Emily; Hecht, Joel Randolph; O'Dwyer, Peter J.; Maru, Dipen; Morris, Van; Janku, Filip; Dasari, Arvind; Chung, Woonbook; Issa, Jean-Pierre J.; Gibbs, Peter; James, Brian; Powis, Garth; Nolop, Keith B.; Bhattacharya, Suman; Saltz, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4032-4038</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is assocd. with poor prognosis.  Vemurafenib, an oralBRAF V600 inhibitor, has pronounced activity in patients with metastatic melanoma, but its activity in patients with BRAF V600E-pos. metastatic CRC was unknown.  In this multi-institutional, open-label study, patients with metastatic CRC with BRAF V600 mutations were recruited to an expansion cohort at the previously detd. max.-tolerated dose of 960 mg orally twice a day.  Twenty-one patients were enrolled, of whom 20 had received at least one prior metastatic chemotherapy regimen.  Grade 3 toxicities included keratoacanthomas, rash, fatigue, and arthralgia.  Of the 21 patients treated, one patient had a confirmed partial response (5%; 95% CI, 1% to 24%) and seven other patients had stable disease by RECIST criteria.  Median progression-free survival was 2.1 mo.  Patterns of concurrent mutations, microsatellite instability status, CpG island methylation status, PTEN loss, EGFR expression, and copy no. alterations were not assocd. with clin. benefit.  In contrast to prior expectations, concurrent KRAS and NRAS mutations were detected at low allele frequency in a subset of the patients' tumors (median, 0.21% allele frequency) and were apparent mechanisms of acquired resistance in vemurafenib-sensitive patient-derived xenograft models.  In marked contrast to the results seen in patients with BRAF V600E-mutant melanoma, single-agent vemurafenib did not show meaningful clin. activity in patients with BRAF V600E mutant CRC.  Combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYRSTz4lRinbVg90H21EOLACvtfcHk0ljLum9rxAscNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvV2gtr8%253D&md5=0486caf26220c2b1fe93ec73ac84ee37</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.63.2497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.63.2497%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DHecht%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DMaru%26aufirst%3DD.%26aulast%3DMorris%26aufirst%3DV.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DDasari%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DIssa%26aufirst%3DJ.-P.%2BJ.%26aulast%3DGibbs%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DB.%26aulast%3DPowis%26aufirst%3DG.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DSaltz%26aufirst%3DL.%26atitle%3DPhase%2520II%2520Pilot%2520Study%2520of%2520Vemurafenib%2520in%2520Patients%2520With%2520Metastatic%2520BRAF-Mutated%2520Colorectal%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D34%26spage%3D4032%26epage%3D4038%26doi%3D10.1200%2FJCO.2015.63.2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faris, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollebecque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elez-Fernandez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofheinz, R.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasserre, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makrutzki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirzen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1502309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa1502309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26287849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFWrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=726-736&issue=8&author=D.+M.+Hymanauthor=I.+Puzanovauthor=V.+Subbiahauthor=J.+E.+Farisauthor=I.+Chauauthor=J.-Y.+Blayauthor=J.+Wolfauthor=N.+S.+Rajeauthor=E.+L.+Diamondauthor=A.+Hollebecqueauthor=R.+Gervaisauthor=M.+E.+Elez-Fernandezauthor=A.+Italianoauthor=R.-D.+Hofheinzauthor=M.+Hidalgoauthor=E.+Chanauthor=M.+Schulerauthor=S.+F.+Lasserreauthor=M.+Makrutzkiauthor=F.+Sirzenauthor=M.+L.+Veroneseauthor=J.+Taberneroauthor=J.+Baselga&title=Vemurafenib+in+Multiple+Nonmelanoma+Cancers+with+BRAF+V600+Mutations&doi=10.1056%2FNEJMoa1502309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations</span></div><div class="casAuthors">Hyman, David M.; Puzanov, Igor; Subbiah, Vivek; Faris, Jason E.; Chau, Ian; Blay, Jean-Yves; Wolf, Jurgen; Raje, Noopur S.; Diamond, Eli L.; Hollebecque, Antoine; Gervais, Radj; Elez-Fernandez, Maria Elena; Italiano, Antoine; Hofheinz, Ralf-Dieter; Hidalgo, Manuel; Chan, Emily; Schuler, Martin; Lasserre, Susan Frances; Makrutzki, Martina; Sirzen, Florin; Veronese, Maria Luisa; Tabernero, Josep; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">726-736</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers.  We undertook a histol.-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation- pos. nonmelanoma cancers.  METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort.  A total of 122 patients with BRAF V600 mutation-pos. cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab.  The primary end point was the response rate; secondary end points included progression-free and overall survival.  RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 mo (95% CI, 3.5 to 10.8).  In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 mo (range, 0.6 to 18.6), and no patients had disease progression during therapy.  There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab.  Safety was similar to that in prior studies of vemurafenib for melanoma.  CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers.  Preliminary vemurafenib activity was obsd. in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.  The histol. context is an important determinant of response in BRAF V600-mutated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov1cskwNZrtLVg90H21EOLACvtfcHk0ljLum9rxAscNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFWrtg%253D%253D&md5=a91d4ce875a05e4bbec36e69dfb08b80</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1502309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1502309%26sid%3Dliteratum%253Aachs%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DFaris%26aufirst%3DJ.%2BE.%26aulast%3DChau%26aufirst%3DI.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DRaje%26aufirst%3DN.%2BS.%26aulast%3DDiamond%26aufirst%3DE.%2BL.%26aulast%3DHollebecque%26aufirst%3DA.%26aulast%3DGervais%26aufirst%3DR.%26aulast%3DElez-Fernandez%26aufirst%3DM.%2BE.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DHofheinz%26aufirst%3DR.-D.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DLasserre%26aufirst%3DS.%2BF.%26aulast%3DMakrutzki%26aufirst%3DM.%26aulast%3DSirzen%26aufirst%3DF.%26aulast%3DVeronese%26aufirst%3DM.%2BL.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DVemurafenib%2520in%2520Multiple%2520Nonmelanoma%2520Cancers%2520with%2520BRAF%2520V600%2520Mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D8%26spage%3D726%26epage%3D736%26doi%3D10.1056%2FNEJMoa1502309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecchin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition through Feedback Activation of EGFR</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>483</i></span> (<span class="NLM_issue">7387</span>),  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1038/nature10868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnature10868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=100-103&issue=7387&author=A.+Prahalladauthor=C.+Sunauthor=S.+Huangauthor=F.+Di+Nicolantonioauthor=R.+Salazarauthor=D.+Zecchinauthor=R.+L.+Beijersbergenauthor=A.+Bardelliauthor=R.+Bernards&title=Unresponsiveness+of+Colon+Cancer+to+BRAF%28V600E%29+Inhibition+through+Feedback+Activation+of+EGFR&doi=10.1038%2Fnature10868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnature10868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10868%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DSalazar%26aufirst%3DR.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DUnresponsiveness%2520of%2520Colon%2520Cancer%2520to%2520BRAF%2528V600E%2529%2520Inhibition%2520through%2520Feedback%2520Activation%2520of%2520EGFR%26jtitle%3DNature%26date%3D2012%26volume%3D483%26issue%3D7387%26spage%3D100%26epage%3D103%26doi%3D10.1038%2Fnature10868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turke, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogdill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pelle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">EGFR-Mediated Re-Activation of MAPK Signaling Contributes to Insensitivity of BRAF Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2159-8290.CD-11-0341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22448344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=227-235&issue=3&author=R.+B.+Corcoranauthor=H.+Ebiauthor=A.+B.+Turkeauthor=E.+M.+Coffeeauthor=M.+Nishinoauthor=A.+P.+Cogdillauthor=R.+D.+Brownauthor=P.+Della+Pelleauthor=D.+Dias-Santagataauthor=K.+E.+Hungauthor=K.+T.+Flahertyauthor=A.+Pirisauthor=J.+A.+Wargoauthor=J.+Settlemanauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=EGFR-Mediated+Re-Activation+of+MAPK+Signaling+Contributes+to+Insensitivity+of+BRAF+Mutant+Colorectal+Cancers+to+RAF+Inhibition+with+Vemurafenib&doi=10.1158%2F2159-8290.CD-11-0341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib</span></div><div class="casAuthors">Corcoran, Ryan B.; Ebi, Hiromichi; Turke, Alexa B.; Coffee, Erin M.; Nishino, Michiya; Cogdill, Alexandria P.; Brown, Ronald D.; Della Pelle, Patricia; Dias-Santagata, Dora; Hung, Kenneth E.; Flaherty, Keith T.; Piris, Adriano; Wargo, Jennifer A.; Settleman, Jeffrey; Mino-Kenudson, Mari; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">227-235</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in the metastatic setting.  Although RAF inhibitors such as vemurafenib (PLX4032) have proven effective in the treatment of BRAF-mutant melanoma, they are surprisingly ineffective in BRAF-mutant colorectal cancers, and the reason for this disparity remains unclear.  Compared with BRAF-mutant melanoma cells, BRAF-mutant colorectal cancer cells were less sensitive to vemurafenib, and phospho-extracellular signal-regulated kinase (P-ERK) suppression was not sustained in response to treatment.  Although transient inhibition of P-ERK by vemurafenib was obsd. in colorectal cancer, rapid ERK reactivation occurred through epidermal growth factor receptor (EGFR)-mediated activation of RAS and CRAF.  BRAF-mutant colorectal cancers expressed greater levels of phospho-EGFR than BRAF-mutant melanomas, suggesting that colorectal cancers are specifically poised for EGFR-mediated resistance.  Combined RAF and EGFR inhibition blocked reactivation of mitogen-activated protein kinase (MAPK) signaling in BRAF-mutant colorectal cancer cells and markedly improved efficacy in vitro and in vivo.  These findings support the evaluation of combined RAF and EGFR inhibition in patients with BRAF-mutant colorectal cancer.  SIGNIFICANCE: BRAF valine 600 (V600) mutations occur in 10% to 15% of colorectal cancers, yet these tumors show a surprisingly low clin. response rate (∼5%) to selective RAF inhibitors such as vemurafenib, which have produced dramatic response rates (60%-80%) in melanomas harboring the identical BRAF V600 mutation.  We found that EGFR-mediated MAPK pathway reactivation leads to resistance to vemurafenib in BRAF-mutant colorectal cancers and that combined RAF and EGFR inhibition can lead to sustained MAPK pathway suppression and improved efficacy in vitro and in tumor xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFZt8toXDqQrVg90H21EOLACvtfcHk0lgHXBUYp24Pqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGntbs%253D&md5=8de601cad959e7ad51ff4a6f96e183f4</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0341%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DCoffee%26aufirst%3DE.%2BM.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DCogdill%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DR.%2BD.%26aulast%3DDella%2BPelle%26aufirst%3DP.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DHung%26aufirst%3DK.%2BE.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPiris%26aufirst%3DA.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DEGFR-Mediated%2520Re-Activation%2520of%2520MAPK%2520Signaling%2520Contributes%2520to%2520Insensitivity%2520of%2520BRAF%2520Mutant%2520Colorectal%2520Cancers%2520to%2520RAF%2520Inhibition%2520with%2520Vemurafenib%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D3%26spage%3D227%26epage%3D235%26doi%3D10.1158%2F2159-8290.CD-11-0341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahrendt, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrigo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, G.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 3: An Increase in Aqueous Solubility via the Disruption of Crystal Packing</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bmcl.2011.12.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=912-915&issue=2&author=S.+Wenglowskyauthor=D.+Morenoauthor=J.+Rudolphauthor=Y.+Ranauthor=K.+A.+Ahrendtauthor=A.+Arrigoauthor=B.+Colsonauthor=S.+L.+Gloorauthor=G.+Hastings&title=Pyrazolopyridine+Inhibitors+of+B-Raf%28V600E%29.+Part+3%3A+An+Increase+in+Aqueous+Solubility+via+the+Disruption+of+Crystal+Packing&doi=10.1016%2Fj.bmcl.2011.12.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DAhrendt%26aufirst%3DK.%2BA.%26aulast%3DArrigo%26aufirst%3DA.%26aulast%3DColson%26aufirst%3DB.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DHastings%26aufirst%3DG.%26atitle%3DPyrazolopyridine%2520Inhibitors%2520of%2520B-Raf%2528V600E%2529.%2520Part%25203%253A%2520An%2520Increase%2520in%2520Aqueous%2520Solubility%2520via%2520the%2520Disruption%2520of%2520Crystal%2520Packing%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D912%26epage%3D915%26doi%3D10.1016%2Fj.bmcl.2011.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telikepalli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobb, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglicmot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(3,3-Dimethylbutyl)-3-(2-Fluoro-4-Methyl-5-(7-Methyl-2-(Methylamino)Pyrido[2,3-d]Pyrimidin-6-Yl)Phenyl)Urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4165</span>– <span class="NLM_lpage">4179</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4165-4179&issue=10&author=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=S.-B.+Pengauthor=Y.+M.+Ahnauthor=T.+M.+Caldwellauthor=L.+Vogetiauthor=H.+Telikepalliauthor=W.-P.+Luauthor=M.+M.+Hoodauthor=T.+J.+Rutkoskiauthor=B.+D.+Smithauthor=S.+Vogetiauthor=D.+Millerauthor=S.+C.+Wiseauthor=L.+Chunauthor=X.+Zhangauthor=Y.+Zhangauthor=L.+Kaysauthor=P.+A.+Hipskindauthor=A.+D.+Wrobleskiauthor=K.+L.+Lobbauthor=J.+M.+Clayauthor=J.+D.+Cohenauthor=J.+L.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=D.+K.+Clawsonauthor=S.+Guoauthor=D.+Manglicmotauthor=C.+Groshongauthor=C.+Loganauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Discovery+of+1-%283%2C3-Dimethylbutyl%29-3-%282-Fluoro-4-Methyl-5-%287-Methyl-2-%28Methylamino%29Pyrido%5B2%2C3-d%5DPyrimidin-6-Yl%29Phenyl%29Urea+%28LY3009120%29+as+a+Pan-RAF+Inhibitor+with+Minimal+Paradoxical+Activation+and+Activity+against+BRAF+or+RAS+Mutant+Tumor+Cells&doi=10.1021%2Facs.jmedchem.5b00067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00067%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DHipskind%26aufirst%3DP.%2BA.%26aulast%3DWrobleski%26aufirst%3DA.%2BD.%26aulast%3DLobb%26aufirst%3DK.%2BL.%26aulast%3DClay%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BD.%26aulast%3DWalgren%26aufirst%3DJ.%2BL.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DClawson%26aufirst%3DD.%2BK.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DManglicmot%26aufirst%3DD.%26aulast%3DGroshong%26aufirst%3DC.%26aulast%3DLogan%26aufirst%3DC.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DDiscovery%2520of%25201-%25283%252C3-Dimethylbutyl%2529-3-%25282-Fluoro-4-Methyl-5-%25287-Methyl-2-%2528Methylamino%2529Pyrido%255B2%252C3-d%255DPyrimidin-6-Yl%2529Phenyl%2529Urea%2520%2528LY3009120%2529%2520as%2520a%2520Pan-RAF%2520Inhibitor%2520with%2520Minimal%2520Paradoxical%2520Activation%2520and%2520Activity%2520against%2520BRAF%2520or%2520RAS%2520Mutant%2520Tumor%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D10%26spage%3D4165%26epage%3D4179%26doi%3D10.1021%2Facs.jmedchem.5b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blosser, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowless, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stancato, L. F.</span></span> <span> </span><span class="NLM_article-title">LY3009120, a PanRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">9251</span>– <span class="NLM_lpage">9266</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.18632%2Foncotarget.14002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=9251-9266&issue=6&author=E.+Vakanaauthor=S.+Prattauthor=W.+Blosserauthor=M.+Dowlessauthor=N.+Simpsonauthor=X.-J.+Yuanauthor=S.+Jakenauthor=J.+Manroauthor=J.+Stephensauthor=Y.+Zhangauthor=L.+Huberauthor=S.-B.+Pengauthor=L.+F.+Stancato&title=LY3009120%2C+a+PanRAF+Inhibitor%2C+Has+Significant+Anti-Tumor+Activity+in+BRAF+and+KRAS+Mutant+Preclinical+Models+of+Colorectal+Cancer&doi=10.18632%2Foncotarget.14002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14002%26sid%3Dliteratum%253Aachs%26aulast%3DVakana%26aufirst%3DE.%26aulast%3DPratt%26aufirst%3DS.%26aulast%3DBlosser%26aufirst%3DW.%26aulast%3DDowless%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DX.-J.%26aulast%3DJaken%26aufirst%3DS.%26aulast%3DManro%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DStancato%26aufirst%3DL.%2BF.%26atitle%3DLY3009120%252C%2520a%2520PanRAF%2520Inhibitor%252C%2520Has%2520Significant%2520Anti-Tumor%2520Activity%2520in%2520BRAF%2520and%2520KRAS%2520Mutant%2520Preclinical%2520Models%2520of%2520Colorectal%2520Cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D6%26spage%3D9251%26epage%3D9266%26doi%3D10.18632%2Foncotarget.14002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span>A Study
of LY3009120 in Participants With Advanced Cancer or Cancer That Has
Spread to Other Parts of Their Body. <a href="https://clinicaltrials.gov/ct2/show/NCT02014116" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02014116</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+LY3009120+in+Participants+With+Advanced+Cancer+or+Cancer+That+Has%0ASpread+to+Other+Parts+of+Their+Body.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02014116+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tottori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">6478</span>– <span class="NLM_lpage">6494</span>, <span class="refDoi"> DOI: 10.1021/jm400778d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400778d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6478-6494&issue=16&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Nakamuraauthor=T.+Takagiauthor=T.+Kawamotoauthor=N.+Uchiyamaauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=Y.+Inuiauthor=B.-C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Discovery+of+a+Selective+Kinase+Inhibitor+%28TAK-632%29+Targeting+Pan-RAF+Inhibition%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+C-7-Substituted+1%2C3-Benzothiazole+Derivatives&doi=10.1021%2Fjm400778d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400778d%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DB.-C.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Kinase%2520Inhibitor%2520%2528TAK-632%2529%2520Targeting%2520Pan-RAF%2520Inhibition%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520C-7-Substituted%25201%252C3-Benzothiazole%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D16%26spage%3D6478%26epage%3D6494%26doi%3D10.1021%2Fjm400778d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberta, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramkissoon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramkissoon, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goumnerova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agar, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, C. D.</span></span> <span> </span><span class="NLM_article-title">A Brain-Penetrant RAF Dimer Antagonist for the Noncanonical BRAF Oncoprotein of Pediatric Low-Grade Astrocytomas</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1093/neuonc/now261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1093%2Fneuonc%2Fnow261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28082416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A280%3ADC%252BC1c7lt1Cjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=774-785&issue=6&author=Y.+Sunauthor=J.+A.+Albertaauthor=C.+Pilarzauthor=D.+Calligarisauthor=E.+J.+Chadwickauthor=S.+H.+Ramkissoonauthor=L.+A.+Ramkissoonauthor=V.+M.+Garciaauthor=E.+Mazzolaauthor=L.+Goumnerovaauthor=M.+Kaneauthor=Z.+Yaoauthor=M.+W.+Kieranauthor=K.+L.+Ligonauthor=W.+C.+Hahnauthor=L.+A.+Garrawayauthor=N.+Rosenauthor=N.+S.+Grayauthor=N.+Y.+Agarauthor=S.+J.+Buhrlageauthor=R.+A.+Segalauthor=C.+D.+Stiles&title=A+Brain-Penetrant+RAF+Dimer+Antagonist+for+the+Noncanonical+BRAF+Oncoprotein+of+Pediatric+Low-Grade+Astrocytomas&doi=10.1093%2Fneuonc%2Fnow261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas</span></div><div class="casAuthors">Sun Yu; Alberta John A; Pilarz Catherine; Chadwick Emily J; Garcia Veronica Matia; Kane Michael; Segal Rosalind A; Stiles Charles D; Sun Yu; Alberta John A; Pilarz Catherine; Chadwick Emily J; Garcia Veronica Matia; Kane Michael; Gray Nathanael S; Buhrlage Sara J; Segal Rosalind A; Stiles Charles D; Calligaris David; Agar Nathalie Y; Ramkissoon Shakti H; Ramkissoon Lori A; Ligon Keith L; Ramkissoon Shakti H; Ligon Keith L; Mazzola Emanuele; Goumnerova Liliana; Yao Zhan; Rosen Neal; Kieran Mark W; Kieran Mark W; Segal Rosalind A; Hahn William C; Garraway Levi A; Hahn William C; Garraway Levi A; Gray Nathanael S; Buhrlage Sara J; Agar Nathalie Y; Agar Nathalie Y</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">774-785</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade astrocytomas (PLGAs).  However, first-generation RAF inhibitors approved for adult melanoma have poor blood-brain penetrance and are only effective on tumors that express the canonical BRAFV600E oncoprotein, which functions as a monomer.  These drugs (type I antagonists that target the "DFG-in" conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA.  Methods:  A panel of small molecule RAF inhibitors (including type II inhibitors, targeting the "DFG-out" conformation of the kinase) was screened for drugs showing efficacy on murine models of PLGA and on authentic human PLGA cells expressing KIAA1549:BRAF.  Results:  We identify a type II RAF inhibitor that serves as an equipotent antagonist of BRAFV600E, KIAA1549:BRAF, and other noncanonical BRAF oncoproteins that function as dimers.  This drug (MLN2480, also known as TAK-580) has good brain penetrance and is active on authentic human PLGA cells in brain organotypic cultures.  Conclusion:  MLN2480 may be an effective therapeutic for BRAF mutant pediatric astrocytomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSShg7-DV6mnENHe_gFldTbfW6udTcc2eZ2N2W9rmkxy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7lt1Cjtw%253D%253D&md5=557c01e0e2fa68750e24b8e863b67fc2</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnow261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnow261%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAlberta%26aufirst%3DJ.%2BA.%26aulast%3DPilarz%26aufirst%3DC.%26aulast%3DCalligaris%26aufirst%3DD.%26aulast%3DChadwick%26aufirst%3DE.%2BJ.%26aulast%3DRamkissoon%26aufirst%3DS.%2BH.%26aulast%3DRamkissoon%26aufirst%3DL.%2BA.%26aulast%3DGarcia%26aufirst%3DV.%2BM.%26aulast%3DMazzola%26aufirst%3DE.%26aulast%3DGoumnerova%26aufirst%3DL.%26aulast%3DKane%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DAgar%26aufirst%3DN.%2BY.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DSegal%26aufirst%3DR.%2BA.%26aulast%3DStiles%26aufirst%3DC.%2BD.%26atitle%3DA%2520Brain-Penetrant%2520RAF%2520Dimer%2520Antagonist%2520for%2520the%2520Noncanonical%2520BRAF%2520Oncoprotein%2520of%2520Pediatric%2520Low-Grade%2520Astrocytomas%26jtitle%3DNeuro-Oncol.%26date%3D2017%26volume%3D19%26issue%3D6%26spage%3D774%26epage%3D785%26doi%3D10.1093%2Fneuonc%2Fnow261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holovanchuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Efficacy of the Paradox-Breaking PanRAF and SRC Drug CCT3833/BAL3833 in KRAS-Driven Cancer Models</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">S199</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)61703-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2FS0959-8049%2816%2961703-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=S199&author=G.+Saturnoauthor=F.+Lopesauthor=M.+R.+Girottiauthor=I.+Niculescu-Duvazauthor=D.+Niculescu-Duvazauthor=A.+Zambonauthor=L.+Daviesauthor=L.+Johnsonauthor=N.+Preeceauthor=A.+Virosauthor=M.+Pedersenauthor=R.+McLearyauthor=R.+Knightauthor=R.+Leeauthor=D.+Holovanchukauthor=A.+Fusiauthor=P.+Loriganauthor=N.+Dhomenauthor=R.+Maraisauthor=C.+Springer&title=Therapeutic+Efficacy+of+the+Paradox-Breaking+PanRAF+and+SRC+Drug+CCT3833%2FBAL3833+in+KRAS-Driven+Cancer+Models&doi=10.1016%2FS0959-8049%2816%2961703-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2961703-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252961703-3%26sid%3Dliteratum%253Aachs%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DHolovanchuk%26aufirst%3DD.%26aulast%3DFusi%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DTherapeutic%2520Efficacy%2520of%2520the%2520Paradox-Breaking%2520PanRAF%2520and%2520SRC%2520Drug%2520CCT3833%252FBAL3833%2520in%2520KRAS-Driven%2520Cancer%2520Models%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D61%26spage%3DS199%26doi%3D10.1016%2FS0959-8049%2816%2961703-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span>A Phase
I, First in Man Study to Evaluate the Safety and Tolerability of a
panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours. <a href="https://clinicaltrials.gov/ct2/show/NCT02437227" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02437227</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Phase%0AI%2C+First+in+Man+Study+to+Evaluate+the+Safety+and+Tolerability+of+a%0ApanRAF+Inhibitor+%28CCT3833%2FBAL3833%29in+Patients+With+Solid+Tumours.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02437227+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span>Study
of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed
by a Dose Expansion in Patients With Metastatic Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01425008" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01425008</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+MLN2480+in+Patients+With+Relapsed+or+Refractory+Solid+Tumors+Followed%0Aby+a+Dose+Expansion+in+Patients+With+Metastatic+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01425008+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuwirth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargfrede, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangolli, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozon, V.</span></span> <span> </span><span class="NLM_article-title">MLN2480, an Investigational Oral Pan-RAF Kinase Inhibitor, in Patients (Pts) with Relapsed or Refractory Solid Tumors: Phase I Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">Suppl.</span>),  <span class="NLM_fpage">2547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2547&issue=Suppl.&author=D.+W.+Rascoauthor=A.+J.+Olszanskiauthor=A.+Patnaikauthor=G.+Espinoauthor=R.+Neuwirthauthor=S.+Faucetteauthor=M.+Bargfredeauthor=E.+A.+Gangolliauthor=R.+M.+Walkerauthor=M.+Kneisslauthor=V.+Bozon&title=MLN2480%2C+an+Investigational+Oral+Pan-RAF+Kinase+Inhibitor%2C+in+Patients+%28Pts%29+with+Relapsed+or+Refractory+Solid+Tumors%3A+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DEspino%26aufirst%3DG.%26aulast%3DNeuwirth%26aufirst%3DR.%26aulast%3DFaucette%26aufirst%3DS.%26aulast%3DBargfrede%26aufirst%3DM.%26aulast%3DGangolli%26aufirst%3DE.%2BA.%26aulast%3DWalker%26aufirst%3DR.%2BM.%26aulast%3DKneissl%26aufirst%3DM.%26aulast%3DBozon%26aufirst%3DV.%26atitle%3DMLN2480%252C%2520an%2520Investigational%2520Oral%2520Pan-RAF%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Relapsed%2520or%2520Refractory%2520Solid%2520Tumors%253A%2520Phase%2520I%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3DSuppl%26spage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span>A Phase
1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel,
or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic
Malignancies. <a href="https://clinicaltrials.gov/ct2/show/NCT02327169" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02327169</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Phase%0A1B+Study+of+MLN2480+in+Combination+With+MLN0128+or+Alisertib%2C+or+Paclitaxel%2C%0Aor+Cetuximab%2C+or+Irinotecan+in+Adult+Patients+With+Advanced+Nonhematologic%0AMalignancies.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02327169+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holovanchuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Abstract LB-212: Therapeutic Efficacy of the Paradox-Breaking PanRAF and SRC Drug CCT3833/BAL3833 in KRAS-Driven Cancer Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">14 Suppl.</span>),  <span class="NLM_fpage">LB-212</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-LB-212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1538-7445.AM2016-LB-212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=LB-212&issue=14+Suppl.&author=G.+Saturnoauthor=F.+Lopesauthor=M.+R.+Girottiauthor=I.+Niculescu-Duvazauthor=D.+Niculescu-Duvazauthor=A.+Zambonauthor=L.+Daviesauthor=L.+Johnsonauthor=N.+Preeceauthor=A.+Virosauthor=M.+Pedersenauthor=R.+McLearyauthor=R.+Knightauthor=R.+Leeauthor=D.+Holovanchukauthor=P.+Loriganauthor=N.+Dhomenauthor=R.+Maraisauthor=C.+Springer&title=Abstract+LB-212%3A+Therapeutic+Efficacy+of+the+Paradox-Breaking+PanRAF+and+SRC+Drug+CCT3833%2FBAL3833+in+KRAS-Driven+Cancer+Models&doi=10.1158%2F1538-7445.AM2016-LB-212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-LB-212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-LB-212%26sid%3Dliteratum%253Aachs%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DHolovanchuk%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DAbstract%2520LB-212%253A%2520Therapeutic%2520Efficacy%2520of%2520the%2520Paradox-Breaking%2520PanRAF%2520and%2520SRC%2520Drug%2520CCT3833%252FBAL3833%2520in%2520KRAS-Driven%2520Cancer%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%2520Suppl%26spage%3DLB-212%26doi%3D10.1158%2F1538-7445.AM2016-LB-212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gould, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afroze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouitar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffey, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iartchouk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paske, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renou, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tregay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K. M.</span></span> <span> </span><span class="NLM_article-title">Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1021/jm101479y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101479y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1836-1846&issue=6&author=A.+E.+Gouldauthor=R.+Adamsauthor=S.+Adhikariauthor=K.+Aertgeertsauthor=R.+Afrozeauthor=C.+Blackburnauthor=E.+F.+Calderwoodauthor=R.+Chauauthor=J.+Chouitarauthor=M.+O.+Duffeyauthor=D.+B.+Englandauthor=C.+Farrerauthor=N.+Forsythauthor=K.+Garciaauthor=J.+Gaulinauthor=P.+D.+Greenspanauthor=R.+Guoauthor=S.+J.+Harrisonauthor=S.-C.+Huangauthor=N.+Iartchoukauthor=D.+Janowickauthor=M.-S.+Kimauthor=B.+Kulkarniauthor=S.+P.+Langstonauthor=J.+X.+Liuauthor=L.-T.+Maauthor=S.+Menonauthor=H.+Mizutaniauthor=E.+Paskeauthor=C.+C.+Renouauthor=M.+Rezaeiauthor=R.+S.+Rowlandauthor=M.+D.+Sintchakauthor=M.+D.+Smithauthor=S.+G.+Stroudauthor=M.+Tregayauthor=Y.+Tianauthor=O.+P.+Veibyauthor=T.+J.+Vosauthor=S.+Vyskocilauthor=J.+Williamsauthor=T.+Xuauthor=J.+J.+Yangauthor=J.+Yanoauthor=H.+Zengauthor=D.+M.+Zhangauthor=Q.+Zhangauthor=K.+M.+Galvin&title=Design+and+Optimization+of+Potent+and+Orally+Bioavailable+Tetrahydronaphthalene+Raf+Inhibitors&doi=10.1021%2Fjm101479y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm101479y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101479y%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%2BE.%26aulast%3DAdams%26aufirst%3DR.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DAfroze%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DCalderwood%26aufirst%3DE.%2BF.%26aulast%3DChau%26aufirst%3DR.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DDuffey%26aufirst%3DM.%2BO.%26aulast%3DEngland%26aufirst%3DD.%2BB.%26aulast%3DFarrer%26aufirst%3DC.%26aulast%3DForsyth%26aufirst%3DN.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DGaulin%26aufirst%3DJ.%26aulast%3DGreenspan%26aufirst%3DP.%2BD.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DHarrison%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DS.-C.%26aulast%3DIartchouk%26aufirst%3DN.%26aulast%3DJanowick%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DKulkarni%26aufirst%3DB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DMa%26aufirst%3DL.-T.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DPaske%26aufirst%3DE.%26aulast%3DRenou%26aufirst%3DC.%2BC.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DR.%2BS.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DStroud%26aufirst%3DS.%2BG.%26aulast%3DTregay%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DVeiby%26aufirst%3DO.%2BP.%26aulast%3DVos%26aufirst%3DT.%2BJ.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGalvin%26aufirst%3DK.%2BM.%26atitle%3DDesign%2520and%2520Optimization%2520of%2520Potent%2520and%2520Orally%2520Bioavailable%2520Tetrahydronaphthalene%2520Raf%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D6%26spage%3D1836%26epage%3D1846%26doi%3D10.1021%2Fjm101479y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span> <span> </span><span class="NLM_article-title">BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2187</span>– <span class="NLM_lpage">2197</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-15-0262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=26208524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2187-2197&issue=10&author=Z.+Tangauthor=X.+Yuanauthor=R.+Duauthor=S.-H.+Cheungauthor=G.+Zhangauthor=J.+Weiauthor=Y.+Zhaoauthor=Y.+Fengauthor=H.+Pengauthor=Y.+Zhangauthor=Y.+Duauthor=X.+Huauthor=W.+Gongauthor=Y.+Liuauthor=Y.+Gaoauthor=Y.+Liuauthor=R.+Haoauthor=S.+Liauthor=S.+Wangauthor=J.+Jiauthor=L.+Zhangauthor=S.+Liauthor=D.+Suttonauthor=M.+Weiauthor=C.+Zhouauthor=L.+Wangauthor=L.+Luo&title=BGB-283%2C+a+Novel+RAF+Kinase+and+EGFR+Inhibitor%2C+Displays+Potent+Antitumor+Activity+in+BRAF-Mutated+Colorectal+Cancers&doi=10.1158%2F1535-7163.MCT-15-0262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers</span></div><div class="casAuthors">Tang, Zhiyu; Yuan, Xi; Du, Rong; Cheung, Shing-Hu; Zhang, Guoliang; Wei, Jing; Zhao, Yuan; Feng, Yingcai; Peng, Hao; Zhang, Yi; Du, Yunguang; Hu, Xiaoxia; Gong, Wenfeng; Liu, Yong; Gao, Yajuan; Liu, Ye; Hao, Rui; Li, Shengjian; Wang, Shaohui; Ji, Jiafu; Zhang, Lianhai; Li, Shuangxi; Sutton, David; Wei, Min; Zhou, Changyou; Wang, Lai; Luo, Lusong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2187-2197</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approx. 50% of human malignant melanomas and 5% to 15% of colorectal cancers.  Despite the remarkable clin. activities achieved by vemurafenib and dabrafenib in treating BRAFV600E metastatic melanoma, their clin. efficacy in BRAFV600E colorectal cancer is far less impressive.  Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors.  Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clin. investigation.  In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation.  It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAFV600E and EGFR mutation/amplification.  In BRAFV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation.  In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAFV600E mutation.  These findings support BGB-283 as a potent antitumor drug candidate with clin. potential for treating colorectal cancer harboring BRAFV600E mutation.  Mol Cancer Ther; 14(10); 2187-97. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreLelFO0aG27Vg90H21EOLACvtfcHk0lhYcOgrZZ88ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsL7L&md5=45f62fb276bd364ece47dd04ecd7bfb3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0262%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DCheung%26aufirst%3DS.-H.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DL.%26atitle%3DBGB-283%252C%2520a%2520Novel%2520RAF%2520Kinase%2520and%2520EGFR%2520Inhibitor%252C%2520Displays%2520Potent%2520Antitumor%2520Activity%2520in%2520BRAF-Mutated%2520Colorectal%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D10%26spage%3D2187%26epage%3D2197%26doi%3D10.1158%2F1535-7163.MCT-15-0262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span>Study
of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid
Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02610361" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02610361</a> (accessed Aug
31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+the+Safety+and+Pharmacokinetics+of+BGB-283+in+Patients+With+Solid%0ATumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02610361+%28accessed+Aug%0A31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">7049</span>– <span class="NLM_lpage">7052</span>, <span class="refDoi"> DOI: 10.1021/jm801050k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801050k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7049-7052&issue=22&author=S.+Ramurthyauthor=S.+Subramanianauthor=M.+Aikawaauthor=P.+Amiriauthor=A.+Costalesauthor=J.+Doveauthor=S.+Fongauthor=J.+M.+Jansenauthor=B.+Levineauthor=S.+Maauthor=C.+M.+McBrideauthor=J.+Michaelianauthor=T.+Pickauthor=D.+J.+Poonauthor=S.+Girishauthor=C.+M.+Shaferauthor=D.+Stuartauthor=L.+Sungauthor=P.+A.+Renhowe&title=Design+and+Synthesis+of+Orally+Bioavailable+Benzimidazoles+as+Raf+Kinase+Inhibitors&doi=10.1021%2Fjm801050k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm801050k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801050k%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DDove%26aufirst%3DJ.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DLevine%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DMichaelian%26aufirst%3DJ.%26aulast%3DPick%26aufirst%3DT.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Orally%2520Bioavailable%2520Benzimidazoles%2520as%2520Raf%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D22%26spage%3D7049%26epage%3D7052%26doi%3D10.1021%2Fjm801050k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span> <span> </span><span class="NLM_article-title">Design and Discovery of of N-(2-Methyl-5′-Morpholino-6′-((Tetrahydro-2H-Pyran-4-Yl)Oxy)-[3,3′-Bipyridin]-5-Yl)-3-(Trifluoromethyl)Benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4881</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4869-4881&issue=12&author=G.+A.+Nishiguchiauthor=A.+Ricoauthor=H.+Tannerauthor=R.+J.+Aversaauthor=B.+R.+Taftauthor=S.+Subramanianauthor=L.+Settiauthor=M.+T.+Burgerauthor=L.+Wanauthor=V.+Tamezauthor=A.+Smithauthor=Y.+Louauthor=P.+A.+Barsantiauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=I.+Dixauthor=J.+E.+Tellewauthor=S.+Huangauthor=L.+A.+Mathews+Grinerauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=S.+Maauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=J.+M.+Jansenauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=E.+Leesauthor=W.+Shaoauthor=D.+D.+Stuartauthor=M.+P.+Dillonauthor=S.+Ramurthy&title=Design+and+Discovery+of+of+N-%282-Methyl-5%E2%80%B2-Morpholino-6%E2%80%B2-%28%28Tetrahydro-2H-Pyran-4-Yl%29Oxy%29-%5B3%2C3%E2%80%B2-Bipyridin%5D-5-Yl%29-3-%28Trifluoromethyl%29Benzamide+%28RAF709%29%3A+A+Potent%2C+Selective%2C+and+Efficacious+RAF+Inhibitor+Targeting+RAS+Mutant+Cancers&doi=10.1021%2Facs.jmedchem.6b01862"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01862%26sid%3Dliteratum%253Aachs%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DRamurthy%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Discovery%2520of%2520of%2520N-%25282-Methyl-5%25E2%2580%25B2-Morpholino-6%25E2%2580%25B2-%2528%2528Tetrahydro-2H-Pyran-4-Yl%2529Oxy%2529-%255B3%252C3%25E2%2580%25B2-Bipyridin%255D-5-Yl%2529-3-%2528Trifluoromethyl%2529Benzamide%2520%2528RAF709%2529%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520RAF%2520Inhibitor%2520Targeting%2520RAS%2520Mutant%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D4869%26epage%3D4881%26doi%3D10.1021%2Facs.jmedchem.6b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonios-McCrea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machajewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aardalen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of RAF265: A Potent Mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1021/ml500526p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500526p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=961-965&issue=9&author=T.+E.+Williamsauthor=S.+Subramanianauthor=J.+Verhagenauthor=C.+M.+McBrideauthor=A.+Costalesauthor=L.+Sungauthor=W.+Antonios-McCreaauthor=M.+McKennaauthor=A.+K.+Louieauthor=S.+Ramurthyauthor=B.+Levineauthor=C.+M.+Shaferauthor=T.+Machajewskiauthor=P.+A.+Renhoweauthor=B.+A.+Appletonauthor=P.+Amiriauthor=J.+Chouauthor=D.+Stuartauthor=K.+Aardalenauthor=D.+Poon&title=Discovery+of+RAF265%3A+A+Potent+Mut-B-RAF+Inhibitor+for+the+Treatment+of+Metastatic+Melanoma&doi=10.1021%2Fml500526p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fml500526p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500526p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DT.%2BE.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DCostales%26aufirst%3DA.%26aulast%3DSung%26aufirst%3DL.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcKenna%26aufirst%3DM.%26aulast%3DLouie%26aufirst%3DA.%2BK.%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DB.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DChou%26aufirst%3DJ.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DPoon%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520RAF265%253A%2520A%2520Potent%2520Mut-B-RAF%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Melanoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D961%26epage%3D965%26doi%3D10.1021%2Fml500526p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span>A Study
to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally
Advanced or Metastatic Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT00304525?term=raf265&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT00304525?term=raf265&rank=1</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Ato+Evaluate+RAF265%2C+an+Oral+Drug+Administered+to+Subjects+With+Locally%0AAdvanced+or+Metastatic+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00304525%3Fterm%3Draf265%26rank%3D1+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markegard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rymar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Efficacy of a RAF Inhibitor That Evades Paradoxical MAPK Pathway Activation in Protein Kinase BRAF-Mutant Lung Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">13456</span>– <span class="NLM_lpage">13461</span>, <span class="refDoi"> DOI: 10.1073/pnas.1610456113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.1610456113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=13456-13461&issue=47&author=R.+A.+Okimotoauthor=L.+Linauthor=V.+Olivasauthor=E.+Chanauthor=E.+Markegardauthor=A.+Rymarauthor=D.+Neelauthor=X.+Chenauthor=G.+Hemmatiauthor=G.+Bollagauthor=T.+G.+Bivona&title=Preclinical+Efficacy+of+a+RAF+Inhibitor+That+Evades+Paradoxical+MAPK+Pathway+Activation+in+Protein+Kinase+BRAF-Mutant+Lung+Cancer&doi=10.1073%2Fpnas.1610456113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1610456113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1610456113%26sid%3Dliteratum%253Aachs%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMarkegard%26aufirst%3DE.%26aulast%3DRymar%26aufirst%3DA.%26aulast%3DNeel%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHemmati%26aufirst%3DG.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DPreclinical%2520Efficacy%2520of%2520a%2520RAF%2520Inhibitor%2520That%2520Evades%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%2520in%2520Protein%2520Kinase%2520BRAF-Mutant%2520Lung%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D47%26spage%3D13456%26epage%3D13461%26doi%3D10.1073%2Fpnas.1610456113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaunwhite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, A. C.</span></span> <span> </span><span class="NLM_article-title">Paradoxical Activation and RAF Inhibitor Resistance of BRAF Protein Kinase Fusions Characterizing Pediatric Astrocytomas</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5957</span>– <span class="NLM_lpage">5962</span>, <span class="refDoi"> DOI: 10.1073/pnas.1219232110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.1219232110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=5957-5962&issue=15&author=A.+J.+Sievertauthor=S.-S.+Langauthor=K.+L.+Boucherauthor=P.+J.+Madsenauthor=E.+Slaunwhiteauthor=N.+Choudhariauthor=M.+Kelletauthor=P.+B.+Stormauthor=A.+C.+Resnick&title=Paradoxical+Activation+and+RAF+Inhibitor+Resistance+of+BRAF+Protein+Kinase+Fusions+Characterizing+Pediatric+Astrocytomas&doi=10.1073%2Fpnas.1219232110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1219232110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1219232110%26sid%3Dliteratum%253Aachs%26aulast%3DSievert%26aufirst%3DA.%2BJ.%26aulast%3DLang%26aufirst%3DS.-S.%26aulast%3DBoucher%26aufirst%3DK.%2BL.%26aulast%3DMadsen%26aufirst%3DP.%2BJ.%26aulast%3DSlaunwhite%26aufirst%3DE.%26aulast%3DChoudhari%26aufirst%3DN.%26aulast%3DKellet%26aufirst%3DM.%26aulast%3DStorm%26aufirst%3DP.%2BB.%26aulast%3DResnick%26aufirst%3DA.%2BC.%26atitle%3DParadoxical%2520Activation%2520and%2520RAF%2520Inhibitor%2520Resistance%2520of%2520BRAF%2520Protein%2520Kinase%2520Fusions%2520Characterizing%2520Pediatric%2520Astrocytomas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D15%26spage%3D5957%26epage%3D5962%26doi%3D10.1073%2Fpnas.1219232110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basile, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartsough, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplin, A. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutant BRAF Splice Variant Signaling by Next-Generation, Selective RAF Inhibitors</span>. <i>Pigm. Cell Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/pcmr.12218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1111%2Fpcmr.12218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24422853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=479-484&issue=3&author=K.+J.+Basileauthor=K.+Leauthor=E.+J.+Hartsoughauthor=A.+E.+Aplin&title=Inhibition+of+Mutant+BRAF+Splice+Variant+Signaling+by+Next-Generation%2C+Selective+RAF+Inhibitors&doi=10.1111%2Fpcmr.12218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors</span></div><div class="casAuthors">Basile, Kevin J.; Le, Kaitlyn; Hartsough, Edward J.; Aplin, Andrew E.</div><div class="citationInfo"><span class="NLM_cas:title">Pigment Cell & Melanoma Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">PCMRCM</span>;
        ISSN:<span class="NLM_cas:issn">1755-1471</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Vemurafenib and dabrafenib block MEK-ERK1/2 signaling and cause tumor regression in the majority of advanced-stage BRAFV600E melanoma patients; however, acquired resistance and paradoxical signaling have driven efforts for more potent and selective RAF inhibitors.  Next-generation RAF inhibitors, such as PLX7904 (PB04), effectively inhibit RAF signaling in BRAFV600E melanoma cells without paradoxical effects in wild-type cells.  Furthermore, PLX7904 blocks the growth of vemurafenib-resistant BRAFV600E cells that express mutant NRAS.  Acquired resistance to vemurafenib and dabrafenib is also frequently driven by expression of mutation BRAF splice variants; thus, we tested the effects of PLX7904 and its clin. analog, PLX8394 (PB03), in BRAFV600E splice variant-mediated vemurafenib-resistant cells.  We show that paradox-breaker RAF inhibitors potently block MEK-ERK1/2 signaling, G1/S cell cycle events, survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAFV600E splice variants.  These data support the further investigation of paradox-breaker RAF inhibitors as a second-line treatment option for patients failing on vemurafenib or dabrafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovvoDjV1fbw7Vg90H21EOLACvtfcHk0ljOYre9W2R7Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D&md5=e9d363cc4fff1821674569c31b8980ee</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1111%2Fpcmr.12218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcmr.12218%26sid%3Dliteratum%253Aachs%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DHartsough%26aufirst%3DE.%2BJ.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DInhibition%2520of%2520Mutant%2520BRAF%2520Splice%2520Variant%2520Signaling%2520by%2520Next-Generation%252C%2520Selective%2520RAF%2520Inhibitors%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2014%26volume%3D27%26issue%3D3%26spage%3D479%26epage%3D484%26doi%3D10.1111%2Fpcmr.12218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span>A Study
of PLX8394 as a Single Agent in Patients With Advanced Unresectable
Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02428712" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02428712</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+PLX8394+as+a+Single+Agent+in+Patients+With+Advanced+Unresectable%0ASolid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02428712+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holladay, M. W.</span></span> <span> </span><span class="NLM_article-title">CEP-32496: A Novel Orally Active BRAF(V600E) Inhibitor with Selective Cellular and in Vivo Antitumor Activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-11-0645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22319199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=930-941&issue=4&author=J.+Jamesauthor=B.+Ruggeriauthor=R.+C.+Armstrongauthor=M.+W.+Rowbottomauthor=S.+Jones-Bolinauthor=R.+N.+Gunawardaneauthor=P.+Dobrzanskiauthor=M.+F.+Gardnerauthor=H.+Zhaoauthor=M.+D.+Cramerauthor=K.+Hunterauthor=R.+R.+Nepomucenoauthor=M.+Chengauthor=D.+Gitnickauthor=M.+Yazdanianauthor=D.+E.+Inskoauthor=M.+A.+Atorauthor=J.+L.+Apuyauthor=R.+Faraoniauthor=B.+D.+Dorseyauthor=M.+Williamsauthor=S.+S.+Bhagwatauthor=M.+W.+Holladay&title=CEP-32496%3A+A+Novel+Orally+Active+BRAF%28V600E%29+Inhibitor+with+Selective+Cellular+and+in+Vivo+Antitumor+Activity&doi=10.1158%2F1535-7163.MCT-11-0645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity</span></div><div class="casAuthors">James, Joyce; Ruggeri, Bruce; Armstrong, Robert C.; Rowbottom, Martin W.; Jones-Bolin, Susan; Gunawardane, Ruwanthi N.; Dobrzanski, Pawel; Gardner, Michael F.; Zhao, Hugh; Cramer, Merryl D.; Hunter, Kathryn; Nepomuceno, Ronald R.; Cheng, Mangeng; Gitnick, Dana; Yazdanian, Mehran; Insko, Darren E.; Ator, Mark A.; Apuy, Julius L.; Faraoni, Raffaella; Dorsey, Bruce D.; Williams, Michael; Bhagwat, Shripad S.; Holladay, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">930-941</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations in the BRAF gene have been identified in approx. 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of papillary thyroid carcinomas, 4% to 16% colorectal cancers, and a lesser extent in serous ovarian and non-small cell lung cancers.  The V600E mutation is found in the vast majority of cases and is an activating mutation, conferring transforming and immortalization potential to cells.  CEP-32496 is a potent BRAF inhibitor in an in vitro binding assay for mutated BRAFV600E (Kd BRAFV600E = 14 nmol/L) and in a mitogen-activated protein (MAP)/extracellular signal-regulated (ER) kinase (MEK) phosphorylation (pMEK) inhibition assay in human melanoma (A375) and colorectal cancer (Colo-205) cell lines (IC50 = 78 and 60 nmol/L).  In vitro, CEP-32496 has multikinase binding activity at other cancer targets of interest; however, it exhibits selective cellular cytotoxicity for BRAFV600E vs. wild-type cells.  CEP-32496 is orally bioavailable in multiple preclin. species (>95% in rats, dogs, and monkeys) and has single oral dose pharmacodynamic inhibition (10-55 mg/kg) of both pMEK and pERK in BRAFV600E colon carcinoma xenografts in nude mice.  Sustained tumor stasis and regressions are obsd. with oral administration (30-100 mg/kg twice daily) against BRAFV600E melanoma and colon carcinoma xenografts, with no adverse effects.  Little or no epithelial hyperplasia was obsd. in rodents and primates with prolonged oral administration and sustained exposure.  CEP-32496 benchmarks favorably with respect to other kinase inhibitors, including RAF-265 (phase I), sorafenib, (approved), and vemurafenib (PLX4032/RG7204, approved).  CEP-32496 represents a novel and pharmacol. active BRAF inhibitor with a favorable side effect profile currently in clin. development.  Mol Cancer Ther; 11(4); 930-41.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozSMo-ZE8g-7Vg90H21EOLACvtfcHk0ljWPIN2CUQT1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nur4%253D&md5=4a27d41e3b140027cd9b17ede9087cb6</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0645%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DApuy%26aufirst%3DJ.%2BL.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DCEP-32496%253A%2520A%2520Novel%2520Orally%2520Active%2520BRAF%2528V600E%2529%2520Inhibitor%2520with%2520Selective%2520Cellular%2520and%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D930%26epage%3D941%26doi%3D10.1158%2F1535-7163.MCT-11-0645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holladay, M. W.</span></span> <span> </span><span class="NLM_article-title">Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-Yloxy)Phenyl)-3-(5-(1,1,1-Trifluoro-2-Methylpropan-2-Yl)Isoxazol-3-Yl)Urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1105</span>, <span class="refDoi"> DOI: 10.1021/jm2009925</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1082-1105&issue=3&author=M.+W.+Rowbottomauthor=R.+Faraoniauthor=Q.+Chaoauthor=B.+T.+Campbellauthor=A.+G.+Laiauthor=E.+Settiauthor=M.+Ezawaauthor=K.+G.+Sprankleauthor=S.+Abrahamauthor=L.+Tranauthor=B.+Strussauthor=M.+Gibneyauthor=R.+C.+Armstrongauthor=R.+N.+Gunawardaneauthor=R.+R.+Nepomucenoauthor=I.+Valentaauthor=H.+Huaauthor=M.+F.+Gardnerauthor=M.+D.+Cramerauthor=D.+Gitnickauthor=D.+E.+Inskoauthor=J.+L.+Apuyauthor=S.+Jones-Bolinauthor=A.+K.+Ghoseauthor=T.+Herbertzauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=B.+Ruggeriauthor=M.+Williamsauthor=S.+Bhagwatauthor=J.+Jamesauthor=M.+W.+Holladay&title=Identification+of+1-%283-%286%2C7-Dimethoxyquinazolin-4-Yloxy%29Phenyl%29-3-%285-%281%2C1%2C1-Trifluoro-2-Methylpropan-2-Yl%29Isoxazol-3-Yl%29Urea+Hydrochloride+%28CEP-32496%29%2C+a+Highly+Potent+and+Orally+Efficacious+Inhibitor+of+V-RAF+Murine+Sarcoma+Viral+Oncogene+Homologue+B1+%28BRAF%29+V600E&doi=10.1021%2Fjm2009925"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fjm2009925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009925%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DEzawa%26aufirst%3DM.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DStruss%26aufirst%3DB.%26aulast%3DGibney%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DApuy%26aufirst%3DJ.%2BL.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DIdentification%2520of%25201-%25283-%25286%252C7-Dimethoxyquinazolin-4-Yloxy%2529Phenyl%2529-3-%25285-%25281%252C1%252C1-Trifluoro-2-Methylpropan-2-Yl%2529Isoxazol-3-Yl%2529Urea%2520Hydrochloride%2520%2528CEP-32496%2529%252C%2520a%2520Highly%2520Potent%2520and%2520Orally%2520Efficacious%2520Inhibitor%2520of%2520V-RAF%2520Murine%2520Sarcoma%2520Viral%2520Oncogene%2520Homologue%2520B1%2520%2528BRAF%2529%2520V600E%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D3%26spage%3D1082%26epage%3D1105%26doi%3D10.1021%2Fjm2009925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span>Study
of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer
and Other Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT01877811" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01877811</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+RXDX-105%2C+Potent+RET+Inhibitor+in+Patients+With+Advanced+Lung+Cancer%0Aand+Other+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01877811+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Abstract 2607: Antitumor Activity of the Selective RAF Inhibitor HM95573 in Solid Tumors and Hematologic Malignancies</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">15 Suppl.</span>),  <span class="NLM_fpage">2607</span>– <span class="NLM_lpage">2607</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-2607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1538-7445.AM2015-2607" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2607-2607&issue=15+Suppl.&author=Y.-M.+Leeauthor=I.+Baeauthor=N.+G.+Moauthor=J.+H.+Leeauthor=S.+Kimauthor=J.+Y.+Songauthor=K.+H.+Leeauthor=T.+H.+Songauthor=Y.+G.+Ahnauthor=Y.+H.+Kimauthor=K.+H.+Suh&title=Abstract+2607%3A+Antitumor+Activity+of+the+Selective+RAF+Inhibitor+HM95573+in+Solid+Tumors+and+Hematologic+Malignancies&doi=10.1158%2F1538-7445.AM2015-2607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-2607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-2607%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DBae%26aufirst%3DI.%26aulast%3DMo%26aufirst%3DN.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DSong%26aufirst%3DT.%2BH.%26aulast%3DAhn%26aufirst%3DY.%2BG.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26atitle%3DAbstract%25202607%253A%2520Antitumor%2520Activity%2520of%2520the%2520Selective%2520RAF%2520Inhibitor%2520HM95573%2520in%2520Solid%2520Tumors%2520and%2520Hematologic%2520Malignancies%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D15%2520Suppl%26spage%3D2607%26epage%3D2607%26doi%3D10.1158%2F1538-7445.AM2015-2607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span>Expansion
Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS
or NRAS Mutant Solid Cancers. <a href="https://clinicaltrials.gov/ct2/show/NCT03118817" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03118817</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Expansion%0AStudy+to+Evaluate+the+Efficacy+and+Safety+of+HM95573+in+BRAF%2C+KRAS%0Aor+NRAS+Mutant+Solid+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03118817+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span>Clinical
Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor
Activity of HM95573. <a href="https://clinicaltrials.gov/ct2/show/NCT02405065" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02405065</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0ATrial+to+Evaluate+Safety%2C+Tolerability+and+Pharmacokinetics+and+Anti-tumor%0AActivity+of+HM95573.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02405065+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span>Phase
I Study of LXH254 in Patients With Advanced Solid Tumors Haboring
MAPK Pathway Alterations. <a href="https://clinicaltrials.gov/ct2/show/NCT02607813" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02607813</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase%0AI+Study+of+LXH254+in+Patients+With+Advanced+Solid+Tumors+Haboring%0AMAPK+Pathway+Alterations.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02607813+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babij, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Purinylpyridinylamino-Based DFG-in/AC-Helix-out B-Raf Inhibitors: Applying Mutant versus Wild-Type B-Raf Selectivity Indices for Compound Profiling</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2215</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bmc.2016.03.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2215-2234&issue=10&author=L.+Liuauthor=M.+R.+Leeauthor=J.+L.+Kimauthor=D.+A.+Whittingtonauthor=H.+Bregmanauthor=Z.+Huaauthor=R.+T.+Lewisauthor=M.+W.+Martinauthor=N.+Nishimuraauthor=M.+Potashmanauthor=K.+Yangauthor=S.+Yiauthor=K.+R.+Vaidaauthor=L.+F.+Epsteinauthor=C.+Babijauthor=M.+Fernandoauthor=J.+Carnahanauthor=M.+H.+Norman&title=Purinylpyridinylamino-Based+DFG-in%2FAC-Helix-out+B-Raf+Inhibitors%3A+Applying+Mutant+versus+Wild-Type+B-Raf+Selectivity+Indices+for+Compound+Profiling&doi=10.1016%2Fj.bmc.2016.03.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.055%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DBregman%26aufirst%3DH.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DPurinylpyridinylamino-Based%2520DFG-in%252FAC-Helix-out%2520B-Raf%2520Inhibitors%253A%2520Applying%2520Mutant%2520versus%2520Wild-Type%2520B-Raf%2520Selectivity%2520Indices%2520for%2520Compound%2520Profiling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D10%26spage%3D2215%26epage%3D2234%26doi%3D10.1016%2Fj.bmc.2016.03.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traquandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modugno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated HERG Inhibition, and Low Paradoxical Effect</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1002%2Fcmdc.201402424" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=276-295&issue=2&author=M.+Puliciauthor=G.+Traquandiauthor=C.+Marchionniauthor=M.+Modugnoauthor=R.+Lupiauthor=N.+Amboldiauthor=E.+Casaleauthor=N.+Colomboauthor=L.+Cortiauthor=M.+Fasoliniauthor=F.+Gasparriauthor=W.+Pastoriauthor=A.+Scolaroauthor=D.+Donatiauthor=E.+Felderauthor=A.+Galvaniauthor=A.+Isacchiauthor=E.+Pesentiauthor=M.+Ciomei&title=Optimization+of+Diarylthiazole+B-Raf+Inhibitors%3A+Identification+of+a+Compound+Endowed+with+High+Oral+Antitumor+Activity%2C+Mitigated+HERG+Inhibition%2C+and+Low+Paradoxical+Effect&doi=10.1002%2Fcmdc.201402424"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402424%26sid%3Dliteratum%253Aachs%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DColombo%26aufirst%3DN.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520Diarylthiazole%2520B-Raf%2520Inhibitors%253A%2520Identification%2520of%2520a%2520Compound%2520Endowed%2520with%2520High%2520Oral%2520Antitumor%2520Activity%252C%2520Mitigated%2520HERG%2520Inhibition%252C%2520and%2520Low%2520Paradoxical%2520Effect%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3D276%26epage%3D295%26doi%3D10.1002%2Fcmdc.201402424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciszewski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frommer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowicz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span> <span> </span><span class="NLM_article-title">Non-Hinge-Binding Pyrazolo[1,5-a]Pyrimidines as Potent B-Raf Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6519</span>– <span class="NLM_lpage">6523</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1016%2Fj.bmcl.2009.10.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6519-6523&issue=23&author=D.+M.+Bergerauthor=N.+Torresauthor=M.+Dutiaauthor=D.+Powellauthor=G.+Ciszewskiauthor=A.+Gopalsamyauthor=J.+I.+Levinauthor=K.-H.+Kimauthor=W.+Xuauthor=J.+Wilhelmauthor=Y.+Huauthor=K.+Collinsauthor=L.+Feldbergauthor=S.+Kimauthor=E.+Frommerauthor=D.+Wojciechowiczauthor=R.+Mallon&title=Non-Hinge-Binding+Pyrazolo%5B1%2C5-a%5DPyrimidines+as+Potent+B-Raf+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2009.10.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DTorres%26aufirst%3DN.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DCiszewski%26aufirst%3DG.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWilhelm%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DFrommer%26aufirst%3DE.%26aulast%3DWojciechowicz%26aufirst%3DD.%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DNon-Hinge-Binding%2520Pyrazolo%255B1%252C5-a%255DPyrimidines%2520as%2520Potent%2520B-Raf%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D23%26spage%3D6519%26epage%3D6523%26doi%3D10.1016%2Fj.bmcl.2009.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B. a. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraresi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probachai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib plus Trametinib versus Dabrafenib Monotherapy in Patients with Metastatic BRAF V600E/K-Mutant Melanoma: Long-Term Survival and Safety Analysis of a Phase 3 Study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1631</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1093%2Fannonc%2Fmdx176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=28475671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A280%3ADC%252BC1crksVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1631-1639&issue=7&author=G.+V.+Longauthor=K.+T.+Flahertyauthor=D.+Stroyakovskiyauthor=H.+Gogasauthor=E.+Levchenkoauthor=F.+de+Braudauthor=J.+Larkinauthor=C.+Garbeauthor=T.+Jouaryauthor=A.+Hauschildauthor=V.+Chiarion-Sileniauthor=C.+Lebbeauthor=M.+Mandal%C3%A0author=M.+Millwardauthor=A.+Aranceauthor=I.+Bondarenkoauthor=J.+B.+a.+G.+Haanenauthor=J.+Hanssonauthor=J.+Utikalauthor=V.+Ferraresiauthor=P.+Mohrauthor=V.+Probachaiauthor=D.+Schadendorfauthor=P.+Nathanauthor=C.+Robertauthor=A.+Ribasauthor=M.+A.+Daviesauthor=S.+R.+Laneauthor=J.+J.+Legosauthor=B.+Mookerjeeauthor=J.-J.+Grob&title=Dabrafenib+plus+Trametinib+versus+Dabrafenib+Monotherapy+in+Patients+with+Metastatic+BRAF+V600E%2FK-Mutant+Melanoma%3A+Long-Term+Survival+and+Safety+Analysis+of+a+Phase+3+Study&doi=10.1093%2Fannonc%2Fmdx176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study</span></div><div class="casAuthors">Long G V; Flaherty K T; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandala M; Millward M; Arance A; Bondarenko I; Haanen J B A G; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Schadendorf D; Nathan P; Robert C; Ribas A; Davies M A; Lane S R; Legos J J; Mookerjee B; Grob J-J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1631-1639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma.  This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients.  Patients and methods:  This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma.  Patients were randomized to receive dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or dabrafenib plus placebo.  The primary endpoint was PFS; secondary endpoints were OS, overall response, duration of response, safety, and pharmacokinetics.  Results:  Between 4 May and 30 November 2012, a total of 423 of 947 screened patients were randomly assigned to receive dabrafenib plus trametinib (n = 211) or dabrafenib monotherapy (n = 212).  At data cut-off (15 February 2016), outcomes remained superior with the combination: 3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively.  Twenty-five patients receiving monotherapy crossed over to combination therapy, with continued follow-up under the monotherapy arm (per intent-to-treat principle).  Of combination-arm patients alive at 3 years, 58% remained on dabrafenib plus trametinib.  Three-year OS with the combination reached 62% in the most favourable subgroup (normal lactate dehydrogenase and <3 organ sites with metastasis) versus only 25% in the unfavourable subgroup (elevated lactate dehydrogenase).  The dabrafenib plus trametinib safety profile was consistent with previous clinical trial observations, and no new safety signals were detected with long-term use.  Conclusions:  These data demonstrate that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoYeNFf5RK-c25P7XSLhESfW6udTcc2eYxIfucpXcv17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crksVartw%253D%253D&md5=9bdf87626d5e107825a3caf99cc19bca</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx176%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DMandal%25C3%25A0%26aufirst%3DM.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%2Ba.%2BG.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DFerraresi%26aufirst%3DV.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DProbachai%26aufirst%3DV.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DLane%26aufirst%3DS.%2BR.%26aulast%3DLegos%26aufirst%3DJ.%2BJ.%26aulast%3DMookerjee%26aufirst%3DB.%26aulast%3DGrob%26aufirst%3DJ.-J.%26atitle%3DDabrafenib%2520plus%2520Trametinib%2520versus%2520Dabrafenib%2520Monotherapy%2520in%2520Patients%2520with%2520Metastatic%2520BRAF%2520V600E%252FK-Mutant%2520Melanoma%253A%2520Long-Term%2520Survival%2520and%2520Safety%2520Analysis%2520of%2520a%2520Phase%25203%2520Study%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26issue%3D7%26spage%3D1631%26epage%3D1639%26doi%3D10.1093%2Fannonc%2Fmdx176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dréno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hack, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&issue=20&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Dr%C3%A9noauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandal%C3%A0author=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+Vemurafenib+and+Cobimetinib+in+BRAF-Mutated+Melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0lju3hlwTkARqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDr%25C3%25A9no%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandal%25C3%25A0%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520Vemurafenib%2520and%2520Cobimetinib%2520in%2520BRAF-Mutated%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D20%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span>Study
Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and
LGX818 Monotherapy in BRAF Mutant Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01909453" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01909453</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0AComparing+Combination+of+LGX818+Plus+MEK162+Versus+Vemurafenib+and%0ALGX818+Monotherapy+in+BRAF+Mutant+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01909453+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span>Study
of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant
Metastatic Colorectal Cancer. <a href="https://clinicaltrials.gov/ct2/show/NCT01719380" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01719380</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study%0Aof+LGX818+and+Cetuximab+or+LGX818%2C+BYL719%2C+and+Cetuximab+in+BRAF+Mutant%0AMetastatic+Colorectal+Cancer.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01719380+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span>LGX818
and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398
or INC280) in Advanced BRAF Melanoma. <a href="https://clinicaltrials.gov/ct2/show/NCT02159066" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02159066</a> (accessed Aug 31, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LGX818%0Aand+MEK162+in+Combination+With+a+Third+Agent+%28BKM120%2C+LEE011%2C+BGJ398%0Aor+INC280%29+in+Advanced+BRAF+Melanoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02159066+%28accessed+Aug+31%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e0155217</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0155217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1371%2Fjournal.pone.0155217" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0155217&issue=5&author=Y.+Xiaauthor=Y.+Liauthor=K.+D.+Westoverauthor=J.+Sunauthor=H.+Chenauthor=J.+Zhangauthor=D.+E.+Fisher&title=Inhibition+of+Cell+Proliferation+in+an+NRAS+Mutant+Melanoma+Cell+Line+by+Combining+Sorafenib+and+%CE%B1-Mangostin&doi=10.1371%2Fjournal.pone.0155217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0155217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0155217%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26atitle%3DInhibition%2520of%2520Cell%2520Proliferation%2520in%2520an%2520NRAS%2520Mutant%2520Melanoma%2520Cell%2520Line%2520by%2520Combining%2520Sorafenib%2520and%2520%25CE%25B1-Mangostin%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D5%26spage%3De0155217%26doi%3D10.1371%2Fjournal.pone.0155217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halilovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">The RAF Inhibitor PLX4032 Inhibits ERK Signaling and Tumor Cell Proliferation in a V600E BRAF-Selective Manner</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">14903</span>– <span class="NLM_lpage">14908</span>, <span class="refDoi"> DOI: 10.1073/pnas.1008990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&issue=33&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+Inhibitor+PLX4032+Inhibits+ERK+Signaling+and+Tumor+Cell+Proliferation+in+a+V600E+BRAF-Selective+Manner&doi=10.1073%2Fpnas.1008990107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520Inhibitor%2520PLX4032%2520Inhibits%2520ERK%2520Signaling%2520and%2520Tumor%2520Cell%2520Proliferation%2520in%2520a%2520V600E%2520BRAF-Selective%2520Manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D33%26spage%3D14903%26epage%3D14908%26doi%3D10.1073%2Fpnas.1008990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleam, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span> <span> </span><span class="NLM_article-title">Combinations of BRAF, MEK, and PI3K/MTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F1535-7163.MCT-11-0989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=22389471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-920&issue=4&author=J.+G.+Gregerauthor=S.+D.+Eastmanauthor=V.+Zhangauthor=M.+R.+Bleamauthor=A.+M.+Hughesauthor=K.+N.+Smithemanauthor=S.+H.+Dickersonauthor=S.+G.+Laquerreauthor=L.+Liuauthor=T.+M.+Gilmer&title=Combinations+of+BRAF%2C+MEK%2C+and+PI3K%2FMTOR+Inhibitors+Overcome+Acquired+Resistance+to+the+BRAF+Inhibitor+GSK2118436+Dabrafenib%2C+Mediated+by+NRAS+or+MEK+Mutations&doi=10.1158%2F1535-7163.MCT-11-0989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations</span></div><div class="casAuthors">Greger, James G.; Eastman, Stephen D.; Zhang, Vivian; Bleam, Maureen R.; Hughes, Ashley M.; Smitheman, Kimberly N.; Dickerson, Scott H.; Laquerre, Sylvie G.; Liu, Li; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-920</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent results from clin. trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown encouraging response rates; however, the duration of response has been limited.  To identify determinants of acquired resistance to GSK2118436 and strategies to overcome the resistance, we isolated GSK2118436 drug-resistant clones from the A375 BRAFV600E and the YUSIT1 BRAFV600K melanoma cell lines.  These clones also showed reduced sensitivity to the allosteric mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor GSK1120212 (trametinib).  Genetic characterization of these clones identified an in-frame deletion in MEK1 (MEK1K59del) or NRAS mutation (NRASQ61K and/or NRASA146T) with and without MEK1P387S in the BRAFV600E background and NRASQ61K in the BRAFV600K background.  Stable knockdown of NRAS with short hairpin RNA partially restored GSK2118436 sensitivity in mutant NRAS clones, whereas expression of NRASQ61K or NRASA146T in the A375 parental cells decreased sensitivity to GSK2118436.  Similarly, expression of MEK1K59del, but not MEK1P387S, decreased sensitivity of A375 cells to GSK2118436.  The combination of GSK2118436 and GSK1120212 effectively inhibited cell growth, decreased ERK phosphorylation, decreased cyclin D1 protein, and increased p27kip1 protein in the resistant clones.  Moreover, the combination of GSK2118436 or GSK1120212 with the phosphoinositide 3-kinase/mTOR inhibitor GSK2126458 enhanced cell growth inhibition and decreased S6 ribosomal protein phosphorylation in these clones.  Our results show that NRAS and/or MEK mutations contribute to BRAF inhibitor resistance in vitro, and the combination of GSK2118436 and GSK1120212 overcomes this resistance.  In addn., these resistant clones respond to the combination of GSK2126458 with GSK2118436 or GSK1120212.  Clin. trials are ongoing or planned to test these combinations.  Mol Cancer Ther; 11(4); 909-20.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-aBjkeaBsgLVg90H21EOLACvtfcHk0ljHKI2hS_rMCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbY%253D&md5=416c0679440a16f76f3622e0b26cf3a2</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0989%26sid%3Dliteratum%253Aachs%26aulast%3DGreger%26aufirst%3DJ.%2BG.%26aulast%3DEastman%26aufirst%3DS.%2BD.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DBleam%26aufirst%3DM.%2BR.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DCombinations%2520of%2520BRAF%252C%2520MEK%252C%2520and%2520PI3K%252FMTOR%2520Inhibitors%2520Overcome%2520Acquired%2520Resistance%2520to%2520the%2520BRAF%2520Inhibitor%2520GSK2118436%2520Dabrafenib%252C%2520Mediated%2520by%2520NRAS%2520or%2520MEK%2520Mutations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D909%26epage%3D920%26doi%3D10.1158%2F1535-7163.MCT-11-0989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">BRAF Targeted Therapy Changes the Treatment Paradigm in Melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2011.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1038%2Fnrclinonc.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=21606968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=426-433&issue=7&author=A.+Ribasauthor=K.+T.+Flaherty&title=BRAF+Targeted+Therapy+Changes+the+Treatment+Paradigm+in+Melanoma&doi=10.1038%2Fnrclinonc.2011.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF targeted therapy changes the treatment paradigm in melanoma</span></div><div class="casAuthors">Ribas, Antoni; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">426-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target.  The authors describe the scientific basis for the targeting of BRAF mutations in cancer, the early clin. data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.  After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon.  The discovery of the genetic underpinnings of this historically refractory disease has exposed potential targets for therapy, BRAF mutations being principal among them.  In the 8 years following the discovery of BRAF mutations in 50-60% of advanced melanomas, only recently have potent and selective inhibitors of this intracellular signaling mol. shown efficacy from early clin. testing.  Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their resp. phase I, II, and III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJ5nnopldxbVg90H21EOLACvtfcHk0ljIBN1ER2wXRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleltrw%253D&md5=710ef1d3ccb02a0c80bf7f9b3fe935a7</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DBRAF%2520Targeted%2520Therapy%2520Changes%2520the%2520Treatment%2520Paradigm%2520in%2520Melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26issue%3D7%26spage%3D426%26epage%3D433%26doi%3D10.1038%2Fnrclinonc.2011.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariyan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merghoub, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-13-0160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=10.1158%2F2326-6066.CIR-13-0160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=24416731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=70-79&issue=1&author=M.+K.+Callahanauthor=G.+Mastersauthor=C.+A.+Pratilasauthor=C.+Ariyanauthor=J.+Katzauthor=S.+Kitanoauthor=V.+Russellauthor=R.+A.+Gordonauthor=S.+Vyasauthor=J.+Yuanauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=N.+Rosenauthor=T.+Merghoubauthor=M.+Jure-Kunkelauthor=J.+D.+Wolchok&title=Paradoxical+Activation+of+T+Cells+via+Augmented+ERK+Signaling+Mediated+by+a+RAF+Inhibitor&doi=10.1158%2F2326-6066.CIR-13-0160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor</span></div><div class="casAuthors">Callahan, Margaret K.; Masters, Gregg; Pratilas, Christine A.; Ariyan, Charlotte; Katz, Jessica; Kitano, Shigehisa; Russell, Valerie; Gordon, Ruth Ann; Vyas, Shachi; Yuan, Jianda; Gupta, Ashok; Wigginton, Jon M.; Rosen, Neal; Merghoub, Taha; Jure-Kunkel, Maria; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RAF inhibitors selectively block extracellular signal-regulated kinase (ERK) signaling in BRAF-mutant melanomas and have defined a genotype-guided approach to care for this disease.  RAF inhibitors have the opposite effect in BRAF wild-type tumor cells, where they cause hyperactivation of ERK signaling.  Here, we predict that RAF inhibitors can enhance T-cell activation, based on the observation that these agents paradoxically activate ERK signaling in BRAF wild-type cells.  To test this hypothesis, we have evaluated the effects of the RAF inhibitor BMS908662 on T-cell activation and signaling in vitro and in vivo.  We observe that T-cell activation is enhanced in a concn.-dependent manner and that this effect corresponds with increased ERK signaling, consistent with paradoxical activation of the pathway.  Furthermore, we find that the combination of BMS908662 with cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockade in vivo potentiates T-cell expansion, corresponding with hyperactivation of ERK signaling in T cells detectable ex vivo.  Finally, this combination demonstrates superior antitumor activity, compared with either agent alone, in two transplantable tumor models.  This study provides clear evidence that RAF inhibitors can modulate T-cell function by potentiating T-cell activation in vitro and in vivo.  Paradoxical activation of ERK signaling in T cells offers one mechanism to explain the enhanced antitumor activity seen when RAF inhibitors are combined with CTLA-4 blockade in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr53PahaKZ3ZrVg90H21EOLACvtfcHk0ljIBN1ER2wXRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ls70%253D&md5=b4c9ea6f475ae79d053577c7eacc22d8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-13-0160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-13-0160%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DMasters%26aufirst%3DG.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DAriyan%26aufirst%3DC.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DKitano%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DV.%26aulast%3DGordon%26aufirst%3DR.%2BA.%26aulast%3DVyas%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DMerghoub%26aufirst%3DT.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DParadoxical%2520Activation%2520of%2520T%2520Cells%2520via%2520Augmented%2520ERK%2520Signaling%2520Mediated%2520by%2520a%2520RAF%2520Inhibitor%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2%26issue%3D1%26spage%3D70%26epage%3D79%26doi%3D10.1158%2F2326-6066.CIR-13-0160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span> <span> </span><span class="NLM_article-title">MLN2480: A Novel Pan-RAF Inhibitor for Treatment of BRAF Mutant and Wild-Type Tumors</span>. Presented at the 103rd Annual Meeting of the AACR, Chicago, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=K.+Galvin&title=MLN2480%3A+A+Novel+Pan-RAF+Inhibitor+for+Treatment+of+BRAF+Mutant+and+Wild-Type+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGalvin%26aufirst%3DK.%26atitle%3DMLN2480%253A%2520A%2520Novel%2520Pan-RAF%2520Inhibitor%2520for%2520Treatment%2520of%2520BRAF%2520Mutant%2520and%2520Wild-Type%2520Tumors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VAM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VAM','PDB','5VAM'); return false;">PDB: 5VAM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH','PDB','1UWH'); return false;">PDB: 1UWH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HID" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HID','PDB','5HID'); return false;">PDB: 5HID</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW','PDB','4RZW'); return false;">PDB: 4RZW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNE','PDB','4MNE'); return false;">PDB: 4MNE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZV','PDB','4RZV'); return false;">PDB: 4RZV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7','PDB','3OG7'); return false;">PDB: 3OG7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OG7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OG7','PDB','5OG7'); return false;">PDB: 5OG7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX','PDB','5CSX'); return false;">PDB: 5CSX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FB8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FB8','PDB','2FB8'); return false;">PDB: 2FB8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ','PDB','1UWJ'); return false;">PDB: 1UWJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HI2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HI2','PDB','5HI2'); return false;">PDB: 5HI2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MNF','PDB','4MNF'); return false;">PDB: 4MNF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4C" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4C','PDB','3C4C'); return false;">PDB: 3C4C</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WO5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WO5','PDB','4WO5'); return false;">PDB: 4WO5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSW','PDB','5CSW'); return false;">PDB: 5CSW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV2','PDB','4XV2'); return false;">PDB: 4XV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HIE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HIE','PDB','5HIE'); return false;">PDB: 5HIE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R','PDB','4G9R'); return false;">PDB: 4G9R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C9C" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C9C','PDB','5C9C'); return false;">PDB: 5C9C</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP','PDB','4KSP'); return false;">PDB: 4KSP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R5Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R5Y','PDB','4R5Y'); return false;">PDB: 4R5Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CT7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CT7','PDB','5CT7'); return false;">PDB: 5CT7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XV1','PDB','4XV1'); return false;">PDB: 4XV1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FD2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FD2','PDB','5FD2'); return false;">PDB: 5FD2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CQE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CQE','PDB','4CQE'); return false;">PDB: 4CQE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3II5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3II5','PDB','3II5'); return false;">PDB: 3II5</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-14%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01306" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01306" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aa375bff93d30","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
